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Summary 
The immune system, and in particular CD8+ T cells, have the potential to eliminate tumours 
and novel immunotherapies are giving encouraging results for cancer patients. This thesis 
focuses on the improvement of one such therapy, adoptive T cell therapy. The aim of this 
thesis was to genetically modify human CD8+ T cells to enhance their anti-tumour potential for 
adoptive T cell therapy. One approach was to mutate the SH2 domain containing protein 
tyrosine phosphatase (SHP-1) gene to reduce T cell checkpoint inhibition. A second approach 
was to express a shedding-resistant form of L-selectin in T cells to promote T cell homing. 
In this thesis, the rapid shedding of L-selectin within minutes after TCR stimulation was shown 
to be ADAM17 dependent. Furthermore, new data indicated a second proteolytic cleavage 
which is γ-secretase dependent. The shedding-resistant L-selectin (ΔM-N) was shown to resist 
proteolysis by both ADAM17 and γ-secretase. 
Previous work by our group and others has shown that the loss of SHP-1 leads to the enhanced 
entrance of T cells into proliferation and gives better protection against tumour growth in 
mice. To study the effect of SHP-1 loss in human CD8+ T cells, SHP-1 deficient tumour-specific T 
cells were generated by lentiviral delivery of a pair of SHP-1 specific zinc finger nucleases in 
conjunction with the Mel TCR. Populations of melanoma-specific CD8+ T cells containing a 
small fraction (< 8 %) of SHP-1 mutant cells showed no enhanced Mel526 target cell killing in 
vitro or in vivo in Mel526 xenograft bearing NSG mice. However, there was some suggestion of 
enhanced survival and/or proliferation in vitro of melanoma-specific CD8+ T cells containing a 
population of SHP-1 CD8+ mutant cells. Overall the proof of principle of gene-editing SHP-1 in T 
cell lines and primary CD8+ T cells was demonstrated which supports further exploitation of 
this approach for testing in adoptive T cell therapy strategies. 
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Chapter 1: Introduction 
1.1 The immune system and cancer 
1.1.1 The immune system and cancer development 
Cancer development is a complicated multifactorial process but put simply, cancer arises due 
to the accumulation of mutations by cells leading to the dysregulation of the cell cycle and 
enhanced cell proliferation. Such mutations can lead to the cells becoming resistant to both 
growth inhibiting and death inducing signals as well as the cancer cells developing a capacity to 
shape their environment by inducing angiogenesis and by invading new tissues (Hanahan and 
Weinberg 2011). 
Although long ignored by many oncologists and cancer researchers, many studies have now 
implicated the immune system in the control of tumour establishment and development. 
There is a striking increase in virally induced malignancies, such as Kaposi’s sarcoma and non-
Hodgkin’s lymphoma, in immunodeficient patients (Boshoff and Weiss 2002). However, one 
can argue that the immune system would be involved in controlling these cancers as they 
express foreign antigens (Ags), a key trigger to a robust immune response. An example that 
shows that the control of tumour growth by the immune system extends to a broader range of 
cancers is that immunosuppressed transplant recipients have been shown to develop 
malignancies such as melanoma when organs from seemingly healthy immunocompetent 
donors are transplanted (Strauss and Thomas 2010). This indicates that the immune system is 
keeping tumour cells under stringent pressure and thereby maintaining tumours in a dormant 
state. Additionally, correlations exist between the number of tumour infiltrating cytotoxic 
immune cells and a favourable prognosis in patients with colon (Galon et al. 2006), ovarian 
(Sato et al. 2005), melanoma (Clemente et al. 1996) and breast tumours (Loi et al. 2013). Not 
only is the number of tumour infiltrating lymphocytes (TILs) important but also the type of 
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immune cell. A high ratio of effector to regulatory T cells (Tregs) has been shown to be 
beneficial, as the latter cell type suppresses the anti-tumour immune response (Curiel et al. 
2004; Sato et al. 2005). Furthermore, patients with a mutation in a gene encoding for a protein 
involved in T cell mediated killing (perforin) have shown an increased frequency of lymphomas 
(Chia et al. 2009). In addition to correlations between naturally mounted immune responses 
and cancer control, therapies aimed at enhancing an anti-tumour immune response have 
shown considerable benefits. Examples of immunotherapies will be given below with special 
emphasis on adoptive T cell therapy (ACT).  
As mentioned above, effector T cells, and more specifically killer CD8+ T cells play a crucial role 
in killing tumour cells via a range of mechanisms described in section 1.2.2. To stimulate an 
efficient T cell response, a number of steps need to be followed as shown in figure 1.1. Firstly, 
antigen presenting cells (APCs) need to take up neo-Ag or tumour-associated Ag (TAA) from 
tumour cells before Ag-loaded APCs migrate to lymph nodes (LNs). Here T cells survey the 
environment for cognate Ag presented by APCs and once T cells find the latter, T cells are 
activated as described in section 1.2.1. Once activated, T cells exit the LNs via the lymphatics, 
re-enter the blood stream and migrate towards the tumour, where T cells extravasate and 
enter the tumour mass, if the endothelial cells express the appropriate adhesion molecules. 
Here T cells will get activated by cognate Ag presented by tumour cells and target cells will be 
killed (Chen and Mellman 2013). 
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Figure 1.1: The cancer-immunity cycle and approach taken in this thesis to improve the 
immune response to cancer. The ideal immune response to cancer starts with the release of 
TAAs from tumour cells which can then be presented by APCs on MHC-I or MHC-II. The third 
step is the priming of naïve T cells by Ag loaded APCs in LNs. Activated T cells, such as cytotoxic 
T cells (CTLs), leave the LNs via the blood stream and are recruited to the tumour site if the 
vasculature provides the right ligands. Finally, T cells will recognise target tumour cells, be 
activated and kill cancer cells by several cytotoxic mechanisms. Lysis of tumour cells will 
release more TAA and the cycle will start all over again. However, in patients manifesting with 
tumours, one or several steps of this cycle are deficient or absent. Therefore the aim of all 
immunotherapies is it to enhance one or several aspects of this cycle. The two main targets in 
this thesis are a negative regulator of T cell activation, SHP-1, and the homing molecule, L-
selectin. Abrogation of the former and prolonged expression of the latter is hypothesised to 
enhance the priming of T cells (step 3) and the homing step to LNs and tumours (step 3 and 5), 
respectively. Figure modified from (Chen and Mellman 2013). 
 
In patients manifesting with tumours, one or multiple of these steps are either faulty, absent 
or inhibited by tumour derived mechanisms. There are multiple mechanisms of tumour escape 
from the immune system and only a few will be briefly described here (Zitvogel et al. 2006). 
Immunoselection of tumour cells expressing low levels of the major histocompatibility 
complex class–I (MHC-I) and Ag processing molecules as well as selection of cells expressing 
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weakly immunogenic Ag can occur. Some tumours have also been found to express PI9, a 
protease inhibitor that can protect against a cytotoxic enzyme called granzyme B (Medema et 
al. 2001). A more active way of escaping deletion by the immune system is by recruiting Tregs or 
myeloid derived suppressor cells to the tumour via the secretion of cytokines and growth 
factors. The latter also influence the maturation of dendritic cells (DCs), keeping them in an 
immature state and thus unable to fully activate CD4+ and CD8+ T cells. Additionally tumour 
cells can express high levels of programmed death ligand-1 (PD-L1) able to interact with an 
inhibitory receptor, PD-1, on activated T cells and induce exhaustion of the T cells (Victor et al. 
2015).  
 
1.1.2 Cancer immunotherapy 
The immune system is an attractive weapon against cancer as it has the ability to form 
memory cells that can patrol the body for reoccurring tumour cells. Cancer immunotherapy is 
also often stated as being potentially less toxic than existing chemotherapies and 
radiotherapies, however this is debatable as some of the most successful therapies, mentioned 
below, are associated with very severe side effects which are often an early indication of the 
success of the treatment. One of the first examples of immunotherapy was the injection of 
bacterial extracts into patients with tumours in 1891 by William B. Coley, the ‘father of 
immunotherapy’ (McCarthy 2006). The rationale behind this partially successful therapy, called 
Coley’s toxin, was that the infection caused by this immunogenic mix would lead to the 
shrinkage of solid tumours. 
Currently, a whole range of immunotherapies are being trialled and some have gained USA 
Food and Drug Administration (FDA) approval. Similarly to Coley’s toxin, the aim of the newer 
therapies is to stimulate the immune response and direct it towards tumour cell killing by 
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altering one or several steps of the cancer-immune cycle (figure 1.1). Based on successes of 
vaccinations in protecting against pathogens, cancer vaccines have been studied extensively 
with limited success (Klebanoff et al. 2011a). Cancer vaccinations aim to stimulate Ag 
presentation by APCs and thus T cell activation (step 2 and 3) by either directly injecting TAA 
and adjuvant or using ex vivo modified DCs (Palucka and Banchereau 2012). A recent 
publication showed that identifying tumour-specific mutations and including them into a 
personalised autologous DC vaccine can induce a robust neo-Ag T cell response in patients 
(Carreno et al. 2015). However, some key questions remain unanswered such as what the 
nature of the Ag and adjuvant should be in order to trigger an efficient non-tolerogenic, 
cytotoxic response. 
Even if the initial priming of T cells is enhanced by cancer vaccines, T cells will face a vast array 
of inhibitory signals within the tumour microenvironment. To overcome this inhibition, 
vaccinations could be combined with antibody (Ab) therapies that prevent these checkpoint 
inhibitors (step 7). Two such molecules are cytotoxic T-lymphocyte-associated protein 4 (CTLA-
4) and PD-1. Blocking Abs against both molecules (ipilimumab and pembrolizumab, 
respectively) have been FDA-approved for the treatment of advanced melanoma based on 
very promising clinical trials (Chen and Mellman 2013; Callahan et al. 2014). The immune 
system is also crucial in the elimination of cancer cells when Abs targeting molecules expressed 
on the tumour cells such as CD20 (rituximab) or Her2/neu (Trastuzumab) are given 
therapeutically (Adler and Dimitrov 2012). Additionally, cytokines stimulating an anti-cancer 
immune response such as IL-2 have been used in patients for 20 years but only yielding modest 
clinical benefits (Votavova et al. 2014). 
It is clear that the most successful therapies will be combinations of two or more approaches, 
targeting multiple steps of the cancer-immune cycle, together with biomarker analysis. One 
study showed a dramatic increase in overall response rate from 17% for radiation and anti-
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CTLA-4 Ab only to 80% for the combination of  radiotherapy, anti-CTLA-4 and anti-PDL-1 Abs 
(Victor et al. 2015). The three treatments were shown to be non-redundant and 
complementary with radiation increasing the repertoire of tumour reactive T cells, anti-PD-L1 
Ab increasing CD8+ TIL numbers and anti-CTLA-4 Ab reducing Treg numbers. 
 
1.1.3 Adoptive T cell therapy 
An immunotherapy aiming to circumvent low frequencies of endogenous tumour-specific T 
cells and poor in vivo priming of T cells is adoptive T cell therapy (ACT). Originally, ACT was 
done by isolating TILs from excised tumours and expanding them in vitro before reinfusing 
them to patients (figure 1.2). For a second type of ACT, T cells can be isolated from peripheral 
blood mononuclear cells (PBMCs) from patients’ blood, T cells genetically modified to confer 
tumour specificity and expanded in vitro before being reinfused to the patients (figure 1.2). 
Both types of ACT can generate large numbers of tumour-reactive T cells (up to 1011). 
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Figure 1.2: Adoptive T cell therapy using TILs or genetically modified PBMCs. Initially ACT 
trials were based on the excision of patients’ tumours and the generation of single cell 
suspensions from the biopsies. Cells were cultured in vitro in conditions favouring T cell growth 
(i.e.: IL-2) and TILs (red and orange) were assayed for tumour reactivity before being further 
expanded and reinfused into patients having undergone preconditioning chemotherapy. More 
recently, PBMCs from patient’s blood were isolated and T cells genetically modified in vitro, be 
it to express tumour-specific T cell receptors (TCRs) or chimeric Ag receptors (CARs). As for the 
TIL therapy, T cells were expanded and reinfused into patients. 
 
One of the earliest ACTs using TIL was done by Rosenberg et al., where 11/20 patients with 
metastatic melanoma showed objective regression when treated with endogenous TILs and 
high doses of IL-2 (Rosenberg et al. 1988). However, a problem with ACT was that the 
transferred T cells engrafted poorly and did not persist in patients and thus the overall clinical 
outcome was not as good as expected (Rosenberg et al. 1990). It is now believed that 
lymphodepletion with chemotherapy, prior to the transfer of T cells, enhances T cell 
engraftment and persistence (Dudley et al. 2002). Lymphodepletion is thought to eliminate 
local inhibitory cells such as myeloid-derived suppressor cells and Tregs and to create ‘space’ by 
reducing cellular competition for engrafting T cells. Additionally in a lymphodepleted host, 
homeostatic cytokine levels are elevated and cytokines such as IL-15 are readily available to 
transferred T cells (Dudley et al. 2008). ACT has also given encouraging results in clinical trials 
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such as a phase 2 trial where Epstein-Barr virus (EBV) specific donor cytotoxic T cells (CTLs) 
were given to patients with EBV-positive post-transplantation lymphoproliferative disease and 
a response rate of 52% was observed (Haque et al. 2007). However in this trial, the Ag targeted 
by T cells is of viral origin as opposed to most tumour Ags that arise from normal or mutated 
self-protein. Overall, TIL therapy has also shown promising results in patients with metastatic 
melanoma with 38% (Pilon-Thomas et al. 2012) to 55% (Rosenberg and Restifo 2015) objective 
response rates. Although other tumours also enable the growth of TILs in vitro, only melanoma 
specific TILs have been shown to consistently give beneficial clinical responses (Rosenberg and 
Restifo 2015). 
To overcome the absence of pre-existing tumour-reactive T cells, the lack of accessible tumour 
and the low success rate of TIL therapy in non-melanoma patients, researchers have been 
genetically engineering patient T cells to redirect their specificity to TAAs. The first study doing 
this was done in 2006, where autologous lymphocytes from melanoma patient peripheral 
blood were isolated and transduced with a retrovirus expressing both the T cell receptor (TCR) 
α and β chains of a melanoma-specific (MART-1) TCR previously isolated from a patient 
undergoing TIL ACT (Morgan et al. 2006). This study showed that T cells persisted for at least 2 
months in vivo, however only 2/15 patients showed a partial response. One of the first trials 
targeting not only metastatic melanoma but also synovial cell sarcoma utilised a NY-ESO-1 
cancer-testis Ag specific TCR and showed response rates of 45% and 67%, respectively 
(Robbins et al. 2011).  
As well as TCRs, chimeric Ag receptors (CARs) have been utilised to confer tumour-specificity 
to T cells. CARs have the advantage that their extracellular Ab fragment recognises Ag in a 
human leucocyte Ag (HLA) independent manner while retaining the intracellular signalling of a 
TCR via the CD3 ζ chain. This HLA-independence circumvents the need to develop HLA-specific 
receptors for patients with different HLA haplotypes. Furthermore, many tumours have been 
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shown to have very low to absent HLA expression, in which case TCR expressing T cells will not 
recognise the tumour cells (Algarra et al. 2004). Additionally, transduced TCR α and β chains 
can mispair with endogenous TCR, potentially giving rise to new pathogenic auto-reactive T cell 
specificities (Bendle et al. 2010). On the other hand, TCRs are able to recognise intracellular 
proteins presented on MHC-I to which CARs will be ignorant. The first generation CARs 
expressed only the CD3ζ chain, whereas the second generation CARs currently used in clinical 
trials also express intracellular signalling domains from costimulatory molecules such as CD28. 
CARs have been developed to recognise the B cell surface Ag CD19, amongst other surface Ags, 
and clinical trials have shown significant regression of patient B cell lymphomas but CAR 
expressing T cells have not yet shown clinical responses in solid tumours (Cheadle et al. 2014). 
An issue with genetically modifying T cells with TCRs or CARs is the selection of the specificity 
of the receptor which ideally should recognise only tumour cells and not cells in healthy tissue. 
Non-mutated self-epitopes, overexpressed in tumour cells, have also been the focus of many 
studies. The main problem with this is the generation of on-target but off-tumour T cells that 
kill healthy tissue expressing the Ag to a low degree. Destruction of healthy tissue is acceptable 
for non-vital tissues, however some studies have shown life-threatening side effects when 
organs such as the liver (Lamers et al. 2013) or the gut (Parkhurst et al. 2011) are attacked by T 
cells. Additionally, altering the sequence of TCRs to enhance their intrinsic affinity has been 
found to have fatal consequences. In a study where an affinity enhanced cancer-testes Ag 
(MAGE-3) specific TCR was transduced into T cells and these were given to patients, the T cells 
attacked cardiac muscle cells expressing a cross-reactive epitope from titin, leading to the 
death of two patients (Linette et al. 2013). 
One of the reasons why TIL therapy works best in melanoma could be the high frequency of 
mutations which is up to 1000 fold more than in other tumours (Lawrence et al. 2013). As self-
reactive T cells are eliminated during thymic selection, T cells recognising self-peptide, such as 
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those proteins upregulated in tumour cells, might simply not exist in the periphery. This might 
explain the low success rate of non-mutated self-peptide Ag vaccines (Klebanoff et al. 2011a). 
It was shown that the number of mutational epitopes in tumours correlated with high CTL 
numbers in the tumour and enhanced survival (Brown et al. 2014). Thus ideally, TCRs specific 
to each patient’s own mutations would be isolated and genetically transferred to T cells for 
ACT.  
Most TCR and CAR gene delivery has been done using retroviral vectors, however lentiviral (LV) 
delivery has been used successfully to deliver a CD19-specific CAR to T cells and 2/3 patients 
showed complete remission (Kalos et al. 2011). The use of transposon systems, such as the 
‘Sleeping Beauty’, might be beneficial for the delivery of TCR or CARs as T cells do not need to 
be activated prior to gene transfer (Huang et al. 2008). This system has now been used to 
deliver a CD19-specific CAR to T cells in a clinical trial (Kebriaei et al. 2012). 
 
1.1.4 Optimisation of ACT protocols 
Ideally, ACT will lead to a large population of effector T cells as well as a considerable number 
of memory T cells. The latter will provide long-term protection due to the capacity of memory 
T cells to proliferate and generate additional differentiated effector T cells. It is crucial to 
optimise the in vitro culture of TILs or genetically modified T cells so as to promote T cell 
differentiation into a memory phenotype and prevent immediate effector phenotypes and T 
cell exhaustion. Reducing the in vitro culture period to produce younger TILs has been trialled 
in patients and has shown promising results (Besser et al. 2010). As an alternative to reducing 
the in vitro culture times, ‘fitter’ T cells can potentially be obtained by varying the Abs and 
cytokines used when activating T cells. One such change, proposed by Gattinoni et al., was to 
culture T cells in IL-15 rather than IL-2 as they demonstrated that T cells grown in the former 
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provided better protection against tumour growth in mice (Gattinoni et al. 2005).  This finding 
was supported by a study where genetically modified human T cells showed improved 
engraftment in immunodeficient mice when grown in the presence of IL-15 and/or IL-7 rather 
than IL-2 (Alcantar-Orozco et al. 2013).  
Contrary to previous thinking, it was found that differentiated effector T cells that showed 
highly cytotoxic phenotypes in vitro were actually poorer at in vivo protection when compared 
to less extensively stimulated T cells (Gattinoni et al. 2005). In a recent study it was also shown 
that signalling pathways, such as the Akt pathway, associated with the differentiation of T cells 
into an effector phenotype, can be inhibited during the in vitro T cell expansion, leading to an 
increase in the memory transcription profile in T cells and enhanced tumour protection by 
these cells in mice (Crompton et al. 2015). This fitted with another study performed in mice 
where T cells with a more memory-like phenotype were better at protecting than their 
effector T cell counterparts (Klebanoff et al. 2011b). As well as the differentiation status, it has 
was shown in mice that the number of transferred T cells is crucial for the success of the 
treatment, with higher T cell numbers giving better outcomes (Klebanoff et al. 2011b; 
Alcantar-Orozco et al. 2013). Additionally, in vivo Ag restimulation with a vaccine was shown to 
enhance the anti-tumour effect both in mice (Klebanoff et al. 2011b) and in humans (Smith et 
al. 2009).  
Overall, it is clear that there are many aspects of ACT that may be optimised to generate a 
maximal clinical impact. As well as conferring Ag specificity, genetic manipulation of T cells in 
vitro can be used to deliver other molecules to enhance their in vivo anti-tumour effect. In this 
thesis, two aspects of T cell biology were addressed by genetic modifications; T cell activation 
and T cell homing. By genetically deleting a negative regulator of T cell activation, SHP-1, and 
prolonging expression of a lymphocyte homing molecule, L-selectin, we aimed at enhancing 
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both the activation of T cells (step 3 in figure 1.1) and the homing of the T cells to LNs and 
possibly tumour (step 3 and 5 in figure 1.1). 
  
 
1.2 CD8+ T cells 
1.2.1 CD8+ T cells and their role in the immune system 
CD8+ T cells are part of the adaptive immune system where their main function it is to kill cells 
infected with virus or an intracellular pathogen. CD8+ T cells originate from haematopoietic 
stem cells in the bone marrow and are subjected to positive and negative selection in the 
thymus; the latter giving T cells their name. The TCR expressed by CD8+ T cells is composed of 
an α and a β chain and each TCR expressed in naïve T cells is unique due to recombination 
events occurring during T cell development. CD8+ T cells can recognise and bind to cognate 
peptide presented in the peptide binding cleft of the MHC-I on cells via the TCR (figure 1.3). 
Subsequent downstream signalling leading to T cell activation will be described in more detail 
later (figure 1.5). To stabilise this interaction, CD8αβ, a heterodimeric co-receptor, binds to a 
conserved region of the MHC-I. MHC-I is expressed on the majority of nucleated cells albeit 
different tissues have different expression levels. High levels can be found in lymphocytes 
whereas cells in the brain or kidney have lower levels and non-nucleated red blood cells do not 
express any MHC-I. The latter observation fits with the inability of red blood cells to support 
viral replication and the role of CD8+ T cells in detecting and eliminating virally infected cells. 
(Kenneth Murphy 2008) 
Naïve T cells have not encountered Ag recognised by their TCR (cognate Ag) outside of the 
primary lymphoid organs (bone marrow and thymus) and have consequently not yet been 
activated. Naïve CD8+ T cells circulate via the blood stream to secondary lymphoid organs such 
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as the spleen, lymph nodes and mucosal-associated lymphoid tissue. Here they scan the 
environment for Ag presented by APCs such as DCs. If cells do not encounter cognate Ag, they 
exit the LNs within 24 h via the lymphatics and recirculate through other secondary lymphoid 
organs. 
Figure 1.3: CD8+ T cell priming by APCs in secondary lymphoid tissues. CD8+ T cells are primed 
in secondary lymphoid organs when the TCR (red) encounters cognate peptide (black line) 
presented within the peptide binding cleft of MHC-I (orange) expressed by APCs. The CD8 co-
receptor (green) stabilises this interaction by binding to the α3 domain of the MHC-I. For 
optimal activation, co-stimulation (e.g.: CD80/86 and CD28) and cytokines provide stimulatory 
signals 2 and 3. A stable conjugate between the two cells is formed once adhesion molecules 
interact (e.g.: LFA-1 and ICAM-1). Once these combined signals are provided, the protein 
tyrosine kinase (PTK), LCK, phosphorylates the ζ-chain of the CD3 receptor enabling the 
recruitment of the PTK, ZAP70, leading to a signalling cascade resulting in metabolic changes to 
the cell, proliferation and gene transcription changes. 
 
Peptides presented by MHC-I complex of APCs can originate both from intracellular proteins 
and extracellular proteins as professional APCs are able to cross-present the latter. Most other 
cells present exclusively intracellular peptide on MHC-I and the vast majority of these peptides 
will not trigger any immune response as strongly self-reactive T cells have been negatively 
selected in the thymus due to a strong response to self-Ag. However, incomplete selection or 
cross reactivity can give rise to potentially self-reactive CD8+ T cells circulating in the body. 
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Indeed, autoimmune disorders, graft-versus-host and graft rejection can all be linked to the 
killing of healthy tissue by self-reactive CD8+ T cells (Barry and Bleackley 2002). 
Consequently, CD8+ T cell activation is highly regulated and not only requires cognate peptide 
presented on MHC-I by APCs but the APCs need to be activated and express co-stimulatory 
molecules such as CD80/86. For maximal CD8+ T cell activation and expansion, an additional 
requirement is an inflammatory cytokine environment such as exposure to interleukin-12 (IL-
12) and type I interferon (IFN). The overall triggering and maintenance of an adaptive immune 
response depends on a wide array of different signals such as cytokines and cell to cell contact 
from different immune and non-immune cells in a variety of locations. Naïve CD8+ T cells will 
not be activated by non-APC cells unless they are found within a highly inflammatory 
environment and are activated as bystanders. (Kenneth Murphy 2008) 
During an infection with a virus not previously seen by a given individual, a phenotypically and 
functionally heterogeneous immune response is mounted by a population of distinct naïve 
CD8+ T cells, expressing a range of TCRs, being activated by DCs. The activation will happen in 
the subcapsular sinus of the draining LN (dnLN) of the infected tissue. This can be independent 
from CD4+ T cells as shown for influenza or Listeria infections or it can require help from CD4+ T 
cells. The latter requires the CD4+ T cells to interact with the APCs and induce their maturation 
to fully competent APCs. This is needed for non-inflammatory Ags and some infections such as 
the herpes simplex virus (Zhang and Bevan 2011). 
It has been found that a naïve CD8+ T cell activated with a strong Ag stimuli, co-stimulation and 
an inflammatory cytokine environment can undergo up to 19 divisions within the first week 
with a maximum rate of cell division of 4-6 h. This expansion is associated with a large change 
in T cell metabolism. The expansion of CD8+ T cells is in contrast to CD4+ T cells which do not 
clonally expand to the same degree (Zhang and Bevan 2011). 
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1.2.2 Cytotoxic T cells and their killing mechanism 
It takes 5-8 days for a naïve CD8+ T cell to be primed in a secondary lymphoid organ, 
differentiate into a CTL and migrate to the site of infection. Each CTL can kill multiple target 
cells without causing significant bystander pathology. This is due to the requirement of the 
target cell to express the cognate peptide-MHC complex. Once differentiated, CTLs do not 
require co-stimulatory signals to kill and the engagement of as few as 3-10 TCRs is enough to 
trigger a CTL (Purbhoo et al. 2004). Once CTLs enter the affected tissue and localise to a target 
cell, the latter undergoes apoptosis within 20-30 min. As reviewed elsewhere, apoptosis or 
necrosis of target cells can be induced via three main mechanisms (figure 1.4), all of which are 
triggered by TCR activation (Barry and Bleackley 2002; de Saint Basile et al. 2010). 
The first mechanism of cytotoxicity used by CTLs is the calcium dependant secretion of 
granules, containing amongst other proteins, perforin and granzyme B, at the immunological 
synapse. Perforin is exclusively found in granules of cytolytic cells (CTLs and NK cells) and is 
thought to form pores in the cytoplasmic membrane or endosomes to release granzymes into 
the cytoplasm of target cells. Granzymes, such as granzyme B, enter the target cell cytoplasm 
via perforin pores or by endocytosis and induce caspase-dependant apoptotic cell death. 
Alternatively, granzyme B can interfere with mitochondrial activity leading to necrotic cell 
death. Perforin and the granzymes are synthesised de novo during the differentiation of a 
naïve CD8+ T cell into a CTL. Lymphocytes and activated DCs are protected against granzyme B 
as they express a specific protease inhibitor (PI9). CD107a is a surrogate marker for 
degranulation of cytotoxic granules (Betts et al. 2003) as CD107a is associated with 
intracellular lysosomal membranes until degranulation occurs and it is translocated to the cell 
surface. 
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A second mechanism by which CTLs induce target cell death is via the contact dependant 
interaction of death receptors and their ligands. One such interaction is that of FAS on the 
target cell and FAS ligand (FASL) on the CTL. The former is a member of the TNF receptor 
(TNFR) family and contains a death domain which leads to downstream activation of caspases 
and the initiation of apoptosis. Besides FAS, there are other TNFRs and TNF-related apoptosis 
inducing ligand receptor (TRAIL) contacts. The FAS-FASL interaction limits the survival of 
repeatedly activated lymphocytes as these cells will start upregulating FASL. Deficiency in the 
human FAS or FASL genes was shown to cause an autoimmune lymphoproliferative syndrome 
due to the lack of apoptosis of  autoreactive B and T cells (Rieux-Laucat et al. 2003). 
Lastly, CTLs can kill target cells by producing cytokines such as interferon-γ (IFN-γ) and tumour-
necrosis factor (TNF) which can damage target cells if secreted in close proximity. 
Figure 1.4: Cytotoxic killing of target cells by CD8+ T cells. CD8+ T cells are activated by cognate 
Ag presented by MHC-I on target cells in the periphery. TCR induced signalling will lead to the 
exocytosis of granulocytes containing perforin and granzyme. The former will form pores in the 
target cell cytoplasm through which the granzymes can enter the cell and induce apoptosis. 
Additionally, CD8+ T cells upregulate the surface expression of the death receptor ligand FASL, 
which interacts with FAS on the target cell and leads to target cell death. Finally, CD8+ T cells 
secrete cytokines such as TNF and IFN-γ. These three arms of attack will lead to target cell 
death by apoptosis or necrosis. 
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1.2.3 CD8+ T cell differentiation into effector and memory cells 
Differentiation of a naïve CD8+ T cell has two goals; clearing the pathogen or malignant cells 
and establishing immunological memory to protect against secondary Ag encounters. To 
enable this, CD8+ T cell responses to novel Ag consist of three phases. Firstly, clonal expansion, 
preceded by the activation of T cells (figure 1.3), yields a large number of effector CD8+ T cells 
to eliminate the Ag. Short lived effector T cells, expressing high levels of the transcription 
factor, T-bet, and proteins of the cytotoxic signature, make up the bulk of the response. IL-12 
has been implicated to induce terminally differentiated CD8+ T cells via the mTOR pathway and 
via the upregulation of T-bet. This is followed by a contraction phase where 90-95% of all CD8+ 
T cells die by apoptosis, once all the Ag has been eliminated. Thirdly, a pool of memory cells is 
formed, constituted of 5-10% of cells from the initial clonal expansion. (Kaech and Cui 2012) 
Several different models have been proposed for the differentiation of CD8+ T cells into 
effector T cells (TEF), effector memory (TEM) and central memory (TCM) T cells. The favoured 
models are based on the principle that the duration and/or strength of the T cell stimulation 
influences the differentiation of the cells. TCM cells are L-selectin (CD62L)high CCR7high cells and 
are found in bone marrow, LNs, the spleen and blood whereas TEM are L-selectinlow CCR7low 
cells and are found in the spleen, blood and liver. The former show high proliferative potential 
and secrete large amounts of IL-2 whereas the latter can rapidly upregulate their cytotoxic 
function when faced with a second challenge. It is important to note that expression of these 
memory markers is not definitive and that some cells can be CCR7+ but L-selectin- (Unsoeld and 
Pircher 2005). A third subset of memory T cells is composed of the tissue-resident memory T 
cells located in mucosal tissues and the brain and similarly to TEM cells they are able to quickly 
respond to a local challenge (Kaech and Cui 2012). 
There are different requirements, such as cytokines and cell to cell contact, for the 
maintenance of the different CD8+ T cell subsets (effector and memory). During an immune 
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response, T cells are activated and start making IL-2 due to signalling via the NFAT pathway 
and IL-2 acts in an auto- and paracrine manner. There are three different possible IL-2 receptor 
combinations; the low affinity CD25 (IL-2DR), the intermediate affinity CD132/CD122 (Jc/E 
chains) or the high affinity DEJ heterotrimer composed of all three units. CD25 is upregulated 
during CD8+ T cell activation leading to a selective IL-2 driven expansion of activated CD8+ T 
cells. IL-2 is required for an optimal CD8+ response generating effector and memory cells. 
However, continued exposure to IL-2 can lead to activation induced cell death (AICD) which 
can be inhibited by the presence of IL-15 signalling. IL-15 is another cytokine implicated in 
CD8+ T cell survival and proliferation. It is produced by type I IFN stimulated cells (non-T cells). 
IL-15 bound to the IL-15αR act in trans with the CD132/CD122 heterodimer expressed on T 
cells. IL-15 has been shown to be critical for CD8+ memory maintenance (Votavova et al. 2014). 
Homeostasis of CD8+ T cells requires IL-7 for both naïve and memory CD8+ T cells, but the latter 
also require IL-15 signalling (Surh and Sprent 2008). 
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1.3 SHP-1 and CD8+ T cell activation 
1.3.1 T cell signalling upon TCR engagement 
As reviewed recently (Brownlie and Zamoyska 2013), when CD8+ T cells are activated via the 
TCR recognising cognate peptide presented on MHC-I, the SRC family kinases (SFKs) LCK and 
FYN are activated (figure 1.5). LCK is associated with CD8 (Veillette et al. 1988), and the binding 
of CD8 to MHC-I will bring it in close proximity with its substrates, the immunoreceptor 
tyrosine-based activation motifs (ITAMs) of the CD3 γ, ε, δ and ζ chains. This phosphorylation 
depends on a threshold of activation and it is not yet clear how this is controlled. 
Phosphorylated ITAMs of the CD3 complex recruit the SYK family kinase zeta-associated-70 
(ZAP70) to the TCR-CD3 complex and the phosphorylation of activating residues on ZAP70 by 
LCK occurs. Once in an active conformation, ZAP70 phosphorylates its substrates, the main one 
being the linker for activation of T cells (LAT). Once the four tyrosines on LAT are 
phosphorylated, a multitude of molecules aggregate to form the LAT signalosome. The latter 
complex is composed amongst others of GRB2, SLP76 and VAV1. This in turn leads to further 
signalling, with the conformational change of integrins (LFA-1), the nuclear translocation of 
NFAT and NF-κB and actin rearrangements. Overall, changes in T cell adhesion, cell growth and 
differentiation will occur.  
Relatively little is known about the negative signalling involved in controlling the threshold of T 
cell activation and the termination of signalling. Several protein tyrosine phosphatases (PTPs), 
such as CD45 and SHP-1, have been implicated in setting the T cell threshold and ending 
signalling via the TCR by dephosphorylating kinases and molecules in the T cell signalling 
cascade. PTPs and in particular SHP-1 will be discussed in more detail below. 
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Figure 1.5: T cell signalling following engagement of cognate peptide MHC. When the TCR recognises cognate peptide presented on MHC-I or MHC-II, and 
CD4 or CD8 engages with MHC, the SRC family kinases FYN and LCK are activated, brought into the proximity of the TCR-CD3 complex and phosphorylate 
ITAM motifs of the CD3 γ, ε, δ and ζ chains. This enables the recruitment of ZAP70, which is phosphorylated by LCK and can in turn phosphorylate key 
tyrosines on LAT. Phosphorylated LAT recruits other proteins such as GRB2, SLP76 and VAV1, forming the LAT signalosome. The latter leads to signal 
propagation down three main pathways; the Ca2+ and NFAT, the MAPK and the NF-κB pathway. Overall, this will lead to altered cytoskeletal organisation, 
gene expression and metabolism. A key negative regulator of this signalling cascade is the protein tyrosine phosphatase, SHP-1 (yellow), possibly 
dephosphorylating and binding to some key molecules such as LCK, ZAP70 and SLP76. Figure adapted from (Brownlie and Zamoyska 2013).  
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1.3.2 Protein tyrosine phosphatases and T cell regulation 
Protein phosphorylation is a major post-translational modification leading to changes in 
cellular activity such as proliferation, differentiation and migration. Tyrosine phosphorylation, 
although only accounting for 0.01-0.05% of all protein phosphorylation (Hunter and Sefton 
1980), is essential for the regulation of all immune cells. The dynamic actions of PTKs are 
counteracted by PTPs and both enzymes are necessary to keep signalling balanced. Whereas 
PTKs add phosphoryl entities to proteins, PTPs remove them and by doing so potentially alter 
protein stability, the binding of adaptor proteins and the degree of enzyme activity (Zhang 
2002). PTPs have been implicated in both positive and negative regulation of T cell activation. 
The PTP family can be divided into four groups, with the two most studied being the classical 
receptor-type PTPs (e.g. CD45 and CD148) and the nonreceptor-like PTPs (PTPN22, PTPN2 and 
SHP-1). The latter are located within the cytoplasm as opposed to being membrane-bound. 
PTPs are characterised by an active site motif (H/V)CXXXXXR(S/T), where X can be any residue, 
within the conserved catalytic domain (Zhang et al. 1994). 
Tightly controlled regulation of T cell activation is crucial in preventing autoimmunity and 
pathology, both during T cell development in the thymus and in the periphery. The importance 
of PTPs has been illustrated in a range of patients with immune disorders linked to altered PTP 
expression. For example, loss of the PTP CD45 has been shown to lead to severe 
immunodeficiency disease, marked by a decrease in T cell numbers and hyporesponsiveness 
(Kung et al. 2000) and a functional polymorphism in the PTP, Lyp (PTPN22), has been shown to 
correlate with the development of different autoimmune disorders (Criswell et al. 2005).  
One downside of this tight control of T cell activation is that tumours, originating from self, are 
poor at activating T cells. Tumour cells express little immunogenic Ag, decreasing the chance of 
T cells being activated by them. Hence lowering the threshold for T cell activation by such 
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tumour Ags has been envisioned as a potential component for successful adoptive T cell 
therapy. One such key negative regulator of T cells is a PTP termed SHP-1, described in more 
detail below. 
 
1.3.3 SHP-1 structure and regulation  
SHP-1, a src homology 2 (SH2) domain containing PTP, has been shown to negatively regulate T 
cell activation. SHP-1 is thought to dephosphorylate key proteins downstream of immune 
receptors, cytokine receptors and receptor PTKs and consequently counteract the actions of 
key PTKs in the T cell signalling cascade. SHP-1 has been implicated in setting the threshold for 
T cell activation; both during development of T cells in the thymus (Carter et al. 1999; Johnson 
et al. 1999) and during an immune response (Lorenz 2009) and evidence for this will be 
discussed here. 
In 1992, the cDNAs for mouse and human SHP-1 (PTPN6) were identified by several different 
groups using reverse genetics, based on the high level of conservation of the PTP domains and 
it was shown that there is 95% homology between the SHP-1 cDNAs of the two species 
(Matthews et al. 1992; Plutzky et al. 1992a; Yi et al. 1992). The SHP-1 cDNA from a pre-B-cell 
line encoded for a 595 aa, 68 kDa protein composed of two distinct N-terminal SH2 domains 
and a C-terminal PTP catalytic domain (figure 1.6 A) (Matthews et al. 1992). It was shown that 
the SHP-1 mRNA is primarily found in haematopoietic tissues such as the BM, thymus and LNs. 
Additional studies showed that SHP-1 is mainly expressed in haematopoietic cells and less 
strongly in epithelial cells and oligodendrocytes in the brain (Massa and Wu 1996). The human 
PTPN6 gene encoding for the SHP-1 protein is located on chromosome 12 and composed of 17 
exons yielding 4 different isoforms (Plutzky et al. 1992b). The two major SHP-1 transcripts 
encode for non-haematopoietic and haematopoietic SHP-1 isoforms of 597 and 595 aa 
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respectively (Banville et al. 1995). Expression of the latter transcript is controlled by a 
downstream promoter, separated by 7 kb from the first promoter used for the non-
haematopoietic transcripts. 
The resolution of the crystal structure of a tail-truncated SHP-1 protein in the inactive state 
confirmed the presence of three main domains, namely the N-terminal SH2 (N-SH2) (residues 
1-108), the C-terminal SH2 (C-SH2) (residues 116-208) and the C-terminal catalytic PTP domain 
(residues 270-532) (Yang et al. 2003). Additionally, it was shown that inactive SHP-1 protein is 
auto-inhibitory due to a conformation where the N-SH2 domain strongly interacts with the PTP 
domain thus obstructing the entrance to the PTP active site (figure 1.6 B). This was supported 
by data showing that the N-SH2 domain was necessary and sufficient for the auto-inhibition of 
SHP-1 (Pei et al. 1996) and SHP-1 deficient in the N-SH2 domain generated more PTP activity in 
vitro than the intact full length SHP-1 (Brockdorff et al. 1999). It was hypothesised that the 
flexibility of the C-SH2 domain enables it to search the environment and recruit 
phosphopeptide ligands. Once bound to ligand, a conformational change occurs and the N-SH2 
detaches from the PTP domain and binds a second tyrosine phosphorylated residue (figure 1.6 
A). This fitted with findings that optimal phosphatase activity was only observed when both 
SH2 domains were engaged, as shown by biphosphorylated peptide inducing SHP-1 catalytic 
activity of up to 4 fold above that of monophosphorylated peptide (Pluskey et al. 1995). 
Another study showed that mutating crucial arginine residues involved with phosphoprotein 
binding led to suboptimal activation (Pei et al. 1996). The resolution of the full-length open 
conformation SHP-1 protein crystal structure confirmed this model (Wang et al. 2011) where 
upon binding to ligand, the N-SH2 domain flips around and interacts with the opposite side of 
the PTP domain (figure 1.6 C). These new interactions help to stabilise the active state of SHP-1 
and allow substrate to enter the PTP domain active site. This study did not resolve the 
structure of the C-terminal tail. 
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Figure 1.6: Model of the activation of SHP-1 by conformational changes and possible 
modifications of the C-terminal tail. A) Model of the activation of SHP-1. In the inactive/closed 
conformation, the N-SH2 domain obstructs the catalytic PTP domain (red) whereas binding of 
phosphorylated ligand (green) by both the N-SH2 (orange) and the C-SH2 (blue) domains leads 
to a rotation in the linker between both domains and the relocation of the N-SH2 to the 
opposite side of the catalytic PTP domain. This results in the stable opening of the catalytic 
domain and its accessibility to substrate. B) The structure of tail-truncated inactive SHP-1 
protein was resolved and showed the obstruction of the active PTP site (red dotted circle) by 
the N-SH2 domain.  The overlay of the SHP-1 and SHP-2 structures are shown and the picture 
was taken from (Yang et al. 2003). C) The structure of the full-length SHP-1 protein in its active 
state is shown. As opposed to B), the N-SH2 domain has flipped to the other side of the PTP 
domain, opening up the catalytic PTP domain (yellow dotted circle) to substrates. The picture 
was taken from (Wang et al. 2011). D) The C-terminal tail of SHP-1 has three potential 
phosphorylation sites (green half circle). The kinases potentially involved in phosphorylating 
Y564 and S591 are shown. Phosphorylation of tyrosines can lead to the recruitment of SH2-
domain containing molecules such as the adaptor GRB2. The potential lipid raft localisation 
sequence (SKHKED at 557-562) (Sankarshanan et al. 2007) is shown in turquoise. 
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SHP-1 PTP activity can be regulated not only by the obstruction of the catalytic domain by the 
N-SH2 domain but also by spatial separation of SHP-1 and its substrates. The SHP-1 C-terminal 
tail has been implicated in regulating the activity of SHP-1 directly, by recruiting adaptor 
proteins and by altering the cellular positioning of SHP-1 (figure 1.6 D). The C-terminal tail was 
shown to have a considerably lower degree of homology with SHP-2 than the rest of the 
molecule (<15 % versus 60 %), indicating its possibly unique function (Yang et al. 2003). The C-
terminal tail also contains a potential nuclear localisation signal (Yang et al. 2002). In non-
haematopoietic cells, the tail has been implicated with the redistribution of SHP-1 into the 
nucleus of cells stimulated with cytokines and growth factors (Yang et al. 2002; He et al. 2005). 
In T cells this has not been reported, however residues 557-562 of the C-terminal tail have 
been implicated with localisation of SHP-1 to lipid rafts (figure 1.6 D) (Fawcett and Lorenz 
2005). This study showed that in Jurkat cells and primary T cells, 20-30% of SHP-1 is located in 
lipid rafts. This lipid raft positioning of SHP-1 was shown to be vital for the inhibition of IL-2 
production by T cells, as cells expressing mutant SHP-1 lacking the lipid raft targeting motif did 
not show any inhibition (Sankarshanan et al. 2007).  
The C-terminal tail serine residue at position 591 has been shown to be phosphorylated in 
resting T cells and it is believed that phosphorylated S591 negatively regulates SHP-1 activity 
(Lorenz et al. 1994; Poole and Jones 2005). Two tyrosines, Y536 and Y564, have been shown to be 
phosphorylated and LCK was implicated in the phosphorylation of Y564 in activated T cells 
(Lorenz et al. 1994). Reports showed that the phosphorylation of Y536 and to a lesser extent 
Y564 enhances SHP-1 activity; however these studies were done with non-haematopoietic SHP-
1 (Uchida et al. 1994; Frank et al. 2004).  Phosphorylated Y536 has been proposed to recruit the 
SH2 domain containing adaptor protein GRB2 and possibly other SH2 domain containing 
molecules such as VAV1 and mSos1 (Kon-Kozlowski et al. 1996; Minoo et al. 2004). Auto-
dephosphorylation of the two tyrosine residues by SHP-1 has been shown, however not in T 
cells (Bouchard et al. 1994).  
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1.3.4 Possible SHP-1 ligands and substrates 
It is clear that SHP-1 needs to bind phospho-proteins with both SH2 domains to enable access 
of the substrate to the active site of the catalytic domain. Such ligands are found on members 
of the inhibitory-receptor superfamily (IRS) expressing immunoreceptor tyrosine-based 
inhibitory motifs (ITIMs) (V/L/IXpYXXL/V) within their cytoplasmic tails (Long 1999). Proteins 
from the IRS family inhibit activation receptors in trans by recruiting PTPs such as SHP-1 and 
bringing them into proximity of substrates. IRS members in T cells often express multiple ITIM 
motifs, enabling both SHP-1 SH2 domains to engage, resulting in a stable activation of the PTP 
(Burshtyn et al. 1997; Vely et al. 1997). SHP-1 has been shown to constitutively interact with 
leucocyte-associated immunoglobulin receptor-1 (LAIR-1), an ITIM containing inhibitory 
receptor (Sathish et al. 2001a). Recruitment of SHP-1 to these receptors might contribute to 
basal inhibitory signalling and thereby keep T cells in an inactive state. The carcinoembryonic 
antigen related cell adhesion molecule 1 (CEACAM1) is upregulated in activated T cells and 
possibly inhibits T cell activation via the recruitment of SHP-1 and the subsequent 
dephosphorylation of ZAP70 and the TCR ζ chain (Nagaishi et al. 2006; Chen et al. 2008). 
Considering the growing use of anti-CTLA-4 and anti-PD1 Abs in cancer immunotherapy, it is of 
interest to know whether SHP-1 interacts with either of the two molecules. CTLA-4 does not 
express any ITIMs but contains two tyrosines to which the SHP-1 SH2 domains could 
potentially bind. An association between SHP-1 and CTLA-4 has been reported (Guntermann 
and Alexander 2002) however there is no direct evidence of SHP-1 binding to CTLA-4 
(Yokosuka et al. 2010). As for PD-1, it was shown that SHP-1 and SHP-2 could potentially bind 
to the ITIM of PD-1 (Sathish et al. 2001a; Chemnitz et al. 2004), however only SHP-2 seems to 
interact with PD-1 in TCR activated T cells (Yokosuka et al. 2012). 
Many potential substrates for SHP-1 have been identified in leucocytes, ranging from ZAP70, 
SFKs and activatory tyrosines on receptors expressing ITAMs to adaptors such as LAT, SH2 
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domain-containing leucocyte protein (SLP-76) and VAV1 (figure 1.5) (Rhee and Veillette 2012). 
However, no direct binding partner for SHP-1 has been established in T cells. Multiple possible 
binding partners and substrates have been proposed and will be discussed below, however 
many studies have not been reproducible due to a variety of experimental settings and cell 
types used. As mentioned previously, SHP-1 is proposed to interact with GRB2 and VAV1 via 
the binding of the SH2 domains of the latter to phosphorylated tyrosines of the SHP-1 C-
terminus (Kon-Kozlowski et al. 1996). One study showed that ZAP70 interacts with SHP-1 in 
Jurkat cells transduced with both proteins and activated via TCR cross-linking. It was proposed 
that this interaction was via the binding of the SHP-1 SH2 domains to phosphorylated tyrosine 
on ZAP70 (Plas et al. 1996). This would lead to the dephosphorylation of the activating tyrosine 
on ZAP70 by SHP-1 (Brockdorff et al. 1999). Another co-expression experiment, using LCK and 
SHP-1 indicated a possible interaction between the LCK SH2 domain and the phosphorylated 
tyrosine of SHP-1, however this was done in unstimulated HEK293T cells and another study 
stated that SHP-1 did not dephosphorylate LCK (Brockdorff et al. 1999; Stefanova et al. 2003). 
As well as ZAP70 and LCK, SLP-76 has been proposed as a substrate (Binstadt et al. 1998). 
 
1.3.5 Functional implications of SHP-1 deficiency 
No individuals have been identified with mutations in the SHP-1 locus, possibly due to the 
predicted severity of such mutations and early death of the foetus. However there are a 
number of diseases where altered levels of SHP-1 have been identified. A study in multiple 
sclerosis patients showed that the haematopoietic SHP-1 promoter 2 transcript was expressed 
less in patient PBMCs when compared to healthy controls and consequently more 
phosphorylated Signal Transducer and Activator of Transcription 6 (STAT6) and STAT1 
molecules were observed (Christophi et al. 2008). This report fits in with findings in SHP-1 
deficient mice that show enhanced disease severity due to myelin basic protein degradation in 
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the central nervous system mediated by T cells (Deng et al. 2002). Low levels of SHP-1 protein 
have also been observed in some leukaemias and lymphomas in humans, probably due to 
epigenetic modifications (Zhang et al. 2000; Oka et al. 2001). Elevated SHP-1 activity was 
observed in T cells from elderly donors and downregulation of SHP-1 activity in these T cells 
enhanced T cell responsiveness, thus linking SHP-1 to the impaired activation of T cells from 
aged people (Le Page et al. 2014).  
The discovery of a natural mutation in the SHP-1 gene in mice greatly advanced the 
understanding of SHP-1 and its role in the immune system. In 1965 a recessive mutation in the 
SHP-1 gene was discovered in a mouse colony at the Jackson Laboratory (Bar Harbor, Main, 
USA) (Dickie et al. 1969). These mice were characterised by a patchy appearance of the coat 
that provides them the name of motheaten (me) (Green and Shultz 1975). As well as skin and 
foot lesions, motheaten mice manifest with, amongst other symptoms, slower growth, 
splenomegaly and premature thymic involution. These mice die at approximately of 2-4 weeks 
due to severe pneumonitis caused by a large infiltration of macrophages and neutrophils (Jiao 
et al. 1997). The me mutation, causing this lethal phenotype, is a point mutation within the 
sequence encoding for the N-SH2 domain that introduces a new splice-donor site leading to a 
premature truncation of the mRNA and a complete loss-of-function mutation. A less severe 
mutation in the SHP-1 locus is called motheaten viable (mev) and its mutation gives SHP-1 
protein levels of approximately 20% of that of wt mice. Hence, mev mice survive up to 3 times 
longer than the me mice (Shultz et al. 1984; Shultz et al. 1993). When mev mice were crossed 
with Rag-1 knockout mice it was found that the observed pathology in these mice is T and B 
cell independent (Yu et al. 1996). A third phenotype linked to a mutation in the SHP-1 locus 
was induced by exposure of mice to a mutagenic compound and this genotype was called spin 
(spontaneous inflammation) (Croker et al. 2008). The pathology associated with the spin 
genotype is less pronounced than that of mev mice. Crucially, this study showed that if these 
mice were house in a germ-free environment, no inflammation or autoimmunity was 
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observed, hence indicating that the pathology in SHP-1 deficient mice is initiated by extrinsic 
rather than intrinsic factors. Additionally, a recent paper using a conditional (floxed) SHP-1 
model in different mouse cells showed that neutrophils are responsible for the cutaneous 
inflammation whereas SHP-1 deficient DCs are responsible for the severe autoimmunity 
(Abram et al. 2013). Overall these studies illustrated the importance of SHP-1 as a negative 
regulator in immune cells. 
To generate enhanced numbers of SHP-1 deficient T cells for adoptive T cell transfer studies,  
our laboratory has  genetically crossed interleukin 1 receptor 1 knockout animals (B6.126S7-
IL1r1tm1Imx/J) with heterozygote C57BL/6J me+/- mice to generate IL-1r1-/- me/me mice 
(unpublished data). These mice survive up to 12 weeks due to a reduction in pathological 
inflammation caused by cells of the innate immune system.  
Although no obvious differences in thymic development were seen in motheaten mice (Lorenz 
et al. 1996), studies using motheaten mice expressing a transgenic TCR showed an increased in 
mature double negative T cells (Johnson et al. 1999) as well as a role for SHP-1 in setting the 
threshold for positive selection (Carter et al. 1999). This suggested that SHP-1 signalling plays a 
role in thymic T cell development. It was shown that me thymocytes showed prolonged activity 
of the PTKs, LCK and Fyn when compared to wt cells (Lorenz et al. 1996). Another group 
showed increased levels of phosphotyrosine in SHP-1 deficient T cells post TCR activation (Pani 
et al. 1996). However, this is in disagreement with studies from our own group using 
motheaten thymocytes and peripheral T cells whereby no differences in the phosphorylation 
of the CD3 ζ chain, ZAP70, SLP-76 and LAT were observed when compared to wt cells (Johnson 
et al. 1999; Sathish et al. 2001b). 
While data on the action of SHP-1 in determining phosphotyrosine levels in T cells is confusing, 
there is no doubt that loss of SHP-1 causes significant functional changes in T cells. The exact 
model of how SHP-1 is implicated in the inhibition of T cell activation and in the regulation of 
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the T cell activation threshold is still unclear and several different models have been proposed 
(Lorenz 2009). The main finding from multiple studies is that loss of SHP-1 leads to a lowered 
threshold for T cell activation and thus T cells enter proliferation more readily at lower Ag 
concentrations. It has been shown that me/me thymocytes proliferate more than their wt 
counterparts in response to anti-CD3 Ab and PHA and that the increased proliferation is not 
due to a decrease of cell death (Lorenz et al. 1996). Activated me/me T cells also produced 
more IL-2 than wt control cells. In another study, OVA specific SHP-1 deficient T cells gave an 
increased and prolonged maximal proliferation response to anti-CD3 and IL-2 or cognate 
peptide (Pani et al. 1996).  
When thymocytes were activated with anti-CD3 and anti-CD28 Ab, no difference in 
proliferation was observed between SHP-1 deficient and wt cells, whereas anti-CD3 alone did 
show significant differences (Sathish et al. 2001b). This indicates that loss of SHP-1 might 
abrogate the need for co-stimulatory signalling, needed in wt cells for optimal priming, due to 
these cells being more easily activated. This would fit earlier findings where TCR transgenic 
SHP-1 deficient T cells from peripheral LNs had elevated levels of activation markers (CD44 and 
CD25) and cells were larger in size ex vivo (Johnson et al. 1999). These T cells had not been 
exposed to cognate peptide in vivo and activation may therefore have been due to interaction 
with MHC-self-peptide complexes, usually not causing activation in T cells from SHP-1 
sufficient mice. One reason for the enhanced entrance into proliferation by motheaten T cells 
could be due to the observed increase in stable APC T cell conjugates formed by SHP-1 
deficient T cells (Sathish et al. 2007). The formation of stable conjugates requires the 
interaction of integrins and their ligands and a reorganisation of the cytoskeleton and it is 
possible that SHP-1 is acting at this level. In this same study, enhanced proliferation was also 
observed in vivo where equal numbers of wt or me T cells were injected and 6 days later, more 
T cells were recovered. Additionally, more target cell killing was observed in vivo in this model, 
most likely due to increased T cell numbers. 
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To ensure that the phenotype in me T cells is due to the intrinsic loss of SHP-1 and not due to 
altered extrinsic signalling by other SHP-1 deficient cell types, a conditional (floxed) SHP-1 
knockout was generated in T cells (Fowler et al. 2010).  Results with these CD8+ T cells 
confirmed previous findings from motheaten mice (Sathish et al. 2007) that the loss of SHP-1 
leads to an enhanced number of cells entering proliferation in vitro without altering the 
cytolytic phenotype of the cells. When mice were challenged with virus, the SHP-1 deficient 
CD8+ T cells showed enhanced proliferation in vivo and increased numbers of effector but not 
memory CD8+ T cells were recovered from both primary and secondary viral challenges (Fowler 
et al. 2010). Another study using the conditional SHP-1 knockout mice showed that there was 
no difference in IL-2 production, whereas they did confirm the enhanced proliferative potential 
of SHP-1 deficient T cells (Johnson et al. 2013).  
SHP-1 has been implicated in controlling T cell anergy, as heterozygote mev T cells caused 
encephalomyelitis when exposed to a peptide that usually induces anergy in wt T cells 
(Wasserman et al. 2008). This could be linked to the enhanced formation of conjugates with 
APCs in SHP-1 deficient cells (Sathish et al. 2007).  
SHP-1 has also been shown to alter signalling downstream of chemokine and cytokine 
receptors. One study showed that SHP-1 can dephosphorylate the IL-2βR and the downstream 
PTKs, Janus kinase 1 (Jak1) and Jak3, as catalytically inactive SHP-1 cells showed increased 
phosphorylation of these molecules (Migone et al. 1998). Migone et al. hypothesised that loss 
of SHP-1 could thus make T cells IL-2 independent as signalling via its receptor was not 
negatively regulated. Additionally, SHP-1 has been linked to controlling signalling via STAT1 
and STAT6 (Christophi et al. 2008; Johnson et al. 2013) and STAT3 (Mauldin et al. 2012). T cells 
from mev mice showed enhanced chemotaxis to stromal-cell derived factor 1 (SDF-1) and SHP-
1 deficient T cells show heightened basal actin polymerisation (Kim et al. 1999).  
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Importantly, lowering of the threshold of T cell activation could potentially increase the 
responsiveness of T cells to poorly immunogenic tumour-associated Ag. Hence, loss of SHP-1 
could be a target for ACT. To study this possibility, CD8+ T cells from conditional SHP-1 
knockout mice were used in an adoptive T cell therapy model of disseminated leukaemia and 
shown to be superior at protecting against leukaemia (Stromnes et al. 2012). Additionally, SHP-
1 deficient T cells showed enhanced proliferation during the expansion phase with elevated 
effector T cell numbers, followed by a contraction phase and equal numbers of memory cells 
when compared to wt T cells (Fowler et al. 2010). A recent study showed that SHP-1 
expression and activatory phosphorylation increased proportionally with the affinity of the TCR 
to the tumour Ag, NY-ESO-1 (Hebeisen et al. 2013), and further demonstrated that a 
pharmacological inhibitor of SHP-1 (SSG) could enhance the cytolytic function of T cells 
expressing a wide range of TCR affinities. The above mentioned sodium stibogluconate (SSG), 
in combination with IFN-α, showed promising reductions of tumour growth in mice (Yi et al. 
2002). However, clinical benefits have not been observed in phase I clinical trials of patients 
with solid tumours (Naing et al. 2011; Yi et al. 2011). Meanwhile, in these patients, a change in 
the immune cell balance was observed with fewer Tregs and more NK cells. More specific SHP-1 
inhibitors, such as tyrosine phosphatase inhibitor-1 (TPI-1) and analogues, have been identified 
and their administration has given decreased tumour growth in mice (Kundu et al. 2010). The 
absence of clinical benefit in humans could be due these inhibitors targeting both SHP-1 and 
SHP-2 and it was shown that SHP-1 and SHP-2 are functionally antagonistic in haematopoiesis 
in SHP-2 knockout/motheaten mice (Qu et al. 2001). 
In summary, SHP-1 is thought to act on many levels of T cell signalling such as downstream of 
the TCR, cytokine receptors and chemokine receptors. These findings in mouse T cells indicate 
that loss of SHP-1 might be a valid target to try and generate greater numbers of tumour-
specific CD8+ T cells for ACT.  
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1.4  L-selectin and CD8+ T cell homing 
L-selectin or CD62L is a crucial molecule for leucocyte migration during homeostatic 
recirculation, immune surveillance and inflammation. Its former name of leucocyte adhesion 
molecule-1 (LAM-1) stresses the role L-selectin plays within the leucocyte adhesion cascade 
where leucocytes are recruited by high endothelial venules (HEVs) in to lymph nodes (LNs) 
(figure 1.7). L-selectin is expressed on most leucocytes and on T cells and L-selectin 
orchestrates the initial capturing (tethering) of the T cells by HEVs. The latter are specialised in 
recruiting lymphocytes, such as L-selectin expressing naïve and memory T cells, in order to 
ensure constant immune surveillance (Girard et al. 2012). Homeostatic trafficking of L-selectin 
positive T cells via HEVs is due to the expression of peripheral node addressin (PNAd) and 
CCL21, interacting with L-selectin and CCR7 respectively on naïve and central memory CD8+ T 
cells. The importance of L-selectin is demonstrated in L-selectin deficient mice, where 
lymphocyte recruitment to peripheral LNs is dramatically decreased (Arbones et al. 1994). 
After cells tether on activated endothelial cells, signalling via L-selectin and chemokine 
receptors leads to the activation of integrins, resulting in a decrease in the rolling velocity of 
lymphocytes and their arrest on endothelial cells (Ley et al. 2007). Finally, cells will start the 
process of transendothelial migration (TEM), allowing lymphocytes to enter the LN. 
After TCR engagement, L-selectin is lost from the cell surface and T cells recovered from 
inflamed sites are L-selectin negative, thus indicating that homing to inflamed tissues is L-
selectin independent. Activation of CD8+ T cells will upregulate the expression a range of 
homing and adhesion molecules such as selectins, chemokine receptors and integrins 
(Brinkman et al. 2013). For the CD8+ T cell to access the right tissue, the vasculature needs to 
express the corresponding ligands.  
Not all T cell recruitment to secondary lymphoid tissues is L-selectin dependant. T cell 
recruitment to mucosal LNs (mesenteric LNs and Peyer’s patches) has been shown to be L-
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selectin independent and mediated via the interaction of α4β7 on T cells and mucosal 
addressin cell adhesion molecule 1 (MAdCAM-1) on endothelial cells and recruitment to the 
spleen is L-selectin independent as the latter does not express HEVs (Guarda et al. 2007; Ivetic 
2013). Additionally, L-selectin negative T cells have been shown to be able to migrate to LNs 
draining inflamed sites (Unsoeld and Pircher 2005). 
 
Figure 1.7: T cell recruitment to lymph nodes (LN) via high endothelial venules (HEVs). Under 
shear flow in LN HEVs, T cells (green) expressing L-selectin (red) will bind to their ligand (e.g.: 
PNAd) and this interaction initiates the capture of T cells from the blood stream. Engagement 
of L-selectin leads to outside-in signals which together with signals from chemokine receptors 
following engagement by chemokines presented on the luminal side of the endothelial cells 
(CCL21 on endothelial cells and CCR7 on lymphocytes in orange) will induce changes in the 
lymphocyte function-associated antigen 1 (LFA-1, purple) integrin conformation (Giblin et al. 
1997; Steeber et al. 1997; Hafezi-Moghadam et al. 2001). The engagement of L-selectin and 
chemokine receptors leads to a decrease in the T cell rolling velocity, followed by the arrest of 
the lymphocyte on the endothelium due to ICAM-1 and LFA-1 interactions. Once arrested, cells 
start transcellular or paracellular transendothelial migration. Adapted from: (Ley et al. 2007). 
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1.4.1 L-selectin protein structure, regulation and function 
L-selectin is a type I transmembrane cell adhesion molecule encoded by the SELL gene and 
found in the microvilli of T cells. It is composed of highly glycosylated extracellular domains 
which results in molecular masses ranging from 70 to 100 kDa depending on the leucocyte 
type (figure 1.8 A). The N-terminal C-type lectin domain was shown to interact with multiple 
ligands via different parts of the domain. Most ligands are glycoproteins, although glycolipids 
ligands have also been identified. The L-selectin ligands in HEVs are glycosylated mucins 
collectively known as PNAds which contain 6-sulphated sialyl Lewis X (sLex). Three known 
PNAds are CD34, GlyCAM-1 and podocalyxin. The best-defined interaction is with sialyl Lewis X 
(sLex) but it was shown that this interaction was not sufficient to support optimal rolling and 
sulphated esters and tyrosines are also needed. P-selectin glycoprotein ligand-1 (PSGL-1) is an 
L-selectin ligand which provides both binding motifs (McEver 2005). PSGL-1 is expressed on 
leucocytes and enables secondary tethering and rolling, where leucocytes tether on leucocytes 
already attached to the endothelium. This is thought to allow additional leucocyte recruitment 
when the endothelium is already covered in cells.  
During T cell recruitment by endothelial cells, bonds between L-selectin and its ligands will 
need to form and dissociate quickly. The formation of ideal interactions between L-selectin 
and its ligands is dependent on shear stress provided by the blood flow. This type of 
interaction is called a catch bond and supports L-selectin dependant tethering and rolling 
(Yago et al. 2004). It is thought that the requirement for shear stress is to prevent unwanted 
cell adhesion in low shear environments such as sinusoids, large veins and the ascending aorta. 
Additionally it will prevent leucocytes binding to each other (Finger et al. 1996). 
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Figure 1.8: L-selectin protein and proteolytic cleavage. A) L-selectin is a heavily glycosylated 
type I transmembrane protein composed of an N-terminus lectin domain, epidermal growth 
factor (EGF) domain, two short consensus repeat (SCR) units followed by a membrane 
proximal region (MPR), a transmembrane domain and a 17 aa short cytoplasmic domain.  
Proteases implicated in L-selectin proteolysis are ADAM17 for the shedding of the extracellular 
fragment (sL-selectin) and γ-secretase for the regulated intramembrane proteolysis (RIPing) of 
the membrane retained fragment (MRF). B) The human L-selectin C-terminus aa sequence is 
shown. Within the extracellular domain the ADAM17 proteolytic site was identified to be 
between K321 S322 (red arrow) and the shed sL-selectin is shown in grey (Kahn et al. 1994). 
Shedding-resistant ΔM-N L-selectin contains a truncation of 8 aa (shown in green) upstream of 
the transmembrane (TM) domain (underlined) (Chen et al. 1995). Within the cytoplasmic tail 
(shown in bold), ERM proteins (purple) interact with R357 and K362 (Ivetic et al. 2002), α-actinin 
(orange) interacts with the COOH tail (Pavalko et al. 1995) and calmodulin (blue) interacts with 
I352, L354 and L358 (Gifford et al. 2012). The importance of binding of these three intracellular 
proteins is shown for L-selectin shedding, microvillar positioning and tethering. Two possible 
phosphorylation sites are S364 and S367 (Steeber et al. 1997). The C-terminal 8 aa epitope for the 
CA21 Ab (Kahn et al. 1994) used for immunoblotting is shown. An I352 to K352 mutant (red) was 
generated and tested in this thesis. Adapted from (Ivetic et al. 2004). 
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The lectin domain is connected to an epidermal growth factor domain by a hinge region (Lou 
et al. 2006) giving the molecule more flexibility when contacting ligands under shear stress. 
Next are two short consensus repeat (SCR) units, distinguishing L-selectin from its family 
members E- and P-selectin which have 6 and 9 SCRs respectively.  
A membrane proximal region (MPR) that is highly conserved between mouse, rat and human 
follows the SCRs. In 1994, phorbol-12-mystrate-13-acetate (PMA) activated cells were shown 
to release an extracellular fragment (sL-selectin) following a proteolytic event within the MPR, 
more specifically between K321 and S322 (figure 1.8 A and B) (Kahn et al. 1994). This proteolytic 
event leaves the cells with a 6 kDa membrane retained fragment (MRF) composed of 11 
extracellular aas, 21 membrane aas and 19 intracellular aas. Shed extracellular L-selectin (sL-
selectin) can be found at high concentrations in healthy human serum (1.5-2.0 µg/ml) and was 
shown to be able to reduce lymphocyte binding to activated endothelial cells (Schleiffenbaum 
et al. 1992). sL-selectin can thus be thought of as an adhesion buffer and might prevent 
excessive inflammation and pathology. 
Small point mutations within the extracellular MPR did not alter PMA induced shedding, 
indicating that the protease involved recognises a conformational shape or length of the MPR 
rather than a specific aa sequence (Stoddart et al. 1996). This was confirmed by the inhibition 
of L-selectin shedding by more dramatic mutations within the MPR such as truncation of 15 
aas within the MPR. Another shedding-resistant L-selectin mutation is a 8 aa truncation shown 
to completely abrogate constitutive and PMA-induced L-selectin shedding (Chen et al. 1995). 
This mutant is called ΔM-N L-selectin, and was used in this thesis (figure 1.8 B).  
The first demonstration of L-selectin shedding induced by exposure to PMA was shown for 
mouse lymphocytes in 1990 (Jung and Dailey 1990). Additionally, L-selectin is rapidly shed 
from the surface of T cells after activation via the TCR (Chao et al. 1997). In a study using in 
vitro generated human tumour-specific CD8+ T cells it was shown L-selectin was shed as early 
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as 1 h into the coculture with Mel526 melanoma target cells (Yang et al. 2011). This seemed to 
correlate with the accumulation of the cytolytic degranulation marker CD107a on the cell 
surface. Furthermore, the introduction of shedding-resistant L-selectin into a CTL cell line 
showed that the lytic activity of the shedding-resistant CD8+ T cells was significantly lower than 
that of wt L-selectin expressing cells and the same was true for PMA activated cells. It was 
hypothesised that this was due to an altered cytoskeletal distribution in cells unable to shed L-
selectin. This data together with reduced viral clearance shown in mice expressing shedding-
resistant L-selectin on T cells (Richards et al. 2008) indicates that there is a possible link 
between granule mediated killing and shedding of L-selectin. 
The intracellular tail of L-selectin has been shown to bind to intracellular proteins (figure 1.8 
B). In a resting state, the tail interacts with calmodulin (Kahn et al. 1998; Gifford et al. 2012). 
Activation of cells by PMA leads to the dissociation of calmodulin from the cytoplasmic tail and 
the shedding of L-selectin, possibly due to a change in the conformation of L-selectin which 
causes the unmasking of the extracellular proteolytic target site (Kahn et al. 1998). 
Additionally, α-actinin (Pavalko et al. 1995) and ezrin and moesin (Ivetic et al. 2002) were 
found to bind to the intracellular tail of L-selectin. α-actinin binds to the membrane distal end 
of the cytoplasmic tail and connects L-selectin to the actin cytoskeleton but it is not essential 
for the positioning of L-selectin within microvilli (Pavalko et al. 1995). The microvilli positioning 
was found to depend on the ability of ezrin-radixin-moesin (ERM) molecules to bind to the 
membrane proximal region of the tail (Ivetic et al. 2004). ERM constitutively binds to the tail of 
L-selectin and abrogation of ERM binding was found to reduce PMA induced L-selectin 
shedding and tethering of cells on PSGL-1 (Killock et al. 2009). Two cytoplasmic serine residues 
(S364 and S367) can be phosphorylated when cells are activated, however phosphorylation was 
not found to be essential for cells to adhere to ligand coated surfaces (Steeber et al. 1997).  
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In accordance with the above mentioned interactions of the cytoplasmic tail, L-selectin has 
been shown to not only act as an adhesion molecule, but also as a signalling molecule. In vitro 
crosslinking of L-selectin showed that outside-in signalling can activate integrins (Giblin et al. 
1997; Steeber et al. 1997). Additionally, an in vivo homing study in mice showed reduced HEV 
egress of splenocytes treated with a spleen tyrosine kinase inhibitor, indicating that L-selectin 
is involved in outside-in signalling (Subramanian et al. 2012). 
As well as by shedding of the extracellular domain, L-selectin surface expression is controlled 
on a transcriptional and post-transcriptional level. Experiments using mouse CD4+ and CD8+ T 
cells showed that within the first 4 h after anti-CD3 Ab stimulation up to 90% of L-selectin is 
shed (Chao et al. 1997). This is followed by a superinduction of L-selectin within the next 48 h 
leading to a 3-4 fold increase above unstimulated cells in L-selectin levels. This was found to be 
due to an increase in L-selectin mRNA quantity and stability. This timing corresponds with in 
vivo activation of T cells in LNs and re-expression of L-selectin 2-3 days later, when cells have 
exited LNs (Klinger et al. 2009). Finally, over the next 3-5 days the majority of activated T cells 
will almost completely lose L-selectin expression due to transcriptional silencing (Chao et al. 
1997).  More recent studies showed that SELL gene expression is controlled by the 
transcription factor (TF) Krueppel-like factor 2 (KLF2), which in turn is controlled by the TF 
Forkhead box protein O1 (FOXO1) (Fabre et al. 2008; Kerdiles et al. 2009). Activation of human 
CD8+ T cells via the TCR or exposure to γ-chain cytokines such as IL-2 lead to the 
dephosphorylation of FOXO1, which leads to its degradation. As FOXO1 controls KLF2 
expression, a reduction in KLF2 and subsequently a loss in L-selectin gene expression is 
observed (Preston et al. 2013). This correlates with the observation that naïve and memory T 
cells have high levels of KLF2. Loss of KLF2 is reversible and levels increase once stimulatory 
signals stop. 
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1.4.2 Proteolytic processing of L-selectin 
To further understand the role of L-selectin and its function, it is crucial to understand its 
processing and regulation. As mentioned above, L-selectin is controlled at the transcriptional, 
post-translational and protein processing level. Further layers of L-selectin regulation are the 
topographic distribution of L-selectin on microvilli and the interaction with the actin 
cytoskeleton (Hasslen et al. 1995).  It was shown that this localisation is not crucial in bringing 
together the protease that induces shedding and L-selectin when cells are activated with PMA 
(Fors et al. 2001). However, L-selectin localisation to microvilli might be of importance for 
tethering and rolling on endothelial cells in the blood stream as shown by abnormal rolling 
behaviour by lymphocytes from patient with abnormal microvilli structures in in vitro flow 
assays (Burns et al. 2010).  
L-selectin shedding can be observed either constitutively to a limited extent or in response to 
ligand binding or cell activation to a much larger degree. Constitutive shedding might 
contribute to the production of sL-selectin which has been shown to function as an adhesion 
buffer within the plasma. However, no adverse effects were observed in mice where the levels 
of sL-selectin were reduced by 70% due to the shedding-resistant (LΔP) L-selectin being 
expressed on T cells (Galkina et al. 2007). 
Inducible L-selectin shedding is mediated by two main triggers in vivo. Firstly, L-selectin is shed 
when T cells tether and roll on endothelial cells in HEVs (Faveeuw et al. 2001). In homeostatic 
conditions, it was shown that L-selectin surface expression on T cells is reduced by 
approximately 70% when cells bind to and transmigrate HEVs (Klinger et al. 2009). 
Additionally, this study showed that T cells within LNs express 30% of L-selectin found on cells 
in the blood and it is only once the T cells leave the LNs that they re-express L-selectin, giving it 
a cyclical expression pattern. It was found that T cells expressing only 50% of wt L-selectin 
levels, due to genetic modifications or T cells activated with PMA or via the TCR, showed 
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reduced rolling and increased rolling velocities in vitro and more importantly fewer cells 
homed to LNs in vivo (Galkina et al. 2007). Supraphysiological L-selectin expression did not 
enhance recruitment to the LNs. It was hypothesised that L-selectin shedding releases T cells 
and enables them to migrate from the lumen towards the basal membrane into the LN. On the 
other hand, more recent studies indicated that there might be a role for L-selectin shedding 
during TEM as L-selectin shedding was shown to take place at this stage and ligands might be 
present within the basal membrane (Klinger et al. 2009). In vivo data from shedding-resistant 
(LΔP) L-selectin mouse lymphocytes suggested that the lack of shedding did not inhibit 
constitutive lymphocyte migration (Galkina et al. 2007). However, migration of activated T cells 
was altered. Additionally it was shown that absence of L-selectin shedding, by using inhibitors 
or expression of LΔP L-selectin on lymphocytes, showed slower transmigration of HEVs with 
cells being ‘stuck’ within the HEVs for longer (Faveeuw et al. 2001; Galkina et al. 2003; 
Subramanian et al. 2012). Data from our lab show that LΔP CD8+ T cells in mice home better to 
vaccinia infected ovaries than their wt counterparts as well as giving better protection in an i.p. 
vaccinia infection model and an intranasal influenza model (unpublished data, R. Mohammed). 
Secondly, L-selectin is shed in response to Ag activation in LNs. This might lead to signalling 
events altering the expression of molecules involved in the mobility of the T cells out of the 
LNs such as sphingosine-1-phosphate receptor-1 (S1P1) (Chao et al. 1997). Loss of L-selectin on 
activated T cells might redirect their migration pattern from LNs to inflamed or cancerous 
tissue. However, a study of influenza challenged mice expressing shedding-resistant or wt L-
selectin showed no differences in the recruitment of effector CD8+ T cells to the site of 
inflammation (Richards et al. 2008).   
Shedding of L-selectin was first found to be mediated by a non-soluble metalloproteinase that 
can cleave L-selectin in cis but not in trans (Preece et al. 1996). Further on, Peschon et al. 
demonstrated that the membrane-anchored metalloproteinase responsible for PMA induced 
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L-selectin shedding in mice was the disintegrin and metalloproteinase 17 (ADAM17), initially 
called TACE (TNF-α converting enzyme) for its proteolytic activity on TNF-α (Peschon et al. 
1998). ADAMs are expressed in the perinuclear membrane compartments and the cell 
membrane and subcellular compartmentalisation is an important part of their regulation (Ager 
2012). ADAMs are thought to be activated by outside-in signals. 
ADAM17 is implicated in the shedding of over thirty proteins that are structurally and 
functionally diverse, for example TNF-α, L-selectin and the amyloid-beta precursor protein 
(Smalley and Ley 2005). It is thought that ADAM17 is the main sheddase involved in PMA 
induced shedding, although ADAM10 has been shown to be able to induce shedding in 
response to ionomycin but not PMA (Le Gall et al. 2009). ADAM10 was shown to be able to 
induce suboptimal shedding in the absence of ADAM17. Additionally, it was shown that in the 
absence of functional ADAM17, basal shedding of L-selectin occurs in fibroblasts (Walcheck et 
al. 2003) indicating a further role for ADAM10, yet fibroblasts are inherently different to T 
cells.  Matrix metalloproteinase 1 and 3 (MMP1 and MMP-3) have been shown to also be able 
to cleave L-selectin and this might be the case in inflamed tissues (Preece et al. 1996).  
To study the dependence of L-selectin shedding on ADAM17, multiple inhibitors are available. 
Low specificity metalloproteinase inhibitors such as GW280264X and GI254023X were found to 
preferentially inhibit ADAM17 or ADAM10 respectively (Hundhausen et al. 2003). A much 
more specific ADAM17 inhibitor is the D1(A12) Ab generated recently (Tape et al. 2011). It has 
not been shown to date whether L-selectin shedding is mediated by direct or indirect ADAM17 
activity.  
Once the extracellular domain of L-selectin is proteolytically released, the MRF is vulnerable to 
regulated intramembrane proteolysis (RIPing). Other molecules such as IL-6 and Notch have 
been shown to undergo ADAM17 mediated proteolysis followed by RIPing by γ-secretase 
(Chalaris et al. 2010). The cytoplasmic tail of Notch but not IL-6 does, once released, act as a 
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TF. The γ-secretase is a complex composed of 4 main subunits, with presenilin 1 and presenilin 
2 being the two catalytic domains. Cleavage of the MRP is thought to occur in a stepwise 
manner with the γ-secretase cleaving every few amino acids. A γ-secretase specific inhibitor 
called DAPT has been shown to inhibit RIPing in vitro and in vivo (Dovey et al. 2001; Geling et 
al. 2002) and was used in this thesis. 
 
1.4.3 L-selectin expression and ACT 
In a study by Gattinoni et al. it was shown that early effector T cells expressing high levels of L-
selectin are superior to T cells expressing low levels of L-selectin at protecting against tumour 
growth in mice, despite the cells expressing similar levels of activation markers and not 
showing any functional differences in vitro (Gattinoni et al. 2005). Furthermore, this paper 
showed that L-selectin knockout T cells were significantly worse at protecting mice against 
tumour growth than their L-selectin expressing counterparts. This was confirmed by 
unpublished mouse data from our group, where L-selectin deficient T cells gave weaker T cell 
protection from viral infections. These data indicate that whilst L-selectin might not have a 
crucial role in vitro, L-selectin was shown to enhance homing to LNs in vivo, where T cells 
encounter peptide loaded DCs and receive homeostatic cytokine signals (Gattinoni et al. 2005).  
L-selectin could also be involved in the recruitment of T cells to tumours as many tumours 
have been shown to express HEVs (Martinet et al. 2011). High HEV density has been correlated 
with infiltration of CD8+ T cells and smaller tumour size (Martinet et al. 2012), overall indicating 
a functional role for HEVs in recruiting immune cells. This might be partly via the L-selectin 
dependant recruitment of L-selectin expressing naïve and memory T cells. Additionally, it is 
possible that tumour blood vessels express a ligand for L-selectin, however no such reports 
have been published. 
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1.5 Genetic modifications of CD8+ T cells for immunotherapy 
In 1988, the first registered human gene transfer trial was run by Rosenberg et al. where 
patients’ TILs were transduced with a retrovirus encoding a neomycin resistance gene and 
infiltration of these T cells into the tumour was studied (Rosenberg et al. 1990). A few years 
later, the first gene therapy trial aiming to replace the defective adenosine deaminase gene 
was performed in ADA-SCID children (Blaese et al. 1995). Since then over 2000 gene therapy 
trials have been registered with 64% of trials being in cancer patients 
(http://www.abedia.com/wiley/indications.php 2015) and some of these trials will have been 
discussed earlier. 
As well as delivering genes to cells, more recently it became possible to induce targeted 
mutations into genes and replace faulty genes. This is achieved using programmable nucleases 
such as zinc finger nucleases. The latter were used in this thesis and will be discussed in more 
detail below. Two other types of programmable nucleases are transcription activator like 
nucleases (TALENs) and RNA-guided DNA endonucleases (RGENs) such as CRISPR which will be 
discussed further in the final discussion. 
 
1.5.1 Discovery and design of zinc finger nucleases 
Zinc finger nucleases (ZFNs) are engineered proteins composed of two separate domains; a 
DNA binding domain and a DNA-cleavage domain (figure 1.9 A). ZFNs have been studied for 
nearly 20 years and are the first members of the set of tools we now utilise for genome 
editing. In 2011, the year of the commencement of this study, ZFNs were named the Method 
of the Year by Nature Methods (2012). 
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Figure 1.9: Zinc finger nucleases (ZFNs) as a tool for targeted genetic modifications. A) ZFNs 
are chimeric proteins composed of two main domains; the zinc finger (ZF) arrays, with each ZF 
(red) binding three nucleotides, and the FokI nuclease domain (blue). These two domains are 
connected by a short peptide linker. The catalytic FokI domain, once heterodimerised, induces 
double stranded breaks (DSBs). The spacer region, where the FokI nuclease domain can induce 
DSBs is between 5 and 7 bp long. The ZFNs shown here represent the SHP-1 specific ZFNs used 
in this thesis. They have a specificity of 30 bp (2 x 15 bp). B) and C) show the two different 
cellular responses to DSBs. B) Error prone non-homologous end joining (NHEJ) is executed by, 
amongst others, the DNA IV ligase. The repair of the DSB results in error-free repair or more 
commonly in the introduction of deletions, insertions or base substitutions (red), leading to 
loss-of-function mutations. C) Cells can fix DSBs by recombining homologous DNA (purple) 
within the region of the DSB. Delivering ZFNs and homologous donor DNA can thus be used to 
repair faulty genes or introduce new genes. 
 
The nuclease domain was isolated from the type IIS Flavobacterium okeanokoites restriction 
endonuclease (FokI), which cleaves DNA outside of its recognition sequence.  The FokI 
endonuclease is composed of a distinct DNA-cleaving domain and a separable DNA-binding 
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domain. It was shown that the FokI catalytic domain cleaves target DNA independently of the 
DNA-binding domain (Li et al. 1992). The same group showed that the DNA binding domain of 
FokI could be replaced with the DNA-binding domain of other molecules without altering the 
nuclease activity (Kim and Chandrasegaran 1994; Kim et al. 1996). 
An example of such DNA-binding proteins are zinc finger proteins (ZFPs) which, due to their 
modular structure, are attractive for the design of DNA specific chimeric nucleases. ZFPs are 
made up of an array of Cys2His2 zinc fingers, each made up of approximately 30 aas with a ββα 
architecture and an ability to bind a single zinc atom. The crystal structure of a ZFP-DNA 
complex shows that each ZF interacts with three consecutive nucleotides (Pavletich and Pabo 
1991) and these contacts are made by the alpha or recognition helix (Jantz et al. 2004). Slight 
variations in key aas give different fingers their specificity. 
In 1996, ZFNs were for the first time shown to cleave DNA in vitro (Kim et al. 1996) and in 2001 
it was shown that ZFNs can cleave DNA assembled into chromatin (Bibikova et al. 2001). The 
first ZFN was designed de novo to recognise a target gene in Drosophila (Bibikova et al. 2002). 
ZFNs are ideal for targeted gene editing as they introduce DSBs into usually inert DNA. DSBs 
are both mutagenic and recombinagenic. DSBs are dangerous to the cell as they can lead to 
cell cycle arrest, translocations, carcinogenesis and apoptosis. Therefore the cell is geared up 
to quickly repair the double helix by either non-homologous end joining (NHEJ) or homologous 
recombination (figure 1.9 B and C).  (Wyman and Kanaar 2006) 
NHEJ is an error prone mechanism wherein the cell fixes the DSB by inserting, deleting or 
substituting nucleotides (figure 1.9 B). Small insertions and deletions (indels) can lead to 
frameshifts in the coding region and transcript degradation by nonsense mediated decay. Thus 
ZFNs are used to generate ‘loss of function’ mutations by inducing NHEJ. ZFNs are able to bind 
and cut the target sequence until the possible mutations abrogate the binding site for either of 
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the two ZFNs. However, mutations can also abrogate the ZFN binding site while being in-
frame. 
Homologous recombination is a complex, high fidelity DNA repair mechanism requiring a >400-
500 bp homologous sequence of DNA (figure 1.9 C). Briefly, DNA homologous to a DNA 
sequence close to the DSB recombines with the genomic DNA and is inserted (Isalan 2012). 
To induce DSBs optimally, it was shown that the FokI nuclease domain needs to dimerise, 
either as a heterodimer or as a homodimer (Bitinaite et al. 1998; Smith et al. 2000). To reduce 
possible off-target effects, the FokI domain was modified to make it preferentially work as a 
heterodimer, thus doubling the degree of sequence specificity (Miller et al. 2007). In the study 
by Miller et al., off-target effects were reduced from 18.9% to 1.7%. ZFNs encompassing 4-6 
ZFs are thought to be ideal as anything shorter will be too unspecific whereas anything longer 
could start binding to non-specific sequences. Additionally, the sequence and length of the 
peptide linker, connecting the ZFP and the FokI nuclease, is crucial in determining the 
efficiency with which the ZFNs work and in determining the distance between the two FokI 
domains (Bibikova et al. 2001; Handel et al. 2009; Shimizu et al. 2009). Commercially available 
ZFNs have a short linker (approximately 6 aa), restricting the nuclease activity to a 5-7 bp 
spacer region (figure 1.9 A). 
Multiple steps are taken during the ZFN design process. To avoid off-target effects, the 
genome is searched using algorithms for unique sequences. For example, Sigma-Aldrich in 
combination with Sangamo Biosciences, a company designing, testing and selling ZFNs will only 
accept ZFN binding sequences that differ from any other sequence by a minimum of 4 
nucleotides. Regions of repeated sequence, single nucleotide polymorphisms and splice 
variants are generally avoided. Statistically, to generate ZFNs binding to a unique sequence in 
the genome, a recognition sequence of 16 bp or more is required. However not all DNA can be 
targeted successfully and compact chromatin structure and epigenetic DNA modifications such 
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as methylation add to the challenge of designing functional ZFNs (Carroll 2011). It was 
calculated that a functional ZFN pair can be designed for approximately every 100 bp of DNA 
(Kim et al. 2009).  
Initially, it was thought that combining any ZFs will yield a functioning ZFP. However it has 
been found that ZFs can statically hinder each other and that each new combination of ZFs 
needs to be empirically tested. Sigma-Aldrich use a dual module assembly strategy where 
modules of two ZFs from a library are combined with other ZF modules and tested for 
functionality (Moore et al. 2001). Major efforts have been made to characterise combinations 
of ZFs that will work in combination but no formal rules for the combination of ZFs have been 
identified yet (Sander et al. 2011). 
 
1.5.2 ZFN delivery 
Multiple ZFN delivery methods have been trialled in cell culture, murine embryos and whole 
organisms (Ain et al. 2014). The safest methods for ZFN delivery are so called ‘hit-and-run’ 
methods, where ZFN proteins are expressed for a short time period and ideally no genetic 
material is inserted into the host genome. ZFNs can be delivered to cells in several forms; 
purified proteins, mRNA, plasmid DNA or encoded in viral vectors. Here the mechanisms for 
ZFN delivery to human T cells will be discussed but with emphasis on lentiviral transduction as 
lentiviral ZFN delivery was chosen in this thesis. This was based on lentiviral transduction being 
a commonly used method of gene delivery and expertise in lentiviral delivery of genes to 
primary T cells being available within Cardiff University. 
The most recently developed and possibly safest delivery method is the direct delivery of 
purified ZFN proteins to cells (Gaj et al. 2012). This study showed that unmodified purified ZFN 
proteins have an intrinsic ability to cross cell membranes. In a range of human cells, including 
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primary CD4+ T cells this induced mutation levels comparable to transient transfection with 
plasmid DNA. However, toxicity was observed in CD4+ T cells when treated with high doses of 
ZFN protein. Additionally, it was shown that direct protein delivery reduced the off-target 
effect, probably by reducing ZFN half-life as ZFN degradation was observed within <4 h for 
protein delivery compared to 16-72 h for plasmid DNA delivery. A more recent report from the 
same group showed that including nuclear localisation signals within the ZFN increased the 
efficacy of delivery 13 fold and that there was little toxicity in primary T cells and 
haematopoietic stem cells (Liu et al. 2015). Additionally, two pairs of ZFNs could be delivered 
simultaneously and induce mutations simultaneously at two genetic loci. 
Electroporation, nucleofection and liposome transfection methods are widely used to deliver 
plasmid DNA (Holt et al. 2010) and mRNA (Urnov et al. 2005). Due to safety considerations, 
mRNA delivery is preferable to DNA plasmid delivery as it avoids possible integration of the 
ZFNs genes into the genome. 
Non-integrating viruses such as adenovirus and adeno-associated virus (AAVs) have been used 
to deliver ZFNs in vitro (Provasi et al. 2012) and in vivo (Li et al. 2011). Adenovirus transduction 
was shown to be transient with ZFNs being detected for no more than 3 days post-infection. 
Integrase-deficient lentiviral vectors (IDLVs) have shown successful gene targeting in human 
primary T cells with mutation rates of up to 13% (Lombardo et al. 2007; Provasi et al. 2012). 
Additionally, IDLVs have been used to deliver ZFNs to human stem cells, but only a very low 
frequency (<0.1%) of cells showed homologous recombination. Hence, not many groups have 
used this method, possibly due to low success rates.  
Integrase-proficient LV delivery is routinely used for the delivery of a variety of genes such as 
TCRs to T cells and can be used to deliver ZFNs (Provasi et al. 2012). However, LV delivery 
carries two major risks; increased off-target effects due to continuous ZFN expression and 
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potential tumourigenic integration. Integrase proficient LV delivery would thus not be a 
therapeutic option. 
 
1.5.3 ZFNs and therapeutic use in humans  
While TALENs and CRISPR are easier and quicker to use in many settings, ZFNs seem to be a 
safer option for now for therapeutic settings. Some key clinical applications in humans will be 
described below. 
The basis for the first clinical trial using ZFN modified cells was the generation of CCR5 
knockout CD4+ T cells using a CCR5 specific ZFN pair delivered by adenovirus or nucleofection 
(Perez et al. 2008). Additionally, ZFN mediated knockout of CCR5 was achieved in 
haematopoietic stem cells, giving the possibility of this technique being used for bone marrow 
transplants in the future (Holt et al. 2010). The rationale behind the ZFN mediated CCR5 
knockout is that loss of the HIV-1 co-receptor, CCR5, in a subpopulation (11-28%) of CD4+ T 
cells renders these cells more resistant to HIV-1 infection. The first clinical trial giving HIV-1 
patients in vitro ZFN modified autologous CD4+ T cells has now finished and was deemed safe 
for all 12 patients studied (Tebas et al. 2014). Additionally, phase II clinical trials are underway 
and research is being undertaken into the use of CCR5 modified haematopoietic stem cells by 
Sangamo BioSciences. 
As well as knocking out genes, ZFNs can be used to correct monogenetic diseases by employing 
the cell’s homologous recombination repair mechanism. For this purpose, a ZFN pair and a 
donor DNA sequence, encoding for the corrected gene, are delivered to the host cell. Previous 
clinical trials in X-linked severe immunodeficiency (SCID) patients showed correction of the 
defective IL-2 receptor γ-chain gene in haematopoietic stem cells using retroviral delivery. 
However, two patients developed T cell leukaemia (Hacein-Bey-Abina et al. 2003). This was 
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due to the activation of an oncogene, LMO2, by the integration of the LTR-flanked IL-2 
receptor γ-chain gene cassette. To avoid this potential eventuality, different groups have used 
ZFNs introducing targeted DSBs either into the faulty gene itself (Urnov et al. 2005; Yusa et al. 
2011) or into a safe harbour locus (Merling et al. 2015). One such ‘safe harbour’ is the AAVS1 
locus. AAVS1 has an open chromatin structure and most importantly it is flanked by insulator 
elements, thus avoiding the potential activation or disruption of neighbouring oncogenes or 
tumour-suppressor genes. 
Of interest for human cancer therapy is a study that showed the feasibility of knocking out α 
and β chains of the endogenous TCR prior to lentiviral transfer of a tumour-Ag specific TCR 
(Provasi et al. 2012). The elimination of the endogenous TCR decreased the off-target effects 
of auto-reactive cells seen in cells expressing both endogenous and exogenous TCR. 
Additionally, enhanced target cell killing was observed. In this study, the most successful 
combination of gene delivery was done in two cycles of adenoviral delivery of the ZFN pairs 
specific for either the α or β chain, followed by cell sorting of CD3- cells and LV transduction of 
either the α or β TCR gene. This study proved the feasibility of multiple genetic manipulations, 
including transient ZFN expression in T cells. 
 
1.5.4 Lentiviral vector gene delivery 
Lentiviral vectors (LVs) are members of the Retroviridae family and are commonly used to 
deliver genes for research. Furthermore, lentiviral gene delivery has been used in over 101 
clinical trials, representing 4.7% of all gene therapy trials 
(http://www.abedia.com/wiley/vectors.php 2015). There are several reasons why LVs are 
particularly good vectors for gene delivery. Firstly, LVs can carry up to approximately 8 kb of 
transgenic DNA (De Meyer et al. 2006). Secondly, LVs are able to transduce both dividing and 
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quiescent cells. Thirdly, LVs show low immunogenicity compared to AAVs for in vivo gene 
delivery. Additionally, LVs can stably integrate and provide prolonged gene expression. 
(Wanisch and Yanez-Munoz 2009) 
In the early 1990s, groups started using replication-deficient vectors derived from human 
immunodeficiency virus type 1 (HIV-1) to transduce CD4+ cells with antibiotic resistance to 
show their potential for gene delivery (Poznansky et al. 1991; Shimada et al. 1991). By 
including heterologous envelope proteins, LVs can be pseudotyped to change the vector 
tropism from CD4+ cells to a more broad range of cells. One such protein with a broad tropism 
for phospholipids is the vesicular stomatitis virus G glycoprotein (VSV-G) and VSV-G 
pseudotyped LV was used in this thesis. It has recently been shown that VSV-G pseudotyped LV 
does not transduce quiescent T cells due to the lack of expression of the VSV-G receptor, low-
density lipid receptor, in unstimulated T cells (Amirache et al. 2014). In cytokine stimulated T 
cells, receptor expression is upregulated thus allowing for efficient LV transduction. Once the 
LV enters the cell and membrane fusion occurs, single stranded RNA (ssRNA) is converted into 
double stranded DNA (dsDNA) by the reverse transcriptase delivered by the LV. The dsDNA is 
then imported to the nucleus and the transgene stably integrated into the host genome and 
this will enable persistent expression of the transgene. Depending on the promoter chosen for 
driving the expression of the transgene, cell type specific gene expression can be achieved. In 
this thesis, the spleen focus-forming virus (SFFV) or the human elongation factor (EF)-1α 
promoters were used to drive expression of transgenes from LV made using transfer vectors 
pSxW and pELN, respectively. 
One major concern about using HIV-1 based gene therapy is the generation of pathogenic 
virus. To avoid this, replication-deficient HIV-1 based LV is generated by transfection of 
packaging cells (human embryonic kidney 293T cells) with three or four distinct plasmids (2nd 
or 3rd generation LV, respectively). These plasmids only encode genes essential for structural 
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proteins and enzymes involved in infection, namely gag, pol and rev (Zufferey et al. 1998). The 
gag genomic region encodes for capsid proteins, the pol region encodes for the reverse 
transcriptase and other essential enzymes. Rev encodes a phosphoprotein whose main 
function is to bind viral mRNA, export it from the nucleus to the cytoplasm and enable 
translation. By dividing the viral genes among two or three different plasmids, safety is 
enhanced due to the increased number of recombination events needed to produce wild-type 
virus. The only genetic material that will be packaged within the virion will be that from the 
transfer vector, expressing the transgene together with a ψ packaging sequences. To further 
enhance biosafety, a mutation in the 3’ long terminal repeat (LTR) was generated to eliminate 
the endogenous enhancer activity associated with the LTR of the transfer vector (Zufferey et 
al. 1998). This mutation led to a tighter control of transgene expression, now mediated solely 
by the exogenous promoter. Additionally, it reduced the interference of the LTR with genes in 
the proximity of the integration site, thus lowering the risk of insertional mutagenesis. 
As well as the transgene and the ψ sequence, the transfer vector may also encode the Rev 
responsive element (RRE), the Woodchuck post-transcriptional regulatory element (WPRE) and 
the central polypurine tract (cPPT). The RRE enables Rev to bind and thus promotes nuclear 
export and utilisation of the mRNA. The WPRE placed downstream of the transgene enhances 
transgene expression on a posttranscriptional level (Higashimoto et al. 2007). The cPPT has 
been proposed to enhance nuclear import of the transgene and thus enhance transduction 
(Van Maele et al. 2003). 
LVs have been mapped to preferentially integrate within active genes located in the proximity 
of the nuclear membrane (Marini et al. 2015). Overall, LV integration site selection seems 
more favourable than that of other viruses as promoter regions are not usually targeted 
(Papayannakos and Daniel 2013). Nevertheless, integration of transgenes bears the risk of 
insertional mutagenesis. Considering this risk and the fact that not all gene therapy requires 
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prolonged expression of the transgene (e.g.: ZFNs), integrase-deficient LVs (IDLVs) have been 
developed. These IDLVs express deficient integrase protein due to mutations within the 
integrase gene such as the D64V mutation, used in this thesis (Yanez-Munoz et al. 2006). IDLV 
transduction has shown a reduction in integration of 3-4 logs compared to LV and is thus 
comparable to plasmid transfections (Leavitt et al. 1996). Transduction of cells with IDLV leads 
to the accumulation of double-stranded episomal DNA in the nucleus. Thus in dividing cells 
such as T cells, the transgene will be diluted out after a certain number of cell divisions, 
whereas in non-dividing cells such as hepatocytes, the transgene will persist for longer. 
In order to detect and/or select cells transduced with LV, surface markers, antibiotic resistance 
genes or fluorescent proteins can be included into the transgene cassette. To generate these 
transgene cassettes encoding for more than one protein, different methods can be used. 
Internal ribosomal entry sites (IRES) can be used to direct ribosomes to initiate translation at 
internal sites of mRNAs. However, this leads to heterogeneous levels of gene expression of 
genes placed upstream or downstream of the IRES. Another downside of IRES sequences is 
that they are large at approximately 500 bp in lengths. An alternative method to express 
multiple proteins that avoids these issues is the use of 2A ribosomal skipping peptides. These 
are 18-22 aa sequences first discovered in foot-mouth disease virus (Ryan et al. 1991) that give 
stoichiometric expression of multiple proteins from a single mRNA. During translation, the 
ribosome skips the glycine-proline peptide bond and thus two separate proteins arise from a 
single mRNA. This leaves the upstream protein with a C-terminal tail of approximately 18 aas 
and the downstream protein with a short (approximately 2 aas) N-terminal aa addition. 2A 
ribosomal skipping elements were used in the generation of transfer vectors in this thesis.  
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1.6 Hypotheses and aims of the thesis 
Work in this thesis was based on two main hypotheses. 
1. Human SHP-1 deficient CD8+ T cells are superior to SHP-1 sufficient CD8+ T cells for ACT, 
due to the loss of SHP-1 leading to a decreased threshold for T cell activation and an 
increased proportion of tumour-specific cells entering proliferation. This is based on 
studies with SHP-1 deficient T cells from motheaten mice. 
To test this hypothesis, the main aims were to: 
x Generate SHP-1 deficient human T cells using ZFNs. 
x Compare SHP-1 deficient and SHP-1 sufficient T cells for functional differences 
in in vitro experiments. 
x Compare SHP-1 deficient and SHP-1 sufficient human CD8+ T cells for 
differences in in vivo ACT experiments. 
2. Continuous expression of L-selectin on activated human T cells can enhance their 
recirculation to LNs, where survival signals are provided, and possibly to tumours, thus 
enhancing their anti-tumour effect for ACT. 
To test this hypothesis more needed to be known about the impact of continuous expression 
of L-selectin in human T cells. Thus in this thesis the aims were to: 
x Generate human T cells expressing wt and shedding-resistant L-selectin under 
an exogenous promoter. 
x Study the mechanism and signalling downstream of L-selectin shedding in 
response to TCR activation. 
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Chapter 2: Materials and Methods 
2.1 Reagents and consumables 
2.1.1 Antibiotics 
Carbenicillin and Kanamycin were purchased from Sigma-Aldrich (St. Louis, USA) and 
reconstituted to 50 mg/ml in dH2O, sterile filtered through a 0.45 µm syringe filter and stored 
at -20°C and freeze thawed no more than three times. Carbenicillin was used at a final 
concentration of 60 µg/ml and Kanamycin was used at a final concentration of 50 µg/ml. 
Penicillin and Streptomycin were purchased from Gibco LifeTechnologies (Paisley, UK) and 
used at 100 IU/ml and 100 µg/ml, respectively and stored at -20°C. 
Geneticin (G418 disulphate salt) (Sigma-Aldrich) was reconstituted to 250 mg/ml in PBS, stored 
at -80°C and used at 500 µg/ml. 
2.1.2 Cell culture media and supplements 
Roswell Park Memorial Institute medium 1640 (RPMI 1640), Dulbecco modified Eagle’s 
minimal essential media (DMEM +4.5 g/L D-Glucose, +L-Glutamine) and all cell culture 
supplements were purchased from Gibco LifeTechnologies. Unless otherwise stated, all cell 
culture medium was supplemented with penicillin (100 IU/ml), streptomycin (100 µg/ml) and 
sodium pyruvate (1 mM). Additionally, RPMI 1640 was supplemented with L-glutamine (2 
mM). 0.05% Trypsin-EDTA was used to dissociate adherent cells. 
Cells were routinely grown in 10% fetal calf serum (FCS) from LifeTechnologies or Sigma-
Aldrich. FCS was heat inactivated for 30 min at -56°C and aliquots were kept at -20°C. Hepes 
buffered solution was added at a final concentration of 10 mM to cell culture medium to 
prevent pH fluctuations. Phosphate buffered saline (PBS) was sterilised by autoclaving.  
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2.1.3 Chemical reagents 
Chemicals were purchased from Fisher Scientific (Loughborough, UK), unless otherwise stated. 
Dimethyl sulphoxide (DMSO) was bought from Sigma-Aldrich.Phorbol 12-myristate 13-acetate 
(PMA) (Sigma-Aldrich) was reconstituted to 10 mM in DMSO and stored at -20°C. The broad 
spectrum metalloproteinase inhibitors, GW280264X (GW) and GI254023X (GI), (Hundhausen et 
al. 2003), were a gift from GSK (Stevenage, UK). Stocks of GW and GI were reconstituted to 10 
mM in DMSO and stored at -20°C. DAPT (N-[N-(3,5-difluoro-phenacetyl)-L-alanyl]-S-
phenylglycine t-butyl ester, ALX-270-416) was purchased from Enzo, Life Sciences (Exeter, UK), 
reconstituted to 5 mM in DMSO and stored at -20°C. 
Phytohaemagglutinin (PHA) (ThermoScientific, Oxoid, Waltham, USA) was reconstituted to 1 
mg/ml in dH2O and stored at -80°C. 
2.1.4 Cytokines 
Recombinant human IL-15 (rhIL-15) and IL-2 (rhIL-2) were purchased from Peprotech (Rocky 
Hill, USA) and the University Hospital Wales Pharmacy (Cardiff, UK), respectively. RhIL-2 was 
produced by Novartis (Basel, Switzerland). RhIL-15 stocks were made up to 25 µg/ml in dH2O 
and 0.1% FCS and rhIL-2 was made up to 20,000 U/ml in dH2O and aliquots stored at -80°C. 
2.1.5 Distilled water (dH2O) and ultrapure water (ddH2O) 
A Millipore (Billerica, USA) reverse osmosis system in combination with a Millipore Milli-Q 
filtration through two ion exchange columns was used to obtain dH2O or ddH2O, respectively. 
For cell culture, dH20 was sterilised by autoclaving. 
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2.1.6 Peptides 
The SLYNTVATL peptide used to activate T cells expressing the gag TCR was purchased from 
Eurofins (Luxembourg, Luxembourg), reconstituted to 5 mM in DMSO and stored at -80°C. The 
EAAGIGILTV peptide used to activate T cells expressing the Mel TCR was purchased from 
Severn Biotech (Kidderminster, UK), reconstituted to 5 mM in DMSO and stored at -80°C. 
2.1.7 Plastics and tissue culture plastics 
All tissue culture flasks (T25, T75 and T175), multiwell plates (6, 24, 48 and 96) and stripettes 
were purchased from Nunc ThermoScientific. Falcon tubes were purchased from Corning 
(Corning, USA). Syringes were purchased from BD (Franklin Lakes, USA). Millex-HP filters (0.45 
µm and 0.22 µm) were purchased from Millipore. 
 
2.2 Molecular biology 
2.2.1 Restriction endonuclease digestion 
To restrict up to 20 Pg of DNA in a 50 Pl reaction, 1 Pl of each restriction endonuclease (NEB, 
Ipswich, USA) was used along with 5 Pl of 10x buffer, selected according to the manufacturer’s 
instructions. The restriction digestion was incubated for 1 h at 37°C before being analysed by 
gel electrophoresis or stored at -20°C. 
2.2.2 Gel electrophoresis 
Agarose gel was prepared by adding 0.5-2.5% of UltraPure Agarose (w/v) (Invitrogen) (table 
2.2) and ethidium bromide solution (final concentration of 0.5 Pg/ml) to 1x TBE buffer (table 
2.1). The solution was heated in a microwave until all agarose was dissolved and the gel was 
poured into Peqlab gel electrophoresis tanks (VWR, Darmstadt, Germany). The DNA sample 
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was mixed 2:1 with either bromophenol or 6x Orange Gloading buffer (table 2.1) and up to 25 
µl of DNA/loading buffer mix and 1-2 Pl of the 1 kb Plus DNA (Invitrogen) or Hyperladder ,  
(Bioline, London, UK) were added to the gel. A 120 V electric voltage was applied for 30-100 
min (table 2.2). To visualise and record gel electrophoresis results, a UV transilluminator (UVP, 
Upland, USA) was used. 
Buffer Composition and preparation 
1x TBE  0.45 M Tris, 0.45 M Boric acid, 10 mM EDTA pH 8.0 
Bromophenol loading 
buffer 
3.6 mM bromophenol blue and 1.2 M sucrose in dH2O 
 
6x Orange G loading buffer 0.25% Orange G (w/v) and 30% glycerol (v/v) in dH2O 
Table 2.1: Buffers used for gel electrophoresis. 
 
DNA size % agarose (w/v) Time of 120 V electrophoresis 
100-1000 bp 2.5% 30-60 min 
>1 kbp 1% 60-100 min 
Multiple fragments >2 kbp 0.7-0.5% 60-90 min 
Table 2.2: Electrophoresis settings for differently sized DNA fragments. 
 
2.2.3 Polymerase chain reaction (PCR) 
Distinct DNA polymerases were used for different PCR reactions. 
The proof-reading high-fidelity DNA polymerase, Phusion (NEB), was used in combination with 
the high-fidelity (HF) Phusion buffer and MgCl2. Aliquots of 100 mM dATP, dCTP, dGTP and 
dTTP (NEB) were stored at -20°C and discarded after one use. All four nucleotides were mixed 
1:1:1:1 before being added to the PCR reaction. The standard composition of the PCR reaction 
is indicated in table 2.3. Most PCR reactions had to be optimised by varying the concentrations 
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of primer, template DNA, MgCl2 and DMSO. Primers (tables in the appendix A1-3) were 
designed using CLC DNA Workbench software, purchased from Eurofins and diluted to 100 
pmol/µl in Tris-EDTA (TE) buffer. PCR cycling conditions are indicated in table 2.4 and a T 
Personal (Biometra, Goettingen, Germany) or a Peltier DNA Engine Dyad thermo cyclers was 
used. The annealing temperature for each primer pair was determined using the Tm 
temperature calculators on the NEB website. 
The ‘ready-to-use’ PCR Supermix (LifeTechnologies) contained the non-proofreading Taq 
polymerase and was used for Cel-I assays (section 2.2.7). 
Component Volume  Final 
Concentration 
dH20 Up to final volume of 50 Pl / 
5x Phusion HF buffer 10 Pl 1x 
dNTPs (100 mM each) 2 Pl 100 µM 
Forward primer (10 pmol/µl) 1.25 Pl 0.25 µM 
Reverse primer (10 pmol/µl) 1.25 Pl 0.25 µM 
Template DNA X Pl (corresponding to 5 ng to 
30 ng) 
0.1 ng/Pl to 0.4 
ng/Pl 
50 mM MgCl2 1.5 Pl 1.5 mM 
DMSO (only for hard to amplify 
template DNA) 
1 Pl to 3 Pl 1% to 3% 
Phusion DNA polymerase 0.5 Pl 0.02 U /Pl 
Table 2.3: Composition of a standard PCR reaction using the Phusion polymerase. 
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Cycle step Cycle name Temperature Time 
1 Initial denaturation 98°C 30 s 
2 Denaturation 98°C 10 s 
3 Annealing X°C 20 s 
4 Extension 72°C 25-30 s  
5 Final extension 72°C 6 min 
6 Pause 4°C hold 
Table 2.4: Cycling conditions for a standard PCR using the Phusion polymerase. Cycle steps 2 
to 4 were repeated 35 times. 
 
2.2.4 Isolation of PCR products and DNA from agarose gels  
PCR product was purified using a PureLink Quick PCR purification kit (Invitrogen) by following 
the manufacturer’s protocol. A QIAquick gel purification kit (Qiagen, Venlo, Netherlands) was 
used to purify DNA from agarose gels and the manufacturer’s instructions were followed. 
2.2.5 DNA cloning using the In-Fusion enzyme 
An In-Fusion cloning kit (Clontech, Mountain View, USA) was used to clone PCR amplified DNA 
into linearised plasmid vector. The In-Fusion enzyme induces homologous recombination 
between linearised vectors and PCR products expressing homologous 3’ and 5’ ends (figure 
2.1). The manufacturer’s protocol was followed when designing primers. Briefly, primers had a 
5’ 15 bp homology with the linearised vector and a 3’ 18-25 bp homology with the gene of 
interest.  
An In-Fusion reaction was set up as described in table 2.5. A negative control reaction was set 
up omitting the PCR product to check for spontaneous religation of the linearised vector. The 
mix was incubated at 50qC for 15 min before 1-2 µl were used to transform DH5α cells. 
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Figure 2.1: Recombination of DNA using the In-Fusion enzyme. Primers were designed, 
according to Clontech’s instructions, to have a 5’ 15 bp homology (red line) with the linearised 
vector (black open circle) and a 3’ 18-25 bp homology (orange) with the gene of interest 
(orange). The Phusion DNA polymerase was used to amplify the gene of interest, the PCR 
product purified and an In-Fusion reaction set up. Incubation at 50qC for 15 min led to 
homologous recombination (blue crosses) of the PCR product and the linearised vector 
mediated by the In-Fusion enzyme (green).  
 
Component Sample Negative control 
5x In-Fusion HD enzyme 
premix 
2 Pl 2 Pl 
Linearised plasmid vector 180-200 ng 180-200 ng 
Insert (PCR product) 80-100 ng none 
dH2O Up to final volume of 10 Pl Up to final volume of 10 Pl 
Table 2.5: Composition of an In-Fusion cloning reaction. 
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2.2.6 In vitro site-directed mutagenesis  
Site-directed mutagenesis was used to eliminate the KpnI site in the pUC-ZFN1-T2A-GFP 
plasmid and to introduce the I-K mutations into the L-selectin gene. The PfuTurbo DNA 
polymerase (Stratagene, La Jolla, USA) was used to amplify the pUC-ZFN1-T2A-GFP plasmid 
using mutagenic primers number 17 and 18 (table A1) or the pLenti-L-selectin-P2A-CD2 
plasmid using primers 64 and 65 (table A3). The PfuTurbo polymerase PCR reaction and the 
cycling conditions are shown in table 2.6 and 2.7. After confirmation of the success of the PCR 
reaction by gel electrophoresis and PCR product purification, parental methylated DNA was 
restricted by incubation with 1 Pl DpnI restriction endonuclease at 37°C for 1 h. DH5α cells 
were transformed with 2 Pl of the purified restriction digestion product and plasmids were 
sequenced to establish the successful introduction of the I-K mut. 
Components Volume per reaction 
dH20 Up to 50 Pl 
10x Pfu turbo DNA polymerase reaction buffer 5 Pl 
dNTPs (100 mM each) 1 Pl of each dNTP 
Primer 17 (10 pmol/µl) 1 µl 
Primer 18 (10 pmol/µl) 1 µl 
DNA template pUC-ZFN1-T2A-GFP Volume corresponding to 12.5 ng 
PfuTurbo DNA polymerase (2.5 U/Pl) 1 Pl 
Table 2.6: Composition of a PCR using the PfuTurbo DNA polymerase. 
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Cycle step Cycle name Temperature Time 
1 Initial denaturation 95°C 30 s 
2 Denaturation 95°C 30 s 
3 Annealing 55°C 60 s 
4 Extension 68°C 5 min 
5 Final extension 68°C 5 min 
6 Pause 4°C hold 
Table 2.7: Cycling conditions for a PCR using the PfuTurbo DNA polymerase.  Steps 2-4 were 
repeated 12 times. 
 
2.2.7 Cel-I mismatch assay 
The Cel-I mismatch assay was used to detect mutations in the SHP-1 gene of cells expressing 
ZFNs. Genomic DNA (gDNA) was extracted from cells using the GenElute Mammalian genomic 
DNA Miniprep kit (Sigma-Aldrich) and the 398 bp SHP-1 region of interest was amplified by PCR 
using 300 ng of gDNA and 20 µl of Supermix polymerase and primers 55 and 56 (table 2.8, 2.9 
and A1). To check for DNA contamination, a negative control PCR reaction was set up omitting 
gDNA. Gel electrophoresis (1% agarose gel) was used to confirm the presence of a 398 bp PCR 
product.  
Component Volume  
Supermix 20 Pl 
Primer 55 (10 pmol/µl) 1.25 Pl 
Primer 56 (10 pmol/µl) 1.25 Pl 
gDNA X Pl (corresponding to 300 ng) 
Table 2.8: Composition of a PCR reaction using Supermix for the Cel-I assay. 
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Cycle step Cycle name Temperature Time 
1 Initial denaturation 94°C 2 min 
2 Denaturation 94°C 30 s 
3 Annealing 55°C 22 s 
4 Extension 72°C 1 min 
5 Final extension 72°C 3 min 
6 Pause 4°C hold 
Table 2.9: Cycling conditions for a PCR reaction using Supermix for the Cel-I assay. Cycle steps 
2 to 4 were repeated 29 times. 
 
Next, 15 µl of the PCR product were mixed with 5 µl of sterile, nuclease-free dH2O and the mix 
of wt and possibly mutant PCR product was hybridised by heating and slow cooling using a 
thermocycler (table 2.10). The 20 µl of hybridised PCR product was mixed with components of 
the SURVEYOR Mutation detection kit (Transgenomic, Omaha, USA), more precisely 1 µl Cel-I 
nuclease, 1 µl enhancer S and 2 µl of MgCl2. The reaction was incubated at 42°C for 60 min. 
The presence of Cel-I digested PCR product, thus mutant SHP-1, was detected by resolving 18 
µl of the Cel-I assay product on a 2.5% agarose gel. As a negative control, 5-10 µl of non-
digested PCR product was also resolved. 
The approximate % of mutant SHP-1 product was determined by densiometry using ImageJ 
software. The intensities of the undigested band (398 bp) and the two Cel-I digestion bands 
(220 bp and 178 bp) were obtained as shown in figure 2.2. The following formula was used to 
determine the approximate % of cells expressing mutant SHP-1 alleles: 
𝑐𝑢𝑡 𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑠
(𝑐𝑢𝑡 + 𝑢𝑛𝑐𝑢𝑡 𝑝𝑟𝑜𝑑𝑢𝑐𝑡)⁄
2
⁄
∗ 100. 
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Cycle step Temperature Rate of temperature change Time 
1 95°C -2°C/s 10 s 
2 85°C -0.3°C/s 1 min 
3 75°C -0.3°C/s 1 min 
4 65°C -0.3°C/s 1 min 
5 55°C -0.3°C/s 1 min 
6 45°C -0.3°C/s 1 min 
7 35°C -0.3°C/s 1 min 
8 25°C -0.3°C/s 1 min 
9 4°C none Hold 
Table 2.10: Cycling conditions for the hybridisation of the 398 bp SHP-1 PCR product for the 
Cel-I assay. 
 
Figure 2.2: Analysis of the % of cells expressing mutant SHP-1 alleles using ImageJ software 
analysis of the Cel-I assay. A) Gel electrophoresis image showing a Cel-I digest of SHP-1 PCR 
product from untransduced (B) or ZFN LV transduced (C) cells. B) Densiometry plot of the area 
of interest encompassing both the undigested 398 bp and the Cel-I digested 220 bp and 178 bp 
DNA fragments. The intensity of the non-digested fragment is shown in terms of the area 
above the horizontal line (17,690). C) Densiometry plot of the same-sized area of interest as in 
B. The intensity of the undigested (18594) and the two Cel-I digested fragments (4851 and 
963) is shown as well as the calculations used to get the final % of cells expressing mutant SHP-
1 alleles. 
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2.2.8 Escherichia coli growth, transformation and clonal selection  
Competent DH5α Escherichia coli (E.coli) cells (Invitrogen, Carlsbad, USA) were stored at -80°C 
in 50 µl aliquots. DH5α cells were transformed following the manufacturer’s guidelines. Briefly, 
1-10 ng of plasmid DNA was added to 50 µl of freshly thawed DH5α cells, cells incubated on ice 
for 10 min before cells were heat shocked for 20 s at 42°C. Cells were incubated in 1 ml of LB 
broth (table 2.11) for one h at 37°C and 90-110 rpm in an orbital shaker incubator 
(Gallenkamp), before being plated onto antibiotic selection agarose plates containing either 
Carbenicillin or Kanamycin (table 2.11). Plates were incubated overnight at 37°C. Colonies with 
antibiotic resistance were picked and grown in 5-400 ml of LB broth containing antibiotic. 
Plasmid DNA was extracted from bacteria using the PureLink Quick plasmid Miniprep kit 
(Invitrogen) for up to 10 ml cultures or the PureLink HiPure plasmid filter Maxiprep kit 
(Invitrogen) for up to 400 ml cultures by following the manufacturer’s instructions. The Sorvall 
Evolution centrifuge and the SLA-3000 rotor (ThermoScientic) were used for centrifuging 
samples for the Maxiprep kit plasmid extraction. Bacterial colonies were screened by 
restriction digestion of the plasmid DNA and gel electrophoresis was used to visualise the DNA 
digestion pattern. Plasmid DNA purity (A260/280 ratio >1.8) and concentration was measured 
using the ND-1000 NanoDropTM spectrophotometer (ThermoScientific). 
Buffer or broth Composition and preparation 
LB broth 1% bacto-tryptone (w/v), 0.5% bacto-yeast (w/v), 0.17 M NaCl, adjusted 
to pH7 and sterilized by autoclaving. 
LB agar LB broth with 1.5% of agar (w/v), autoclaved and cooled down to 50°C 
before addition of antibiotics. Approximately 30 ml were poured into 
Petri dishes and left to settle at room temperature before storing at 4°C. 
Glycerol freezing 
buffer 
65% glycerol (w/v), 0.1M MgSO4 and 0.23 M Tris pH 8.0 
Table 2.11: Buffers and broths used for E. coli. growth and storage. 
 
 85 
 
2.2.9 E. coli storage 
To store bacteria, densely grown bacteria in LB broth were mixed 1:1 with glycerol freezing 
buffer (table 2.11) and stored at -80°C.  
2.2.10 TA cloning 
The pGEM-T Easy Vector system from Promega was used to perform TA cloning in order to 
establish the nature of the SHP-1 mutations within cloned cells. The manufacturer’s protocol 
was followed. Briefly, the 398 bp SHP-1 sequence encompassing both ZFN binding sites was 
PCR amplified from gDNA extracted from clones. The PCR product was column purified and a 
ligation was set up with 20 ng of purified PCR product, 50 ng pGEM-T Easy vector and 3 Weiss 
units of T4 DNA ligase and incubated at 4°C overnight. Next, bacteria were transformed with 1-
2 µl of ligation mix as described previously and bacteria plated on selection plates (LB agar 
plates with carbenicillin, 0.5 mM IPTG and 80 µg/ml X-Gal) and incubated at 37°C overnight. 8-
16 white colonies were picked and for each clone, bacteria amplified and plasmid extracted 
using a Miniprep kit as described previously. Plasmids were restriction digested with EcoRI to 
check for the presence of a SHP-1 insert and positive plasmids were sent to be sequenced 
using the T7 and SP6 primers (table A2). 70% of the TA cloning was performed by an 
intercalating BSc student Adam Clark, Cardiff University. 
2.2.11 DNA sequencing 
To verify the DNA sequences of all cloned plasmids, sequencing was conducted by the Cardiff 
University Central Biotechnology Services (Cardiff, UK) or using the Smart Seq service from 
Eurofins. Sequencing primers were purchased from Eurofins and all sequencing primers used 
are shown in tables A2 and A3 in the appendix. 
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2.2.12 Origin of transgenes 
The HIV gag TCR specific for the immunodominant HLA-A*02 restricted SLYNTVATL peptide 
was first described in 2008 (Varela-Rohena et al. 2008) and Jurkat and MOLT-3 cells expressing 
the gag TCR were provided by Dr John Bridgeman (Cardiff University, UK). 
The LV packaging plasmid encoding the Mel TCR, also called MEL5, was provided by Dr John 
Bridgeman (Cole et al. 2009). The Mel TCR recognises the HLA-A*02 restricted MART126-135 
peptide (EAAGIGILTV). 
The truncated rat CD2 (called rCD2 or CD2 throughout this thesis) (He et al. 1988) was 
provided in a plasmid from Dr John Bridgeman.  
The SHP-1 specific ZFNs were designed and purchased from Sigma-Aldrich (CKOZFN1061-1kt). 
Plasmid encoding the non-haematopoietic SHP-1 cDNA isoform (NCBI accession code 
BC002523) was purchased from ThermoScientific (MGC Human PTPN6 Sequence-Verified 
cDNA, clone 3140265). 
 
2.3 Tissue culture and LV transduction 
2.3.1 Cell lines 
Cell culture of cell lines 
All cells were grown in a humidified atmosphere at 37°C and 5% CO2 in a HERA cell Hereaus 
incubator. The Jurkat, MOLT-3, C1R, Mel526, Mel624 and HEK293T cells lines were kindly 
provided by Dr John Bridgeman.  
Leukaemic cells were routinely grown in R10 medium (table 2.12), split every 3 days and never 
grown above a density of 1.5 x 106 cells/ml. Jurkat 3 T3.5 cells, lacking TCR expression due to a 
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mutation in the TCR β chain, were lentivirally transduced with the GLuciferase NFAT reporter 
cassette and were cultured in R10 supplemented with 500 µg/ml of G418.  
HEK293T, Mel526 and Mel624 cells were cultured in D10 medium (table 2.12). Cells were split 
once they reached 80% confluency. Cells were washed with PBS, 0.05% Trypsin-EDTA solution 
was added and cells incubated for up to 5 min at 37°C before D10 was added and cells pelleted 
using a Heraeus Megafuge 4R (ThermoScientific) at 1500 rpm (491 g) for 5 min. 
Medium Composition Use 
R10 (complete 
RPMI) 
RPMI 1640 (4.5 g/L glucose), 10% FCS, 2 mM L-
Glutamine, 100 IU penicillin, 100 µg/ml 
streptomycin and 1 mM sodium pyruvate 
Culture of Jurkat, 
MOLT-3 and C1R cells 
R20 RPMI 1640 (4.5 g/L glucose), 20% FCS, 2 mM L-
Glutamine, 100 IU penicillin, 100 µg/ml 
streptomycin and 1 mM sodium pyruvate 
CD8+ T cells on day of 
isolation 
R1 RPMI 1640, 1% FCS and 10 mM Hepes L-selectin shedding 
experiments 
R2 RPMI 1640 (4.5 g/L glucose), 2% FCS, 2 mM L-
Glutamine, 100 IU penicillin, 100 µg/ml 
streptomycin and 1 mM sodium pyruvate 
Peptide activation of T 
cells 
Primary T cell 
stimulation 
medium 
R10, 15 x 106 irradiated PBMCs from three 
different donors, PHA (1 µg/ml), rhIL-2 (20 
IU/ml) and rhIL-15 (25 ng/ml) 
Stimulation of CD8+ T 
cell expansion 
Complete DMEM 
(D10) 
DMEM (4.5g/L glucose and 4.0 mM L-
Glutamine), 10% FCS, 100 IU penicillin, 100 
µg/ml streptomycin and 1 mM sodium pyruvate 
Culture of HEK293T, 
Mel526 and Mel624 
cells 
Table 2.12: Composition of cell culture media. 
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Cell cloning of cell lines 
To obtain leukaemic T cell clones, cells were resuspended in R10 at 1.25 cells/ml and 5 to 10 96 
U-bottom well plates were plated with 200 µl of cells in R10 per well. Plates were incubated 
and inspected weekly for clonal colonies. Medium was changed once the culture medium had 
changed colour. Cells were expanded by transferring them into gradually increasing volumes of 
culture medium. 
LV transduction of cell lines 
Leukaemic T cells were transduced with LV by plating 1 x 106 PBS washed cells in a 24 well 
plate and adding up to 1 ml of R10, polybrene (4 µg/ml) and varying volumes of LV. Cells were 
incubated for 24 h before the medium was replaced with fresh R10 and cells grown as normal. 
Mel526 and Mel624 cells were transduced by growing cells to 80% confluency in D10 in a 24 
well plate and by following the same protocol as described above using D10 instead of R10. 
Control cells were incubated with R10 or D10 and polybrene only. Cells were routinely 
analysed for transgene expression 72 h post transfection unless otherwise stated. 
2.3.2 Culture of human umbilical vein endothelial cells (HUVEC) 
HUVEC cells were grown in EGM-2 basal medium (Lonza, Basel, Switzerland) supplemented 
with fetal bovine serum and eight other supplements and growth factors provided in the  
EGM-2 SingleQuot supplement and growth factor kit (Lonza). Medium was incubated for 30 
min at 37°C and 5% CO2 before addition to cells. Cells were grown to 80%-90% confluency 
before splitting. 
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2.3.3 Peripheral blood monocyte cell (PBMC) isolation 
PBMC isolation 
PBMCs were isolated from fresh blood taken from healthy donors, with their consent, or from 
buffy coats obtained from the Welsh Blood Service (Pontyclun, UK). Fresh blood was diluted 
1:1 with PBS 5 mM EDTA to prevent clotting. Fresh blood and buffy coats were diluted 1:1 in 
PBS and 30 ml were carefully layered on top of a 15 ml Ficoll gradient (Lymphoprep, Alere 
Limited, Cheshire, UK). The samples were centrifuged at 2000 rpm (872 g) for 20 min. The 
breaks on the centrifuge were deactivated to not disturb the gradient. The layer of PBMCs was 
removed using a plastic Pasteur pipette, cells washed in PBS and centrifuged at 1200 rpm (314 
g) for 10 min. Red blood cells (RBC) were lysed by adding 5 ml of 1x RBC lysis (BioLegend, San 
Diego, USA) buffer for 5 min on ice. Cells were washed once more in PBS before being 
resuspended in R10 medium and counted. 
Irradiation of feeder cells 
For the generation of feeders for primary T cell cultures, PBMCs originating from three donors 
were exposed  to 30 Gy (3000 rad) of radioactivity from a Caesium137 source in a Gammacell 
1000 Elite Blood Irradiator (MDS Nordion, Ottawa, Canada), cells washed once and 
resuspended in T cell medium. 
2.3.4 Primary CD8+ T cell isolation, LV transduction and stimulation 
CD8+ T cell isolation from PBMCs by magnetic cell isolation and cell separation (MACS) 
Primary CD8+ T cells were isolated from PBMCs by following the human CD8 Microbeads MACS 
Miltenyi isolation protocol (Bergisch Gladbach, Germany). Briefly, 10 µl of CD8 Microbeads 
were added per 107 PBMCs in MACS buffer (PBS, pH 7.2, 0.5% BSA, 2 mM EDTA) and cells 
incubated for 15 min at 4°C. Cells were washed in 1-2 ml of MACS buffer per 107 cells and 
centrifuged at 1200 rpm (314 g) for 8 min. Cells were resuspended in MACS buffer and added 
 90 
 
onto a MS MACS column inserted into a MACS magnet. Unlabelled cells were washed off the 
column by three MACS buffer washings before dissociation of the column from the magnet 
and collection of CD8+ T cells. A small proportion of cells was used to check for the purity of 
the sort by flow cytometry. The remaining CD8+ T cells were incubated overnight in R20 
medium (table 2.12) at 1 x 106 cells/ml (figure 2.3). 
CD8+ T cell transduction with LV 
The following day, cells were washed, counted and plated in 48 well plates at 1 x 106 cells in 1 
ml/well of R10 medium supplemented with rhIL-2 (30 IU/ml) and 4 µg/ml of polybrene. Cells 
were activated with 25 µl of a human T-Activator CD3/28 Dynabeads (LifeTechnologies) and LV 
was added at volumes indicated in the corresponding experiments. Cells were incubated for 
two days, before starting the T cell stimulation cycle. 
CD8+ T cell stimulation and culture 
LV transduced cells were collected, washed and resuspended in 12 ml of T cell stimulation 
medium (table 2.12) in a T25 flask and the flask incubated at a 45° angle. Medium was 
replaced 3-4 days later as indicated in figure 2.3, depending on the extent of cell growth. One 
week post stimulation, 11 ml of medium was removed and replaced with 12 ml R10 medium 
supplemented with high rhIL-2 (200 UI/ml) and rhIL-15 (25 ng/ml). Cells were grown for an 
additional one or two weeks and medium was exchanged if the colour of the medium had 
changed. At this point, cells were analysed by flow cytometry, used for experiments or a new 
stimulation cycle was started. For this, 1 x 106 cells were incubated at in 12 ml of stimulation 
medium in a T25 flask. 
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Figure 2.3: Primary CD8+ T cell transduction and stimulation cycle. 
 
2.3.5 Cryopreservation of cells 
Cells were pelleted and resuspended in freezing buffer (60% FCS, 10% DMSO in RPMI 1640) at 
1-6 x 106 cells/ml and added to cryo-vials. The latter were placed into Nalgene 5100 cryo 
freezing containers (Merc Laboratory Supplies, Dorset, UK) and stored at -80°C for up to 48 h 
before being transferred to liquid nitrogen storage tanks. 
When cells were thawed from cryopreservation, vials were added to a 37°C water bath and 
once thawed, rapidly added into preheated R10 or D10 medium, pelleted by centrifugation at 
1200 rpm (314 g) for 5 min and placed into culture. 
 
2.4 Cell based techniques 
2.4.1 Cell counting by trypan blue exclusion 
Cells were mixed 1:1 with trypan blue (ThermoScientific) and live cells were counted using a 
haemocytometer (Hausser Scientific, Horsham, USA), based on the exclusion of trypan blue 
positive cells.  
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2.4.2 CaCl2 transfection of HEK293T cells, LV production and LV quantification 
LV was generated by CaCl2 transfection of HEK293T packaging cells with either three or four 
distinct plasmids (2nd or 3rd generation of LV, respectively). The 2nd generation transfer vector, 
pSxW, was used in combination with pMD29 and pCMVΔ8.91 or pCMVΔR8.74intD64V to 
generate integrase sufficient or integrase deficient LV, respectively (Demaison et al. 2002; 
Yanez-Munoz et al. 2006). The third generation transfer vector pELN was used in combination 
with pRSV.Rev, pVSV-G and pMDLg/pRRE (Richardson et al. 2008). All plasmids were resistant 
to ampicillin. 
A CaCl2 transfection protocol described below was used to produce LV and to transfect 
HEK293T cells with plasmids expressing ZFNs. Briefly, HEK293T cells were plated at 15-20 x 106 
cells in 20 ml D10 medium in a T175 flask. After 24 h, medium was removed, 12 ml of pH 7.9 
medium (table 2.13) added and 3 ml of transfection mix, made up with pH 7.1 medium, added 
carefully (table 2.13). The latter contains 30 µg of pSxW, 30 µg of 
pCMVΔ8.91/pCMVΔR8.74intD64V and 15 µg of pMD29 or 15 µg of pELN, 18 µg of pRSV.Rev, 7 
µg of pVSV-G and 18 µg of pMDLg/pRRE for the generation of 2nd or 3rd generation LVs, 
respectively. After 24 h, medium was removed and replaced with 20 ml fresh D10. 48 and 72 h 
post transfection, medium was collected, replaced with 20 ml fresh D10 and both supernatant 
collections passed through a 0.45 µm filter and stored at 4°C. Pooled supernatant was added 
to 38.5 ml Beckmann Coulter (Brea, USA) thin walled centrifugation tubes placed into a 
Beckman Coulter SW28.1 rotor and centrifuged in a Beckman Coulter Optima L-100 XP 
Ultracentrifuge at 24,000 rpm for 2 h at 4°C. After centrifugation, supernatant was discarded, 
the pellet resuspended in 3.5 ml (10x LV concentration) or 0.35 ml (100x LV concentration) of 
R10 or D10 medium, aliquoted and snap frozen on dry-ice and stored at -80°C until use. 
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Medium Composition Use 
pH 7.1 medium DMEM, 25 mM Hepes, pH adjusted to pH 7.1. 
Filtered through a 0.22 µm filter. 
Plasmid transfection 
of HEK293T 
pH 7.9 medium D10, 25 mM Hepes, pH adjusted to pH 7.9. 
Filtered through a 0.22 µm filter. 
Plasmid transfection 
of HEK293T 
Transfection mix All plasmids in a final volume of 3 ml in pH 7.1 
medium with a final CaCl2 concentration of 50 
mM. 
Plasmid transfection 
of HEK293T 
Table 2.13: Composition of media used for the CaCl2 transfection of HEK293T cells. 
 
2.4.3 LV quantification 
To quantify the LV preparations, a Lenti-X p24 rapid titre ELISA kit (Clontech Laboratories) was 
used according to the manufacturer’s instructions. All p24 ELISAs were kindly done by Dr Paul 
Michell (Cardiff University). LV preparations to be tested were lysed using Triton X-100 (Sigma-
Aldrich). 
2.4.4 Flow Cytometry 
Ab staining for live and fixed cell analysis 
2 x 105 cells/sample were resuspended in 100 µl PBS and stained with 1/1000 diluted AmCyan 
live/dead fixable stain (Invitrogen) for 30 min at 4°C. Cells were centrifuged, stained with Abs 
diluted to a final volume of 25 µl FACS buffer (PBS, 0.1% FCS) and incubated for 20 min at 4°C 
(table 2.14). Cells were washed in FACS buffer, centrifuged and fixed in 100 µl of 4% 
paraformaldehyde in PBS (ThermoScientific) for 15 min at room temperature. For analysis of 
live cells, cells were not fixed and the viability of cells was determined by adding Pacific Blue 
Cytox blue dead stain (Invitrogen) at a final dilution of 1/10000 to the cells prior to flow 
cytometric analysis. Finally, cells were resuspended in 200 µl FACS buffer and analysed on a BD 
FACS Canto II. 
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Tetramer staining of T cells 
Tetramers were used to determine the frequency T cells expressing the Mel TCR. The high 
affinity FLTGIGIITV (FLT) tetramer (5.1 µM) and the lower affinity ELAGIGLTV (ELA) tetramer 
(18 µM) were used (Ekeruche-Makinde et al. 2012). To generate PE-conjugated tetramer, the 
final volume of Streptavidin-PE (LifeTechnologies) (15.8 µl Streptavidin per 10 µg of monomer) 
was divided into 5 doses and one dose added was added every 20 min to the monomer 
(provided by Dr Matt Clement and Andrea Schauenburg, Cardiff University), on ice. Cells were 
stained with live/dead stain, washed and incubated with 40 µl FACS buffer containing 
Dasatinib at a final concentration of 50 nM (Axon Medchem, Groningen, Netherlands) for 30 
min at 37°C. 0.04-1 µg of tetramer was added to each well and cells were incubated for 15 min 
at 37°C. Next, 10 µl FACS buffer containing Abs was added (table 2.14) and cells incubated for 
20 min at 4°C, before fixation. If cells were stained for FASC or MACS sorting, the tetramer 
incubation step was done at 4°C for 30 min to prevent T cell activation. 
Compensation 
Compensation was done using Abc anti-mouse compensation beads (LifeTechnologies) 
labelled with the individual Abs used in the experiment. To compensate the live/dead stain, 
ArC reactive beads were labelled with 2 µl of AmCyan live/dead stain stock solution. Beads 
were incubated for 20-30 min at 4°C, washed and centrifuged. Beads were resuspended in 200 
µl FACS buffer and a drop of negative beads was added. Electronic compensation was done 
either using the BD Diva programme or FlowJo. 
Cell counting using Cytocount beads by flow cytometry 
Cytocount beads (Dako, Glostrup, Denmark) were used according to the manufacturer’s 
protocol to count cell populations by flow cytometry. Briefly, 20 µl of cytocount beads were 
added by reverse pipetting to 200 µl of cells in FACS buffer prior to analysis using the BD Facs 
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Canto II. The formula used to enumerate cells from the flow cytometry plots was: 
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑒𝑠𝑡
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑏𝑒𝑎𝑑𝑠⁄ ∗ 𝑏𝑒𝑎𝑑 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 ∗
𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒. 
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Specificity Conjugate Clone name 
(isotype) 
Company name, 
product code (#) 
Dilution 
CD62L/ L-
selectin 
(human) 
PE Dreg56 (IgG1,  κ) eBioscience, #12-0629-
42 
1/50 
Isotype control PE P3.6.2.8.1 (IgG1, κ) eBioscience, #12-4714-
82 
1/50 
CD19 (human) APC HIB19 (IgG1, κ) BD Pharmigen, #555415 1/25 
Isotype control APC 11711 (IgG1, κ) R&D Systems, #IC002A 1/25 
CD3 (human) FITC HIT3a (IgG2a, κ) BD Pharmigen, #555339 3/25 
Isotype control FITC 20102 (IgG2a, κ) R&D Systems, #IC003F 3/25 
TCR V beta 5a FITC 1C1 (IgG1, κ) Thermo Scientific, 
#TCR2642 
1/25 
Isotype control FITC MOPC-31C (IgG1, κ) BD Pharmigen, #550616 1/25 
CD8α (human) APC RPA-T8 (IgG1, κ) BioLegend, # 301014 1/50 
CCR7 (human) PE-Cy7 3D12 (IgG2a, κ) BD Biosciences, # 
557648 
1/50 
CD69 (human) APC FN50 (IgG1, κ) BioLegend, # 310910 1/25 
CD69 (human) PE FN50 (IgG1, κ) BioLegend, # 310906 1/25 
rCD2 PE MCA154 (IgG2a,  κ) Serotec, #MCA154PE 1/10 
rCD2 PE  OX-34 (IgG2a,  κ) BioLegend, #201305 1/100 
Isotype control PE MOPC-173 (IgG2a κ) BioLegend, #400212 1/100 
rCD2 FITC  OX-34 (IgG2a, κ)  BioLegend, #201303 1/100 
HLA-A2 (human) FITC  BB7.2 (IgG2b)  AbD Serotech, 
#MCA2090F 
1/50 
Table 2.14: Antibodies used for flow cytometry. Dilution of Ab is shown for 0.2-1 x 106 cells. 
FACS buffer was used as a diluent. 
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2.4.5 Fluorescence activated cell sorting (FACS) 
LV transduced T cells were stained with tetramer and Ab as described in section 2.4.4, not 
fixed, and filtered through a 70 µm cell strainer. Cells were run on a modified FACSAria II flow 
cytometer (BD Biosciences) by Dr Kristin Ladell or Kelly Miners (Cardiff University). After 
sorting, cells were added to prewarmed medium, centrifuged and cultured. 
2.4.6 Magnetic cell isolation and cell separation (MACS) 
LV transduced T cells were stained with PE conjugated tetramer or Ab as described in section 
2.4.4 and cells incubated with anti-PE Microbeads (Miltenyi) as described in the 
manufacturer’s protocol and in section 2.3.4. After sorting, cells were added to prewarmed 
medium, centrifuged and cultured. 
 
2.5 Protein analysis 
2.5.1 Immunoblot 
Lysis of cells for L-selectin, ZFN and SHP-1 immunoblotting 
For lysis, cells were collected, washed in PBS, counted and pelleted at 1-2 x 106 cells/well. To 
the pelleted cells, 35 µl of the complete lysis buffer was added and cells incubated for 30 min 
on ice. One Roche complete ULTRA Tablet (Basel, Switzerland) as well as a final concentration 
of 1 mM Sodium orthovanadate and 1.8 mg/ml 1,10 Phenanthroline was added to 10 ml of 
lysis buffer (25 mM Hepes pH 7.4, 150 mM NaCl, 10 mM MgCl2, 1 mM EDTA, 2% glycerol, 1% 
Triton X-100) for the detection of L-selectin and V5 tagged and 3xFlag tagged ZFN proteins. For 
the detection of SHP-1 protein, the same lysis buffer was used but other protease inhibitors 
were added (10 µg/ml Aprotinin, 10 µg/ml Leupeptin, 10 µg/ml Pepstatin A, 1 mM EDTA and 1 
mM Phenylmethylsulfonyl fluoride). Cells were centrifuged at 1500 rpm for 5 min and 15 µl of 
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supernatant added to 15 µl of 2x reducing buffer (660 mM Tris-HCl pH 6.8, 26% glycerol (v/v), 
2.1% SDS (w/v), 0.01% bromophenol blue (w/v), 5% β2-mercaptoethanol (v/v)). This was 
stored at -20°C or used immediately.  
SDS-polyacrylamide gel electrophoresis  
Proteins were resolved using NuPAGE Novex 4-12% Bis-Tris gels (Invitrogen) and a XCell 
SureLock Mini Cell system (Invitrogen) filled with 1x MES SDS running buffer (Invitrogen) 
according to the manufacturer’s protocol. Cell lysates were boiled for 5 min at 95°C and 
centrifuged at 1500 rpm for 5 min and the supernatant was added to the Bis-Tris gel. 10 µl of 
SeeBlue Plus 2 prestained protein standard (LifeTechnologies) was added as a protein ladder. 
The gels were resolved at 200 V for approximately 35 min or 60 min for SHP-1 protein 
resolution. For the 60 min running time, cooling elements were placed around the gel tank. 
Immunoblotting 
0.2 µm Immobilon-PSQ PVDF membrane (Millipore) and filter papers were soaked in dH2O, 
followed by pure methanol and finally 1x transfer buffer (1x NuPAGE transfer buffer 
(Invitrogen), 10% or 20% methanol (v/v)) for 1, 1 and 10 min respectively. Electrophoresis gels 
were removed from their casing and added to transfer sandwiches according to Invitrogen’s 
instructions. The protein transfer was done at 30 V for 60 min. 
Immuno-detection of proteins 
The PVDF membrane was removed from the blotting sandwich and incubated with blocking 
buffer (PBS, 5% non-skimmed milk) for 1 h at room temperature. All incubations were done on 
a rocker. To probe for L-selectin, ZFN or SHP-1 proteins, the membrane was incubated with 
blocking buffer containing primary Ab (table 2.15) overnight at 4°C. The following day, the 
membrane was washed 3x 10 min in washing buffer (PBS, 0.05% Tween 20) and the membrane 
incubated for 1 h in blocking buffer. Secondary Ab (table 2.15) was added to the blocking 
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buffer and incubated for 1 h before the membrane was washed 3x 10 min with wash buffer. In 
a dark room, the membrane was covered in SuperSignal West Pico Chemiluminescence 
developing solution (1:1 mix of Peroxide and Luminol/enhancer, ThermoScientific) and 
incubated for 1 min, before the liquid was drained and the membrane sealed in a cling film 
sleeve. Photographic film (GE Healthcare, Little Chalfont, UK) was exposed to the membrane 
for the indicated amount of time (10 s to 30 min) and the films developed using a Compact X2 
Processor (X-Ograph Ltd, Wiltshire, UK). 
Specificity Origin Concentration 
V5 tag Sigma-Aldrich, monoclonal 
mouse 
1/2500 
HRP-conjugated 3xFlag tag Sigma-Aldrich, monoclonal 
mouse 
1/2500 
SHP-1, SH2 domain Polyclonal rabbit antiserum 
made by Dr James Matthews 
1/1000 
L-selectin (CA21), cytoplasmic domain Monoclonal mouse IgG, 
(Kahn et al. 1994) 
1/400 
Actin Sigma-Aldrich, monoclonal 
rabbit 
1/3000 
GAPDH Sigma-Aldrich , monoclonal 
mouse 
1/3000 
Secondary HRP-conjugated anti rabbit IgG 
(H +L) 
BioRad, monoclonal goat 1/2500 
Secondary HRP-conjugated goat anti-
mouse IgG (H+L)  
BioRad, monoclonal goat 1/2500 
Table 2.15: Abs used for the detection of proteins by immunoblotting. 
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2.5.2 Luciferase assay 
Luciferase protein in the supernatant was measured using the BioLux GLuciferase assay (NEB) 
by following the manufacturer’s instructions. Briefly, the BioLux assay buffer was mixed with 
the substrate at a 100:1 ratio and 25 µl added to each well of a white walled half-area 96 well 
plate (Corning). 5 µl of culture supernatant was added quickly to each well and a FLUOstar 
Optima spectrometer (BMG Labtech, Offenburg, Germany), set to read luminescence, used to 
read the GLuciferase activity. 
 
2.6 In vitro functional assays 
2.6.1 Leukaemic T cell activation 
For L-selectin shedding experiments, cells were incubated in R1 medium (table 2.12) and for 
other experiments R2 medium was used.  
PMA activation of leukaemic T cells 
1 x 106 gag+ MOLT-3 or Jurkat cells were resuspended in 100 µl/well of medium supplemented 
with PMA (SIGMA, USA) or equivalent volumes of DMSO in 96 well U-bottom plates and 
incubated at 37°C, 5% CO2 for 30 min, unless otherwise stated. The final concentration of PMA 
was 300 nM and 500 nM for MOLT-3 and Jurkat cells, respectively, unless otherwise indicated. 
To study the effect of shedding inhibitors, cells were incubated at 37°C, 5% CO2 in R1 medium 
containing the indicated concentrations of GW or GI for 30 min or D1(A12) Ab for 60 min, 
before PMA was added to the medium. DMSO and IgG Ab were used as negative controls 
respectively. Cells were washed in cold PBS and stained with live/dead marker, anti-L-selectin 
Ab and if indicated, anti-CD69 or anti-TCRV5β Ab for flow cytometry (table 2.14). Stocks of 
ADAM-17 specific inhibitory Ab D1(A12) (Tape et al. 2011) were kept at 10 µM at -80 °C. The % 
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of L-selectin expression was calculated relative to DMSO treated cells, after subtracting the 
isotype or FMO MFI from all samples:  
%𝐿 − 𝑠𝑒𝑙𝑒𝑐𝑡𝑖𝑛 = 100 ∗ 𝑀𝐹𝐼 𝑠𝑎𝑚𝑝𝑙𝑒−𝑀𝐹𝐼 𝑖𝑠𝑜𝑡𝑦𝑝𝑒 𝑜𝑟 𝐹𝑀𝑂𝑀𝐹𝐼 𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠−𝑀𝐹𝐼 𝑖𝑠𝑜𝑡𝑦𝑝𝑒 𝑜𝑟 𝐹𝑀𝑂 
 
Cognate peptide and CD3/28 Dynabead activation of leukaemic T cells 
CD3/28 Dynabeads were used to induce L-selectin shedding for immunoblot analysis. Briefly, 
25 µl of washed Dynabeads were incubated with 1 x 106 T cells in 100 µl/well of medium in a 
96 well U-bottom plate for 1 h, before cells were centrifuged and lysed as described in section 
2.5.1. 
L-selectin shedding and TCR downregulation in response to cognate peptide stimulation were 
studied using SLYNTVATL peptide to activate gag TCR expressing cells and EAAGIGILTV to 
activate MEL TCR expressing cells. T cells and HLA-A2+ C1R APCs were rested overnight in R2 
medium (table 2.12) at 0.9 x 106 cells/ml. The following day, C1R cells were resuspended to 5 x 
105 cells/ml in R2 medium, in the presence or absence of SLY or EAA peptide (10-4 M to 10-8 M) 
and 100 µl of the cells added into wells of a 96 well U-bottom plate. All peptide concentrations 
were set up in triplicates and cells were incubated for 1 h at 37°C before being washed once in 
R2 medium. MOLT-3 or Jurkat cells were added in 100 µl of 1.5 x 106 cells/ml in R2 medium, 
giving a final 3:1 ratio of effector:target cells. The cells were incubated for 1 h at 37°C, washed 
and stained with Abs for flow cytometry. To study the effect of shedding inhibitors, T cells 
were preincubated with GW, GI or D1(A12) for 30 min or 60 min, respectively and T cells in the 
R2 medium containing the inhibitors added to washed C1R cells in no medium. 
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 NFAT Jurkat cell activation 
Jurkat cells were rested overnight in R2 medium. The next day, 1 x 105 cells were incubated in 
100 µl/well D10 medium with PMA/Ionomycin (81 nM / 669 nM), PHA (1 µg/ml) or equivalent 
volumes of DMSO in a 96 well U-bottom plate. 1 x 105 Jurkat cells were incubated with the 
equivalent of 1:1, 3:1 and 5:1 E:T ratios of Mel526 and Mel624 cells in a final volume of 100 µl 
D10. All conditions were set up in duplicates and cells incubated for 18 h at 37°C. Cells were 
centrifuged, the supernatant collected for the luciferase assay (section 2.5.2) and cells stained 
for flow cytometry. 
2.6.2 CFSE dilution assay 
CFSE was kept at a stock concentration of 5 mM at -20°C. Single cell suspensions was of 
unstimulated and stimulated MOLT-3 and Jurkat cells were prepared and resuspended at up to 
4 x 106 cells/ml in PBS 0.1% FCS. A 2x working solution of CFSE (1 µM) in PBS 0.1% FCS was 
added to cells at a 1:1 ratio and cells mixed by pipetting. Cells were incubated for 10 min at 
37°C in the dark. To quench the reaction, 1ml of ice cold R10 medium was added and cells left 
on ice for 5 min before centrifugation. Cells were washed twice in R10, counted and incubated 
at 0.7 x 106 cells per well in 1 ml R10 medium in a 48 well plate. To determine the level of 
staining at day 0, 2 x 105 of the labelled cells were fixed and analysed by flow cytometry. Cells 
from one well per condition were thereafter collected every 24 h, fixed and analysed by flow 
cytometry. Due to the frequent division of the leukaemic cells, cells were split every 2-3 days 
at a 1:3 ratio. 
2.6.3 Killing assay using primary CD8+ T cells and Mel526 cells 
On day 0, 200 µl/well of 4 x 106 cells/ml RFP-GLuciferase+ Mel526 cells were plated in D10 
medium in a 96 flat-bottom well plate and primary CD8+ T cells rested in R10 medium without 
cytokines. The following day, CD8+ T cells were counted and resuspended in R10, rhIL-2 (20 
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IU/ml) and 10 mM Hepes. The D10 medium was removed from the Mel526 cells and T cells 
added to the adherent Mel526 cells in a final volume of 200 µl, to give final E:T ratios of 0.3:1 
to 10:1. T cells at the start of the experiment were analysed by flow cytometry for CD2 and 
TCR expression and counted using cytocount beads. All conditions were set up in triplicate and 
wells without T cells and without Mel526 were set up as controls. Supernatant was collected at 
the indicated times and assayed for luciferase (section 2.5.2). To generate the 100% lysis 
control, Mel526 cells from three wells of ‘Mel526 cells only’ were detached and lysed by 
freeze/thawing three times using dry ice and a 37°C waterbath. The % of killing was obtained 
using the following formula: 
% 𝑙𝑦𝑠𝑖𝑠 =  100 ∗ 𝑙𝑢𝑐𝑖𝑓𝑒𝑟𝑎𝑠𝑒 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒−𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑𝑚𝑒𝑎𝑛 𝑙𝑢𝑐𝑖𝑓𝑒𝑟𝑎𝑠𝑒 𝑜𝑓 (3 𝑙𝑦𝑠𝑖𝑠 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑤𝑒𝑙𝑙𝑠−𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑).  
At the end of the experiment, all non-adherent cells were collected and analysed by flow 
cytometry. At each time point, a representative well for each condition was photographed at 
4x and 10x magnification using the Evos XL Core cell imaging system (LifeTechnologies). 
2.6.4 In vitro flow assay 
The in vitro flow assay was done at King’s College in collaboration with Dr Aleksandar Ivetic. 35 
mm coverslips were coated with 10 µg/ml of fibronectin for 1 h at 37°C, 5% CO2. HUVEC cells 
were collected and plated onto the coverslips and grown for approximately three days until 
confluent. HUVECs were stimulated with 10 ng/ml TNF-α for 4 h at 37°, 5% CO2. MOLT-3 cells 
were resuspended at 0.5 x 106 cells/ml in R10 medium, 10 mM Hepes. The GlycoTec flow 
chamber (Glycotech, Gaithersburg, USA) with a 200 µm gasket was attached to two tubes, one 
connected to a Harvard pump and the other tube immersed in the MOLT-3 cell suspension 
(figure 2.4). The flow chamber was carefully mounted onto the HUVEC coated coverslip and 
the vacuum started to create an isolated flow chamber.  The latter was mounted onto the 
microscope slide holder, the Harvard pump set to generate a shear stress of 1.2 dyn/cm2 and 
the flow started. The inverted microscope was surrounded by a heated chamber keeping cells 
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at 37°C. A 10x magnification objective was used and an automated camera was set to acquire 
one picture every 15 s from 4 areas per coverslide for a total of 15-20 min. The programme 
used to control the camera and acquire images was Volocity (PerkinElmer, Waltham, USA) and 
images were saved as TIFF files. 
Figure 2.4: In vitro flow assay. The flow chamber was mounted onto a coverslip coated with 
TNF-α activated HUVEC cells (purple) and the vacuum (blue arrows) was activated to create 
the isolated flow chamber. MOLT-3 cells (red) flow over the HUVEC cells due to suction (red 
arrow) generated by the Harvard pump attached to the right tube.  
 
 
2.7 In vivo experiments 
2.7.1 Animal husbandry 
NOD-SCID mice were kindly provided by Dr Susan Wong (Cardiff University, UK) who has 
maintained a colony for the last 15 years. The colony originated from the Jackson Laboratory 
(Maine, USA) and the full genotype is NOD.CB17-Prkdcscid/J. All NOD-SCID mice used were male 
and age-matched within experiments. NOD-SCID mice were aged between 7 and 13 weeks at 
the start of the experiments. NSG (NOD.Cg-Prkdcscid IL-2rgtm1Wjl/SzJ) mice were purchased from 
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Charles River (Kent, UK) and received at 8 weeks of age. Female NSG mice were used for 
experiments and all mice were age matched within experiments. Mice were used for 
experiments 2-9 weeks post arrival at the Cardiff University facility. Animals were treated 
according to the UK Home Office laws under the project licence of Dr Ann Ager (PPL 30/3188) 
and the personal licence holder PIL 30/9878. All mice were housed in pathogen free 
Scantainers at the Cardiff University Heath Park facilities. Sentinel health screens of mice were 
done every three months. At the end of experiments or when mice were ill, mice were culled 
using CO2 asphyxiation and dissociation of the neck, according to schedule 1. 
2.7.2 Experimental procedures with mice 
The left flank of mice was injected subcutaneously with 200 µl sterile saline solution containing 
between 0.5-15 x 106 DsRed+ Mel526 cells. The area of injection was shaved before injection, 
and regularly thereafter, to enable better DsRed signal detection. For adoptive cell therapy 
experiments, 200 µl sterile saline containing up to 5.7 x 106 human CD8+ T cells were 
administered intravenously. For experiments requiring host leucocyte depletion, mice were 
exposed to 2 Gy radioactivity from a Caesium137 source in a Gammacell 1000 Elite Blood 
Irradiator (MDS Nordion, Ottawa, Canada). 
2.7.3 Tumour growth monitoring in vivo 
For imaging of DsRed tumour growth, mice were anaesthetised with isoflurane and white light 
and fluorescence pictures taken using a Bruker In-Vivo FX-Pro imaging system (CBS, Cardiff 
University). Overlays of the white light and fluorescent pictures and analysis of the DsRed 
signal strength was done using the Carestream MI SE molecular imaging analysis programme 
(Bruker, Massachusetts, USA). The excitation and emission wavelengths for DsRed detection 
are 550 and 580 nm and the excitation and emission filters used were 550 and 600 nm, 
respectively. The DsRed signal intensity was calculated by setting a fixed size region of interest 
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(ROI) around the tumour and one around the thorax of each mouse (background) and 
subtracting the sum intensity for the background ROI from the tumour ROI. The background 
ROI was not shaved and thus in some cases gave a higher background to the shaved tumour 
ROI. 
Calliper measurements of tumours were done on a regular basis by measuring the height, 
width and depth (if big enough) of the tumour. Mice were weighed regularly and weights 
recorded. Tumour area was calculated using a formula requiring only height and width (1.33 ∗
𝜋 ∗ ℎ𝑒𝑖𝑔ℎ𝑡 ∗ 𝑤𝑖𝑑𝑡ℎ) or a second formula taking into account the depth of the tumour 
(𝜋 6⁄  ∗ ℎ𝑒𝑖𝑔ℎ𝑡 ∗  𝑤𝑖𝑑𝑡ℎ ∗ 𝑑𝑒𝑝𝑡ℎ) was used to calculate tumour volume. 
2.7.4 Organ harvest and processing 
At the end of an experiment, mice were culled and tumours collected. Tumours were weighed 
and whole tumours fixed in 4% paraformaldehyde for histology. If adoptive T cell transfers 
were done, blood was harvested by cardiac puncture and collected into 700 µl of 13 mM 
sodium citrate dihydrate to prevent clotting. Additionally, the spleen, lungs, tumour draining 
LN and the tumour were harvested. In one experiment, the mesenteric, axillary, brachial and 
inguinal LNs were also collected. A single cell suspension was obtained by physically 
dissociating the organs on a 70 µm Nylon mesh (Fisher Scientific, New Hampshire, USA). Large 
tumours were cut into half, one half was fixed for histology and the rest was dissociated, 
washed in PBS and added to a Ficoll gradient to isolate lymphocytes. Briefly, 7 ml of Ficoll was 
added to tubes and 2-3 ml of the tumour cells in PBS added carefully before a spinning of the 
cells at 2000 rpm for 20 min and collecting the lymphocyte layer. Spleens, blood and some 
tumour samples were incubated for 5 min on ice with RBC lysis buffer, before washing with 
PBS. Once all cells were washed, cells were stained for flow cytometry. 
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2.8 Statistical analysis 
All statistical analysis was done using Prism 5. Two-way ANOVA tests were done using the 
Bonferroni post-test. Tumour growth rates (k) were obtained by calculating the exponential 
growth equation of the nonlinear regression and obtaining the rate constant, k. A one-way 
ANOVA test with a Tuckey post-hoc test was used to analyse differences between tumour 
growth rates. Correlations between tumour area and/or DsRed and/or tumour weight were 
obtained by doing a Spearman correlation test (for non-parametric data) or a Pearson test (for 
data of Gaussian distribution as determined by a D’ Agostino and Pearson test). The 
correlation coefficient ‘r’ was obtained from these tests. 
 
2.9 Software used for data collection and analysis 
DNA sequence data was analysis using the CLC DNA Workbench 7 programme (CLC bio by 
Qiagen, Venlo Netherlands). GraphPad Prism 5 (GraphPad Software, La Jolla, USA) was used to 
plot graphs and for statistical analysis. Flow cytometry data was acquired using the BD 
FACSDiva Software (BD Biosciences, Franklin Lakes, USA) and analysed using FlowJo V10 
(Ashland, USA). To quantify the Cel-I DNA restriction fragments and immunoblot signals, 
ImageJ software was used (NIH, USA). Fluorescent images of mice were analysed using the 
Carestream MI SE molecular imaging analysis programme (Bruker, Massachusetts, USA). 
Annealing temperatures were determined using online calculation tools, such as the Tm 
calculator from NEB (http://tmcalculator.neb.com/#!/). 
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Chapter 3: Generation of SHP-1 deficient human 
leukaemic T cells 
3.1 Introduction 
It has been shown that mouse CD8+ T cells deficient in SH2 domain-containing phosphatase-1 
(SHP-1) more readily form conjugates with antigen presenting cells (APCs) and more likely 
enter into proliferation in response to cognate peptide stimulation than control T cells (Sathish 
et al. 2007). In order to generate human SHP-1 deficient CD8+ T cells, it was decided to ablate 
the SHP-1 gene expressed in human T cells via delivery of two SHP-1 specific zinc finger 
nucleases (ZFNs); ZFN1 and ZFN2. The SHP-1 gene specific ZFNs are each composed of 5 ZFs 
recognising a distinct 15 bp (figure 1.9 A). The latter were designed, verified and purchased 
from Sigma-Aldrich (CKOZFN1061-1kt) in order to potentially introduce double stranded 
breaks within the first intron exon junction of exon 8 of the SHP-1 gene (figure 3.1). At the 
commencement of this study, lentiviral delivery of the ZFNs was estimated to be the best 
option. 
In this study, we initially chose two leukaemic T cell lines expressing a human 
immunodeficiency virus-1 (HIV-1) Gag p17 (77-85) (SLYNTVATL) specific TCR (gag+) to establish 
a robust model for ZFN delivery and for the detection of mutations (Varela-Rohena et al. 
2008). The initial plan to deliver the two SHP-1 specific ZFNs together with a detectable surface 
marker, rat CD2 (rCD2 or CD2), in one single lentivirus (LV) proved to be ineffective in 
generating SHP-1 deficient T cells. It was therefore required to generate two LVs, each 
expressing one of the required pair of SHP-1 ZFNs. Additionally, the efficiency of gene delivery 
using LV and integrase-deficient LV (IDLV) was compared. 
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All primers used in this chapter, for cloning or sequencing, are listed in the appendix (tables A1 
and A2) as are the sequences of all lentiviral transfer plasmids (appendix A2). 
 
Figure 3.1: SHP-1 gene and protein sequence and ZFN binding sites. The hematopoietic PTPN-
6 or SHP-1 isoform utilises promoter 2 of exon 2 (red box) leading to a SHP-1 protein 2 aa 
shorter than the non-hematopoietic isoform utilising promoter 1 of exon 1. The SHP-1 gene is 
composed of 17 exons and the binding sites for ZFN1 and ZFN2 (grey) are in the intron 
preceding exon 8 and within exon 8 respectively. The SHP-1 specific ZFNs were designed to 
introduce double stranded breaks within an exon intron junction that would lead to mutations 
in the SHP-1 gene upstream of the protein tyrosine phosphatase catalytic domain (dark red). 
The primer pair 55 and 56 (orange boxes) was used to PCR amplify a 398 bp SHP-1 DNA 
sequence encompassing the site of potential mutation. Mutations introduced in the ZFN 
cutting region can potentially lead to loss of SHP-1 protein expression due to splicing errors 
and frame shifts. The introduction of premature stop codons will lead to the loss of the 
catalytic protein tyrosine phosphatase domain (dark red) downstream of the two SH2 binding 
domains (blue). The NCBI accession numbers are: ID 5777 (gene), NM_002831.5 (mRNA) and 
NP_002822.2 (peptide). 
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3.2 Generation of a single lentiviral transfer plasmid encoding both SHP-
1 specific ZFN1 and ZFN2 
In order to generate SHP-1 mutant cells, LV encoding the SHP-1 specific ZFNS had to be made 
and cells transduced with the LV. 
A DNA cassette encoding both SHP-1 gene-specific ZFN sequences and a rat CD2 (CD2) surface 
marker was generated where the three genes were separated by two 2A sequences (de Felipe 
et al. 2006), T2A and P2A (table 3.1), generating the ZFN1-T2A-ZFN2-P2A-CD2 gene cassette, 
from here onwards termed ZFN1/2-CD2. Stoichiometric gene expression was intended by using 
the T2A and P2A sequences. The ZFN1/2-CD2 gene cassette was introduced into the HIV based 
lentiviral transfer vector, pSxW, also referred to as pLenti (Demaison et al. 2002). Figure 3.2 
outlines the five sub-cloning steps required to obtain the final pLenti-ZFN1/2-CD2 plasmid. 
 
Nucleotide sequence 
Amino acid 
sequence 
T2A 
 
AGCGGCAGCGGGCGCAGCGGCAGCGGCGAAGGCCGCGGCAGC
CTGCTGACCTGCGGCGATGTGGAAGAAAACCCTGGCCCGCGC 
SGSGRSGSGEGRGSL
LTCGDVEENPGPR 
P2A 
 
AGCGGCTCCGGTGCCACCAACTTCTCTCTGCTGAAGCAGGCCGG
GGATGTCGAAGAGAATCCAGGCCCC 
SGSGATNFSLLKQAG
DVEENPGP 
Table 3.1: Nucleotide and amino acid sequence of the T2A and P2A ribosomal skipping 
elements used in the pLenti-ZFN1/2-CD2 plasmid. The P2A sequence originates from the 
porcine teschovirus-1 whereas T2A is isolated from the Thosea asigna virus (de Felipe et al. 
2006). Underlined amino acid sequences indicate the original sequence of the 2A and bold GSG 
sequences were added to improve cleavage efficiency. The ribosomal skipping arises between 
the Glycine and Proline, highlighted in red. 
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Figure 3.2: Cloning strategy to generate the lentiviral transfer vector pLenti-ZFN1/2-CD2. The 
pUC19-RFP-T2A-GFP plasmid was used to clone the ZFN1-T2A-ZFN2-P2A-CD2 cassette before it 
was introduced into the pLenti plasmid. First, an XbaI and XhoI double restriction digest 
allowed for the ZFN1 (green) to be introduced into the plasmid. The KpnI site within the ZFN1 
sequence (orange) in the pUC19-ZFN1-T2A-GFP was removed by site-directed mutagenesis to 
enable a KpnI and NotI double restriction digest and allow for the ZFN2 (blue) to be inserted 
into the vector. A single restriction digest of pUC19-ZFN1-T2A-ZFN2 with NotI allowed for the 
P2A-CD2 sequence to be inserted. Finally, the ZFN1/2-CD2 gene cassette was inserted into the 
lentiviral transfer vector, pLenti. 
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The ZFN1 gene was PCR amplified from the plasmids provided by SIGMA using primers 9 and 
10 (table A1) and introduced into the pUC19-RFP-T2A-GFP vector (made by Dr Pratigya 
Gautam) using the In-Fusion cloning technique (figure 3.3). Primer 9 introduced a Kozak 
consensus sequence (GCCGCCACC) upstream of the ZFN1 start codon. The T2A sequence of 
the pUC19-RFP-T2A-GFP vector has an additional amino acid sequence of SGSGRS upstream of 
the T2A and an additional R downstream, which do not influence the ribosomal skipping. The 
nucleotide sequence of the pUC19-ZFN1-T2A-GFP plasmid was confirmed by DNA sequencing 
using primers 11-16 (table A2). 
Figure 3.3: Cloning of the ZFN1 gene into a pUC19-X-T2A-GFP plasmid using the In-Fusion 
protocol. Lane 1 shows the 1kb plus DNA ladder. Lanes 2-4 show an XbaI and XhoI double 
digest of plasmids isolated from different DH5α colonies previously transformed with 2 µl of 
In-Fusion reaction comprising the ZFN1 PCR product (primers 9 and 10) and the XbaI and XhoI 
linearised pUC19-X-T2A-GFP plasmid. The lower sized DNA band corresponds to the 1164 bp 
ZFN1 DNA and the upper band to the 3474 bp pUC19-X-T2A-GFP, where X indicates the 
missing DNA due to the XbaI/XhoI restriction digestion. Plasmid electrophoresed in lane 3 was 
chosen to be sequenced and used for further steps. 
 
In order to restriction digest the pUC19-ZFN1-T2A-GFP plasmid with KpnI and NotI, site-
directed mutagenesis was done to first remove a KpnI site within the ZFN1 sequence (figure 
3.4). The proofreading DNA polymerase, PfuTurbo, was used to amplify the pUC19-ZFN1-T2A-
GFP plasmid with the mutagenic primers 17 and 18. The primers were designed to replace an 
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Adenosine by a Thymidine at the KpnI restriction site (GGTACCÆGGTTCC) whilst conserving 
the codon for Valine (GTAÆGTT). 
Figure 3.4: Site-directed mutagenesis of the KpnI site within the ZFN1 sequence of the 
pUC19-ZFN1-T2A-GFP plasmid. A) Lanes 2-5 show the result of different reaction conditions 
for the PCR amplification using the pUC19-ZFN1-T2A-GFP (4638 bp) as template with the 
mutagenic primers 17 and 18 and the proofreading DNA polymerase, PfuTurbo. The PCR 
product from lane 4 was restricted with the DpnI restriction enzyme that targets only parental 
methylated plasmid DNA for digestion. DH5α bacteria were transformed with the DpnI digest 
product and grown on Carbenicillin containing agar plates. B) Lanes 2-5 show a KpnI single 
restriction digest of plasmid DNA that was isolated from four different DH5α colonies 
transformed as described above. Lane 6 shows a KpnI restriction digest of non-mutated 
pUC19-ZFN1-T2A-GFP with the smaller sized DNA band corresponding to a 1132 bp ZFN1-T2A 
DNA fragment produced by the restriction with KpnI within the ZFN1 and downstream of the 
T2A sequence. The pUC19-ZFN1('KpnI)-T2A-GFP plasmid from lane number 4 was DNA 
sequenced and used for further steps. 
 
After confirmation of the modifications in the pUC19-ZFN1('KpnI)-T2A-GFP plasmid by DNA 
sequencing using primers 11-16, it was possible to introduce the ZFN2 sequence into the NotI 
and KpnI restricted pUC19-ZFN1('KpnI)-T2A-GFP (figure 3.5). The ZFN2 gene was amplified 
from the SIGMA plasmid using primers 19 and 20. For simplicity from here onwards, the 
ZFN1(ΔKpnI) will be called ZFN1. To sequence the pUC19-ZFN1-T2A-ZFN2 plasmid, two 
restriction digests had to be used because primers for sequencing ZFN1 also bind to ZFN2 due 
to a high sequence homology. First, the pUC19-ZFN1-T2A-ZFN2 plasmid was digested with XbaI 
and XhoI and the pUC19-X-T2A-ZFN2 linearised plasmid was sequenced using primers 22-26. In 
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a second restriction digest using BamHI, the ZFN1(partly)-T2A-ZFN2 fragment was sequenced 
using primer 21 and the pUC19-ZFN1-T2A-ZFN2 DNA sequence was confirmed. 
Figure 3.5: Cloning of the ZFN2 gene into the pUC19-ZFN1('KpnI)-T2A-GFP plasmid using the 
In-Fusion protocol. A) Lane 2 shows the amplified 1186 bp ZFN2 gene from the PCR reaction 
using primers 19 and 20 and the SIGMA ZFN2 template. B) The preparative agarose gel was 
loaded with the KpnI and NotI restricted pUC19-ZFN1('KpnI)-T2A-GFP. The lower band 
corresponds to the 717 bp GFP DNA fragment and the upper band to the linearised pUC19-
ZFN1('KpnI)-T2A-X. The latter was extracted from the gel and purified. An In-Fusion reaction 
was done using the PCR product in A) and the linearised vector in B) and DH5α cells were 
transformed with 2 µl of In-Fusion mix. C) Plasmid DNA extracted from DH5α colonies 
transformed as described above and selected for Ampicillin resistance was restriction digested 
with KpnI and NotI and was loaded in lane 2. The lower size band in lane 2 corresponds to the 
1148 bp ZFN2 and the upper to the pUC19-ZFN1('KpnI)-T2A-X. Lane 3 is non-restricted 
plasmid from the same clone. This plasmid was DNA sequenced and confirmed to be the 
pUC19-ZFN1('KpnI)-T2A-ZFN2 nucleotide sequence. 
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As mentioned above, the DNA sequences of both ZFNs have a high homology resulting in 
primers binding to both ZFN sequences; hence the initial plan to introduce the ZFN1-T2A-ZFN2 
cassette into a pUC19-X-P2A-CD2 vector had to be revised. The new strategy was to introduce 
the P2A-CD2 fragment into the NotI linearised pUC19-ZFN1-T2A-ZFN2-X plasmid (figure 3.6). 
To restore the reading frame altered by the introduction of an additional NotI site (8 bp) 
upstream of the P2A sequence, an additional adenosine was added to primer 57 to restore the 
reading frame. The plasmid was sequenced using primers 4-8. 
Figure 3.6: Cloning of the P2A-CD2 sequence into the pUC19-ZFN1-T2A-ZFN2 using the In-
Fusion protocol. A) Lane 2 shows the 811 bp P2A-CD2 DNA sequence amplified by PCR using 
primers 57 and 30. B) Lane 2 shows the NotI single restriction digest of the pUC19-ZFN1-T2A-
ZFN2-X plasmid whereas lane 3 shows the non-restricted pUC19-ZFN1-T2A-ZFN2 plasmid. The 
product in lane 2 was purified and used together with the PCR product in A) to set up an In-
Fusion reaction. DH5α cells were transformed with 2 µl of In-Fusion mix. C) Plasmid DNA 
extracted from three different DH5α colonies transformed as described above and selected for 
Ampicillin resistance was restriction digested with NotI and resolved in lanes 2 to 4. The lower 
size band corresponds to the 786 bp P2A-CD2 DNA sequence. All three colonies had the 
pUC19-ZFN1/2-CD2 plasmid. The plasmid in lane 3 was DNA sequenced and confirmed to be 
the pUC19-ZFN1/2-CD2 sequence. 
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The ZFN1/2-CD2 cassette was introduced into the lentiviral transfer plasmid pLenti to give the 
final product of pLenti-ZFN1/2-CD2. Amplification of the cassette with primers 52 and 32 gave 
a shorter ZFN2-P2A-CD2 and the longer ZFN1/2-CD2 fragment due to the sequence homology 
between ZFN1 and ZFN2 leading to the forward primer 52 binding to both genes (figure 3.7). 
Only the full cassette was introduced into the pLenti vector and sequencing with primers 4, 6, 
7, 22, 23, 33, 34, 53 and 54 confirmed the plasmid as pLenti-ZFN1/2-CD2. 
Figure 3.7: Cloning of ZFN1/2-CD2 into the BamHI linearised pSxW lentiviral transfer vector 
using the In-Fusion protocol. A) Lanes 2-5 show the PCR products from the amplification of 
ZFN1/2-CD2 from the pUC19-ZFN1/2-CD2 using primers 52 and 32. The ZFN homology led to 
the amplification of two products; the unwanted ZFN2-P2A-CD2 (1969 bp) and the ZFN1/2-CD2 
(3223 bp) fragment. All four PCR products were pooled and the 3223 bp DNA band purified. B) 
Lane 2 shows the BamHI restriction digest of the pSxW plasmid. The linearised 8942 bp pSxW 
vector was purified and used together with the purified PCR product in A) to set up an In-
Fusion reaction. DH5α cells were transformed with 2 µl of In-Fusion mix. C) Lanes 2-4 show 
plasmid DNA extracted from different Ampicillin selected DH5α colonies transformed as 
described above and digested with KpnI. This gave three diagnostic fragments for the pLenti-
ZFN1/2-CD2 plasmid; one at 10174 bp, one at 119 bp (not visible) and a distinct 1843 bp band. 
The latter represents a part of the ZFN2 and the whole of P2A-CD2. Lane 4 did not show this 
pattern. The plasmid corresponding to lane 3 was DNA sequenced, confirmed to be the pLenti-
ZFN1/2-CD2 and used for lentiviral production. 
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3.3 Analysis of gag+ MOLT-3 cells transduced with CD2 or ZFN1/2-CD2 LV 
As a control for LV production and transduction efficiency, LV encoding CD2 was made, as 
described in the Materials and Methods, using a pLenti-CD2 transfer vector kindly provided by 
Dr Liam Morgan. The LV used in the majority of experiments was not quantified and 
transductions were done with volumes of LV previously showing high transduction efficiency. 
Quantification of the gag protein for a limited number of LV productions was done by ELISA 
and readings of 1-30 ng/µl were measured. However, due to the expense and variability of 
results obtained with the ELISA, it was decided to revert back to using defined volumes of 10x 
or 100x concentrated LV. 
MOLT-3 cells expressing the gag TCR (referred to as gag+ MOLT-3), previously shown to express 
SHP-1 (Yi et al. 1992), were transduced with increasing volumes of 10x concentrated CD2 LV 
(figure 3.8 B). The highest LV dose (500 µl) gave the highest CD2 MFI while even the lowest 
dose of 40 µl LV yielded a majority of CD2+ cells, although with a considerably lower MFI, 
indicating the potency of the LV at transducing MOLT-3 cells. 
Recombinant ZFN1/2-CD2 LV was used at two different volumes of 10x concentrated LV to 
transduce gag+ MOLT-3. After 72h, high levels of CD2 surface expression were observed by 
flow cytometry in cells transduced with 150 µl and 350 µl of LV (figure 3.8 C). Hence, the third 
gene of the ZFN1/2-CD2 cassette was properly folded and expressed on the cell surface, 
pointing towards the 2A ribosomal skipping elements yielding separate proteins as expected. 
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Figure 3.8: CD2 expression on gag+ MOLT-3 cells transduced with varying volumes of CD2 or 
ZFN1/2-CD2 LV. A) Gating strategy for LV transduced gag+ MOLT-3 cells in B) and C). B) Gag+ 
MOLT-3 cells, incubated for 72 h with RPMI only (grey filled), 40 µl (orange), 125 µl (blue), 250 
µl (green) or 500 µl (red) of 10x concentrated CD2 LV, were stained using a PE-conjugated anti-
CD2 Ab or unstained (black). C) 2 x 105 gag+ MOLT-3 cells were incubated for 72 h with RPMI 
only, 150 µl or 350 µl of 10x concentrated ZFN1/2-CD2 LV. Cells were either not stained for 
CD2 (black) or the PE-conjugated mouse anti-CD2 Ab was added to cells incubated with RPMI 
only (grey filled), 150 µl (blue) or 350 µl (red) of LV. 
 
Both ZFN genes in the ZFN1/2-CD2 cassette encode a 3xFlag tag (Flag) upstream of the ZFN 
start codon (table 3.2). To determine whether the ZFN proteins were being expressed, the 
transduced gag+ MOLT-3 cells depicted in figure 3.8 C cells were lysed and the Flag tag 
detected by immunoblotting. As shown in figure 3.9, both doses of LV gave a strong band at 
the expected size of the ZFN proteins (49 kDa), which was absent in non-transduced cells. 
However, as both ZFNs are Flag-tagged, it was not possible to distinguish between the 
expression of the ZFN1 and ZFN2 proteins. 
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Nucleotide sequence Amino acid sequence 
ZFN1 
 
ATGGACTACAAAGACCATGACGGTGATTATAAAGATCATGAC
ATCGATTACAAGGATGACGATGACAAG 
MDYKDHDGDTKDHDID
YKDDDDK 
ZFN2 
 
ATGAGATCTGACTACAAAGACCATGACGGTGATTATAAAGAT
CATGACATCGATTACAAGGATGACGATGACAAG 
MRSDYKDHDGDYKDHD
IDYKDDDDK 
Table 3.2: 3xFlag sequences encoded in the pLenti-ZFN1/2-CD2 plasmid. Nucleotide and 
amino acid sequences of 3xFlag tags positioned upstream of the start codon of the ZFN1 and 
ZFN2. The underlined amino acids indicate the differences between the two ZFNs. 
 
 
Figure 3.9: Immunoblotting for the Flag-tagged ZFNs in gag+ MOLT-3 cells transduced with 
ZFN1/2-CD2 LV. Gag+ MOLT-3 cells were either untransduced (0μl) or transduced with 150μl or 
350μl of ZFN1/2-CD2 LV. Per condition, 0.5 x 106 cells were lysed and used for immunoblotting. 
An anti-Flag-HRP Ab was used to probe for the expression of the ZFNs. Bands at the expected 
size of the ZFNs are indicated. The expected sizes of the 3xFlag-ZFN1 and 3xFlag-ZFN2 with the 
T2A or P2A C-terminal tails would be 49.56 kDa and 49.43k Da, respectively. 
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3.4 Mutation analysis of the human SHP-1 gene in gag+ MOLT-3 cells 
transduced with ZFN1/-2-CD2 LV 
The ZFN1/2-CD2 LV transduced gag+ MOLT-3 cells from figure 3.8 C (350 µl), were analysed for 
the presence of mutations in the SHP-1 gene using the Cel-I mismatch assay and sequencing of 
the ZFN target region.  
Firstly, genomic DNA (gDNA) was isolated from the non-transduced or 350 µl LV transduced 
gag+ MOLT-3 cells and a 398 bp region of the SHP-1 gene, encompassing the potential ZFN 
cutting site, was amplified by PCR using primers 55 and 56 (figure 3.1). Initially, to reduce the 
introduction of random mutations by the polymerase, a proofreading polymerase (Phusion) 
was used to amplify the SHP-1 region. However, no Cel-I signal was obtained and it was 
presumed that the PCR buffer mix was not compatible with the Cel-I enzyme, inhibiting further 
processing of the DNA by the Cel-I nuclease. Consequently a non-proofreading Taq polymerase 
mix (Supermix) was used for the PCR amplification. No false positive Cel-I signal was ever 
observed in non-transduced cells and thus this system was robust.  
After amplification, the 398 bp SHP-1 PCR product (figure 3.10 A) was hybridised by heating 
and gradual cooling and finally it was incubated with the Cel-I nuclease. The Cel-I nuclease 
recognises mismatched DNA and introduces a double stranded break at the site. For the SHP-1 
product, this would be expected to yield two shorter 178 bp and 220 bp DNA fragments. As 
shown in figure 3.10 B, a single band was observed, indicating a lack of SHP-1 mutations in the 
cells analysed. 
To verify the lack of mutations in the SHP-1 gene, a longer sequence of the SHP-1 gene was 
amplified, encompassing the ZFN binding sites.  Primers 58 and 59 were used and the PCR 
reaction yielded a 1733 bp SHP-1 fragment (figure 3.11 A) which was purified and sequenced 
using primers 55 and 56 (figure 3.11 B). The latter showed that the DNA perfectly matched 
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that of wild type SHP-1, confirming the absence of mutations in the gag+ MOLT-3 cells.  The 
absence of SHP-1 mutations was surprising due to the complete transduction of these cells 
shown by the CD2 surface staining (figure 3.8 C) and the presence of 3xFlag tag protein (figure 
3.9) within the ZFN1/2-CD2 LV transduced gag+ MOLT-3 cell pool. 
Figure 3.10: Cel-I mismatch assay of gag+ MOLT-3 transduced with ZFN1/2-CD2 LV. Gag+ 
MOLT-3 cells were either untransduced or transduced with 350 µl of ZFN1/2-CD2 LV. A) gDNA 
was extracted from the cells and a 398 bp SHP-1 gene sequence encompassing the potential 
ZFN cutting site was amplified using primer 55 and 56. Lane 4 shows the product from a PCR 
without gDNA and acts as a control for gDNA contamination. B) The PCR products from A) 
were hybridised and incubated with the Cel-I nuclease. A positive control provided by the 
manufacturer was incubated alongside to ensure the activity of the Cel-I enzyme (not shown). 
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Figure 3.11: Sequencing of the SHP-1 gene sequence encompassing the ZFN cutting site from 
gag+ MOLT-3 transduced with ZFN1/2-CD2 LV. A) gDNA was extracted from 350 µl ZFN1/2-
CD2 LV transduced gag+ MOLT-3 cells and a 1733 bp fragment encompassing the ZFN cutting 
site was amplified using primers 58 and 59. B) The PCR products from A) were purified and the 
1733 bp DNA fragment was sequenced with primers 55 and 56. The results for both primer 
readings are shown. 
 
 
3.5 SHP-1 specific ZFNs induce mutations in the SHP-1 gene in HEK293T 
cells 
One hypothesis as to why the ZFNs did not induce any mutations in the leukaemic cells was 
that the 2A tails at the C termini of the ZFN proteins might inhibit nuclear translocation or 
proper protein folding and thus stop the ZFNs accessing the SHP-1 gene.  In order to test this 
hypothesis, HEK293T cells were transiently transfected with the pLenti-ZFN1/2-CD2 plasmid 
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using CaCl2. In parallel, cells were transfected simultaneously with two plasmids expressing 
either ZFN1 or ZFN2. The plasmids, called pZFN1 and pZFN2, were the plasmid constructs 
provided by SIGMA figure 3.12. The plasmids were amplified and used to transiently transfect 
HEK293T cells using CaCl2. 
Figure 3.12: Vector map of the pZFN plasmid. The pZFN plasmids provided by SIGMA encode 
either the ZFN1 or ZFN2 sequence. ZFN gene expression is driven by the SFFV promoter. A 
3xFlag tag is located upstream of the start codon of the ZFN gene. 
 
HEK293T cells were transfected with 10 µg or 30 µg of pLenti-ZFN1/2-CD2 plasmid or with 2x5 
µg or 2x15 µg of pZFN1 and pZFN2. Cells transfected with the pLenti-ZFN1/2-CD2 plasmid were 
analysed for CD2 surface expression at 41 h and 65 h post-transfection and shown to be 
successfully transfected shown by the high levels of CD2 (figure 3.13 B). The double peaked 
CD2 expression might indicate the transfection of two plasmids per cell. The shift of the CD2 
peak, from the higher to the lower expression levels from 41 h to 65 h, confirms the transient 
gene expression as opposed to stable integration of the genes by LV transduction. Cells 
transfected with 10 µg or 30 µg of pLenti-ZFN1/2-CD2 or pZFN1 and pZFN2 were lysed at 41 h 
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and 65 h. The lysate was immunoblotted for the Flag tagged ZFNs and all transfected cells 
were shown to express ZFN protein (figure 3.13 C). 
Figure 3.13: CD2 surface expression and ZFN protein expression in HEK293T cells transfected 
with pLenti-ZFN1/2-CD2 or pZFN1 and pZFN2. HEK293T cells were CaCl2 transfected with 10 
µg or 20 µg of the pLenti-ZFN1/2-CD2 (pLenti) or 2 x 5 µg or 2 x 10 µg of the pZFN1 and pZFN2 
plasmids (2 x pZFN). A) HEK293T cells were dissociated from the culture flasks, at 41 and 65 h, 
using a non-enzymatic dissociation buffer and the gating strategy is shown. B) CD2 expression 
on HEK293T cells that were untransfected (grey filled) or transfected with 10 µg (orange) or 30 
µg (red) of pLenti-ZFN1/2-CD2 plasmid and stained with an anti-CD2 Ab or unstained (blue). C) 
Lysate from untransfected (wt) or transfected cells, 41 or 65 h post transfection, was 
immunoblotted for the 3xFlag tag. The predicted sizes of the ZFN1 and ZFN2 are 44.33 kDa and 
44.65 kDa, respectively. The predicted sizes for the C terminal tail of T2A and P2A and ZFN1 
and ZFN2 in the pLenti-ZFN1/2-CD2 plasmid are 49.56 and 49.43 kDa, respectively. The 
immunoblot was not exposed as the signal was visible by eye. 
 
 125 
 
After having established the expression of the plasmids in the HEK293T cells, gDNA was 
extracted and it was used for the Cel-I mismatch assay. As shown in figure 3.14, cells 
transfected either with the pLenti-ZFN1/2-CD2 plasmid or both the pZFN1 and pZFN2 plasmids, 
showed clear Cel-I nuclease digestion bands at 220 bp and 178 bp. Both transfections resulted 
in approximately 19% of cells expressing mutant SHP-1. Thus the pLenti-ZFN1/2-CD2 construct, 
when delivered by CaCl2 transfection, is providing functional ZFN1 and ZFN2 proteins that can 
target the SHP-1 gene site and introduce double stranded breaks leading to mutations. 
Figure 3.14: HEK293T cells, transfected with the pZFN1 and pZFN2 plasmids or the pLenti-
ZFN1/2-CD2 plasmid, show mutations in the SHP-1 gene when analysed by the Cel-I 
mismatch assay. HEK293T cells were CaCl2 transfected with 30 µg pLenti-ZFN1/2-CD2 plasmid 
or 2 x 15 µg pZFN1 and pZFN2 plasmid and the gDNA collected at 65 h post-transfection. A) 
gDNA from HEK293T cells was used to amplify a 398 bp SHP-1 gene sequence encompassing 
the potential ZFN cutting site with primers 55 and 56. B) The PCR products were hybridised 
and mismatched DNA was restricted by the Cel-I nuclease resulting in two smaller DNA bands 
(220 bp and 178 bp). The % of cells harbouring SHP-1 mutations was obtained by ImageJ 
analysis. 
 
In summary, the ZFN proteins designed by SIGMA bind to the SHP-1 gene and introduce 
double stranded breaks when delivered by transient transfection, as shown in the HEK293T 
cells. Although lentiviral delivery showed expression of the CD2 protein and also expression of 
the 3xFlag of at least one of the ZFNs, no mutations were detected. This is likely due to 
 126 
 
recombination events between the homologous ZFN sequences when the pLenti plasmid is 
packaged into the LV particle in the HEK293T packaging cells, resulting in the deletions of parts 
of the sequences. This has been observed in studies using TALENs and HIV-based lentiviral 
vectors (Holkers et al. 2013). 
 
 
3.6 Generation of lentiviral transfer plasmids encoding each SHP-1 ZFN1 
and ZFN2 separately  
To avoid the recombination of the ZFN sequences, two single plasmids were generated 
encoding either the ZFN1 or ZFN2 genes. 
The pLenti-3xFlag-ZFN1 (pLenti-ZFN1) plasmid construct was generated by amplifying the 
3xFlag-ZFN1 gene from the SIGMA pZFN1 plasmid, using primers 60 and 61, and cloning it into 
the pLenti transfer vector (figure 3.15). The cloning was confirmed by sequencing the plasmid 
using primers 12-15 and 33-34. 
To allow the detection of both ZFNs in transduced cells, the 3xFlag tag of the pZFN2 plasmid 
from SIGMA was exchanged for a V5 tag (figure 3.16). The V5 tag amino acid sequence 
(MGKPIPNPLLGLDST) is encoded by the DNA sequence 
ATGGGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCTACG, which was introduced upstream 
of the ZFN2 start codon by adding it to primer 62. The pLenti-V5-ZFN2 (pLenti-ZFN2) plasmid 
was confirmed by sequencing using primers 22-25 and 33-34. 
To be able to select viable transduced cells, the CD2 surface marker was introduced into the 
transfer vector alongside the ZFN2 gene. Primer number 66 and 32 were used to amplify the 
ZFN2 gene. Primer 66 was designed to introduce a Kozak sequence upstream of the start 
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codon of the ZFN2 thus eliminating the previously present 3xFlag tag. The pLenti-ZFN2-P2A-
CD2 plasmid (pLenti-ZFN2-CD2) was constructed as described in figure 3.17 and sequenced 
using primers 4, 6-7, 22, 24-25 and 33-34. 
Figure 3.15: Generation of the pLenti-3xFlag-ZFN1 transfer vector. A) Cloning strategy to 
generate the lentiviral transfer vector pLenti-ZFN1. B) Lane 2 shows the 1193 bp 3xFlag-ZFN1 
DNA amplified using primers 60 and 61 from the SIGMA pZFN1 plasmid. C) Lane 3 shows the 
BamHI restriction digest of the pSxW plasmid and lane 2 shows the non-restriction digested 
plasmid. The linearised 8942 bp pSxW vector was purified and used together with the purified 
PCR product in B) to set up an In-Fusion reaction. DH5α cells were transformed with 2 µl of In-
Fusion mix. D) Plasmid DNA extracted from DH5α colonies transformed as described above 
and selected for Ampicillin resistance was restriction digested with BamHI is shown in lane 2. 
The upper band shows the BamHI linearised 8942 bp pSxW and the two lower bands 
correspond to the two BamHI restriction fragments of 3xFlag-ZFN1 (564 bp and 603 bp). 
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Figure 3.16: Generation of the pLenti-V5-ZFN2 transfer vector. A) Cloning strategy to generate 
the lentiviral transfer vector pLenti-ZFN2. B) Lane 2 shows the 1163 bp V5-ZFN2 DNA amplified 
using primers 62 and 63 from the pZFN2 SIGMA template expressing 3xFlag-ZFN2. Only the 
upper band was selected by gel excision for further steps. C) Lane 3 shows the BamHI 
restriction digest of the pSxW plasmid and lane 2 shows the non-restricted plasmid. The 
linearised 8942 bp pSxW vector was purified and used together with the purified PCR product 
in B) to set up an In-Fusion reaction. DH5α cells were transformed with 2 µl of In-Fusion mix. 
D) Plasmid DNA extracted from DH5α colonies transformed as described above and selected 
for Ampicillin resistance was restriction digested with BamHI is shown in lane 2. The upper 
band shows the BamHI linearised 8942 bp pSxW and the two lower bands correspond to the 
two BamHI restriction fragments of V5-ZFN2 (540 bp and 597 bp). 
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Figure 3.17: Generation of the pLenti-ZFN2-P2A-CD2 transfer vector. A) Cloning strategy to 
generate the lentiviral transfer vector pLenti-ZFN2-CD2. B) Lane 2 shows the PCR reaction for 
primers 66 and 32 and the DNA template of XhoI and HindIII restriction digested pUC19-
ZFN1/2-CD2. The 1901 bp PCR product was purified and used for further steps. C) Lane 2 
shows the BamHI restriction digest of the pSxW plasmid. The linearised 8942 bp pSxW vector 
was purified and used together with the purified PCR product in B) to set up an In-Fusion 
reaction. DH5α cells were transformed with 2 µl of In-Fusion mix. D) Plasmid DNA extracted 
from DH5α colonies transformed as described above and selected for Ampicillin resistance was 
restriction digested with BamHI is shown in lane 2. The upper band shows the BamHI linearised 
8942 bp pSxW and the two lower bands correspond to the two BamHI restriction fragments of 
a part of 495 bp ZFN2 and the remaining of 1380 bp ZFN2-CD2. 
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3.7 Analysis of gag+ leukaemic T cells transduced with ZFN1 and ZFN2 or 
ZFN2-CD2 LV 
Gag+ Jurkat cells were transduced with either 250 µl of 10x concentrated ZFN1 or ZFN2 LV. 
Cells were lysed 5 days post transduction and the lysate immunoblotted for V5 and 3xFlag tag 
(figure 3.18). Transduced gag+ Jurkat cells gave strong signals for the tags, indicating successful 
transduction and protein expression of the ZFNs. 
Figure 3.18: Gag+ Jurkat cells, transduced with pLenti-3xFlag-ZFN1 or pLenti-V5-ZFN2 LV, 
express 3xFlag or V5 tag respectively. Gag+ Jurkat cells were untransduced or transduced with 
250 µl of 10x concentrated LV as indicated. Cells were collected and lysed 5 days post-
transduction. A) Cell lysate was probed for the presence of the 3xFlag tag. The predicted size of 
the 3xFlag-ZFN1 protein is 44.33 kDa. B) Cell lysate was probed for the presence of V5 tag. The 
predicted size of the V5-ZFN2 protein is 45.09 kDa. 
 
In order to detect and sort LV transduced cells, the CD2 surface marker was introduced into 
the ZFN2-CD2 LV and transduction of gag+ Jurkat cells with 150 ng of each the ZFN1 and ZFN2-
CD2 LVs was evaluated by flow cytometry for the cell surface expression of CD2 2 days post 
transduction (figure 3.19). All gag+ Jurkat cells were transduced with the ZFN2-CD2 LV; 
however the efficiency of ZFN1 LV transduction could not be assessed. 
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Figure 3.19: CD2 surface expression of gag+ Jurkat cells transduced with ZFN1 and ZFN2-CD2 
LV. Gag+ Jurkat cells were transduced with 150ng of ZFN1 and ZFN2-CD2 LV and cells collected 
and stained for flow cytometry 48 h post-transduction. A) Gating strategy for transduced gag+ 
Jurkat cells. B) Untransduced (grey filled) and transduced (red) cells were stained with anti-CD2 
Ab and transduced cells were stained with isotype control (blue). 
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3.8 Mutation analysis in the human SHP-1 gene in gag+ leukaemic T cells 
transduced with ZFN1 and ZFN2 or ZFN2-CD2 LV 
Cells as highlighted in figure 3.18 were transduced with the ZFN1 and ZFN2 LV and analysed for 
mutations by performing a Cel-I assay (figure 3.20). Cel-I treated gDNA from gag+ Jurkat cells 
transduced with both ZFN LVs, but not with a control CD2 LV or no LV, showed strong bands at 
220 bp and 178 bp corresponding to approximately 30% of cells expressing mutant SHP-1. For 
the first time in human T cells, SHP-1 specific mutations induced by the SHP-1 specific ZFNs 
were detectable. 
Figure 3.20: SHP-1 mutation analysis of gag+ Jurkat cells, transduced with ZFN1 and ZFN2 LV. 
gDNA from gag+ Jurkat cells, shown in figure 3.18, was used to amplify a 398 bp SHP-1 gene 
sequence encompassing the potential ZFN cutting site with primers 55 and 56. The PCR 
products were hybridised and mismatched DNA was restricted by the Cel-I nuclease resulting 
in two smaller DNA bands (220 bp and 178 bp). Untransduced and rCD2 LV transduced cells 
were used as negative controls. 
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To be able to sort on ZFN2 transduced cells, the ZFN2-CD2 and ZFN1 LVs were used for the 
transduction of gag+ Jurkat (figure 3.19) and gDNA was extracted and restricted with the Cel-I 
nuclease (figure 3.21). Cells showed a strong signal when transduced with both ZFN expressing 
LVs, indicating that this combination of LVs can also give a high proportion of mutations in the 
SHP-1 gene. The transduced cells from this experiment were cloned and clone analysis is 
shown in chapter 4. 
Figure 3.21: SHP-1 mutation analysis of gag+ Jurkat cells, transduced with ZFN1 and ZFN2-
CD2 LV. gDNA from gag+ Jurkat cells, shown in figure 3.19, was used to amplify a 398 bp SHP-1 
gene sequence encompassing the potential ZFN cutting site with primers 55 and 56. The PCR 
products were hybridised and mismatched DNA was restricted by the Cel-I nuclease resulting 
in two smaller DNA bands (220 bp and 178 bp). Untransduced and cells were used as a 
negative control. 
 
 
 
 
 
 134 
 
3.9 Integrase deficient LV delivery of SHP-1 ZFNs to leukaemic T cells 
In order to reduce the likelihood of potential off-target mutations by the SHP-1 specific ZFNs, a 
non-integrating ZFN gene delivery method would be preferential. An integrase-deficient LV 
(IDLV) was therefore produced in the same way as the LV with the exception of using a mutant 
D64V integrase encoding plasmid (Yanez-Munoz et al. 2006) when doing the LV packing 
reaction as described in Materials and Methods. Firstly, the time course of protein expression 
from an IDLV delivery was studied by using the CD2 IDLV. Secondly, both ZFN1 and ZFN2-CD2 
IDLVs were used with the aim to introduce SHP-1 specific mutations in leukaemic T cells. 
Gag+ Jurkat and MOLT-3 cells were transduced with 250 µl of 10x concentrated IDLV or LV and 
cell surface expression was measured 3, 5 and 9 days post-transduction (figure 3.22). At day 3, 
LV and IDLV gave complete transduction of the cells with the LV delivery yielding more strongly 
CD2 expressing cells. Whereas the integrated CD2 gave a stable high expression level of CD2, 
the IDLV infection resulted in a quick dilution of the CD2 signal to a complete disappearance by 
day 9. This was not surprising considering the high division rate demonstrated by both 
leukaemic T cells (shown in Chapter 4). This result showed that the window for sorting cells on 
the basis of CD2 expression would have to be within the first three days. 
Gag+ MOLT-3 cells were transduced with ZFN1 and ZFN2-CD2 IDLV and LV. Despite a complete 
transduction of MOLT-3 cells using both the 2x200 ng and 2x400 ng IDLV doses (figure 3.23 A), 
no SHP-1 mutations were observed in these cells in comparison with 25% of cells carrying 
mutant SHP-1 when transduced with LV (figure 3.23 B). 
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Figure 3.22: Time course of CD2 expression of CD2 IDLV or LV transduced leukaemic T cells. 
Gag+ Jurkat and gag+ MOLT-3 cells were transduced with 250 µl of 10x concentrated CD2 IDLV 
or LV and CD2 protein expression was measured by flow cytometry using an anti-CD2 Ab. Cells 
were gated on FSC/SSC, live/dead stain and single cell profiles. A) Histogram overlay of CD2 
surface expression on gag+ Jurkat cells at day 3 (blue), 5 (red) and 9 (green) days post-
transduction. Unstained IDLV or LV transduced cells at day 3 are shown in grey filled and 
untransduced cells are shown as a black line. B) Levels of CD2 expression on Jurkat and MOLT-
3 cells, transduced with CD2 IDLV or LV, shown using the CD2 MFI minus the MFI of the 
corresponding unstained cells. 
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Figure 3.23: Gag+ MOLT-3 cells, transduced with ZFN1 and ZFN2-CD2 IDLV or LV, were 
analysed for CD2 surface expression and SHP-1 mutations. A) Gag+ MOLT-3 cells were 
transduced with 200 ng (bright green) or 400 ng (dark green) of ZFN1 and ZFN2-CD2 IDLV, 
alongside a control transduction of 75 µl of 100x concentrated CD2 LV (red) and non-
transduced cells (grey filled). Cells were then stained using an anti-CD2 Ab and or left 
unstained (black). B) Gag+ MOLT-3 from A) as well as cells transduced with ZFN1 and ZFN2-CD2 
LV (+ve control) had their gDNA extracted and a 398 bp SHP-1 gene part amplified by PCR. This 
was then hybridised and used in the Cel-I mismatch assay. 
 
 
 
 
 
 
 137 
 
3.10 Discussion 
In this chapter it was shown that the SHP-1 specific ZFNs can induce mutations within the 
target SHP-1 DNA sequence in approximately 25-30% of ZFN expressing leukaemic T cells. 
However mutations were only observed when the two ZFNs were delivered in two separate 
integrase proficient LVs or when cells were transfected with the plasmid expressing both ZFNs. 
The initial attempt at delivering both ZFNs within a single LV was unsuccessful, most probably 
due to the deletion of parts of the ZFN sequences by homologous recombination. The two 
ZFNs have a high sequence homology, as illustrated by the difficulty faced when designing 
specific primers for sequencing of the pLenti-ZFN1-ZFN2-CD2 plasmid.  It has previously been 
shown that the reverse transcription process, active when generating LV in HEK293T packaging 
cells, is very prone to recombination if repeat DNA sequences are present (Holkers et al. 2013). 
Additionally, the frequency of recombination depends on the distance between the repeat 
DNA sequences. At distances similar to that observed between ZFN1 and ZFN2 in the pLenti-
ZFN1-ZFN2-CD2 plasmid (1200 bp), approximately 60-80% of the DNA will recombine (Delviks 
and Pathak 1999). This high level of deletion of ZFN sequence during LV production in HEK293T 
cells could thus explain the observed absence of mutated SHP-1 in MOLT-3 cells transduced 
with ZFN1/2-CD2 LV (figure 3.10-11). 
Additionally, no SHP-1 mutations were observed when delivering the ZFNs with IDLVs and 
there are at least two possible reasons for this. The first possibility is the high proliferation rate 
of leukaemic cells and the resulting rapid dilution of ZFN transgenes and ZFN protein (no CD2 
signal at day 9). However, this short expression should nevertheless be enough to induce 
mutations as the short duration of expression when ZFNs are delivered as mRNA has shown 
the induction of mutations. The second possibility is the lower transduction efficiency of IDLV 
(approximately 0.25x that of LV in figure 3.22). Both factors will lead to lower levels and 
shorter expression times of ZFN proteins in the cells, resulting in a lack of targeted SHP-1 
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mutations. Additionally, only two studies have reported the use of IDLV delivery of ZFNs 
(Lombardo et al. 2007; Provasi et al. 2012) indicating that this technique is not simple to get to 
work and the experiments by Lombardo et al. were done using commercially produced and 
purified high titre IDLV. Due to the unavailability of this service and the unsuccessful IDLV 
delivery, LV delivery of the ZFNs was chosen for the rest of this study. 
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Chapter 4: SHP-1 deficient leukaemic T cells and 
functional consequences 
4.1 Introduction 
In the previous chapter, lentiviral delivery of the two SHP-1 specific ZFNs successfully induced 
mutations in the SHP-1 gene. Here, leukaemic cells transduced with ZFN LVs will be examined, 
on a clonal level, for potentially altered SHP-1 protein expression and changes in T cell 
function. 
Initially, gag+ leukaemic cells were transduced with SHP-1 specific ZFN LVs, cells were cloned 
and the clones analysed for SHP-1 protein expression. Established SHP-1 deficient clones were 
activated with peptide pulsed antigen presenting cells (APCs). The APCs used were HLA-A2 
expressing C1R cells, a leukaemic B cell line. T cell activation readouts such as TCR 
downregulation and CD69 upregulation were examined (figure 4.1 A) as CD69 is one of the 
earliest molecules to be expressed de novo during T cell activation (Cebrián et al. 1988). 
A T cell activation reporter system was also used to measure activation in Jurkat cells 
expressing a tumour-specific TCR recognising the MART-126-35 peptide (EAAGIGILTV) when 
presented by HLA-A2 (Cole et al. 2009). This TCR will subsequently be referred to as the Mel 
TCR. In this model, a Gaussia Luciferase (GLuciferase) gene is under the control of nuclear 
factor of activated T cells (NFAT) response elements (RE) and a minimal IL-2 promoter (Govers 
et al. 2011). Once cells are activated, dephosphorylation of the NFAT protein by the calmodulin 
and calcineurin complex leads to the nuclear translocation of NFAT, NFAT binding to the NFAT 
REs, initiation of the GLuciferase gene transcription and secretion of GLuciferase protein 
(figure 4.1 B).  
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Figure 4.1: Leukaemic T cell models used to study the effect of SHP-1 deficiency on T cell 
activation. A) The two different TCRs used in this chapter are shown. The high affinity gag TCR, 
recognising viral peptide, was expressed in MOLT-3 and Jurkat cells and T cell activation 
readouts were TCR downregulation and CD69 upregulation. The melanoma specific Mel TCR 
was expressed in Jurkat cells alongside the NFAT reporter cassette. B) The lentivirally delivered 
GLuciferase gene cassette has a six times NFAT response element to which nuclear NFAT binds 
and initiates GLuciferase gene expression. Following activation of Jurkat cells, either via the 
TCR or by chemical stimulation, Ca2+ levels in the cytoplasm increase and the Ca2+ binds to 
calmodulin. The latter activates calcineurin which subsequently dephosphorylates NFAT 
allowing NFAT to translocate to the nucleus leading to GLuciferase protein secretion. 
GLuciferase activity in the supernatant of activated cells can be measured by adding luciferin 
substrate. 
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4.2 Cloning of ZFN LVs transduced gag+ MOLT-3 cells and characterisation 
of SHP-1 deficient clones 
To establish the clones shown in figure 4.2 A, gag+ MOLT-3 cells were transduced with the 
ZFN1 and ZFN2 LVs and the cells analysed for SHP-1 mutations using the Cel-I assay (figure 4.2 
B). Analysis of the signal intensity of the restricted DNA fragments (220 and 178 bp) in relation 
to the non-restricted fragment (398 bp), using ImageJ software, indicated a mutation 
frequency of 24%. This analysis was used as an estimate of the frequency as it is only semi-
quantitative. Nevertheless, it is instructive to perform when considering cell cloning, as 
mutation frequencies lower than 1% are a counter-indication for cloning as stated by Sigma-
Aldrich representatives. 
To fully establish mutation frequencies, ZFN LV transduced cells were cloned and analysed for 
mutations in the SHP-1 gene by Cel-I (figure 4.3 B). After PCR amplification of the 398 bp SHP-1 
DNA sequence, clones P3 3G and P2 3E showed a 398 bp wt DNA band as well as a smaller 
fragment (figure 4.3 A). This indicated deletions introduced by the SHP-1 specific ZFNs of 
roughly ten and one hundred nucleotides for the P3 3G and P2 3E clones, respectively. 
Interestingly, every clone showed Cel-I restriction fragments, thus each clone has at least one 
mutated SHP-1 allele (figure 4.3 B). These mutations are probably less than 10 nucleotides, as 
PCR products do not show two distinct bands. However, large deletions abrogating a PCR 
primer binding site are also possible and would not be picked up by these assays. 
To further characterise the clones, cell lysates from wt cells and the clones were 
immunoblotted for the SHP-1 protein and an actin loading control. Thirteen gag+ MOLT-3 cells 
were analysed for SHP-1 protein expression and 31% (4/13) were SHP-1 protein deficient, 46% 
(6/13) showed reduced SHP-1 protein expression and 23% (3/13) showed levels comparable to 
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wt (figure 4.4). Overall, a majority of analysed cells have mutations in the SHP-1 gene that 
affect protein expression. 
Figure 4.2: Overview of the cloning of ZFN LVs transduced gag+ MOLT-3 and analysis of SHP-1 
mutations. A) Overview of the cloning strategy for gag+ MOLT-3 cells. Wt and CD2 cells were 
not cloned whereas the ZFN LVs transduced cells were cloned and analysed for SHP-1 
mutations. Yellow arrows indicate mutations in the SHP-1 due to ZFN activity and SHP-1+/- and 
SHP-1-/- indicated cells with reduced or absent SHP-1 protein respectively. B) Gag+ MOLT-3 cells 
were either untransduced or transduced with 250 µl of 10x concentrated ZFN1 and ZFN2 LVs. 
Genomic DNA was isolated, the 398 bp SHP-1 DNA sequence was amplified by PCR and 
subsequently restriction digested with the Cel-I enzyme. The % of cells harbouring SHP-1 
mutations was obtained by ImageJ analysis. 
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Figure 4.3: SHP-1 mutation analysis in gag+ MOLT-3 cell clones transduced with ZFN1 and 
ZFN2 LV. Gag+ MOLT-3 cells, previously transduced with ZFN1 and ZFN2 LV, were cloned and 
clone names are indicated at the top of the electrophoresis gels. A) Genomic DNA was isolated 
from clones and the 398 bp ZFN target site was amplified by PCR using primers 55 and 56. The 
wt wells show the PCR results for gDNA from untransduced cells and the negative control (-ve 
ctrl) shows the PCR result when no gDNA was added. Two clones showed visible deletions in 
the SHP-1 PCR product (orange box). B) The PCR products of each clone and wt cells were 
hybridised and restriction digested by the Cel-I nuclease, giving rise to the 200 bp and 178 bp 
restriction fragments. 
 
Figure 4.4: Immunoblotting for SHP-1 protein expression of gag+ MOLT-3 clones. Gag+ MOLT-
3 wt cells and clones were lysed and the cell lysate immunoblotted with anti-SHP-1 and anti-
actin Abs. Clones with complete SHP-1 protein loss and clones with intermediate levels of SHP-
1 protein are encased by red and blue boxes, respectively. Non-transduced cells (wt) were 
used as a positive control. A repeat immunoblot with the clones gave similar results. The anti-
SHP-1 blots were exposed for longer than the anti-actin blots. 
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Five clones, either deficient for SHP-1 protein (P6 11E and P5 3G) or with reduced SHP-1 
protein levels (P4 10F, P6 7E and P3 10G), were selected for DNA sequence analysis of the 398 
bp PCR product. Due to the ZFNs causing independent and most probably different mutations 
in each allele, the sequencing readings showed peaks for two nucleotides in regions where 
more than one sequence of PCR product was present. These regions of mutations are 
indicated by missing DNA sequence in figure 4.5 A. As expected, all five clones showed 
mutations within the region of the ZFN binding site and due to the mutations being close or 
within a splice acceptor site, these mutations are predicted to lead to a reduction of SHP-1 
protein. The results for clone P5 3G were the only interpretable readings showing an insertion 
of a single nucleotide on one allele and a deletion of 9 nucleotides on the other allele (figure 
4.5 A and B). The insertion introduces a premature stop codon in the following exon whereas 
the deletion gives a three amino acid truncation in the SHP-1 protein upstream of the protein 
tyrosine phosphatase domain (figure 3.1). As shown by immunoblotting, overall this led to the 
P5 3G clone being SHP-1 deficient. No additional genetic analysis was done for these clones.  
Due to complete SHP-1 deficiency, clones P2 2E and P5 3G were selected to study the effect of 
SHP-1 loss on T cell activation and proliferation. T cell activation induced TCR downregulation 
was measured for two SHP-1 mutant clones, CD2 LV transduced cells and wt cells in response 
to cognate peptide (SLY) pulsed APCs (figure 4.6 C). The gag+ TCR has a TCRV5β chain and 
therefore an anti-TCRV5β Ab was used to detect TCR levels. At similar T cell to APC ratios, TCR 
levels decreased in a peptide dose dependent manner with 10-4 M SLY peptide (figure 4.6 C 
and D). The SHP-1 deficient clone P5 3G showed significantly greater decreases in TCR 
expression at 10-4 M peptide than the three other cell types, reflecting enhanced TCR 
activation. However, the P5 3G clone had much higher basal TCR levels than the other groups. 
Furthermore, the wt and CD2 transduced cells were not clonal and comparing clones to cell 
pools was not ideal (figure 4.6 B). The P2 2E SHP-1 deficient clone did not show any significant 
differences in activation when compared to wt or CD2 controls but it also had very low TCR 
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levels. Overall, these results indicate that cells with differing TCR levels are not useful for 
comparing activation potential. 
Figure 4.5: DNA sequencing of the 398 bp SHP-1 PCR products from gag+ MOLT-3 clones 
transduced with ZFN1 and ZFN2 LV. Genomic DNA from five gag+ MOLT-3 clones, previously 
transduced with the ZFN LVs, and wt cells was isolated, primers 55 and 56 used to PCR a 398 
bp DNA sequence and the same primers were used for DNA sequencing of the PCR products. 
A) Results for the wt and five MOLT-3 clones are shown with red and blue boxes indicating loss 
or reduction in SHP-1 protein, respectively. The ZFN binding sites are underlined and sequence 
in bold indicates the SHP-1 exon 8. The regions of double peaked DNA sequence readings are 
indicated by missing nucleotides. B) The DNA sequencing results for the forward and reverse 
primer readings of the SHP-1 protein deficient P5 3G clone are shown. C) SHP-1 alleles of the 
P5 3G clone are shown after analysis of DNA sequencing results shown in B. 
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Figure 4.6: TCR downregulation in response to cognate peptide stimulation in SHP-1 deficient 
gag+ MOLT-3 clones. Antigen presenting C1R cells were unpulsed or pulsed with increasing 
doses of cognate SLY peptide for 30 min. Control wt and CD2 transduced gag+ MOLT-3 cells 
and two SHP-1 deficient gag+ MOLT-3 clones, P2 2E and P5 3G, were stimulated with the APCs 
for 60 min, followed by staining for live/dead stain, anti-CD19 Ab and anti-TCRV5β Ab and flow 
cytometric analysis.  A) Gating strategy for the analysis of cells in B-D. Cells analysed were live, 
single CD19 negative cells. B) TCRV5β cell surface levels for unstimulated wt (green), CD2 
transduced (blue), P2 2E (pink dotted) and P5 3G (red) and unstained (grey filled) CD19 
negative cells are shown. C) TCR downregulation is expressed as percentage of TCR expression 
in peptide pulsed cells relative to non-peptide pulsed cells for each cell type. The P5 3G clone 
showed significant differences with the wt (asterisk in green) and CD2 (asterisk in blue) cells. 
The P2 2E clone showed no significant differences when compared to wt and CD2 transduced 
cells. D) The percentage of T cells (CD19 negative) in the population of live single cells is 
shown. No significant differences were observed. C and D show pooled data from three 
independent experiments with triplicates for each condition and the error bars show the SEM. 
**p<0.01, ****p<0.0001. %TCR = MFI of sample / (mean of MFI of non-peptide pulsed 
cells)*100. 
 
 
 147 
 
4.3 CFSE dilution in leukaemic T cells with or without peptide stimulation 
Next, proliferation of unstimulated wt, CD2 transduced gag+ MOLT-3 cells and SHP-1 deficient 
gag+ MOLT-3 clones, P2 2E and P5 3G, was studied by doing a CFSE dilution experiment over 3 
days (figure 4.7 B). Neither CD2 transduced cells nor the SHP-1 deficient P5 3G clone showed 
differences in basal proliferation compared to wt cells. The SHP-1 deficient P2 2E clone showed 
slightly slower division than wt MOLT-3 cells. The P2 2E clone was smaller in overall size in 
comparison to the three other cells types, which indicated that this clone is inherently 
different and thus the slower division might be related to this phenotypic change (figure 4.7 A). 
Overall, gag+ MOLT-3 cells divide daily without the need of any external stimulation and in the 
absence of SHP-1, MOLT-3 cells did not show accelerated basal division. 
In parallel to the above experiment using MOLT-3 cell clones, gag+ Jurkat cell proliferation was 
analysed in response to cell activation. SHP-1 proficient gag+ Jurkat cells were labelled with 
CFSE and division in response to cognate SLY peptide was analysed.  No difference on CFSE 
dilution could be detected with the addition of up to 10-4 M SLY peptide (figure 4.8). In 
summary, neither leukaemic cell lines were suitable to studying the effect of SHP-1 deficiency 
on basal and TCR induced proliferation. 
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Figure 4.7: Proliferation of unstimulated SHP-1 deficient gag+ MOLT-3 clones. Wt and CD2 
transduced gag+ MOLT-3 cells and SHP-1 deficient gag+ MOLT-3 clones, P2 2E and P5 3G, were 
stained with 2 µM CFSE at day 0. A) Forward and side scatter plots of the wt, CD2, P2 2E and 
P5 3G cells. B) Cells were cultured and collected at 0 h, 24, 48 and 72 h (dark > bright line) and 
analysed by flow cytometry for the CFSE content of cells gated on FSC/SSC and single cells. The 
green line represents the wt cells and the dotted purple line represents either CD2 transduced 
cells, the P2 2E or the P5 3G clone. The grey filled and grey dotted lines show unstained cells at 
day 0 and the two peaks furthest to the right represent CFSE stained cells at day 0.  
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Figure 4.8: CFSE dilution of gag+ Jurkat cells stimulated with SLY peptide pulsed APCs. Gag+ 
Jurkat cells were labelled with 2 µM CFSE at day 0. CFSE labelled cells were cultured alone 
(black) or co-cultured with unpulsed (green) or 10-4 M SLY peptide pulsed (red) APCs. Cells 
were collected every 24 h as indicated and analysed by flow cytometry. Cells were gated on 
FSC/SSC and single cells. A) The overlays of the CFSE staining of the three CFSE labelled Jurkat 
culture conditions at five different time points (24 h  – 120 h) is shown. B) CFSE MFI is shown 
for the three culture conditions at the five time points. Each condition represents a single 
observation. 
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4.4 Cloning of ZFN LVs transduced gag+ Jurkat cells and characterisation 
of SHP-1 deficient clones  
For a better comparison of T cell activation, leukaemic clones proficient and deficient in SHP-1 
protein with similar TCR levels were derived and studied in this section (figure 4.9). This goal 
required the cloning of gag+ Jurkat T cells generated in the previous chapter  (figures 3.19 and 
3.21). 35 individual clones were analysed for SHP-1 protein expression, out of which 26% 
(9/35) showed complete lack of SHP-1 protein, 20% (7/35) showed decreased SHP-1 protein 
levels and 54% (19/35) showed levels similar to wt (figure 4.10). 
 
Figure 4.9: Overview of the cloning strategy for ZFN LVs transduced gag+ Jurkat cells. A gag+ 
Jurkat cell pool was transduced with ZFN LVs and cells were cloned. Yellow arrows indicate 
mutations in the SHP-1 gene due to ZFN activity and SHP-1+/- and SHP-1-/- indicated cells with 
reduced or absent SHP-1 protein respectively. The cell membrane colour indicates gag TCR 
levels. 
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Figure 4.10: Immunoblotting for SHP-1 protein expression of gag+ Jurkat cell clones. Gag+ 
Jurkat clones, transduced with ZFN1 and ZFN2-CD2 LVs, and non-transduced wt cells were 
lysed and the cell lysate immunoblotted with anti-SHP-1 and anti-actin Abs. Clones with 
complete SHP-1 protein loss and clones with significant reductions in SHP-1 protein are 
encased by red and blue boxes, respectively. Non-transduced cells (Jurkat wt) were used as a 
positive control. The anti-SHP-1 blots were exposed for longer than the anti-actin blots. 
 
In order to precisely map SHP-1 mutations on both alleles of a clone, TA cloning of the 398 bp 
SHP-1 PCR product was done as described in the ‘Materials and Methods’ and carried out 
mostly by Adam Clark, an intercalating BSc student. SHP-1 mutations in clones showing 
conclusive results are shown in table 4.1. All analysed mutations were concentrated within the 
expected ZFN spacer region. The minority of mutations (1/9) were substitutions, such as the C 
to T substitution in the intron region which matched the SHP-1+/+ status of the clone obtained 
by immunoblotting (figure 4.10). The majority of mutations (7/9) were deletions of between 1-
183 bp and 2/9 mutations were small insertions of 1-5 bp. For two clones, no second allele 
could be identified. Two possible reasons for this were the preferential PCR amplification of 
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shorter PCR products or the occurrence of a large deletion within the allele, deleting the 
primer binding site, 220 bp upstream or 178 bp downstream of the ZFN cutting site. 
Clone SHP-1 
protein 
Allele 1 Allele 2 
P2 F10 SHP-1+/+ Wt (3/6) C ÆT in intron (3/6) 
P2 C2 SHP-1+/+ Δ9 in exon (7/14) Δ1 in exon (5/14) 
P3 F4 SHP-1-/- Δ29 in intron Æ deletion of 3’ splicing 
site (6/6) 
? 
P3 A5 SHP-1-/- Δ9 in exon (14/14) ? 
P4 H1 SHP-1-/- Δ1 and Δ6 Æ deletion of 3’ splicing 
site (5/6) 
+1 G in exon (1/6) Æ 
premature stop codon in 
exon 9 (1/6) 
P2 A8 SHP-1-/- Δ183 of which 176 in intron and 7 in 
exon Æ deletion of 3’ splicing and 
premature stop codon (14/15) 
Δ1 and +5 Cs (1/15) Æ 
premature stop codon in 
exon 9 
Table 4.1: Analysis of SHP-1 mutations on both alleles of Jurkat T cell clones. TA cloning was 
done for a number of Jurkat clones transduced with ZFN LVs and the types of mutations and 
consequences for the protein expression are shown. The number of TA cloning plasmids 
sequenced for each clone is shown in brackets. The size of deletions (Δ) and insertions (+) in 
nucleotides is shown. Immunoblotting was used to determine the SHP-1 protein expression. 
 
As seen in gag+ MOLT-3 clones (figure 4.6 B), gag TCR levels can vary between clones obtained 
from a pool of transduced cells. To enable comparison between gag+ Jurkat clones, SHP-1 
proficient and deficient clones with matched TCR levels were paired. Pairs were chosen to 
have high, medium and low TCR expression (figure 4.11 A, B and C respectively). 
The three pairs of clones were activated with cognate SLY peptide pulsed APCs and 
downregulation of the gag TCR was analysed (figure 4.12). Two of the SHP-1 deficient clones, 
the ones with high and medium TCR levels, showed more TCR downregulation than their 
matched SHP-1 proficient clones at certain peptide doses (figure 4.12 B and C). However, 
despite trying to ensure equivalent T cell to APC ratios, it is important to highlight that the high 
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TCR pair showed a small but statistically significant difference in the T cell to APC ratio, with 
the SHP-1 proficient clone having been incubated with fewer APCs and thus observed 
differences in activation could be due to this factor. In addition, analysing overall levels of TCR 
downregulation between the three pairs showed that cells expressing high levels of TCR have a 
higher potential for TCR downregulation (50% downregulation versus 95%). Hence, the slightly 
higher TCR levels for the unstimulated SHP-1 deficient clones in pairs A and B might be 
contributing to the observed differences.  This is however not true for the pair in C, as the SHP-
1 proficient clone had a higher basal TCR level without showing enhanced TCR downregulation. 
Overall, these results show that the loss of SHP-1 protein enhanced gag+ Jurkat cell activation 
in this model system. 
 
 154 
 
Figure 4.11: Analysis of SHP-1 protein and TCRV5β levels of gag+ Jurkat clones. Gag+ Jurkat 
clones were analysed for SHP-1 protein levels (immunoblot images from figure 4.9) and for 
TCRV5β levels by flow cytometry. SHP-1 deficient clones (left lane on immunoblot and solid 
lines on histogram) were matched for TCRV5β levels with SHP-1 proficient clones (right lane on 
immunoblot and dotted lines on histogram). Controls were unstained SHP-1 proficient (grey 
filled) and deficient (black line) cells. Gag+ Jurkat clones were paired for high (A), intermediate 
(B) and low (C) TCRV5β levels. 
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Figure 4.12: TCR downregulation in response to peptide stimulation of SHP-1 proficient and 
deficient Jurkat clones matched for gag TCR levels. APCs were pulsed with increasing doses of 
cognate SLY peptide or unpulsed for 30 min. SHP-1 proficient (dotted) and deficient (solid) 
Jurkat clones were incubated with peptide pulsed APCs for 60 min and stained for live/dead 
stain, anti-CD19 Ab and anti-TCRV5β Ab. The percentage of TCR downregulation for all three 
pairs of TCR matched clones in relation to unstimulated CD19 negative cells is shown in A), B) 
and C). D) Percentage of T cells (CD19 negative) for each peptide dose and clone is shown. 
Data shown is a single experiment with triplicate wells and the error bars show the SEM. 
**p<0.01 and ****p<0.0001. %TCR=sample MFI/(mean of MFI of non-peptide pulsed 
cells)*100. 
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4.5 Cloning of a gaghigh Jurkat clone transduced with ZFN LVS and 
characterisation of SHP-1 deficient clones 
To obtain SHP-1 deficient and proficient cells that are identical for gag TCR levels, a gag+ Jurkat 
clone expressing high levels of TCR (gaghigh) was either left untransduced or transduced with 
CD2 or ZFN1 and ZFN2-CD2 LVs (figure 4.13). Cells were analysed for CD2 surface expression by 
flow cytometry, SHP-1 mutations by Cel-I and cloned as described before (data not shown). All 
clones (wt, CD2 and ZFN) were immunoblotted for SHP-1 and an absence of SHP-1 protein was 
established in 4/21 SHP-1 ZFN transduced clones (data not shown). 
Figure 4.13: Overview of the cloning strategy to obtain gaghigh clones deficient in SHP-1. 
Clones from a gag+ Jurkat cell pool were obtained and a gaghigh clone was chosen to be 
transduced with either ZFN LVs, CD2 LV or left untransduced.  Transduced and untransduced 
cells were cloned a second time and two SHP-1 deficient clones were chosen from the ZFN LVs 
transduced cells in addition to two clones representing control CD2 and wt cells. Yellow arrows 
indicate mutations in the SHP-1 gene due to ZFN activity and SHP-1+/+ and SHP-1-/- labels 
represent cells with SHP-1 protein present or absent, respectively. 
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Based on SHP-1 protein levels and matching gag TCR levels, two SHP-1 deficient clones (#1 and 
#5), one wt clone and one CD2 transduced clone were selected (figure 4.14 A and B). Although 
all 21 ZFN transduced clones analysed originated from a single clone, varying levels of TCRV5β 
were observed after subcloning (data not shown). The two SHP-1 deficient and two control 
clones were activated with SLY peptide pulsed APCs (10-8 to 10-4 M) and levels of surface 
expression of CD69 were analysed (figure 4.14 C and D). The two SHP-1 deficient clones had 
significantly higher relative upregulation of CD69 than the CD2 transduced control for peptide 
doses above 10-8 M. Yet no significant differences were seen between the wt clone and the 
two SHP-1 deficient clones. All three transduced clones had less CD69 surface expression in the 
absence of peptide stimulation than the wt clone (figure 4.14 C). However, the potential to 
upregulate CD69 in response to high peptide stimulation was not dependant on initial CD69 
levels as clone number 1 had lower basal levels than the CD2 clone but higher CD69 expression 
at 10-4 M (figure 4.14 C). No significant differences in T cell to APC ratios were observed (figure 
4.14 E). Additionally, TCR levels did not seem the limiting factor for CD69 upregulation, as 
clone #5 with the lowest TCR levels showed the highest relative CD69 increase. In summary, 
when only examining transduced cells, the SHP-1 deficient clones were clearly more 
responsive to peptide stimulation than the CD2 control again suggesting that loss of SHP-1 
might enhance T cell activation. 
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Figure 4.14: CD69 upregulation in response to peptide stimulation of two SPH-1 deficient and 
two control gaghigh Jurkat clones. A) Immunoblot for SHP-1 and actin protein using cell lysate 
from two SHP-1 deficient gaghigh Jurkat clones (#1 and #5), one CD2 transduced and one wt 
control gaghigh Jurkat clones. B) The four clones in A were unstained (grey filled) or stained with 
anti-TCRV5β Ab and cells were gated on FSC/SSC, live dead and single cells. Gag TCR levels for 
wt (green dashed), CD2 transduced (blue dotted), SHP-1 deficient clones #1 (red) and #5 
(purple) are shown. C) Histogram overlays for CD69 surface expression are shown for the four 
clones and the isotype control (grey filled) of CD19 negative Jurkat cells either incubated with 
unpulsed APCs (left) or 10-4 M peptide (right). Cells were gated on FSC/SSC, live dead, single 
cell and CD19 negative. D) The fold increase of CD69 surface expression above unstimulated 
cells is shown for cells gated as in C. The CD2 clone was significantly different for all peptide 
doses above 10-8 M (asterisks not shown). Clone #1 was significantly different at 10-5 M and 10-
4 M peptide to clone #5 (*** and **** respectively). E) Percentages of CD19 negative cells 
(Jurkat cells) in total population are shown. No significant differences were observed. Data 
shown is a single experiment with triplicate wells and the error bars show the SEM. 
***p<0.001 and ****p<0.0001. CD69 ratio=sample MFI/(mean of MFI of non-peptide pulsed 
cells). 
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4.6 Generation and characterisation of tumour specific, SHP-1 mutant 
NFAT reporter Jurkat cells 
GLuciferase NFAT reporter Jurkat cells not expressing endogenous TCR were transduced with 
the ZFN LVs as well as a melanoma specific Mel TCR LV (figure 4.15 A and B). All doses of Mel 
TCR (5 µl, 15 µl or 30 µl) and/or ZFN1 and ZFN2-CD2 (5 µl or 15 µl) LV gave complete 
transduction of all cells as indicated by staining for CD2 and FLT tetramer. The Mel TCR 
encoding LV was a 3rd generation whereas the three other LVs were 2nd generation LVs and 
they use the pELN or pSxW (pLenti) transfer vectors respectively. 
When analysed for SHP-1 mutations, all cells transduced with ZFN LVs alone or in combination 
with Mel TCR LV gave strong Cel-I digestion bands (figure 4.15 C).  Cells transduced with 5 µl 
TCR and ZFN LVs showed the highest % of mutant SHP-1 cells at 21%, whereas transduction 
with 3x more LV showed only 14.7%. The LV transduced NFAT Jurkat cells were sorted for 
expression of CD2 and/or tetramer as shown in figures 4.15 D and E and the sorted cells used 
for functional experiments. 
To look at differences in activation between tetramer sorted Mel TCR SHP-1 proficient (Mel+ 
SHP-1+/+) or tetramer and CD2 sorted SHP-1 mutant (Mel+ SHP-1+/-) NFAT Jurkat cells, cells were 
activated for 18 h and luciferase concentrations in the supernatant were measured. It is 
important to remember that the Mel+ SHP-1+/- NFAT Jurkat cells will be a mix of SHP-1 
proficient and deficient cells. Duplicate wells of Jurkat cells were incubated with 
PMA/Ionomycin and PHA as positive controls and with two different melanoma target cell 
lines, Mel526 and Mel624 (figure 4.17). The latter two cell lines present melanoma Ag on HLA-
A2 which can stimulate Mel TCR expressing Jurkat cells and were given to us by Dr John 
Bridgeman. Mel526 and Mel625 cells were checked for HLA-A2 expression and both were HLA-
A2 positive as expected (figure 4.16). 
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Figure 4.15: Analysis of NFAT reporter Jurkat cells for SHP-1 mutations and Mel TCR 
expression. NFAT reporter Jurkat cells were transduced with Mel TCR and/or ZFN1 and ZFN2-
CD2 LV. A) Day 2 post-transduction, cells transfected with 5 µl (green) or 15 µl (red) ZFN1 and 
ZFN2-CD2 LV, 5 µl (orange) or 15 µl (blue) TCR plus ZFN1 and ZFN2-CD2 LV or untransduced 
(grey filled), were stained with live/dead stain, anti-CD2 Ab or isotype ctrl (black).  Cells were 
gated on FSC/SSC, single cells and live/dead. B) Day 9 post-transduction, cells transduced with 
15 µl (blue) or 30 µl (red) TCR LV were stained with 1 µg of FLT tetramer or 0.5 µg (green) of 
FLT tetramer for the 30 µl TCR LV cells or left unstained (black).  Cells were gated on FSC/SSC 
and single cells only. C) At day 6 post-transduction, gDNA was extracted from cells transduced 
as indicated, the 398 bp SHP-1 fragment was amplified by PCR, the PCR product was hybridised 
and digested using Cel-I enzyme. Mutant SHP-1 DNA is indicated by Cel-I digestion DNA 
fragments of 220 bp and 178 bp. D) NFAT Jurkat cells, transduced with 5 µl ZFN1 and ZFN2-CD2 
LV (black) or 5 µl Mel TCR plus ZFN1 and ZFN2-CD2 LV (red), were sorted for CD2 expression by 
MACS separation. Negative (dashed) and positive (solid) fractions of the CD2 sort were 
analysed by flow cytometry after gating on FSC/SSC and single cells. E) NFAT Jurkat cells, 
transduced with 15 µl TCR LV (blue) or 15 µl Mel TCR plus ZFN1 and ZFN2-CD2 LV (red), were 
sorted for tetramer expression by MACS separation. Negative (dashed) and positive (solid) 
fractions of the tetramer sort were analysed by flow cytometry after gating on FSC/SSC and 
single cells. 
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Figure 4.16: Mel526 and Mel624 express HLA-A2. Mel526 and Mel624 cells were collected 
using dissociation buffer and stained using live/dead stain and an α-HLA-A2 Ab. A) Gating 
strategy for Mel526 and Mel624 cells. B) Mel526 and Mel624 were stained with an α-HLA-A2 
Ab (red) or unstained for HLA-A2 (grey filled). 
 
As expected, cells expressing no Mel TCR (wt and SHP-1+/-) did not secrete luciferase when 
activated with the melanoma cells whereas activation by PMA/Ionomycin and PHA gave strong 
signals (figure 4.17). Mel TCR expressing cells (Mel+ and Mel+ SHP-1+/-) were activated by the 
Mel526 and Mel624 tumour target cells as shown by a 2-6 fold increase in luciferase release. 
Interestingly, the Mel+ SHP-1+/- Jurkat cells showed more activation than the Mel+ SHP-1 wt 
Jurkat cells when activated with target cells (2.6 versus 1.9 fold increase in luciferase at 3:1 T 
cells to Mel526 and 6.1 versus 3.4 fold increase at 3:1 T cells to Mel624 cells). However they 
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also showed an increase in activation by PMA/Ionomycin of 364 fold versus 282 fold for the 
Mel+ cells.  
 
Figure 4.17: Activation of Mel TCR expressing NFAT Jurkat cells, wt or mutant for SHP-1, by 
Mel526 and Mel624 melanoma cells. Mel TCR LV (Mel+), Mel TCR and ZFN LVs (Mel+ SHP-1+/-), 
ZFN LVs (SHP-1+/-) transduced and untransduced (wt) GLuciferase NFAT reporter Jurkat cells 
were activated for 18 h with melanoma target cell lines (Mel526 and Mel624) at different E:T 
ratios. PMA/Ionomycin and PHA were used as positive controls for Jurkat activation. 
GLuciferase activity in the supernatant was measured and the data expressed as fold increase 
of luciferase activity over unstimulated cells. The experiment was done in duplicates and each 
single well is shown. 
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In order to test whether reconstituting the Mel+ SHP-1+/- Jurkat cells would lead to a decrease 
in Jurkat cell responsiveness to TCR stimulation, SHP-1 rescue cells were generated by 
transducing cells with a LV encoding the haematopoietic SHP-1 cDNA. To generate the LV 
encoding the SHP-1 cDNA, plasmid encoding the non-haematopoietic SHP-1 cDNA isoform 
(NCBI accession code BC002523) was purchased from ThermoScientific (MGC Human PTPN6 
Sequence-Verified cDNA, clone 3140265). The haematopoietic SHP-1 isoform is distinguished 
from the non-haematopoietic SHP-1 isoform by the use of alternative promoter exons, 
encoding the amino acid sequences MLSRG and MVR, respectively.  
A pLenti-SHP-1 lentiviral transfer plasmid was designed to encode a Kozak sequence followed 
by the haematopoietic SHP-1 cDNA sequence and a stop codon.  Primer 68 encoded the Kozak 
sequence (GCC GCC ACC) upstream of the start codon, the sequence for haematopoietic SHP-1 
cDNA (ATG GTG AGG Æ MVR) as well as a short DNA sequence homologous to both SHP-1 
isoforms (TGG TTT CAC CGA GAC CTC). Primer 68 and 69 were used to amplify the SHP-1 cDNA 
from the purchased plasmid (figure 4.15 A). The PCR product was purified further amplified 
using primers 70 and 71 to generate a SHP-1 cDNA with homology for the pLenti vector, thus 
allowing for an In-Fusion recombination reaction (figure 4.18 B and C). 
NFAT Jurkat cells, previously transduced with the Mel TCR and ZFN LVs (Mel+ SHP-1+/-) (figure 
4.15), were transduced with the haematopoietic SHP-1 cDNA LV (Mel+ SHP-1+/- ‘rescued’) and it 
was shown by immunoblotting that the Mel+ SHP-1+/- ‘rescued’ Jurkat cells strongly express 
SHP-1 whereas mutations in the SHP-1 gene were still observed by the Cel-I assay (figure 4.19). 
In fact, all three cell types transduced with ZFNs contain approximately 25% of cells with SHP-1 
mutations (figure 4.19 A). The SHP-1 protein expression in the LV transduced cells is driven by 
the SFFV promoter and consequently the SHP-1 levels are not physiological (figure 4.19 B). It is 
of note that the SHP-1 cDNA will not be liable to mutation by the ZFNs as the binding site of 
ZFN1 is located in an intron and thus absent in the cDNA. Additionally primers 55 and 56 will 
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not amplify the cDNA as primer 55 binds within the intron. This matches with the equal 
percentage of SHP-1 mutant cells observed.  
To check the SHP-1 ‘rescued’ Mel+ Jurkat cells for altered activation, cells were activated with 
peptide pulsed APCs and the supernatant assayed for luciferase activity (figure 4.20 A). The 
APCs were pulsed with increasing doses of cognate EAAGIGILTV peptide (10-8 M to 10-4 M). At 
similar T cell to APC ratios, the Mel+ and Mel+ SHP-1+/- cells showed a significant difference at 
10-5 M peptide but at no other peptide doses (figure 4.20 A and B).  Meanwhile, the Mel+ SHP-
1+/- ‘rescued’ cells showed significantly lower activation at the two highest peptide doses. Thus 
this suggests that the SHP-1 mutations present in the Mel+ SHP-1+/- cell population may lead to 
increased Jurkat activation whereas overexpression of the SHP-1 protein clearly inhibits 
activation. 
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Figure 4.18: Cloning of the haematopoietic SHP-1 cDNA into the pLenti transfer plasmid. A) 
Lane 2 shows the 1797 bp Kozak and haematopoietic SHP-1 cDNA sequence amplified from the 
ThermoScientific plasmid template using primers 68 and 69. The PCR product was gel purified. 
B) Lane 2 shows the 1829 bp PCR reaction product of the purified PCR product from A) and 
primers 70 and 71. The linearised pSxW vector was purified and used with the purified PCR 
product to set up an In-Fusion reaction. DH5α cells were transformed with 2 µl of In-Fusion 
mix. C) Plasmid DNA extracted from DH5α colonies transformed as described above and 
selected for Ampicillin resistance was restriction digested with BamHI. The upper DNA 
fragment shows the BamHI linearised 8942 bp pSxW and the two lower bands correspond to 
the two BamHI restriction fragments of the haematopoietic SHP-1 (1631 bp and 172 bp 
respectively). Primers 33-34 and 72-77 were used to sequence the pLenti-SHP-1 plasmid and 
the correct sequence was confirmed. 
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Figure 4.19: SHP-1 gene and protein analysis in Mel+ SHP-1+/- ‘rescued’ NFAT Jurkat cells. 
NFAT Jurkat cells were either left untransduced (wt), transduced with Mel TCR LV (Mel+), ZFN 
LVs (SHP-1+/-) or with Mel TCR and ZFN LVs (Mel+ SHP-1+/-). The latter cells were additionally 
transduced with haematopoietic SHP-1 cDNA LV (Mel+ SHP-1+/- ‘rescued’). A) Genomic DNA 
was extracted from cells and the Cel-I assay was done giving 398 bp wt and 220 bp and 178 bp 
Cel-I restriction bands. B) Cell lysate was extracted from cells as indicated and an immunoblot 
using anti-SHP-1 and anti-actin Abs was done. 
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Figure 4.20: Activation of Mel TCR expressing NFAT Jurkat cells, wt, mutant or ‘rescued’ for 
SHP-1, by peptide pulsed APCs. Mel TCR LV (Mel+), Mel TCR and ZFN LVs (Mel+ SHP-1+/-) and 
Mel+ SHP-1+/- ‘rescued’ cells, ZFN LVs (SHP-1+/-) transduced and untransduced (wt) GLuciferase 
NFAT reporter Jurkat cells were activated for 18 h with APCs pulsed with a titration of cognate 
EAA peptide. A) Luciferase activity in the supernatant was measured and the fold increase over 
unstimulated cells is shown for each cell type. Statistical analysis was done and significant 
differences between Mel+ and Mel+ SHP-1+/- or Mel+ SHP-1+/- ‘rescued’ cells are indicated. B) 
The ratio of Jurkat cells to APCs was measured by flow cytometry. Cells were gated on 
FSC/SSC, live/dead, single cells and CD19 negative. Each condition was done in triplicates and 
the SEM is shown. *p<0.05, **p<0.01 and ****p<0.0001.  
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4.7 Discussion 
In this chapter, nearly 100 leukaemic T cell clones, lentivirally transduced with SHP-1 specific 
ZFNs, were analysed for SHP-1 protein expression by immunoblotting (table 4.2) and overall, 
approximately a quarter of cells showed a complete lack of detectable SHP-1 protein.  
 SHP-1+/+ SHP-1+/- SHP-1-/- unclear Number of clones studied 
Chapter 
heading 
gag+ Jurkat clones 19 (54%) 7 (20%) 9 (26%)  35 4.4 
gag+ high Jurkat 
clones 
9 (43%) 4 (19%) 4 (19%) 4 (19%) 21 4.5 
Total gag+ Jurkat 
cells 
28 (50%) 11 
(19.6%) 
13 
(23.2%) 
4 (7.1%) 56  
gag+ MOLT-3 clones 3 (23%) 6 (46%) 4 (31%)  13 4.2 
gag+ high MOLT-3 
clones 
3 (20%) 5 (33%) 6 (40%) 1 (7%) 15 not 
shown 
gag+ high MOLT-3 
clones 
4 (29%) 7 (50%) 1 (7%) 2 (14%) 14 not 
shown 
Total gag+ MOLT-3 
clones 
10 
(23.8%) 
18 
(42.9%) 
11 
(26.2%) 
3 (7.1%) 42  
Total 38 
(38.8%) 
29 
(29.6%) 
24 
(24.5%) 
7 
(7.1%) 
98  
Table 4.2: Summary of SHP-1 protein expression of all ZFN1 and ZFN2 or ZFN2-CD2 LV 
transduced leukaemic cell clones. Percentages of SHP-1 proficient (SHP-1+/+), SHP-1 
intermediate (SHP-1+/-) and SHP-1 deficient (SHP-1-/-) gag+ Jurkat and gag+ MOLT-3 cells are 
shown from all the cells analysed after ZFN1 and ZFN2 or ZFN2-CD2 transduction. 
 
As well as immunoblotting for the SHP-1 protein, cells were analysed using the Cel-I mismatch 
assay. Both assays were used as it is possible that the Cel-I assay gives an overestimation of the 
extent of SHP-1 protein loss, due to some mutations being silent or in-frame, whereas 
immunoblotting can give an underestimation of SHP-1 protein loss, due to the presence of 
functionally defective full length SHP-1. Conversely, the Cel-I assay showed a low signal for 
 169 
 
clone P5 3G but no SHP-1 protein was detected by immunoblotting and it is thus of use to 
perform both assays. 
To analyse the precise nature of SHP-1 mutations on both alleles of a clone, TA cloning was 
performed and it was shown that the predominant mutations were deletions which is in 
accordance with other studies such as the ZFN mediated knockout of CCR5 (Perez et al. 2008). 
Once SHP-1 deficient T cell clones were identified, they were used for functional assays such as 
CD69 upregulation, TCR downregulation and proliferation. Although clones were grown under 
the same conditions during the cloning process, differences in TCR were observed indicating 
that levels of other molecules could also differ and that the final clones were inherently 
distinct. This was even observed, albeit to a lesser degree, when cloning was set up from a 
single clone.  
The most likely explanation for the lack of a clear phenotype in SHP-1 deficient leukaemic T cell 
clones is that the most pronounced effect of SHP-1 loss is on increasing the likelihood of cell 
entry into proliferation (Sathish et al. 2007). However, the latter cannot be studied in 
leukaemic T cells, as shown in this chapter, due to the rapid and constitutive proliferation of 
these cells under basal conditions. Additionally, it is possible that cells expressing wt levels of 
SHP-1 as demonstrated by immunoblotting had acquired mutations by the time the functional 
assays were started, due to the nature of the integrase proficient ZFN delivery.  
In addition, most of the functional assays were done with cells expressing the high affinity gag 
TCR which may also have contributed to the lack of consistent statistically significant 
differences observed between SHP-1 sufficient and deficient cells. As mentioned in the 
Introduction, the phenotypic differences seen in SHP-1 deficient T cells might only be 
applicable when T cells are stimulated suboptimally (Migone et al. 1998; Sathish et al. 2001b). 
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The inhibition of T cell activation observed in Jurkat cells overexpressing SHP-1 (figure 4.20) is 
in contrast to findings by Plas et al. that showed that overexpression of SHP-1 in a T cell 
hybridoma cell line did not change the activation of these cells (Plas et al. 1996). However, the 
SHP-1 overexpression in the Plas study was not as marked as the one seen here and might thus 
not have had such a strong effect. This observation was not studied further in this thesis. 
Overall, it was shown that the mutations induced by the SHP-1 specific ZFNs can lead to the 
complete loss of SHP-1 protein expression in leukaemic T cell clones. Meanwhile, no clear 
phenotype could be identified in SHP-1 deficient leukaemic T cells therefore further 
experiments were performed in primary CD8+ T cells. 
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Chapter 5: Generation of mutant SHP-1 tumour-specific 
primary CD8+ T cells and functional analysis 
5.1 Introduction 
In this chapter, the growth and subsequent lentiviral transduction of primary CD8+ T cells was 
optimised in order to obtain tumour-specific mutant SHP-1 CD8+ T cells (figure 5.1 A and C). 
The T cells were transduced with the melanoma-specific Mel TCR recognising the HLA-A2 
presented MART-126-35 peptide. Additionally, the ZFN1 and ZFN2-CD2 LVs (also referred to as 
ZFN LVs) were delivered to the T cells to induce mutations in the SHP-1 gene. Different 
strategies of transduction were tried such as delivering the three lentiviruses simultaneously or 
consecutively, at different ratios and varying LV quantities (figure 5.1 C). The delay between 
the consecutive transductions was either very short (15 or 30 min) or a whole restimulation 
cycle (2-3 weeks). Mel TCR expressing (Mel+) and mutant SHP-1 (ZFN2-CD2+) cell populations 
were generated and sorted using two different techniques, MACS or FACS separations. All LV 
used in this chapter was 100x concentrated and the ZFN LVs were generated using a 2nd 
generation packaging system whereas the Mel LV and RFP-GLuciferase LVs were generated 
using the 3rd generation packaging system. Initially, LV was quantified using a p24 ELISA and 
the four different LV preparations tested gave readings of 1-28 ng/µl. However due to 
inaccuracy and high costs, this assay was not used throughout. An assumption had to be made 
that each LV preparation would contain approximately the same quantity of LV and hence the 
amount of LV was estimated by volume. 
The Mel526 melanoma target cell line was genetically engineered to express non-secreted 
GLuciferase protein, which is only released upon lysis (figure 5.1 D). The GLuciferase Mel526 
cells were used as targets for the SHP-1 sufficient and mutant SHP-1 Mel+ CD8+ T cells and 
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cytotoxicity assessed by measuring GLuciferase released into the supernatant. Additionally, 
cell survival and proliferation was estimated for both the SHP-1 sufficient and mutant SHP-1 
Mel+ CD8+ T cells. 
Figure 5.1: Summary of the growth and LV transduction of primary CD8+ T cells and the CD8+ 
T cell cytotoxicity assay used in this chapter. A) Protocol for the growth and LV transduction 
of primary CD8+ T cells isolated from PBMCs. A more detailed protocol can be found in the 
‘Material and Methods’. B) Primary CD8+ T cells were transduced with Mel TCR, ZFN1 and 
ZFN2-CD2 LVs to generate mutant SHP-1 (yellow encircled DNA) Mel TCR expressing (red 
receptors) CD8+ T cells. C) The optimisation steps for the LV transduction of CD8+ T cells with 
the ZFN and Mel LVs are shown along with the corresponding sections in this chapter. The 
ratio of LV shown indicates ZFN1:ZFN2:Mel LV. D) The HLA-A2+ Mel526 melanoma cell line was 
transduced with an RFP-GLuciferase LV to obtain RFP+ (pink) Mel526 cells expressing the non-
secreted GLuciferase protein (orange box). The CD8+ T cells generated in B were used in 
Mel526 killing experiments, whereby the release of GLuciferase into the supernatant was used 
as a readout for cytotoxicity. 
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5.2 Optimisation of the generation of mutant SHP-1 melanoma-specific 
primary CD8+ T cells 
To generate melanoma-specific CD8+ T cells deficient in SHP-1, three lentiviruses expressing 
the melanoma-specific Mel TCR plus the two SHP-1 specific ZFNs were delivered to cells. 
Multiple optimisation steps were needed to achieve this goal as described below. 
 
5.2.1 Simultaneous and consecutive transduction of CD8+ T cells with ZFN1 and ZFN2-
CD2 LVs 
PBMCs, from an HLA-A2 negative O- buffy coat obtained from the Welsh Blood Service, were 
isolated by Ficoll density gradient centrifugation and CD8+ T cells selected by a positive CD8 
MACS sort (figure 5.2 A and B). The transduction protocol described in ‘Materials and 
Methods’ was followed and cells that were initially rested in RPMI, 20% FCS overnight, were 
transduced with either 10 µl or 20 µl of 100x concentrated ZFN1, ZFN2-CD2 LV stock or both 
LVs together. Cells were expanded two days post-transduction with irradiated PBMCs and 
eight days post-transduction, were stained for CD2 surface expression after gating on live CD8+ 
cells (figure 5.2 C-F). Cells transduced with 10 µl or 20 µl ZFN2-CD2 LV were 91% and 89%  CD2+ 
respectively, whereas only 60-61% of cells transduced with both the ZFN1 and ZFN2-CD2 LVs 
were CD2+. This indicated the possibility of the LVs competing for access to the cells and/or 
integration into the genome. 
To test whether cells could be consecutively transduced after one cycle of restimulation (day 
12 post-transduction), ZFN1 LV was added to cells previously transduced with ZFN2-CD2 LV 
and vice versa. Consecutive transduction was less successful than simultaneous transduction 
as only 3.4-7.6% of cells were CD2+ (figure 5.2 G and H). Moreover, the frequency of CD2+ cells 
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in the population of cells initially transduced with ZFN2-CD2 LV decreased after the second 
transduction with ZFN1 LV from 71% to 35% (figure 5.2 I). 
Figure 5.2: Simultaneous and consecutive transduction of HLA-A2- CD8+ T cells with ZFN1 
or/and ZFN2-CD2 LVs. A) PBMCs were isolated from buffy coats and CD8+ T cells were sorted 
by positive MACS selection. The positively (red) and negatively (blue) sorted fractions of cells 
were stained using an anti-CD8 Ab and analysed by flow cytometry. B) The CD8+ T cells were 
stained for surface expression of HLA-A2 (red). A HLA-A2 positive cell line, C1R, was used as a 
staining control (blue). C) Gating strategy for CD8+ T cells stained with live/dead stain and anti-
CD8 Ab. D-F) CD8+ T cells were transduced with either 10 µl (red) or 20 µl (blue) of ZFN1 or/and 
ZFN2-CD2 LVs and stained with anti-CD2 Ab, 8 days post-transduction. G-I) Cells transduced 
with either 10 µl or 20 µl ZFN1 or 20 µl ZFN2-CD2 LV were transduced a second time with 10 µl 
ZFN2-CD2 or ZFN1 LV respectively (blue) or not transduced (red) and stained with anti-CD2 Ab. 
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Cells consecutively transduced with ZFN1 and ZFN2-CD2 LV, were positively sorted for CD2 and 
the Cel-I assay performed on gDNA extracted from CD2 negative and positive fractions as well 
as cells from single transductions (figure 5.3). Cells that were transduced simultaneously with 
both ZFN LVs (figure 5.2 F) showed a mismatch signal indicating 8.3% of mutated cells whereas 
the consecutively transduced CD2+ cells did not show any signal. This indicates that the small 
number of cells that were transduced in the second round were the cells that had not been 
transduced with the first LV and thus did not express both ZFNs necessary to induce 
mutations. Overall, this indicated that SHP-1 mutations can be achieved in CD8+ T cells 
transduced simultaneously with both ZFN LVs, rather than consecutively. 
Figure 5.3: Cel-I assay of CD8+ T cells transduced with ZFN1 or/and ZFN2-CD2 LVs. A) gDNA 
was extracted from cells transduced with different combinations of LVs, as indicated below 
each lane. The CD2+ and CD2- fractions represent cells from a CD2 positive MACS sort of cells 
consecutively transduced with ZFN1 and ZFN2-CD2 LV. A 398 bp SHP-1 genomic segment was 
amplified by PCR. The negative control (-ve ctrl) was a PCR reaction without gDNA. B) After 
hybridisation of the PCR product and digestion of the DNA with the Cel-I enzyme, mutated 
SHP-1 DNA is indicated by 178 bp and 220 bp DNA cleavage fragments. Gag+ MOLT-3 cells 
transduced with the ZFN1 and ZFN2 LVs were used as a positive control. The % of cells 
harbouring SHP-1 mutations was obtained by ImageJ analysis. 
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5.2.2 Transduction of HLA-A2+ CD8+ T cells with ZFN and Mel LVs 
Cells from a HLA-A2+ donor were transduced simultaneously with both ZFN and the Mel LVs, in 
order to generate SHP-1 deficient CD8+ T cells that can recognise the HLA-A2+ melanoma cell 
lines Mel526 and Mel624 (figure 5.4 A). 
Cells were either transduced with control CD2 LV (100 µl), ZFN1 and ZFN2-CD2 LVs (50 µl / 80 
µl), Mel LV (50 µl or 150 µl) or the latter three LVs together (3 x 50 µl or 3 x 100 µl) (figure 5.4 
B).  At day 12 post-transduction, 90% of the CD2 transduced cells were CD2+ whereas only 34-
44% of the ZFN1 and ZFN2-CD2 transduced cells were CD2+. Doubling the volume of LV used, 
from 50 µl to 100 µl, did not increase the fraction of transduced cells thus the lower dose of 
the ZFN LVs was used in the subsequent experiments.  
To determine the transduction efficiency of the Mel LV, cells were stained with FLT tetramer. 
Cells transduced with Mel LV alone showed 16-20% of FLT tetramer+ staining. However, cells 
transduced with Mel LV and the two ZFN LVs showed a maximum of 0.5% tetramer+ cells 
(figure 5.4 B and C). At equivalent volumes of Mel LV, the singly transduced cells gave a much 
larger tetramer+ population than the triply transduced cells, with 16.4% and 0.5% respectively. 
Once more, this indicated that there is competition between the LVs when added to cells 
simultaneously and showed that the ZFN LVs outcompete the Mel LV. 
Cells shown in figure 5.4 were stained using an FLT tetramer in the absence of the reversible 
protein kinase inhibitor Dasatinib, which has been shown to inhibit T cell activation by the 
tetramer and thus inhibit TCR downregulation and cell death (Lissina et al. 2009). Staining of 
the cells 3 days later in the absence or presence of Dasatinib showed an increase of tetramer 
staining from 16.7% to 25.4% (figure 5.4 B and figure 5.5) for the 150 µl Mel LV transduced 
cells. Thus tetramer staining in figure 5.4 gave an underestimation of successfully transduced 
tetramer+ cells. However, in the presence of Dasatinib, the triply transduced cell did not show 
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any tetramer staining above background. Dasatinib was subsequently included in all tetramer 
staining. 
Figure 5.4: Transduction of HLA-A2+ CD8+ T cells with Mel and/or ZFN LVs.  CD8+ T cells 
isolated from an HLA-A2+ donor were transduced with varying volumes of Mel and/or ZFN LVs 
and stained with anti-CD2 Ab or FLT tetramer 12 days post-transduction. Cells were gated on 
FSC/SSC, live/dead stain, single cells and CD8+. A) Cells were stained with anti-HLA-A2 antibody 
(red) or left unstained (grey filled) and an overlay of both samples is shown for live CD8+ T 
cells.  B) Histograms showing overlays for tetramer (left) or CD2 (right) staining. Cells were 
transduced with 50 µl (red) or 150 µl (purple) of Mel LV, 50 µl of ZFN1 and 80 µl ZFN2-CD2 of 
LVs (orange), 50 µl (bright green) or 100 µl (dark green) of the ZFNs and Mel LVs and 100 µl of 
CD2 LV (blue). C) Frequencies in % of CD2+ (green) and tetramer+ (blue) cells in the PE gated, 
live CD8+ cells populations shown in B). The dotted line indicates the background levels of 
tetramer staining. 
 
 178 
 
Figure 5.5: Effect of the protein kinase inhibitor Dasatinib on FLT tetramer staining of CD8+ T 
cells transduced with Mel LV. CD8+ T cells, transduced as described in figure 5.4, were stained 
with FLT tetramer and anti-CD3 Ab, in the presence or absence of Dasatinib, 15 days post-
transduction. Cells were gated on FSC/SSC, live/dead stain, single cells and CD8+. 
 
T cells were stained with either PE conjugated anti-CD2 Ab or FLT tetramer and cells sorted 
using a PE positive MACS sort (figure 5.6). 96% and 91% of the positively sorted cells for CD2 
and tetramer, respectively, showed strong CD2 expression. The negatively sorted fractions 
showed a mix of CD2 positive and negative cells with 27% of CD2+ cells in the CD2 negative 
sorted fraction of the ZFNs and TCR transduced cells and 14% of tetramer+ cells in the negative 
tetramer fraction. Thus this sorting method results in a loss of a substantial fraction of the CD2 
and tetramer expressing population, reducing the number of potential mutant SHP-1 Mel+ cells 
available for further studies. 
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Figure 5.6: Lentivirally transduced CD8+ T cells were sorted for CD2+ or tetramer+ by MACS 
separation.  Cells shown were gated on FSC/SSC profile and single cells only. A) CD8+ T cells 
transduced with control CD2 LV, both ZFN LVs or both ZFN and Mel LVs were stained with a PE 
conjugated anti-CD2 Ab and sorted into PE positive (red) and PE negative (blue) fractions using 
MACS columns. B) CD8+ T cells transduced with Mel LV were stained with PE-conjugated FLT 
and sorted for PE positivity into a PE positive (red) and a PE negative (blue) fraction using 
MACS columns. 
 
Unsorted and sorted cells were collected, gDNA extracted and used for the Cel-I mismatch 
assay shown in figure 5.7. Mutant SHP-1 cells were found in all cell populations transduced 
with both ZFN LVs (lanes 3 and 5-9). The strongest Cel-I signal of 12% mutant cells was seen in 
the CD2+ sorted cells transduced with both ZFN LVs but not the Mel LV in lane 3. Comparing 
CD2+ sorted cells to unsorted cells (lanes 3 and 5) showed that sorting cells for expression of 
ZFN2-CD2 clearly increased the Cel-I signal from 2% to 12% of mutant cells. The CD2- sorted 
cells in lane 6 encompass a population of 2.5% of mutated cells matching the observation that 
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the CD2- population includes cells expressing ZFN2-CD2 (figure 5.6 A). Interestingly, cells 
transduced with the three LVs and positively sorted for CD2 in lane 8, showed much lower 
mutation frequencies than sorted cells transduced with the ZFN LVs alone in lane 3 (3.5% 
versus 12%). Overall, transduction of multiple LVs seems to reduce the frequency of uptake of 
any of the three LVs, hence the possibility that fewer cells will express both non-tagged ZFN1 
and ZFN2-CD2 when Mel LV was added causing the overall reduction of mutant SHP-1 alleles. 
Figure 5.7: Cel-I assay of CD8+ T cells transduced with the ZFN and/or Mel LVs. A) gDNA was 
extracted from cells transduced with LVs as indicated below each lane and a 398 bp SHP-1 
genomic segment was amplified by PCR. The negative control (-ve ctrl) was a PCR reaction 
without gDNA. B) After hybridisation of the PCR product and digestion of the DNA with the Cel-
I enzyme, the presence of mutated SHP-1 DNA is indicated by 178 bp and 220 bp DNA cleavage 
fragments. Tetramer+ or CD2+ indicates cells that were sorted for PE positivity by MACS (Mel 
TCR or ZFN2-CD2, respectively). Gag+ Jurkat cells transduced with the ZFN LVs were used as a 
positive control. 
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To increase the number of mutant SHP-1 cells expressing Mel TCR, CD2+ sorted cells were 
transduced a second time with Mel LV (figure 5.8 B). Cells stained 20 days later showed a very 
low frequency of tetramer+ cells previously transduced with control CD2 LV (1.15%) and only 
background tetramer staining for cells previously transduced with the ZFN LVs (0.23%). This 
result together with results shown in figure 5.2 E confirm that consecutive lentiviral 
transductions is not efficient for primary CD8+ T cells whereas it was for leukaemic T cell lines. 
The strategy used for future experiments was to co-transduce T cells with all three LVs 
simultaneously. 
Figure 5.8: Transduction with Mel LV of CD2+ sorted CD8+ T cells previously transduced with 
ZFN LVs. A) CD8+ T cells transduced with Mel LV and tetramer+ sorted were stained with anti-
CD8 Ab and FLT tetramer (right panel) or no tetramer (left panel). These cells were used as a 
positive and negative controls for B. B) CD8+ T cells transduced with CD2 (left panel) or ZFN LVs 
(right panel) were CD2+ sorted and subsequently transduced a second time with Mel LV. Cells 
were stained with anti-CD8 Ab and FLT tetramer 20 days post-transduction. All graphs were 
gated on FSC/SSC, live/dead and single cells. 
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5.2.3 Transduction of HLA-A2+ CD8+ T cells with delayed addition of ZFN and Mel LVs 
at a different ratio 
Previous results seemed to indicate that the 2nd generation ZFN LVs outcompete the 3rd 
generation Mel LV, so to optimise transduction with all three LVs, the ratio between the ZFN 
LVs and the Mel LV was altered from a 1:1:1 to a 1:1:6.25 ratio. Additionally, the ZFN LVs were 
added with a delay of 15 or 30 min to test whether this could increase Mel LV transduction of T 
cells. Earlier results had shown that different volumes of ZFN2-CD2 LV (50, 80 or 100 µl) gave 
similar levels of transduction of approximately 38%, indicating that lower LV volumes might be 
sufficient. Here, 16 µl of each of the ZFN LVs were added to cells. As shown in figure 5.9, 
delayed addition of the ZFN LVs to the Mel LV gave a lower frequency of ‘tetramer+’ or 
‘tetramer+ CD2+’ cells. However the 1:1:6.25 ratio of Mel to ZFN LVs did increase the frequency 
of double positive cells to 1.4% above background, compared to 0.5% in figure 5.4 at a 1:1:1 
ratio. 
Cells transduced with the Mel LV only or with all three LVs were sorted for Mel TCR expression 
by MACS column separation. The latter were expanded for two weeks and then sorted for CD2 
expression by MACS column separation. The tetramer+ sorted cells were stained two weeks 
later with both the high affinity FLT tetramer (5.1 µM) and the lower affinity ELA tetramer (18 
µM) (Ekeruche-Makinde et al. 2012) to compare staining as the ELA tetramer was more readily 
available (figure 5.10 A). Although the ELA tetramer gave a slightly lower frequency of 
tetramer positive cells (77.5% versus 80.7%), the ELA tetramer was used for all further Mel TCR 
staining due to its availability.  
The tetramer and CD2 MACS separations yielded large populations of double negative (19-
28%) or CD2+ (26%) cells (figure 5.10 A). To enrich for single and double positive cells, flow 
cytometry sorting was done after cells had undergone a further, 3rd cycle of restimulation. The 
sort reports are shown in figure 5.10 B and C for ‘tetramer+’ sorts of the Mel LV cells and 
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‘tetramer+ CD2+’ or ‘tetramer- CD2-’ sorts of the Mel and ZFNs LVs cells respectively. The doubly 
negative ‘tetramer- CD2’ cells were isolated to use as a control in cytotoxicity assays. 
Figure 5.9: Delayed addition of ZFN LV to Mel LV treated HLA-A2+ CD8+ T cells.  A) CD8+ T cells 
from an HLA-A2+ donor were transduced with 100 µl Mel LV and 16 µl each of the ZFN1 and 
ZFN2-CD2 LVs were added either simultaneously or with a 15 min or 30 min delay. Ten days 
post-transduction, cells were stained using an anti-CD2 Ab and FLT tetramer and gated on 
FSC/SSC, live/dead stain, single cells and CD8+. B) Frequencies of CD2+ (green), ‘tetramer+’ 
(blue) or ‘CD2+ and tetramer+’ cells in the live CD8+ T cell population shown in A. 
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Figure 5.10: MACS and FACS sorting of Mel and/or ZFN LVs transduced CD8+ T cells into 
‘tetramer+’ and  ‘tetramer+ CD2+’ populations. A) CD8+ T cells transduced with Mel LV (top 
panels) or Mel and ZFN LVs (bottom panel) were sort by anti-PE MACS separation columns for 
tetramer or tetramer and CD2, respectively. Cells were expanded for two weeks before 
undergoing the second MACS sort for CD2+ cells. Cells were gated on FSC/SSC, live/dead stain 
and single cells. B) Tetramer+ sorted cells from A, top panel, were stained with 1.42 µg FLT and 
2.06 µg ELA tetramer and sorted by flow cytometry. Cells were gated on FSC/SSC (P1), single 
cells (P2) and 2.8 x 106 ‘tetramer+’ cells (P3) were collected and expanded. C) ‘Tetramer+ and 
CD2+’ sorted cells from A, bottom panel, were stained with 1.42 µg FLT and 2.06 µg ELA 
tetramer and sorted by flow cytometry. Cells were gated on FSC/SSC (P1), single cells (P2) and 
5.4 x 106 ‘tetramer+ CD2+’ cells (P5) and 0.8 x 106 double negative cells (P6) were collected and 
expanded. 
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The Cel-I mismatch assay was done on the ‘tetramer+’, ‘tetramer+ CD2+’ and ‘tetramer- CD2-’ 
FACS sorted cells (figure 5.11). A Cel-I signal indicating 3.7% mutant cells was observed with 
the ‘tetramer+ CD2+’ cells. The low level of SHP-1 germline mutations may have resulted from 
cells not having been transduced with the ZFN1 LV and thus not expressing both ZFNs 
necessary to induce mutations. However, the lack of reporter gene in the ZFN1 LV meant that 
no further sorting was possible. 
Figure 5.11: Cel-I assay of ‘tetramer+’, ‘CD2+ and tetramer+’ or ‘tetramer- CD2-’ CD8+ T cells. A) 
gDNA was extracted from tetramer+ populations of Mel LV only cells and CD2+ and tetramer+ 
or double negative populations of Mel and ZFN LVs cells. A 398 bp SHP-1 genomic segment 
was amplified by PCR. The negative control was a PCR reaction without gDNA. B) After 
hybridisation, the PCR product was digested with the Cel-I enzyme and mutated SHP-1 DNA is 
indicated by the presence of 178 bp and 220 bp DNA cleavage fragments. 
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5.2.4 Transduction of HLA-A2+ CD8+ T cells with varying volumes of ZFN and Mel LVs 
As the previous transductions showed no improvement when delaying the addition of ZFN LVs, 
all three LVs were added simultaneously to cells and at the same ratio as before (1:1:6.25). To 
optimise transduction further, not only 100 µl but also 50 µl of the Mel LV was added, keeping 
the same ratio. Similarly to the previous experiment, transduction of HLA-A2+ CD8+ T cells with 
60 µl Mel LV gave 18% ‘tetramer+’ cells, whereas 22% of cells were CD2+ when transduced with 
16 µl of each of ZFN1 and ZFN2-CD2 (figure 5.12). Most importantly, transduction with Mel LV 
and ZFN LVs showed only 0.03-0.86% ‘tetramer+ CD2+’ cells above background of non-
transduced cells. 
Cells from the Mel LV transductions were pooled and FACS sorted for tetramer+, ZFN LVs 
transduced cells were pooled and FACS sorted for CD2+ and triply transduced cells were pooled 
and FACS sorted into ‘tetramer+ CD2+’ or ‘tetramer- CD2-’ populations. Sort reports are shown 
in figure 5.13. 
Sorted cells were analysed for SHP-1 mutations using the Cel-I mismatch assay. However, due 
to an inadvertent bacterial infection in the CD2+ sorted ZFN LVs transduced population, only 
the ‘tetramer+’, ‘tetramer- CD2-‘ and the ‘tetramer+ CD2+’ cell populations were analysed 
(figure 5.14). The samples from the Cel-I assay in figure 5.11 B were run on the same 
electrophoresis gel as the samples in figure 5.14 B, and when comparing the two, the latter 
transduction showed a higher transduction frequency indicated by 7.2% of mutant cells 
compared to 3.7% previously. 
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Figure 5.12: Transduction of HLA-A2+ CD8+ T cells with the Mel and/or ZFN LVs.  A) CD8+ T 
cells isolated from an HLA-A2+ donor were transduced with 16 µl of ZFN1 and ZFN2-CD2 LVs 
(top right panel), 20 µl or 60 µl Mel LV (middle two panels), 50 µl or 100 µl Mel and 8 µl or 16 
µl ZFN LVs (bottom two panels) and stained with anti-CD2 Ab and FLT tetramer 9 days later. 
Cells were gated on FSC/SSC, live/dead stain, single cells and CD8+. B) Frequencies of CD2+ 
(green), ‘tetramer+’ (blue) or ‘tetramer+ CD2+’ (red) cells are shown for cells gated as in A, after 
subtracting the frequency of the matching population of the FMO controls. 
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Figure 5.13: Mel and/or ZFN LVs transduced CD8+ T cells were sorted into ‘tetramer+’ or 
‘tetramer+ CD2+’ populations by FACS. CD8+ T cells transduced with Mel LV (A), ZFN1 and 
ZFN2-CD2 LVs (B) or Mel and ZFN LVs (C) were stained with anti-CD2 Ab, 1.42 µg FLT and 2.06 
µg ELA tetramer and sorted by flow cytometry. All cells were gated on FSC/SSC (P1) and single 
cell gates (P2). A) 0.2 x 106 tetramer+ cells (P3) were collected and expanded. B) 0.6 x 106 CD2+ 
cells (P5) were collected and expanded. C) 0.02 x 106 ‘tetramer+ CD2+’ cells (P5) and 2.1 x 106 
double negative cells (P6) were collected and expanded. 
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Figure 5.14: Cel-I assay of ‘tetramer+’, ‘tetramer+ CD2+’ or ‘tetramer- CD2-’ CD8+ T cells. A) 
gDNA was extracted from ‘tetramer+’, ‘tetramer+ CD2+’ or ‘tetramer- CD2-’ FACS sorted cells 
and a 398 bp SHP-1 genomic segment. The negative control was a PCR reaction without gDNA. 
B) After hybridisation of the PCR product and digestion of the DNA with the Cel-I enzyme, 
mutated SHP-1 DNA is indicated by 178 bp and 220 bp DNA cleavage fragments. 
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5.3 Killing and proliferation of mutant SHP-1 Mel+ CD8+ T cells in 
response to melanoma target cells 
As shown in experiments in the previous chapter, the Mel TCR recognises the HLA-A2+ Mel526 
and Mel624 melanoma cell lines (figure 4.18). Here, killing of melanoma target cells by SHP-1 
sufficient and mutant SHP-1 Mel+ CD8+ T cells was studied as well as cell survival and 
proliferation of these cells. Table 5.1 shows the different cells used in the following 
experiments. It is important to remember that the mutant SHP-1 population will only have a 
small percentage (<4-8% as shown by Cel-I assays) of cells with complete lack of functional 
SHP-1 protein and is hence not referred to as a SHP-1 deficient population. 
 wt/CD2
+ 
CD8+ 
Mel+ 
CD8+ 
Mel- CD2- 
CD8+ 
Mel+ CD2- CD8+ 
(SHP-1 sufficient) 
Mel+ CD2+ CD8+ 
(mutant SHP-1) 
Mel TCR - + - + + 
SHP-1 +/+ +/+ +/+ +/+ +/+, +/- and -/- 
      
LV used none/CD2 Mel ZFN and Mel LVs Mel LV ZFN and Mel LVs 
Reference Figure 5.10 A 
Figure 
5.10 A 
Figure 5.10 
B / 5.13 C 
Figure 5.10 B / 
5.13 A 
Figure 5.10 B / 
5.13 C 
Table 5.1: Characterisation of primary CD8+ T cells used in killing experiments. Orange shaded 
boxes indicate cells expressing the Mel TCR and the green box indicates cells carrying mutated 
SHP-1. 
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5.3.1 Generation of GLuciferase expressing Mel526 and Mel624 cells 
To quantify the extent of melanoma cell killing by CD8+ T cells, Mel526 and Mel624 cells were 
transduced with lentivirus encoding a non-secreted GLuciferase gene. Upon melanoma cell 
death, the GLuciferase will be released into the supernatant and measured using a luciferase 
assay. Additionally, the lentiviral transfer vector encodes a RFP gene, followed by a T2A 
ribosomal skipping element as well as the above mentioned GLuciferase gene. The expression 
of the gene cassette is driven by an EF-1α promoter (figure 5.15 A). The construct was kindly 
provided by Dr John Bridgeman (manuscript in preparation). The RFP-GLuciferase transduced 
Mel526 and Mel624 cells were sorted by flow cytometry for high levels of RFP expression 
(figure 5.15 B and C). The sorted cells were expanded and used for in vitro (Chapter 5) and in 
vivo (Chapter 7) experiments. 
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Figure 5.15: FACS sort of RFP-GLuciferase LV transduced Mel526 and Mel624. A) The pELN 
lentiviral transfer plasmid encoding the RFP-T2A-GLuciferase cassette, under the control of the 
EF-1α promoter, was used to produce LV to transduce Mel526 and Mel624 cells. B) and C) 
show the gating strategy used for the FACS sorting of RFP-GLuciferase LV transduced Mel526 
and Mel624 cells respectively. Cells were sorted on FSC/SSC (P1), on single cells (P2) and for 
high levels of RFP expression in the PE channel (P3). The sort statistics are shown in the table. 
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5.3.2 Optimisation of a cytotoxicity assay using primary CD8+ T cells expressing the 
Mel TCR 
To optimise the Mel TCR dependent melanoma cell killing assay, MACS sorted Mel+ CD8+ T cells 
were incubated for the indicated amount of time onto 80% confluent RFP-GLuciferase FACS 
sorted Mel526 cells. Control Mel TCR negative T cells were pooled from untransduced and CD2 
LV transduced T cells (wt/CD2+) due to low CD2+ cell numbers. All cells went through a total of 
4 stimulation cycles before being used in this experiment. As shown in figure 5.16, wt/CD2+ 
CD8+ T cells do not kill the tumour target cells, whereas the Mel+ CD8+ T cells kill the Mel526 
cells in a dose dependent manner (16 h). At a 3:1 ratio of T cells to Mel526, the majority of 
Mel526 cells are killed in less than 16 h. At the lowest T cell dose of 0.3:1, maximum killing is 
reached at 48 h. High T cell:Mel526 ratios showed decreased cytotoxicity beyond 24 h possibly 
due to technical aspects of the assay. Possibly the continuous proliferation of Mel526 cells and 
thus increase in GLuciferase protein in ‘Mel526 cells only’ control wells used to obtain the 
100% lysis reading (by freeze thawing the cells) may have been a contributing factor in 
conjunction with the constant level of GLuciferase in the supernatant of wells with high T cell 
numbers due to the quick initial killing of all Mel526 cells (<16 h).  
Figure 5.17 shows the above experiment as a representation of killing against time. It 
demonstrates that this assay is most efficient for short incubation periods (<48 h) with very 
potent cytotoxic cells at high ratios, whereas it can be used for long-term killing (>48 h) of less 
potent T cells or T cells at lower ratios. 
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Figure 5.16: Mel526 tumour cell killing by wt/CD2+ and Mel+ CD8+ T cells. RFP-GLuciferase 
sorted Mel526 cells were grown to confluency before either control wt/CD2+ or Mel+ CD8+ T 
cells were added at different ratios and cells co-incubated for 72 h. A) Representative wells 
coated with RFP-GLuciferase Mel526 and incubated with varying numbers of either wt/CD2+ or 
Mel+ CD8+ T cell (T to Mel526 ratios of 0.3:1 to 10:1) were photographed at four different 
times (10x magnification). B) GLuciferase, released by lysed RFP-GLuciferase Mel526, was 
measured for wells incubated with wt/CD2+ (black) and Mel+ (blue) CD8+ T cell. GLuciferase 
released into the supernatant was expressed as a % of total GLuciferase in RFP-GLuciferase 
Mel526 cell only wells. Data shown is one experiment with triplicates for each condition and 
the error bars represent the SEM. 
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Figure 5.17: Mel526 tumour cell killing by Mel+ CD8+ T cells over a 72 h period. Data shown 
are represented as % cytotoxicity over time for the Mel+ CD8+ T cells only and is from the same 
experiment as figure 5.16. Different colours indicate different T cell to Mel526 cell ratios. 
Triplicates for each condition are shown and error bars indicate the SEM. 
 
 
5.3.3 Mel526 tumour cell killing by SHP-1 sufficient and mutant SHP-1 Mel+ CD8+ T 
cells 
The ability of FACS sorted SHP-1 sufficient (Mel+ CD2-) and mutant SHP-1 (Mel+ CD2+) Mel+ 
CD8+ T cells to kill Mel526 cells was compared using GLuciferase expressing targets. It is 
important to recall that only 3.7% of the ‘mutant SHP-1 Mel+ CD8+ T’ cells were found to 
contain mutated SHP-1 genes (figure 5.11 B). The ‘Mel- CD2-‘, ‘Mel+ CD2-‘ and ‘Mel+ CD2+’ cell 
populations used in the experiment were stained with FLT tetramer and anti-CD2 antibody as 
shown in figure 5.18 B. It is also important to note that the control ‘Mel- CD2- CD8+’ cell 
population, obtained from a double negative FACS sort of ZFN and Mel LV transduction, also 
contained a low number of ‘Mel+ CD2+’ cells (3.44%), presumably due to an impure FACS sort. 
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Additionally, a substantial frequency of Mel- cells was observed in positively sorted cells with a 
frequency of 4.0% for the ‘Mel+ CD2-‘ and 9.7% for the ‘Mel+ CD2+’ populations. To cross-check 
the cell counting done using a haemocytometer, input cell numbers at one ratio (3:1 T:Mel526) 
were measured by flow cytometry using cytocount beads (figure 5.18 C). Importantly, after 
gating on live and single cells similar numbers were observed for the two Mel+ populations, 
however, about 2.5 times more for the control double negative cells. 
No cytotoxicity was detected at 4 h, however, the Mel+ T cells showed maximal killing at 24 h 
at high T:Mel526 ratios (figure 5.19). The control Mel- CD2- T cells also showed very potent 
target cell killing at 72 h which is likely due to the contamination of the cells with 4% Mel+ cells 
and fits with the slower killing of low T:Mel526 ratios observed in the previous experiment 
(figure 5.17). It is of note that the ordinate axis in B for 24 and 72 h exceeds 100% cytotoxicity. 
This might be due to incomplete cell lysis of the control Mel526 wells or possibly the addition 
of T cells promoted Mel526 proliferation before bringing about killing.  
Supporting the luciferase data, the microscopic pictures in figure 5.19 A show that at 24 h most 
of the Mel526 cells were lysed for the 1:1-10:1 ratios of the Mel+ CD2- cells, whereas the same 
was not true for the 1:1 ratio of the Mel+ CD2+. This experiment might indicate that the mutant 
SHP-1 Mel+ CD8+ T cells are slower and potentially less potent at killing target Mel526 cells. 
However, the difference in frequency of Mel+ cells for the SHP-1 sufficient (96%) and mutant 
SHP-1 cells (90%) observed in figure 5.18 B may have been a contributing factor. 
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Figure 5.18: Characterisation of input SHP-1 sufficient and mutant SHP-1 Mel+ CD8+ T cells for 
a cytotoxicity assay. FACS sorted cells were stimulated for one cycle after the sort, cells 
analysed by flow cytometry and assessed for cytotoxicity. ‘Mel- CD2-‘, ‘Mel+ CD2-‘ and ‘Mel+ 
CD2+’ CD8+ T cells stained with AmCyan live/dead, anti-CD8 APC antibody, anti-CD2 FITC 
antibody and ELA tetramer PE. A) Cells were gated on FSC/SSC, live/dead stain, single cells and 
CD8+. Cytocount beads were added to the T cells to enumerate the exact T cell numbers. B) T 
cells gated as shown in A were further analysed for CD2 and ELA tetramer staining. C) T cell 
numbers from the 3:1 T:Mel526 ratio for each group were enumerated using cytocount beads 
as reference. 
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Figure 5.19: Mel526 tumour cell killing by SHP-1 sufficient and mutant SHP-1 Mel+ CD8+ T 
cells. RFP-GLuciferase sorted Mel526 cells were grown to confluency before either control 
‘Mel- CD2-‘, ‘Mel+ CD2-‘ or ‘Mel+ CD2+’ CD8+ T cells were added at different ratios and cells co-
incubated for 72 h. A) Representative wells coated with RFP-GLuciferase Mel526 and 
incubated with varying numbers of ‘Mel+ CD2-‘ or ‘Mel+ CD2+’ CD8+ T cell (T to Mel526 ratios of 
0.3:1 to 10:1) were photographed at four different times (10x magnification). B) GLuciferase, 
released by lysed RFP-GLuciferase Mel526, was measured for ‘Mel- CD2-‘ (black), ‘Mel+ CD2-‘ 
(blue) and ‘Mel+ CD2+’ (red) CD8+ T cell. GLuciferase released into the supernatant was 
expressed as a % of total GLuciferase in RFP-GLuciferase Mel526 cell only wells. Data shown is 
one experiment with triplicates for each condition and error bars indicate the SEM. Asterisks 
show statistically significant differences between the SHP-1 sufficient and mutant SHP-1 Mel+ T 
cells with *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001.  
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To compare survival and proliferation of SHP-1 sufficient and mutant SHP-1 cells, non-
adherent cells from the above Mel526 killing experiment were collected after 72 h and live 
CD8+ T cells counted for each condition (figure 5.20 A). No significant differences were 
observed between the SHP-1 sufficient and mutant SHP-1 Mel+ cells. Higher ‘Mel- CD2-‘ cell 
numbers were present at the 10:1 ratio, which considering the 2.3 fold higher input cell 
number (figure 5.18 C) actually indicates a decrease in cell survival of these ‘Mel- CD2-‘ cells. 
Experimental design allowed looking at T cell survival and/or proliferation of the three 
different T cell groups. T cell numbers at the start of the experiment were recorded for the 3:1 
T cell:Mel526 ratio (figure 5.18 C) and  control wells with T cells only at the equivalent of the 
1:1 ratio were used as controls for the luciferase assay. All the T cell numbers extrapolated 
from this experiment were used to calculate the fold increase of the three groups of T cells. 
The fold increase of ‘0 versus 72’ h was obtained from dividing stimulated T cell numbers at 72 
h by the input T cell numbers (0 h) at the 3:1 ratio. The fold increase of ‘stimulated versus non-
stimulated’ cells was obtained from dividing the T cell numbers of stimulated (+Mel526) wells 
by T cell numbers of non-stimulated (no Mel526) wells at 72 h at the 1:1 ratio. The ‘Mel- CD2-‘ 
control cells did not expand when incubated with Mel526 cells, presumably as they were not 
stimulated by cognate antigen (figure 5.20 C). Compared to the SHP-1 sufficient Mel+ T cells, 
the mutant SHP-1 Mel+ T cells showed a slightly larger fold increase from 0 to 72 h and a 
significantly higher fold increase in cell expansion of stimulated versus non-stimulated cells.  
All in all, these results hint towards an increased survival and/or proliferation profile of the 
mutant SHP-1 cells with a possibly slower and less potent cytotoxic potential, when compared 
to SHP-1 sufficient cells. 
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Figure 5.20: Survival and proliferation of SHP-1 sufficient and mutant SHP-1 Mel+ T cells 
during a cytotoxicity assay. A) At the end of the 72 h cytotoxicity assay shown in figure 5.19, 
non-adherent cells were collected and the number of CD8+ T cells determined using flow 
cytometry and cytocount beads as in figure 5.18 A. Error bars show the SEM for triplicates of 
each condition. B) The fold increase in live CD8+ T cell numbers at 72 h over the input cell 
numbers at 0 h at the 3:1 ratio are shown. One cell count was obtained for the input cells and 
triplicate counts were at 72 h. Error bars show the SEM. C) The fold increase in live CD8+ T cell 
numbers of Mel526 stimulated over non-stimulated (no Mel526) T cells is shown at the 1:1 
ratio. Error bars show the SEM. Asterisks indicate statistically significant differences with 
**p<0.01 and ****p<0.0001. 
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5.3.4 Repeat of Mel526 cytotoxicity assay using SHP-1 sufficient and mutant SHP-1 
Mel+ CD8+ T cells 
To test the reproducibility of the above findings, the experiment was repeated by comparing 
the killing of Mel526 cells by SHP-1 sufficient and mutant SHP-1 Mel+ CD8+ T cells. The ‘Mel- 
CD2-‘, ‘Mel+ CD2-‘ and ‘Mel+ CD2+’ CD8+ T cells used here were generated during an 
independent LV transduction, FACS sort and stimulation experiment. It was shown that 7.2% of 
the mutant SHP-1 Mel+ CD8+ T cells contained mutant SHP-1 genes (figure 5.14 B). Input cell 
numbers were checked by flow cytometry and the numbers of live CD8+ Mel+ SHP-1 sufficient 
and mutant SHP-1 cells added were similar, whereas approximately 9x fewer control cells were 
added (figure 5.22 A).  
As shown with the previous Mel526 killing experiment, the SHP-1 sufficient and mutant SHP-1 
Mel+ cells demonstrated no differences in killing at the low 0.3:1 T cell ratio after 24 h (figure 
5.21). However, at the 1:1 ratio, the mutant SHP-1 Mel+ cells were less potent at killing target 
cells than their SHP-1 sufficient counterparts. The control Mel- CD2- cells did not lyse Mel526 
cells. 
After 72 h, live CD8+ T cell numbers from unstimulated T cell (T cells only) and Mel526 
stimulated wells were obtained (figure 5.22 B). When looking at cell numbers in A and B, it is 
notable that the mutant SHP-1 Mel+ cells survive better than the SHP-1 sufficient Mel+ cells. 
Additionally, the fold increase in cell numbers of the ‘stimulated over the unstimulated’ cells 
showed that at the 0.3:1 ratio, the mutant SHP-1 Mel+ cells proliferated about three times 
more compared to the other two groups (figure 5.22 C). However, at the 1:1 ratio, there is no 
significant difference between the Mel+ SHP-1 sufficient and mutant SHP-1 cells. When data 
from the previous experiment and this experiment are combined, significant differences are 
seen (figure 5.22 D), supporting that the mutant SHP-1 Mel+ T cells survive and/or proliferate 
better than their SHP-1 sufficient counterparts. 
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In summary, mutant SHP-1 Mel+ cells show less target cell killing within 72 h than the SHP-1 
sufficient Mel+ cell although there are higher numbers of mutant SHP-1 cells surviving. There 
are at least two possible explanations for this. Firstly, the mutant SHP-1 cells are slower at 
killing but proliferate more or secondly the SHP-1 sufficient cells kill quickly and die after 
having lysed all the targets.  
Figure 5.21: Mel526 tumour cell killing by SHP-1 sufficient and mutant SHP-1 Mel+ CD8+ T 
cells. RFP-GLuciferase sorted Mel526 cells were grown to confluency before either control Mel- 
CD2-, Mel+ CD2- or Mel+ CD2+ CD8+ T cells were added at different ratios and cells co-incubated 
for 72 h. A) Representative wells coated with RFP-GLuciferase Mel526 and incubated with 
‘Mel- CD2-‘, ‘Mel+ CD2-‘ or ‘Mel+ CD2+’ CD8+ T cell at either 0.3:1 or 1:1 T:Mel526 ratios were 
photographed at three different times (10x magnification). B) GLuciferase, released by lysed 
RFP-GLuciferase Mel526, was measured for ‘Mel- CD2-‘ (black), ‘Mel+ CD2-‘ (blue) and ‘Mel+ 
CD2+’ (red) CD8+ T cell. GLuciferase released into the supernatant was expressed as a % of total 
GLuciferase in RFP-GLuciferase Mel526 cell only wells. Data shown is one experiment with 
triplicates for each condition and error bars indicate the SEM. Asterisks show statistically 
significant differences between the SHP-1 sufficient and mutant SHP-1 Mel+ T cells with 
**p<0.01 and ***p<0.001. 
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Figure 5.22: Survival and proliferation of SHP-1 sufficient and mutant SHP-1 Mel+ T cells 
during a cytotoxicity assay. A) Flow cytometry analysis of the 1:1 T:Mel526 cell ratio was used 
to extract T cell numbers for each group using cytocount beads. Cells were gated on FSC/SSC, 
live/dead stain, single cells and CD8+. B) At the end of the 72 h cytotoxicity assay, non-
adherent cells were collected and the number of CD8+ T cells determined using flow cytometry 
and cytocount beads. Triplicates are shown for all but the 1:1 ‘Mel- CD2-‘ T cells only, where 
only one value was obtained. Error bars show the SEM. C) The fold increase in live CD8+ T cell 
numbers of Mel526 stimulated over non-stimulated (no Mel526) T cells is shown at the 0.3:1 
and the 1:1 ratio triplicates are shown for all but the 1:1 ‘Mel- CD2-‘ T cells only, where only 
one value was obtained. D) Combined data of the fold increase of stimulated over 
unstimulated T cells at a 1:1 ratio of the two killing experiments in figure 5.20 C and 5.21 B. 
Error bars show the SEM. Asterisks indicate statistically significant differences with *p<0.05, 
**p<0.01 and ****p<0.0001. 
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5.4 Conclusion 
It was shown that LV delivery of both the ZFNs and the Mel TCR can be achieved in primary 
CD8+ T cells, albeit with significantly lower transduction efficiencies than those observed in 
leukaemic T cells. Ideally it would be possible to sort for cells lacking SHP-1 protein, but as SHP-
1 is an intracellular protein this is not possible. Hence, multiple transduction optimisation 
steps, as well as MACS or FACS sorting of transduced cells was necessary to obtain a maximal 
Cel-I signal of 7.2%. This could probably be enhanced by including a selection marker into the 
ZFN1 expressing transgene cassette as it possible that the low frequency of mutations 
observed is due to the absence of ZFN1 in a majority of cells. Here it was shown that the SHP-1 
specific ZFNs only induce targeted mutations when heterodimerised, as expression of ZFN1 or 
ZFN2 alone did not induce detectable mutations.  
There are multiple reasons why the consecutive, and to a lesser degree the simultaneous, LV 
transductions were inefficient. For the consecutive transduction it is possible that the 
exposure of the cells to LV induces an antiviral response (IFN-α/β) and this leads to the 
upregulation of restriction factors (Evans et al. 2014). Another hypothesis is that LVs compete 
for the transduction of the cells due to the limited amount of available proteins involved in the 
integration and transcription of transgenes in a single cell. 
Mel526 target cell killing by wt, Mel+ or SHP-1 mutant Mel+ T cells was evaluated using a 
luciferase release assay. This killing assay is advantageous to conventional chromium release 
assays as it is a non-radioactive, direct measure of luciferase release which is proportional to 
the number of lysed Mel526 cells. It was shown that the Mel+ CD8+ T cells containing up to 
7.2% of SHP-1 mutants did not kill target cells better than the SHP-1 sufficient Mel+ CD8+ T 
cells. However, the SHP-1 mutant Mel+ CD8+ T cell population did show significantly higher cell 
numbers at the end of the experiment indicating possible enhanced survival or proliferation of 
these cells. These findings would be in line with previous reports showing no difference in in 
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vitro cytotoxic killing of SHP-1 deficient cells but an enhanced entrance into proliferation 
(Sathish et al. 2007). It is important to remember that in the mouse studies, pure populations 
of SHP-1 deficient T cells were used and the functional effect of SHP-1 loss in the cells in this 
chapter might be masked by the large number of SHP-1 sufficient T cells still present. Ideally, if 
time had allowed, a pool of SHP-1 deficient clones would have been generated and 
cytotoxicity, proliferation and survival would have been studied in comparison to a pool of 
SHP-1 sufficient CD8+ T cells. 
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Chapter 6: L-selectin shedding in human T cells 
6.1 Introduction 
L-selectin is a critical protein in the first steps of the leucocyte adhesion cascade, namely those 
of tethering and rolling. In T cells, it plays a crucial role in the homing of T cells to LNs via HEVs 
and furthermore has been shown to be shed from T cells during the tethering and rolling on 
HEVs (Faveeuw et al. 2001). Here it is hypothesised that prolonging L-selectin expression on 
activated tumour-specific T cells could enhance their potential for cancer therapy by enabling 
their recirculation to LNs for further activation and survival and/or allowing their recruitment 
to tumours expressing HEVs or L-selectin ligands on tumour blood vessels. It has previously 
been shown that many tumours express HEV like structures and that these are associated with 
enhanced numbers of B and T cell infiltrates in tumours (Martinet et al. 2011).  
L-selectin downregulation is controlled on multiple levels such as transcriptional silencing 
(Chao et al. 1997) or ectodomain proteolytic shedding from the cell surface both in humans 
and in mice (figure 6.1 A and C) (Chen et al. 1995; Zhao et al. 2001). By expressing L-selectin 
under a heterologous SFFV promoter in T cells, transcriptional silencing was overcome. The 
second level of regulation, namely shedding of the ectodomain, was overcome by expressing a 
shedding-resistant form of L-selectin in T cells. The ΔM-N mutant has a truncation of 8 aa in 
the membrane proximal region rendering it resistant to proteolytic attack by ADAMs (figure 
6.1 B).  
Additionally, an in vitro endothelial flow assay was used to determine the impact of L-selectin 
expression on the rolling and transmigration of MOLT-3 leukaemic cells expressing either wt or 
ΔM-N L-selectin. This assay was done to determine whether lentivirally delivered L-selectin 
was functional and to study the impact of shedding on the recruitment of T cells on cytokine 
activated endothelium. 
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All primers used in this chapter, for cloning or sequencing are listed in the appendix (tables A3) 
as are the sequences of all lentiviral transfer plasmids (A2). 
Figure 6.1: L-selectin and the possible enzymes involved in its proteolysis upon activation of 
T cells. A) L-selectin is a type I transmembrane protein encompassing multiple domains; the 
lectin domain at the N terminus, an epidermal growth factor domain (EGF), two short 
consensus repeats, a membrane proximal region (MPR), a transmembrane domain and a 
cytoplasmic tail. ADAM17 (green scissor) and γ-secretase (purple scissor) are two enzymes 
hypothesised to be involved in the shedding and further processing of L-selectin. B) The ΔM-N 
mutant form of L-selectin gene has a truncation of eight amino acids in the MPR, thereby 
inhibiting proteolysis (red X). C) In this chapter the proteolysis of L-selectin following 
stimulation with PMA or activation of the TCR (left) was studied to determine the enzymes 
involved in the initial shedding event. The ectodomain of L-selectin is shed first possibly by 
ADAM17 (middle), followed by a second proteolytic step targeting the membrane retained 
fragment possibly orchestrated by the γ-secretase complex (right). 
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6.2 Generation of lentiviral transfer plasmids expressing wt, 'M-N or I-K 
L-selectin 
6.2.1 Generation of pLenti-L-selectin wt or 'M-N 
To study the effect of shedding-resistant L-selectin expression on human T cells, gag+ MOLT-3 
L-selectin negative T cells were transduced with LV encoding wt or shedding-resistant 'M-N L-
selectin. The two LV transfer vectors were generated as shown in figure 6.2 and all primers 
used can be found in table A3. 
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Figure 6.2: Cloning of the lentiviral transfer vector pLenti-L-selectin wt or 'M-N. A) A single 
In-Fusion step was needed to clone either the wt or 'M-N L-selectin (in green) into the BamHI 
linearised pSxW vector. B) Both gels show the 1kb plus DNA ladder in lanes 1. Lanes 2 show the 
PCR product of 1184 bp wt L-selectin (left) or 1160 bp 'M-N L-selectin (right) using primers 
number 45 and 46. The wt plasmid was provided by Dr Aleksander Ivetic and the ΔM-N 
plasmid was provided by Prof. Tom Tedder. Primer number 45 introduces a Kozak consensus 
sequence (GCCGCCACC) upstream of the L-selectin start codon and primer 46 introduces a 
stop codon (TAA) downstream of the L-selectin sequence. C) Lanes 2 shows the BamHI 
restriction digest of the pSxW plasmid. The linearised 8942 bp pSxW vector was purified and 
used together with the purified PCR products in A) to set up In-Fusion reactions. DH5α cells 
were transformed with 2 µl of In-Fusion mix. D) Lanes 2 show plasmid DNA extracted from 
Ampicillin selected DH5α colonies transformed as described above and digested with BamHI. 
The lower size band corresponds to the 1173 bp wt L-selectin (left) or 1149 bp 'M-N L-selectin 
(right) and the upper band to the 8942 bp pSxW. The plasmids were sequenced using primers 
33-34 and 38-41 and confirmed to be the pLenti-L-selectin wt or 'M-N sequence. 
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6.2.2 Generation of pLenti-CD2-L-selectin wt or 'M-N  
To enable the identification of L-selectin LV transduced T cells expressing endogenous L-
selectin, a second set of lentiviral transfer vectors was generated to include the rat CD2 (CD2) 
surface marker, separated from the wt or 'M-N L-selectin gene by the P2A ribosomal skipping 
element (figures 6.3). The CD2 gene was placed upstream of the L-selectin gene as the P2A 
ribosomal skipping element leaves a 24 amino acid tail attached to the upstream protein, 
potentially more than doubling the 17 amino acid long cytoplasmic tail of L-selectin. Figures 
6.4-6.6 show the three In-Fusion cloning steps required to generate the pLenti-CD2-L-selectin 
wt and 'M-N plasmids. 
Figure 6.3: Cloning strategy to generate the lentiviral transfer vectors pLenti-CD2-L-selectin 
wt or 'M-N. A NsiI and SalI restriction digest of the pUC19-TCRα-P2A-TCRβ-P2A-CD2 plasmid 
was used to replace the CD2 gene with the L-selectin wt or 'M-N gene (green) downstream of 
the P2A sequence. In order to insert the CD2 gene (red) upstream of L-selectin, an XbaI and 
XhoI restriction digestion was done to replace the TCRα-T2A-TCRβ fragment with the CD2 
gene. Finally the CD2-P2A-L-selectin wt or 'M-N cassette was inserted into the lentiviral 
transfer vector pSxW giving the pLenti-CD2-L-selectin wt or 'M-N plasmids. 
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Figure 6.4: Cloning of wt or 'M-N L-selectin into the pUC-TCRD-T2A-TCRE-P2A-X vector. A) 
Lane 1 shows the 1kb plus DNA ladder. The 1184 bp wt and the 1160 bp 'M-N L-selectin PCR 
products shown in lane 2 and 3 respectively were obtained using primers 47 and 48. Primer 48 
introduced a TAA stop codon downstream of the L-selectin cDNA. B) Lane 2 shows the NsiI and 
SalI restriction digest of the pUC-TCRD-T2A-TCRE-P2A-CD2 plasmid (plasmid provided by Dr. 
John Bridgeman). The linearised 4236 bp pUC-TCRD-T2A-TCRE-P2A-X vector was purified and 
used together with the purified PCR products in A) to set up In-Fusion reactions. DH5α cells 
were transformed with 2 µl of In-Fusion mix. C) Lanes 2 and 3 show plasmid DNA extracted 
from Kanamycin selected DH5α colonies, transformed as described above and digested with 
NsiI and SalI. The lower size DNA bands in lanes 2 and 3 correspond to the 1160 bp wt and the 
1136 bp 'M-N L-selectin genes. The upper band corresponds to the linearised 4236 bp pUC-
TCRD-T2A-TCRE-P2A-X plasmid. The plasmids were sequenced using primers 37-42 and 
confirmed to be the pUC-TCRD-T2A-TCRE-P2A-L-selectin wt or 'M-N sequences. 
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Figure 6.5: Cloning of CD2 into the pUC-X-P2A-L-selectin wt or 'M-N vector. A) Lane 1 shows 
the 1kb plus DNA ladder. Lane 2 shows the 740 bp CD2 PCR reaction product using primers 49 
and 50. Primer 49 introduces a Kozak (GCCGCCACC) consensus sequence upstream of the CD2 
cDNA. B) Lane 2 and 3 show the XbaI and XhoI restriction digest of the pUC-TCRD-T2A-TCRE-
P2A-L-selectin wt or'M-N plasmid. The linearised pUC-X-P2A-L-selectin wt (3552 bp) or 'M-N 
(3528 bp) vector was purified and used together with the purified PCR products in A) to set up 
In-Fusion reactions. DH5α cells were transformed with 2 µl of In-Fusion mix. C) Lanes 2 and 3 
show plasmid DNA extracted from Kanamycin selected DH5α colonies transformed as 
described above and digested with XbaI and XhoI. The lower size DNA bands in lanes 2 and 3 
correspond to the 714 bp CD2. The upper band corresponds to the pUC-X-P2A-L-selectin wt or 
'M-N. The plasmids were sequenced using primers 4-8 and 37-42 and confirmed to be the 
pUC-CD2-P2A-L-selectin wt or 'M-N sequences. 
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Figure 6.6: Cloning of CD2-P2A-L-selectin wt or 'M-N into the pSxW lentiviral transfer vector. 
A) Lane 1 shows the 1kb plus DNA ladder. Lanes 2 and 3 show the 1979 bp and 1955 bp CD2-
P2A-L-selectin wt and 'M-N products of the PCR reaction using primers 51 and 46. B) Lane 2 
shows the BamHI restriction digest of the pSxW plasmid. The linearised 8942 bp pSxW vector 
was purified and used together with the purified PCR products in A) to set up In-Fusion 
reactions. DH5α cells were transformed with 2 µl of In-Fusion mix. C) Lanes 2 and 3 show 
plasmid DNA extracted from Ampicillin selected DH5α colonies transformed as described 
above and digested with BamHI. The lower size DNA bands correspond to the 1953 bp or 1929 
bp CD2-P2A-L-selectin wt or 'M-N sequences respectively. The upper band corresponds to the 
8942 bp pSxW. The plasmids were sequenced using primers 4-8, 33-34 and 38-41 and 
confirmed to be the pLenti-rCD2-P2A-L-selectin wt or 'M-N sequences. 
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6.2.3 Generation of pLenti-I-K-L-selectin 
Shedding of the L-selectin ectodomain is followed by a second cleavage within the membrane 
retained fragment. It was hypothesised that the γ-secretase complex orchestrates the second 
cleavage event. To study the effect of abrogating this cleavage, a point mutation was 
introduced into the transmembrane domain leading to an isoleucine to lysine change at 
position 352. The mutant was called I-K L-selectin. The I-K mutant was based on a publication 
where a similar mutation abrogated the γ-secretase cleavage of Trop2, a protein undergoing 
similar proteolysis to L-selectin by both ADAM17 and γ-secretase (Stoyanova et al. 2012).  Site 
directed mutagenesis was done by a fellow PhD student, Andrew Newman, using primers 64 
and 65 to change the ATT to an AAG codon (table A3). The I-K L-selectin gene was then 
introduced into the lentiviral transfer vector pLenti (figure 6.7). 
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Figure 6.7: Cloning of the pLenti-L-selectin I-K. A) Targeted mutagenesis using primers 64 and 
65 was performed to generate a new L-selectin mutant with a point mutation at position 352 
of a lysine (K) instead of isoleucine (I). Subsequently, the L-selectin I-K gene was inserted into 
the BamHI linearised pSxW plasmid. B) Lane 1 shows the 1kb plus DNA ladder. Lane 2 shows 
the 1184 bp I-K L-selectin product of the PCR reaction using primers 45 and 46. BamHI 
linearised pSxW vector was purified and used together with the purified PCR product in B) to 
set up an In-Fusion reaction. DH5α cells were transformed with 2 µl of In-Fusion mix. C) Lane 2 
show plasmid DNA extracted from Ampicillin selected DH5α colonies transformed as described 
above and digested with BamHI. The lower size band corresponds to the 1173 bp I-K L-selectin 
and the upper band to the 8942 bp pSxW. The plasmid was sequenced using primers 33-34 
and 38-41 and confirmed to be the pLenti-I-K-L-selectin. 
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6.3 Generation of gag+ MOLT-3 cells expressing wt or 'M-N L-selectin  
It was established that gag+ MOLT-3 cells do not express any L-selectin protein on their cell 
surface, neither before nor after transduction with control CD2 LV (figure 6.8 A). This made 
MOLT-3 cells ideal to study the biology of L-selectin shedding, as the level of L-selectin protein 
present in the cells could be controlled using an exogenous promoter as well as the use of the 
shedding-resistant ΔM-N mutant. As a result, gag+ MOLT-3 cells were transduced with a 
titration of 10x concentrated wt or ΔM-N L-selectin LV (figure 6.8 B-C). The highest volume of 
500 Pl LV gave the highest level of transduction, with the level of L-selectin expression in the 
ΔM-N cells higher than that in the wt L-selectin expressing cells. This might be due to 
constitutive L-selectin shedding in the wt but not the ΔM-N L-selectin cells. 
Cells transduced with 500 Pl of LV were expanded for several weeks, during which a marked 
decrease in expression of the transgenes was observed. To achieve equal levels of L-selectin 
and gag TCR surface expression, cells were sorted by flow cytometry as shown in figure 6.9 
into wt and ΔM-N L-selectin high or low expressing cells with high levels of gag TCR.  
Levels of L-selectin transgene expression in L-selectinhigh gag+ MOLT-3 cells was compared to 
cells expressing endogenous L-selectin, namely gag+ Jurkat cells and primary CD8+ T cells 
freshly isolated from blood (figure 6.10). The primary CD8+ T cells showed two populations, L-
selectin positive and L-selectin negative cells whereas Jurkat cells all express high levels of L-
selectin. The FACS sorted L-selectinhigh MOLT-3 cells express lower levels of L-selectin than both 
the Jurkat and the L-selectin expressing primary CD8+ T cells. 
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Figure 6.8: Transduction of L-selectin negative gag+ MOLT-3 cells with wt or ΔM-N L-selectin 
LV. A) Gag+ MOLT-3 cells were transduced with 250 µl CD2 LV (middle and left) and stained 
with anti-L-selectin Ab (blue in left and middle) or anti-CD2 Ab (blue in right). Cells were 
stained with PE-conjugated isotype control (grey in all). B) Gag+ MOLT-3 cell were transduced 
with 500 µl (blue), 250 µl (orange), 125 µl (light green) and 62.5 µl (dark green) wt or ΔM-N L-
selectin LV. Cells were stained with anti-L-selectin Ab or isotype control  (grey filled) and 
analysed by flow cytometry. C) The median fluorescent intensity (MFI) is shown for cells 
transduced as described in B), with the wt L-selectin in black and the 'M-N L-selectin in red.  
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Figure 6.9: Wt or ΔM-N L-selectin LV transduced gag+ MOLT-3 T cells were sorted into L-
selectinhigh and L-selectinlow gag+ populations by FACS. Gag+ MOLT-3 T cells transduced with wt 
(A) and ΔM-N (B) L-selectin LV were stained with anti-TCRV5β and anti-L-selectin Ab, in the 
presence of Dasatinib and FACS sorted. All cells were gated on FSC/SSC, a single cell gate and 
expression of the gag TCR. Cells were further sorted for high (orange) or low (green) L-selectin 
expression. 
 
Figure 6.10: L-selectin expression of primary CD8+ T cells, gag+ Jurkat and gag+ MOLT-3 cells. 
Primary CD8+ T cells (turquoise), gag+ Jurkat cells (orange) and FACS sorted L-selectinhigh MOLT-
3 cells (red) were stained with anti-L-selectin Ab. Jurkat cells (lined) and MOLT-3 cells (dotted) 
were stained with isotype control. The FMO control is shown for CD8+ T cells (grey filled). 
PBMCs were freshly isolated from blood, stained with anti-CD8 and anti-L-selectin Ab and 
gated on FSC/SSC, Pacific blue live/dead and CD8+. Cells were analysed on different days using 
the same experimental settings. 
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6.4 The role of ADAM17 in the shedding of L-selectin in T cells 
To study the involvement of two metalloproteinases, ADAM10 and ADAM17 in the shedding of 
L-selectin in human T cells, gag+ MOLT-3 leukaemic cells were activated with PMA or with 
cognate peptide in the presence or absence of ADAM10 or ADAM17 specific inhibitors.  PMA 
induced L-selectin shedding has been extensively studied previously (Jung and Dailey 1990; 
Peschon et al. 1998) and is used here to confirm that lentivirally expressed L-selectin protein 
behaves in the same manner. Subsequently, gag+ MOLT-3 cells were activated with cognate 
peptide pulsed APCs and L-selectin shedding studied. 
 
6.4.1 PMA induced L-selectin shedding and the role of ADAM17 
To establish the optimal conditions for PMA induced L-selectin shedding, L-selectinhigh or L-
selectinlow wt or ΔM-N  gag+ MOLT-3 cells were activated with a titration of PMA (3-1000 nM) 
and 300 nM was established as the ideal dose of PMA to induce maximal shedding of 50-60%, 
without being toxic to the cells (figure 6.11 A-B). As expected, no shedding was observed in the 
ΔM-Nhigh or ΔM-Nlow cells. The slight decrease in L-selectin levels at high PMA doses was most 
likely due to the cells not having been fixed and being analysed last, leading to a certain level 
of endocytosis of the Ab. To establish the optimal time to incubate cells with PMA, L-
selectinhigh expressing cells were incubated for 1-60 min with the 300 nM PMA and 30 min was 
established as the ideal duration of PMA exposure as shedding plateaued after this time point 
(figure 6.11 C). 
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Figure 6.11: Titration and time course of PMA induced L-selectin shedding in gag+ MOLT-3 T 
cells. FACS sorted L-selectinhigh or L-selectinlow wt or ΔM-N  gag+ MOLT-3 were incubated with 
0-1000 nM of PMA and L-selectin surface expression analysed by flow cytometry. A) Flow 
cytometry histograms for L-selectinhigh wt (left) or ΔM-N (right) gag+ MOLT-3 cells incubated 
with 3-1000 nM of PMA. B) L-selectinhigh or L-selectinlow wt or ΔM-N gag+ MOLT-3 were 
incubated for 30 min with 3-1000 nM PMA and the percentage of L-selectin was obtained by 
subtracting the MFI of the isotype from the MFI of each sample and it was normalised to 
untreated cells, representing 100% L-selectin. Results show single observations for L-selectinlow 
cells and means from two experiments with single wells for L-selectinhigh cells. The black box 
indicates the 300 nM PMA concentration chosen for further experiments. C) Wt L-selectinhigh 
MOLT-3 cells were incubated for 1, 5, 10, 20, 30 and 60 min with 300 nM PMA. Each condition 
was done in single wells. The black box indicates the 30 min incubation period chosen for 
further PMA induced L-selectin shedding experiments. 
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Next, L-selectinhigh wt or ΔM-N MOLT-3 cells were incubated with two metalloproteinase 
inhibitors, GW and GI, and activated with 300 nM PMA. GW was shown to preferentially inhibit 
ADAM17 whereas GI is thought to be 100 times more potent at inhibiting ADAM10 than 
ADAM17 (Hundhausen et al. 2003). Thus both inhibitors are not exclusively inhibitory to one or 
the other ADAMs. It was shown that 10 µM of GW is sufficient to completely inhibit PMA 
induced L-selectin shedding whereas GI only inhibited L-selectin shedding by a maximum of 
20% at 30 µM (figures 6.12 B and 6.13 B). Additionally, GW also inhibits constitutive L-selectin 
shedding as levels increased above that of untreated cells for 3 µM or above of GW. No 
shedding was observed in ΔM-Nhigh L-selectin gag+ MOLT-3 cells and neither GW nor GI altered 
L-selectin levels. 
The above results and previous publications (Peschon et al. 1998) indicate that ADAM17 is the 
main protease involved in PMA induced L-selectin shedding. To confirm this finding, we tested 
whether the ADAM17 specific cross-domain blocking Ab, D1(A12) (Tape et al. 2011), inhibits 
PMA induced L-selectin shedding. As shown in figure 6.14 B, complete inhibition of shedding 
was achieved with 300 nM of the ADAM17 blocking Ab. The control Ab did not inhibit L-
selectin shedding. 
Overall these results show that PMA induced shedding of L-selectin in the MOLT-3 T cell line is 
driven by ADAM17 and that ADAM17 also has a role in constitutive L-selectin cleavage. 
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Figure 6.12: Effect of metalloproteinase inhibitors, GW, on PMA induced shedding. L-
selectinhigh wt (left) or ΔM-N (right) gag+ MOLT-3 cells were incubated for an h with 0.1-30 µM 
of the metalloproteinase inhibitor GW before activation with 300 nM PMA for 30 min and 
analysed of the cells by flow cytometry. A) Flow cytometry histograms showing representative 
samples incubated with 1-30 µM GW and activated with PMA. B) The percentage of L-selectin 
was obtained by subtracting the MFI of the isotype from the MFI of each sample and 
normalising it to the untreated cells, representing 100% L-selectin. Results for single wells are 
shown for the wt L-selectinhigh cells at 0.1, 0.3, 10 and 30 µM GW and for all ΔM-N L-selectinhigh 
cells. The wt L-selectinhigh cells at 1 and 3 µM GW show results from two independent 
experiments with single wells. Dotted lines indicate the levels of L-selectin in the absence of 
GW with (lower) or without (upper) PMA.  
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Figure 6.13: Effect of metalloproteinase inhibitors, GI, on PMA induced shedding. L-
selectinhigh wt (left) or ΔM-N (right) gag+ MOLT-3 cells were incubated for an h with 0.1-30 µM 
of the metalloproteinase inhibitor GI before activation with 300 nM PMA for 30 min and 
analysed of the cells by flow cytometry. A) Flow cytometry histograms showing representative 
samples incubated with 1-30 µM GI and activated with PMA. B) The percentage of L-selectin 
was obtained by subtracting the MFI of the isotype from the MFI of each sample and 
normalising it to the untreated cells, representing 100% L-selectin. Results for single wells are 
shown. Dotted lines indicate the levels of L-selectin in the absence of GI with (lower) or 
without (upper) PMA.  
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Figure 6.14: Effect of an ADAM17 specific blocking Ab D1(A12) on PMA induced L-selectin 
shedding. Wt L-selectinhigh gag+ MOLT-3 cells were incubated for 1 h with 1-300 nM of 
ADAM17 specific inhibiting Ab D1(A12) or control human IgG and activated with 300 nM PMA 
for 30 min. A) Flow cytometry histograms showing representative samples incubated with 3-
300 nM of D1(A12) Ab and activated with PMA. B) The percentage of L-selectin was obtained 
by subtracting the MFI of the isotype from the MFI of each sample and normalising it to the 
untreated cells, representing 100% L-selectin. Results for single wells are shown. The dotted 
line indicates the levels of L-selectin in the absence of Ab and without PMA.  
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6.4.2 TCR induced L-selectin shedding and the role of ADAM17 
Activation of T cells by PMA is via the activation of protein kinase C whereas activation of T 
cells by the engagement of the TCR and peptide-MHC triggers a signalling cascade initiated by 
Src family kinases (Brownlie and Zamoyska 2013). Due to the different signalling pathways 
involved, we wanted to establish whether ADAM17 was also the main protease involved in TCR 
induced L-selectin shedding or whether the two pathways operated differently. To establish 
the ideal conditions for TCR induced L-selectin shedding, gag+ MOLT-3 cells were activated with 
a titration of cognate SLY peptide (10-9-10-4 M) pulsed C1R cells. At 10-6 M SLY peptide or 
higher, 70% of L-selectin was shed from the cell surface of wt L-selectinhigh gag+ MOLT-3 cells 
(figure 6.15 A). No shedding was observed for the ΔM-N L-selectinhigh gag+ MOLT-3 cells. To 
establish the ideal incubation time, wt L-selectinhigh gag+ MOLT-3 cells were incubated for 1-
120 min with 10-4 M peptide pulsed C1R cells and L-selectin and TCR levels analysed (figure 
6.15 B). TCR downregulation was used as a control for MOLT-3 cell activation. Both molecules 
showed a very similar pattern of loss of expression followed by re-expression beyond 60 min; 
however the underlying mechanisms are distinct. Upon activation, L-selectin undergoes 
shedding due to cleavage by a metalloproteinase whereas the TCR is internalised (Valitutti et 
al. 1995). It was established that 60 min was the ideal incubation period for TCR induced L-
selectin shedding experiments. 
In order to confirm that the TCR activation induced L-selectin shedding observed in gag+ MOLT-
3 cells is physiologically relevant, gag+ Jurkat cells expressing endogenous L-selectin were 
stimulated with 10-8-10-4 M SLY peptide for either 18 or 24 h and L-selectin and CD69 
expression levels analysed (figure 6.15 C). L-selectin shedding occurred in a peptide dose 
dependent manner alongside increased expression in the activation marker CD69. Overall L-
selectin shedding was shown to occur in gag+ Jurkat and L-selectin+ gag+ MOLT-3 cells in 
response to cognate peptide pulsed APCs in a dose dependant manner.  
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Figure 6.15: Titration and time course of TCR induced L-selectin shedding in gag+ MOLT-3 and 
gag+ Jurkat T cells. A) FACS sorted wt (red) or ΔM-N (blue) L-selectinhigh gag+ MOLT-3 cells were 
incubated for one h with 10-9-10-4 M SLY peptide pulsed C1R cells. The APC:T cell ratio was 1:3. 
L-selectin surface expression analysed by flow cytometry. Triplicate wells are shown and error 
bars show the SEM. B) L-selectinhigh gag+ MOLT-3 cells were incubated for 1, 5, 10, 20, 30, 60, 
90 and 120 min with 10-4 M SLY peptide pulsed C1R cells and levels of L-selectin (black) and 
TCR (grey) surface expression analysed by flow cytometry. PE anti-L-selectin and FITC-anti-
TCRV5β Abs were used to stain the cells. Triplicate wells are shown and error bars show the 
SEM. C) Gag+ Jurkat cells, expressing endogenous L-selectin, were activated with 10-8-10-4 M 
SLY peptide pulsed C1R cells for either 18 (open symbol) or 24 (filled symbol) h and surface 
expression of L-selectin (left) and CD69 (right) analysed by flow cytometry. The Abs against L-
selectin and CD69 were both PE conjugated, thus these results represent single well 
experiments and cells were different for the L-selectin and the CD69 staining. All cells were 
gated on FSC/SSC, AmCyan live/dead negativity, single cells and APC CD19-. The percentages of 
L-selectin, TCR and CD69 were obtained by subtracting the MFI of the isotype from the MFI of 
each sample and normalising it to untreated cells, representing 100% L-selectin, TCR or CD69 
respectively. 
 
 
To determine whether TCR induced L-selectin shedding is mediated by ADAM17, gag+ MOLT-3 
cells were preincubated with 0.1-30 µM of GI or GW and activated with 10-4 M SLY peptide 
pulsed C1R cells (figure 6.16 A). As with PMA induced L-selectin shedding, at 10 µM, GW 
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completely inhibited L-selectin shedding whereas GI showed only partial inhibition. At 3 µM or 
less of GI there is no inhibition of L-selectin shedding, indicating that ADAM10 is not involved 
and that the inhibition observed is due to inhibition of ADAM17 at high GI doses. For further 
experiments, GW and GI were used at 30 µM as this concentration showed the highest level of 
inhibition. 
To further study the importance of ADAM17 or ADAM10 for L-selectin shedding, wt or ΔM-N L-
selectinhigh gag+ MOLT-3 cells were incubated with GW, GI or no inhibitor and activated with a 
titration of SLY peptide pulsed C1R cells. In the absence of inhibitors, up to 74% of L-selectin 
was shed at 10-4 M, which was completely blocked by GW and only partially by GI, with 3% and 
47% of observed L-selectin shedding respectively (figure 6.16 B). This intermediate level of 
inhibition by GI was observed at all five peptide doses. Again, GW inhibited constitutive L-
selectin shedding, as at low stimulation of 10-8-10-6 M peptide, L-selectin levels were above the 
background. Neither inhibitor affected the expression levels of ΔM-N L-selectin on gag+ MOLT-
3 cells. As a control for the effects of GW and GI on T cell activation, TCR levels were analysed 
(figure 6.16 C). Wt and ΔM-N L-selectinhigh gag+ MOLT-3 cells showed matching loss of the TCR 
in response to activation and the highest peptide dose of 10-4 M led to the highest level of TCR 
endocytosis of 80%. GW or GI did not affect the loss of TCR from the cell surface.  
These results indicated that ADAM17 is probably the predominant metalloproteinase 
controlling L-selectin shedding in response to cognate peptide activation in T cells. To confirm 
these findings, wt L-selectinhigh gag+ MOLT-3 cells were incubated with 1-300 nM of the 
ADAM17 specific blocking Ab, D1(A12), and activated with 10-4 M SLY peptide (figure 6.17). 
Control human IgG Ab did not inhibit L-selectin shedding even at the highest dose, whereas 
the D1(A12) Ab inhibited shedding in a dose-dependent manner, with complete inhibition at 
300 nM.  
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In summary, L-selectin shedding was confirmed to be mediated by ADAM17 either when cells 
were activated with PMA or by engagement of TCR. 
Figure 6.16: Effect of metalloproteinase inhibitors, GW and GI, on TCR induced shedding. A) 
L-selectinhigh gag+ MOLT-3 cells were incubated with a 0.1-30 µM GI (red) or GW (purple) for 60 
min and activated with 10-4 M cognate SLY peptide pulsed C1R cells for 60 min. The APC:T cell 
ratio was 1:3. L-selectin surface expression was analysed by flow cytometry. B) Wt (left) or ΔM-
N (right) L-selectinhigh gag+ MOLT-3 cells were incubated for an h with medium alone (black), 30 
µM GW (red) or GI (purple) and activated for an h with a 10-8-10-4 M SLY peptide pulsed C1R 
cells. Cells were stained using anti-L-selectin (B) and anti-TCRV5β (C) Ab and flow cytometry 
analysis was done. The percentage of L-selectin and TCR expression was obtained by 
subtracting the MFI of the FMO from the MFI of the samples and normalising it to the 
untreated cells, representing 100% L-selectin expression. All results represent triplicates and 
the error bars show the SEM. Dotted lines indicate the levels of L-selectin or TCR in the 
absence of inhibitors with (bottom) or without (top) 10-4 M peptide activation. All cells were 
gated on FSC/SSC, AmCyan live/dead negativity, single cells, and APC CD19-. 
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Figure 6.17: Effect of an ADAM17 specific blocking Ab D1(A12) on TCR induced L-selectin 
shedding. L-selectinhigh gag+ MOLT-3 cells were incubated for an h with 1-300 nM of ADAM17 
specific inhibiting Ab D1(A12) or control human IgG and activated with 10-4 M SLY peptide 
pulsed C1R cells for 60 min and analysed by flow cytometry. The APC:T cell ratio was 1:3. The 
percentage of L-selectin expression was obtained by subtracting the MFI of the isotype from 
the MFI of each sample and normalising it to the untreated cells, representing 100% L-selectin. 
All results represent triplicates and the error bars show the SEM. Dotted lines indicate the 
levels of L-selectin expression in the absence of Ab with (bottom) or without (top) 10-4 M 
peptide activation. All cells were gated on FSC/SSC, AmCyan live/dead negativity, single cells, 
and APC CD19-. 
 
 
6.5 The role of γ-secretase in the proteolysis of L-selectin in T cells 
After the first proteolytic cleavage of L-selectin by a metalloproteinase, such as ADAM17, the 
membrane retained fragment (MRF) can be further cleaved, a process called regulated 
intramembrane proteolysis (RIP). Proteins such as Trop2 undergo cleavage by ADAM17 leaving 
a MRF that can then be cleaved by the γ-secretase complex (Stoyanova et al. 2012). Here we 
wanted to investigate whether the same process could be happening for L-selectin. 
Initially, gag+ Jurkat cells expressing endogenous L-selectin were activated with either PMA or 
anti-CD3/28 Dynabeads. Dynabeads were used to generate TCR induced L-selectin shedding as 
peptide pulsed C1R cells could not be used since C1R cells express high levels of L-selectin. This 
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would interfere with the interpretation of the protein analysis and immunoblotting results. 
Gag+ Jurkat cells were incubated with either medium alone or DAPT, a γ-secretase inhibitor, 
and activated with PMA or Dynabeads. As shown in figure 6.18 A, PMA induced very strong L-
selectin shedding whereas the Dynabeads gave much weaker shedding. This is reflected by the 
complete loss of full length L-selectin (68 kDa) in PMA activated groups (lane 3-4) but not in 
Dynabead activated cells (lanes 5-6). In the absence of γ-secretase activity the MRF 
accumulates, as there is a clear difference in the quantity of MRF (6 kDa) present in the DAPT 
treated cells (lanes 4 and 6) compared to the non-treated cells (lanes 3 and 6). This result, 
although not definitive as no loading control protein was measured, hinted towards γ-
secretase as the main candidate involved in further processing of the MRF. 
Figure 6.18: L-selectin shedding and further processing in the presence of a γ-secretase 
inhibitor, DAPT, in gag+ Jurkat cells. A) Gag+ Jurkat cells were incubated without (solid line) or 
with 5 µM DAPT (dotted lines) for 30 min and activated with either a 1:1 ratio of CD3/28 
Dynabeads (blue) or 500 nM PMA (red) for 60 or 30 min, respectively. Control wells were left 
unstimulated (black). A small fraction of the cells was collected and L-selectin expression was 
analysed by flow cytometry. Cells were gated on FSC/SSC, single cells and CD19-. B) The 
remaining cells from A were lysed and the lysate was probed for L-selectin protein by 
immunoblotting. 
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Gag+ MOLT-3 cells were used to further study the processing of the MRF as these cells do not 
express endogenous L-selectin and it was possible to transduce them with either wt, ΔM-N or 
I-K L-selectin LV. To confirm that L-selectin shedding in response to CD3/28 Dynabeads was 
similar to activation with cognate peptide pulsed APCs, a 1:1 ratio of cells:Dynabeads was 
compared to 10-4 M peptide pulsed C1R activation (figure 6.19). The L-selectin shedding was 
very similar with the peptide giving 58% and the Dynabeads 55% loss of L-selectin. 
Figure 6.19: Comparison of peptide and Dynabead induced L-selectin shedding in gag+ MOLT-
3 cells. A) Gag+ L-selectinhigh MOLT-3 cells were incubated for 60 min with medium alone 
(black), 10-4 M SLY peptide pulsed C1R cells (orange) or a 1:1 ratio of CD3/28 Dynabeads (blue) 
and cells collected for flow cytometry analysis. Representative plots of L-selectin expression 
for all three treatment samples are shown and the isotype control is shown in grey filled. B) 
The percentage of L-selectin expression was obtained by subtracting the MFI of the isotype 
from the MFI of each sample and normalising it to the MFI mean of the untreated cells, 
representing 100% L-selectin. Triplicates are shown and the error bars show the SEM. All cells 
were gated on FSC/SSC, Pacific Blue live/dead negativity, single cells, and CD19-. 
 
 
 
 
 232 
 
The expression levels of wt, ΔM-N and I-K L-selectin on gag+ MOLT-3 cells were compared and 
found to be very similar (figure 6.20 A). These three groups of cells were pre-incubated with 
DAPT and activated with either PMA or Dynabeads in the presence of DAPT and L-selectin 
expression analysed by flow cytometry and immunoblotting. In both the wt and I-K expressing 
cells, PMA induced more shedding than the Dynabeads (figure 6.20 B). There was no shedding 
in the ΔM-N cells. DAPT did not influence the shedding of the L-selectin ectodomain. Most 
importantly, the results observed with the gag+ Jurkat cells were reproduced with the wt L-
selectin gag+ MOLT-3 cells; inhibition of γ-secretase by DAPT led to an accumulation of the 
MRF (figure 6.20 C). In addition to a strong MRF signal present for DAPT treated PMA (3.6 fold) 
or TCR (5.5 fold) stimulated cells, an MRF signal is also observed in cells that were DAPT 
treated but not activated (1 fold), indicating the role of γ-secretase in constitutive L-selectin 
processing. The full length L-selectin protein was not observed in some lanes, possibly due to 
the high threshold of detection for the anti-L-selectin Ab used. No MRF was detected with the 
ΔM-N gag+ MOLT-3 cells, which was expected considering that the ΔM-N mutant is not cleaved 
by ADAM17 thus not producing any MRF. The I-K L-selectin mutation was generated to be 
resistant to γ-secretase lysis; however the results show that this is not the case. There is a very 
weak signal for the MRF of cells that were stimulated with PMA or Dynabeads but not DAPT 
(0.2 and 0.1); however this is a much weaker MRF signal than the MRF signal in the DAPT 
treated and PMA and TCR activated cells (3.7 and 2.2). If the I-K mutant influences γ-secretase 
activity, it is only slight and might not be an ideal system to take forward. 
1 
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Figure 6.20: L-selectin shedding and further processing in the presence of a γ-secretase 
inhibitor, DAPT, in wt, ΔM-N and I-K L-selectinhigh gag+ MOLT-3 cells. A) Comparison of L-
selectin surface expression for wt (orange), ΔM-N (pink) and I-K (turquoise) L-selectinhigh gag+ 
MOLT-3 cells. The grey filled cells were stained with an isotype control Ab. B) Wt, ΔM-N and I-K 
L-selectinhigh gag+ MOLT-3 cells were incubated with medium alone (solid line) or 5 µM DAPT 
(dotted line) for 30 min and activated with either a 1:1 ratio of CD3/28 Dynabeads (blue) or 
300 nM PMA (red) for one or half an h, respectively. L-selectin expression was analysed by flow 
cytometry and representative plots are shown. Control wells were left unstimulated (black) or 
stained with isotype control (grey filled). Cells were all gated on FSC/SSC, AmCyan live/dead 
negativity and CD19-. C) The remaining cells from B were lysed and the lysate was probed for L-
selectin protein by doing an immunoblot. The blots were also probed for the housekeeping 
protein GAPDH as a loading control. Exposure time for the L-selectin probe was 10 min and the 
GAPDH probe was 30 s. The signal for the MRF was normalised to GAPDH and the fold increase 
over the DAPT only treated wt L-selectinhigh cells is shown. 
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6.6 In vitro flow assay of gag+ MOLT-3 cells over TNF-α activated HUVEC 
cells 
To study the role of wt or ΔM-N L-selectin in the tethering, rolling and arrest of T cells on 
activated endothelial cells, in vitro flow experiments were performed in collaboration with Dr 
Aleksandar Ivetic at King’s College London. These assays were performed in London and the 
details can be found in the ‘Materials and Methods’. Briefly, human umbilical vein endothelial 
cells (HUVECs) were grown on fibronectin covered microscope slides and activated with TNF-α 
for 4-6 h before the flow chamber was fitted onto the slide and gag+ MOLT-3 cells were added 
under shear flow. Three different gag+ MOLT-3 cells were used; untransduced cells expressing 
no L-selectin and transduced cells expressing matched levels of either wt or ΔM-N L-selectin to 
levels similar to gag+ Jurkat cells (figure 6.22 A). Figure 6.21 shows images captured at the start 
and at the end (15-21 min) of the flow assay. Representative full movies, made of photographs 
captured every 15 s, of each of a total of four regions per slide can be found on DVDs attached 
in the appendix A3. No transendothelial migration (TEM) was observed for any MOLT-3 cells, 
indicating that either the cells are not capable of TEM or the conditions to trigger TEM are not 
met. The number of MOLT-3 cells that rolled or arrested on the HUVEC cells was obtained by 
counting newly attached cells in each frame. No striking differences between cells expressing 
no, wt or ΔM-N L-selectin were found in the total number of cells attached, in the rate of 
recruitment or in the % of cells attached at the end of the experiment (figure 6.22 B-D).  
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Figure 6.21: Tethering, rolling and adhesion of gag+ MOLT-3 cells expressing no, wt or ΔM-N 
L-selectin on TNF-α activated HUVEC cells. Gag+ MOLT-3 cells (bright round cells) expressing 
no, wt or ΔM-N L-selectin were used in an in vitro flow assay to look at the impact of L-selectin 
on adherence to TNF-α activated HUVEC cells (elongated dark cells). Every 15 s, a picture was 
taken by an inverted bright field microscope of a set region on the coverslip. Four points of 
view were recorded per assay and one per cell type is shown. The overall period of recording 
(end) was 15 min for the no and ΔM-N L-selectin cells and 21 min for the wt L-selectin cells. 
The direction of flow is indicated by an arrow. 
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Figure 6.22: Quantification of adhesion of gag+ MOLT-3 cells expressing no, wt or ΔM-N L-
selectin on TNF-α activated HUVEC cells under flow. Adhesion of gag+ MOLT-3 cells expressing 
no (black), wt (red) or ΔM-N (blue) L-selectin to TNF-α activated HUVEC cells under flow was 
quantified. A) Gag+ MOLT-3 cells were analysed for L-selectin expression by flow cytometry. Wt 
(red) and ΔM-N (blue) expressing cells were compared to gag+ Jurkat cells (green dotted) Cells 
stained with an isotype control Ab are shown in grey. B) Adhesion of gag+ MOLT-3 cells from 
the experiment shown in figure 6.21 was quantified by counting all cells that attached over a 
15 min (no L-selectin and ΔM-N) or a 21 min (wt L-selectin) timeframe. C) The number of newly 
attached cells is shown for 3 min intervals. D) The percentage of attached cells at the end of 
the assay over the overall attached cells is shown.  For each cell type, four points of view from 
a single coverslip were analysed and the error bars show the SEM. 
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6.7 Generation of human CD8+ T cells expressing CD2-L-selectin or CD2-
'M-N 
 Melanoma-specific CD8+ T cells expressing either wt L-selectin or shedding-resistant ΔM-N L-
selectin under a heterologous promoter were generated subsequently with the aim to use 
these cells in future cytotoxic experiments and in vitro flow assays and in vivo homing assays. 
Cells from a HLA-A2+ donor were transduced simultaneously with both the CD2-L-selectin wt or 
ΔM-N and the Mel LVs (figure 6.23). The CD2-L-selectin LV was used to enable identification of 
successfully transduced cells, as primary CD8+ T cells express endogenous L-selectin. Cells were 
sorted by MACS for both Mel TCR and CD2 expression and 60% of the wt L-selectin cells were 
double positives after 6 stimulation cycles, whereas only 7% of the ΔM-N L-selectin cells were 
co-expressing the Mel TCR and CD2. It was also observed that the levels of CD2 surface 
expression were considerably lower in cells transduced with the CD2-L-selectin LV than cells 
stimulated and sorted identically but transduced with the ZFN2-CD2 and (figure 7.10). 
Whether this is due to the CD2 being upstream of the 2A sequence in the L-selectin LV or 
whether there is a level of gene silencing is presently unknown. 
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Figure 6.23: Generation of primary CD8+ T cells transduced with CD2-L-selectin wt or ΔM-N. 
Primary CD8+ T cells were transduced with 100 µl Mel LV or/and 25 µl of CD2-L-selectin wt or 
ΔM-N. AT day 13 post transduction, cells were analysed by flow cytometry for the surface 
expression of CD2 and Mel TCR (before). After an expansion of the cells, they were sorted for 
the expression of tetramer and an expansion cycle later for the expression of CD2 by MACS 
separation. Cells were analysed again by flow cytometry once they had undergone a total of 6 
stimulation cycles (after). Cells were all gated on FSC/SSC, AmCyan live/dead negativity and 
APC CD8+. The gates for the tetramer and CD2 staining are set in relation to the FMOs and in 
accordance with cells grown at the same time that were transduced with Mel and ZFN LVs 
(figure 7.10 B). 
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6.8 Conclusion 
In this chapter, it was confirmed that PMA induced shedding was ADAM17 dependant. 
Additionally it was found that TCR induced L-selectin shedding is also ADAM17 mediated. L-
selectin shedding showed a similar time course and intensity in response to PMA or TCR 
activation. Additionally, it was established that the MRF was cleaved by γ-secretase after cells 
were activated by PMA or TCR. Shedding-resistant ΔM-N L-selectin was not shed or further 
processed, confirming that, similarly to other ADAM17 and γ-secretase substrates, L-selectin 
ectodomain shedding has to proceed γ-secretase proteolysis.  Constitutive L-selectin shedding 
and further processing was also shown to be ADAM17 and γ-secretase driven. 
The I-K mutant, hypothesised to be γ-secretase-resistant only showed a slight increase in the 
MRF above wt L-selectin. Thus this mutation might not be useful for further studies especially 
as the I-K mutation might interfere with the binding of calmodulin to the cytoplasmic tail of L-
selectin (Gifford et al. 2012). This interference might lead to the spontaneous or premature 
release of calmodulin and the shedding of L-selectin (figure 1.8 B). 
The effect of shedding-resistant ΔM-N L-selectin on the rolling and tethering of T cells on 
endothelial cells was assessed by doing the in vitro flow assay. However, there was no 
difference in the recruitment of MOLT-3 on TNF-D activated HUVECs between cells expressing 
no, wt or ΔM-N L-selectin. This could simply be due to the lentivirally delivered L-selectin not 
being functional, for example due to abnormal glycosylation. However, the shedding in 
response to PMA in lentivirally transduced MOLT-3 cells did fit with that of cells expressing 
endogenous L-selectin and previous studies using lentivirally delivered L-selectin. It is possible 
that MOLT-3 cells use alternative proteins to tether and roll on activated HUVECs, such as LFA-
1, which is expressed at high levels in MOLT-3 cells (Phongpradist et al. 2010). Alternatively it 
has been shown in vitro that α4 integrins, such as α4β1 and α4β7, can support tethering and 
rolling of leucocytes (Berlin et al. 1995) and MOLT-3 cells express α4β1 (Tomczuk et al. 2003). 
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Additionally, it is possible that L-selectin expression on MOLT-3 cells was not high enough to 
support tethering and rolling or that TNF-α activated HUVECs do not express L-selectin ligands. 
For further studies, a different cell line or primary CD8+ T cells should be used. A reason for the 
absence of TEM in the in vitro flow assay might have been the absence of basal membrane, 
pericytes and chemokine gradients. 
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Chapter 7: Adoptive transfer of human CD8+ T cells into 
Mel526 tumour bearing NOD-SCID or NSG mice 
7.1 Introduction  
The aim of this chapter was to establish an in vivo xenograft model to compare the anti-
tumour potential of populations of Mel+ CD8+ T cells, sufficient or mutant in SHP-1. Two 
different types of immunodeficient mice were used; NOD-SCID mice, lacking both functional T 
and B cells and having a decreased level of NK and myeloid cell activity (Shultz et al. 1995), and 
NSG mice, lacking functional B, T and NK cells and having a decreased myeloid cell activity 
(Ishikawa et al. 2005). 
Initial tumour cell titration and ACT experiments were done using NOD-SCID mice, due to their 
local availability. The Mel526 cells used here were generated in Chapter 5, and express the 
RFP-GLuciferase gene cassette and the RFP expressed is the DsRed protein from the coral of 
the Discoma genus (Matz et al. 1999; Baird et al. 2000). Expression of RFP allowed for the 
monitoring of tumour growth by non-invasive fluorescence imaging. 
Tumour cell titration experiments were based on a study by Liddy et al. where they used 2 x 
106 Mel526 cells to establish tumours in Beige-SCID mice (Liddy et al. 2012). The optimal 
Mel526 cell number necessary to generate reliable tumour take was established in NOD-SCID 
mice. Two small T cell transfer experiments were conducted after which it was decided to use 
NSG mice for further experiments due to their higher level of immunodeficiency. A second 
Mel526 cell titration experiment was performed in NSG mice, followed by an ACT experiment 
comparing the anti-tumour potential of wt, Mel+ and a Mel+ population of T cells containing a 
minority of mutant SHP-1 cells. 
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7.2 Mel526 tumour cell titration in NOD-SCID mice 
The optimal Mel526 cell number for tumour take in male NOD-SCID mice was established by 
titrating Mel526 cells. One mouse was injected with 2 x 106 and a second mouse was injected 
with 10 x 106 and two mice were injected with 15 x 106 DsRed labelled Mel526 cells, 
subcutaneously into the left flank. One mouse did not receive any Mel526 cells and was used 
as a negative control for tumour imaging. At day 0, the indicated tumour cell number in 200 µl 
of saline was injected and the mice imaged daily for the first 3 days and twice weekly 
thereafter (figure 7.1 B). The DsRed signal at day 0 was detected over a large area due to the 
high volume of injected fluid containing fluorescent cells.  At day 2, this area had shrunk and 
Mel526 cells started forming a more localised tumour; in future experiments imaging of the 
tumour commenced on day 3. Calliper measurements of the tumour commenced on day 8 and 
were used to calculate the tumour area and thus obtain a second measurement of tumour 
growth. 
The lowest Mel526 cell dose (2 x 106) generated a palpable tumour on day 10 but not 
thereafter; imaging showed that the tumour shrank after day 8 (figure 7.1 B-D). The mouse 
injected with 10 x 106 Mel526 cells gave a palpable tumour throughout the experiment 
however the tumour did not grow for 20 days, as shown by the stable tumour size and DsRed 
intensity, before showing signs of growth. The two mice injected with 15 x 106 Mel526 cells 
showed continual tumour growth from day 3 onwards as shown by DsRed signal and tumour 
area. Overall, it was decided to inject 15 x 106 Mel526 cells in future experiments. 
At day 28, tumours were imaged and measured by callipers, mice were sacrificed and tumours 
excised. When opening the peritoneal cavity, the tumours looked very different between the 
low and high dose of Mel526 cells (figure 7.2 D). The smallest tumour looked entirely white 
whereas the bigger tumours were partly red/pink indicating the presence of Mel526 cells. The 
15 x 106 Mel526 cell tumours were bigger in calliper measured size and in weight than the 
 243 
 
lower dose tumours (figure 7.1 C and 7.2 A). The two smaller tumours as well as one of the 15 
x 106 Mel526 tumours had a layer of white tissue around it possibly indicating a capsular 
structure formed to segregate the tumour from the rest of the body. The weight of the 
tumours at the endpoint were plotted against the caliper measurements and the DSRed signal 
(figure 7.2 B and C). 
Figure 7.1: Titration of Mel526 tumour cells in NOD-SCID mice. A) Experimental layout for the 
titration of Mel526 tumour cells in NOD-SCID mice. Single mice were injected subcutaneously 
with 0, 2 x 106 (blue), 10 x 106 (red) Mel526 cells and two mice received 15 x 106 (purple solid 
and dotted) Mel526 cells. B) and D) Tumour growth was monitored by imaging and the 
fluorescence images were superimposed on white light images and the pixel intensity in a 
defined a region of interest (ROI) around the tumour was quantified by subtracting the pixel 
intensity of a ROI outside of the tumour. C) Tumour growth was monitored from day 8 
onwards by measuring the tumour dimensions using callipers. 
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Figure 7.2: Analysis of the Mel526 tumours from NOS-SCID mice at day 28. A) Tumours were 
weighed after tumour excision. B) Correlation between the tumour area and tumour weight at 
day 28 is shown. C) Correlation between the sum intensity of the DsRed signal and tumour 
weight at the day 28 is shown. D) Photographs of tumour before (lower) and after (upper) 
opening of the peritoneal cavity were taken for mice injected with 2 x 106 (blue), 10 x 106 (red) 
or 15 x 106 (purple) Mel526 cells. The Mel526 cells are bright red/pink and the white tissue is 
indicated by arrows. 
 
 245 
 
7.3 Adoptive transfer of human CD8+ T cells into irradiated and non-
irradiated NOD-SCID mice 
To establish whether human CD8+ T cells can survive and potentially exhibit an anti-tumour 
effect in vivo, two male NOD-SCID mice were injected intravenously (i.v.) with 5.7 x 106 human 
CD8+ T cells. The cells were sorted for CD8 expression and stimulated for three cycles in vitro 
before injection. It was hypothesised that irradiation of the mice could reduce CD8+ T cell 
rejection by the host’s immune cells by reducing the remaining NK cells. Hence, one mouse 
was irradiated with 2 Gy and the other one left untreated and both mice injected i.v. with 5.7 x 
106 CD8+ T cells (figure 7.3 A). The injected CD8+ T cells comprised two cell populations that 
differed in size; a small population of mostly CCR7+ L-selectin- (70.8%) cells and a larger 
population of mostly CCR7- L-selectin- (73.9%) cells (figure 7.3 B). 
Two days post T cell transfer, the mice were culled, their organs collected and single cell 
suspensions stained for human CD8+ and analysed by flow cytometry. The overall cell numbers 
of live cells in the spleen, blood and lungs were between 2.3 and 17 times higher in the non-
irradiated mouse than the irradiated one (figure 7.4 A and B). This reduced cell number in the 
irradiated mouse was also seen in samples from the mesenteric LN and the combined axillary, 
brachial and inguinal LNs. On the other hand, more human CD8+ T cells were recovered from 
the irradiated mouse with 1.4 to 2.8 fold more human CD8+ T cells in the spleen, blood and 
lungs of this mouse (figure 7.4 C). Overall this showed that irradiation might enhance human 
CD8+ T cell survival and irradiation was adopted in the next adoptive T cell transfer experiment. 
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Figure 7.3: Adoptive transfer of human CD8+ T cells into irradiated or non-irradiated NOD-
SCID mice. A) Experimental layout for the adoptive transfer of 5.7 x 106 human CD8+ T cells 
into an irradiated (2 Gy) or a non-irradiated NOD-SCID mouse. B) Flow cytometry analysis of 
the human CD8+ T cells injected. Cells were stained with an anti-CD8, anti-CCR7 and anti-L-
selectin Ab and the gating strategy is shown. Two populations of T cells with different SSC/FSC 
appearances (bottom right) were further analysed for L-selectin and CCR7 expression. 
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Figure 7.4: Comparison between mouse and human lymphocytes numbers from irradiated 
and non-irradiated NOD-SCID mice. Non-irradiated (blue) and 2 Gy irradiated (red) NOD-SCID 
mice were injected i.v. with 5.7 x 106 human CD8+ T cells and the spleen, blood, lungs and LNs 
collected two days later. A) The total number of live cells in each sample was enumerated by 
flow cytometry using cytocount beads. B) Flow cytometry gating of AmCyan- live cells in 
different organs. C) The total number of live human CD8+ T cells in each sample was 
enumerated by flow cytometry using cytocount beads. 
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7.4 Adoptive transfer of human wt or Mel+ CD8+ T cells into irradiated 
Mel526 tumour bearing NOD-SCID mice 
Following the two pilot experiments above, a therapeutic adoptive T cell experiment using 13 
male NOD-SCID mice was conducted. Mice were injected subcutaneously with 15 x 106 Mel526 
cells and once tumours had established at day 7, mice were irradiated at 2 Gy and injected i.v. 
with saline, human wt or Mel+ CD8+ T cells (figure 7.5 A). The human CD8+ T cells injected were 
enumerated and analysed by flow cytometry as shown in figure 7.5 B and C. Due to a problem 
with the stimulation cycle of the CD8+ T cells, large numbers of the T cells had died and only 
3.8% and 8.6% of the wt respectively Mel+ T cells analysed cells were alive. Therefore the mice 
were injected with human CD8+ T cells and a large quantity of apoptotic cells and cell debris. 
The total number of CD8+ T cells available for injection was low and only 1.3 x 105 and 1.4 x 105 
wt or Mel+ live CD8+ T cells respectively were injected (figure 7.5 C). Out of the 1.4 x 105 Mel+ T 
cell population injected, 59.7% were actually Mel+ giving a total of 0.83 x 105 tumour-specific 
CD8+ T cells. It is also of note that 19.2% of Mel+ CD8+ T cells were CCR7+ L-selectin+ whereas 
the only 3.1% of wt cells were CCR7+ L-selectin+. 
Mice were weighed and tumour growth measured by calliper and by imaging for 21 days 
(figure 7.6 A-C). Mice did not lose weight following irradiation or during the experimental 
period (figure 7.6 D). Tumour growth was slowest in the saline control group compared to the 
two groups that received CD8+ T cells. However tumours in the saline group were smaller at 
the start which could partly explain the observed slower growth. The group of mice that 
received wt CD8+ T cell was reduced to one mouse by day 21 as two mice were found dead on 
day 14 and a third mouse had to be culled on day 19 due to sickness. This may have been due 
to a missing filter on the scantainer cage leading to an infection of these immunodeficient 
irradiated mice. No statistically significant differences were found between the growth rates of 
the tumours in the three groups (figure 7.6 E). 
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At day 21, mice were sacrificed and tumours excised and weighed (figure 7.7 A). Due to the 
scales not detecting tumours below 10 mg, 3/5 tumours in the saline control group could not 
be weighed whereas 5/6 tumours from mice that received T cells were large enough to be 
weighed. The spleen, blood, lungs, draining LNs (dLNs) and non-draining LNs (ndLNs) were 
collected as well as the tumours. Single cell suspensions were stained for human CD8 and 
analysed by flow cytometry. The tumour was dissociated and tumour infiltrating lymphocytes 
(TILs) were isolated by flotation on Ficoll. Human CD8+ T cells were not detected in any organ 
of any mouse which may simply reflect the low number of CD8+ T cells injected. 
Tumour measurement by calliper was compared to DsRed signal and as shown in figure 7.7 B, 
the two measurements correlated (r2 = 0.75, p < 0.0001). However, the correlation between 
calliper measurements and tumour weight (r2 = 0.75, p < 0.0001) was better than that 
between DsRed intensity and tumour weight (r2 = 0.66, p < 0.027) (figure 7.7 C and D). 
Overall, Mel+ CD8+ T cells did not control tumour growth in a superior manner to wt CD8+ T 
cells. However, tumour growth was increased in mice receiving T cell injections with large 
amounts of cell debris. One explanation for this could be that the cell debris together with NK 
recognition of human T cells led to an inflammatory environment enhancing tumour growth. 
Thus in subsequent adoptive T cell transfer experiments NSG mice were used. 
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Figure 7.5: Adoptive transfer of human wt or Mel+ CD8+ T cells into irradiated Mel526 tumour 
bearing NOD-SCID mice. A) Experimental layout for the adoptive transfer of human wt or Mel+ 
CD8+ T cells into irradiated (2 Gy) NOD-SCID mice 7 days post subcutaneous injection of 15 x 
106 Mel526 cells. B) Flow cytometry analysis of the human CD8+ T cells used for injection. Cells 
were stained with an ELA tetramer, anti-CD8, anti-CCR7 and anti-L-selectin Ab and the gating 
strategy is shown. C) The total number of live human CD8+ T cells injected per mouse was 
enumerated by flow cytometry using cytocount beads. The number of live Mel+ CD8+ T cells 
was obtained from the % of tetramer+ cells in B). 
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Figure 7.6: Tumour growth in irradiated Mel526 tumour bearing NOD-SCID mice injected 
with human wt or Mel+ CD8+ T cells. A) and C) Tumour growth was monitored by imaging. The 
fluorescence images were superimposed on white light images and the pixel intensity in a 
defined a region of interest (ROI) around the tumour was quantified by subtracting the pixel 
intensity of a ROI outside of the tumour. Data was grouped into saline (grey), wt (black) or 
Mel+ (blue) CD8+ T cell groups. Measurements on day 7 were done before T cells were injected. 
B) Tumour growth was monitored by measuring the tumour dimensions using callipers and 
data grouped. D) Mice were weighed throughout the experiment and grouped data is shown. 
E) The tumour growth rate for each group is shown (two mice found dead at day 14 were 
excluded). No statistically significant differences were observed by a One-way ANOVA with a 
post-hoc Tukey test. ‡ indicates two mice found dead on day 14 and † indicates the culling of 
one mouse due to sickness on day 19. Error bars show the SEM. 
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Figure 7.7: Tumour weight at the day 21 and comparison of different methods used to 
measure tumour growth. A) Tumours were weighed after mice from the saline (grey), wt 
(black) or Mel+ (blue) CD8+ T cell groups were culled and tumours excised.  B) Correlation of 
the tumour area measured by calliper and the sum intensity of DsRed signal measured by 
Kodak imaging of each tumour is shown at the endpoint (day 14, 19 and 21 respectively). C) 
Correlation between the tumour area and tumour weight at the endpoint (day 19 or 21). D) 
Correlation between the sum intensity of the DsRed signal and tumour weight at the endpoint 
(day 19 or 21) for each tumour is shown. The r2 Pearson’s correlation coefficient was 
calculated for data in B-D. 
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7.5 Mel526 tumour cell titration in NSG mice 
Age-matched female NSG mice were purchased from Charles River (Kent, UK) and mice rested 
for more than a week after arrival. Mice were not irradiated as NSG mice are more 
immunodeficient than NOD-SCID mice. A Mel526 tumour cell titration was done to determine 
the optimal Mel526 cell dose to generate reproducible tumour take in NSG mice.  
A total of 9 NSG mice were injected subcutaneously into the left flank with 0.5, 2 or 8 x 106 
Mel526 cells and tumour growth was measured for 34 days (figure 7.8). At the low dose of 0.5 
x 106 Mel526 cells, tumours were only visible by day 14 using Kodak imaging and day 21 using 
callipers. Both the middle and the high tumour cell dose yielded large tumours within 34 days, 
as shown by calliper and Kodak measurements (figure 7.8 A and D). Both groups showed 
similar sized tumours and growth curves. 
The dissection of the tumours at day 34, or day 28 for mouse number 9, showed that the 
tumour in mouse number 4 was much bigger than the other tumours (figure 7.9 A). This was 
not evident from the calliper or Kodak measurements and was due to the tumour growing into 
the peritoneal cavity as well as subcutaneously. No statistically significant correlation was 
observed between the tumour weight and area or weight and DsRed signal (figure 7.9 C-D). 
However the area and DsRed signal measurements correlated (r2 = 0.76, P = 0.002) (figure 7.9 
B). 
Overall, the results for the 2 x 106 and 8 x 106 Mel526 cell doses showed that all 6 mice 
established growing tumours. It was concluded that a subcutaneous injection of 7.5 fold fewer  
Mel526 cells in the NSG mice (2 x 106) than in the NOD-SCID mice (15 x 106) was sufficient to 
generate established tumours by day 7, the chosen day for adoptive T cell transfers (figure 7.8 
E). This tumour cell number was thus chosen for subsequent ACT experiments. 
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Figure 7.8: Titration of Mel526 tumour cells in NSG mice. A) Experimental layout for the 
titration of Mel526 tumour cells in NSG mice. Three mice were each injected subcutaneously 
with 0.5 x 106 (blue), 2 x 106 (red) or 8 x 106 (purple) Mel526 cells. B) and D) Tumour growth 
was monitored by imaging. The fluorescence images were superimposed on white light images 
and the pixel intensity in a defined a region of interest (ROI) around the tumour was quantified 
by subtracting the pixel intensity of a ROI outside of the tumour. C) Tumour growth was 
monitored by measuring the tumour dimensions using callipers and data grouped. † indicates 
the culling of mouse number 9 due to a large tumour at day 28. Error bars show the SEM. E) 
Comparison of tumour growth in NOD-SCID or NSG mice injected with 15 x 106 (figure 7.6 B) or 
2 x 106 Mel526 (C) cells respectively and no human T cells. 
 255 
 
Figure 7.9: Tumour weight and comparison of different methods used to measure tumour 
growth. A) Tumours were weighed after mice injected with 0.5 x 106 (blue), 2 x 106 (red) or 8 x 
106 (purple) Mel526 cells were culled and tumours excised.  B) Correlation of the tumour area 
measured by calliper and the sum intensity of DsRed signal of each tumour is shown at the 
endpoint (day 28 and 31 respectively). C) Correlation between the tumour area and tumour 
weight at the endpoint (day 28 and 31). D) Correlation between the sum intensity of the DsRed 
signal and tumour weight at the endpoint (day 28 and 31) for each tumour is shown. Pearson’s 
correlation coefficient was calculated for data in B-D. The tumour of mouse 4 was found to 
have grown intraperitoneally (i.p.). 
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7.6 Adoptive transfer of human wt, Mel+ or mutant SHP-1 Mel+ CD8+ T 
cells into Mel526 tumour bearing NSG mice 
The tumour cell killing potentials of Mel+ SHP-1 sufficient and mutant CD8+ T cells were 
compared in vivo in a therapeutic adoptive T cell experiment. Female NSG mice were injected 
subcutaneously with 2 x 106 Mel526 cells and once tumours had established at day 7, mice 
were injected i.v. with saline, human wt, Mel+ or mutant SHP-1 Mel+ CD8+ T cells (figure 7.10). 
The latter being a population encompassing a minority of T cells with SHP-1 mutations. The 
human CD8+ T cells injected were enumerated and analysed by flow cytometry as shown in 
figure 7.10 B and C. Groups of 4 mice each received either no T cells or a low number of wt or 
Mel+ T cells (2.3 and 2.0 x 106 cells respectively) and groups of 4, 7 and 5 mice received a high 
number of wt, Mel+ or mutant SHP-1 Mel+ T cells (3.7, 3.1 and 3.2 x 106 cells respectively) 
(figure 7.10 C). There were insufficient mutant SHP-1 Mel+ T cells to test at the lower dose of T 
cells. 
84.4% of cells in the Mel+ population and 90.5% of cells in the mutant SHP-1 Mel+ population 
actually expressed tumour-specific TCR measured by ELA tetramer binding. The latter 
contained 80.5% ZFN2-CD2+ Mel+ cells. A Cel-I assay confirmed the presence of mutant SHP-1 
cells and approximately 10.1% of the mutant SHP-1 Mel+ cells were found to contain mutations 
in the SHP-1 gene (figure 7.10 D). 
As shown in figure 7.11 A, tumours formed in all 28 mice and grew up to 747 mm2 in area 
(mouse number 3). Overall, the sizes of tumours the day before adoptive T cell transfer (day 6) 
were largest in the ‘high mutant SHP-1 Mel+ CD8+’ group and smallest in the ‘saline’ and the 
‘low wt CD8+’ groups. From day 34 onwards 11/27 mice started to develop necrotic lesions 
within the tumour as shown in figure 7.11 B. These lesions were independent of the treatment 
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group. Necrotic tissue covered the DsRed signal of healthy tumour cells as seen in figure 7.11 A 
for mice numbered 3, 16, 21 and 28 on day 41. 
Figure 7.10: Adoptive transfer of human wt, Mel+ or mutant SHP-1 Mel+ CD8+ T cells into 
Mel526 tumour bearing NSG mice. A) Experimental layout for the adoptive transfer of human 
wt, Mel+ or mutant SHP-1 Mel+ CD8+ T cells into NSG mice 7 days post subcutaneous injection 
of 2 x 106 Mel526 cells. B) Flow cytometry analysis of the human CD8+ T cells injected. Cells 
were stained with ELA tetramer, anti-CD8, anti-CCR7 and anti-L-selectin Ab. C) The total 
number of live human CD8+ T cells injected per mouse was enumerated by flow cytometry 
using cytocount beads. D) gDNA extracted from wt, Mel+ and mutant SHP-1 Mel+ CD8+ T cells 
was used to PCR amplify 398 bp SHP-1 genomic segment. After hybridisation of the PCR 
product and digestion of the DNA with the Cel-I enzyme, mutated SHP-1 DNA is indicated by 
178 bp and 220 bp DNA cleavage fragments. Jurkat cells transduced with both ZFN LVs were 
used as a positive control. The % of cells harbouring SHP-1 mutations was obtained by ImageJ 
analysis.
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Figure 7.11: Growth of Mel526 tumours in NSG mice injected with human wt, Mel+ or mutant SHP-1 Mel+ CD8+ T cells. A) Tumour growth was monitored 
by imaging the DsRed signal using the Kodak FX-Pro camera and the signal was analysed using the Carestream software.  The fluorescence images were 
superimposed on white light images. * indicates mice sacrificed on day 41 due to a high level of necrotic lesions, except for mouse number 11 which was 
culled on day 14 due to sickness. B) Representative images of necrotic lesions within intact tumours of four different groups are shown at day 37. 
 259 
 
Looking at the grouped growth curves for mice injected with low (figure 7.12) or high (figure 
7.13) doses of CD8+ T cells, no significant differences were found between the groups using 
either tumour areas or DsRed signals as a readout. There are differences between the growth 
curves using either the user-dependant or user-independent measuring method but overall 
the trends of the growth curves look similar (figure 7.12 and 7.13 A and B). The tumour growth 
curves for each mouse show that the variation between mice in each group is large. For 
example, tumours in the saline group ranged from 137 to 747 mm2 at the endpoint (figure 7.12 
and 7.13 C). 
Mice were sacrificed on day 41 or day 44 and tumours were weighed (figure 7.14 A). The 
tumour from mouse 17 had grown into the peritoneum and was found to be considerably 
larger than the others at 107 mg. There was better correlation between the calliper measured 
area and the tumour weight than the DsRed signal and the tumour weight (r = 0.66 vs. r = 0.46) 
(figure 7.14 C and D). There were no statistically significant differences between the growth 
rates of tumours from all five groups (figure 7.14 E).  
Overall this experiment showed that Mel+ CD8+ T cells were not able to kill Mel526 tumour 
cells in vivo and that mutations in the SHP-1 gene did not overcome this. The absence of an 
anti-tumour effect could be due to poor survival of the human CD8+ T cells in the mouse host 
as at the end of this experiment no human CD8+ T cells were found in the spleen, blood, 
tumour and dLNs (data not shown). 
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Figure 7.12: Tumour growth in NSG mice that received a low dose of human wt or Mel+ CD8+ 
T cells. A) Tumour growth of the saline (grey), low wt (black dotted) or low Mel+ (blue dotted) 
CD8+ T cell groups was monitored by measuring the tumour dimensions using callipers. 
Individual tumour growth curves are shown in C). B) Tumour growth was monitored by 
imaging. The fluorescence images were superimposed on white light images and the pixel 
intensity in a defined a region of interest (ROI) around the tumour was quantified by 
subtracting the pixel intensity of a ROI outside of the tumour. † indicates the culling of one 
mouse due to sickness at day 14. The error bars show the SEM. No statistically significant 
differences were observed. 
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Figure 7.13: Tumour growth in NSG mice that received a high dose human wt, Mel+ or 
mutant SHP-1 Mel+ CD8+ T cells. A) Tumour growth of the saline (grey), high wt (black), high 
Mel+ (blue) or mutant SHP-1 Mel+ (red) CD8+ T cell groups was monitored by measuring the 
tumour dimensions using callipers.  Individual tumour growth curves are shown in C). B) 
Tumour growth was monitored by imaging. The fluorescence images were superimposed on 
white light images and the pixel intensity in a defined a region of interest (ROI) around the 
tumour was quantified by subtracting the pixel intensity of a ROI outside of the tumour. The 
error bars show the SEM. No statistically significant differences were observed. 
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Figure 7.14: Tumour weight at the day 41/44 and comparison of different tumour measuring 
methods.  A) Tumours were weighed after mice from the saline (grey), low wt (black dotted), 
low Mel+ (blue dotted), high wt (black), high Mel+ (blue) or high mutant SHP-1 Mel+ (red) CD8+ 
T cell groups were culled and tumours excised.  The tumour in mouse 17 had grown into the 
peritoneum (i.p.). B) Correlation of the tumour area measured by calliper and the sum 
intensity of DsRed signal of each tumour is shown at the endpoint (day 41 or 44). C) 
Correlation between the tumour area and tumour weight at the endpoint (day 41 or 44) for 
each tumour is shown. D) Correlation between the sum intensity of the DsRed signal and 
tumour weight at the endpoint (day 41 or 44) for each tumour is shown. Spearman correlation 
coefficient was calculated for data in B, C and D. E) Tumour growth rates for all 5 groups are 
shown. No statistically significant differences were observed. The error bars show the SEM. 
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7.7 Conclusion 
The finding that 5x greater numbers of Mel526 cells were needed to establish tumours in NOD-
SCID mice compared to NSG mice could be explained by the residual NK activity observed in 
the NOD-SCID mice compared to much less NK activity in the NSG mice (Shultz et al. 1995). It is 
possible that the white ‘capsular’ structure around the Mel526 tumour in section 7.2 is part of 
the rejection of the tumour by host NK and myeloid cells. Graft rejection of both the human 
tumour and T cells could contribute to suboptimal experimental results in the NOD-SCID model 
and, although irradiation potentially reduced the NK activity in the short-term, long term 
tumour regression experiments may require a more robust and long-term immunodeficiency. 
Due to these concerns, subsequent experiments were done in NSG mice. 
It was shown here that the measurement of the tumour by calliper and by DsRed imaging 
correlated in most instances and both measurement methods have their advantages and 
disadvantages. The DsRed signal can be covered by necrotic tissue or cells might lose the 
DsRed transgene expression in vivo due to transgene silencing (Ellis 2005), both resulting in an 
underestimation of the tumour size. Meanwhile, calliper measurements are user-dependant 
and small tumours, such as those at day 14 in figure 7.8 B), were not detectable by calliper 
measurement, yet they showed up by imaging. 
The lack of anti-tumour effect of the adoptively transferred tumour-specific Mel+ T cells could 
be due to several factors. Firstly, most of the T cells generated here by several rounds of 
stimulation in IL-2 and IL-15 (3 or 5 cycles) were L-selectin and CCR7 negative, indicating a 
terminally differentiated effector phenotype. It has been shown by several groups that 
‘younger’ and/or memory T cells are better for therapy rather than effector T cells. This might 
be due to the prolonged survival of the memory rather than the effector T cells in vivo, as 
shown in NOD-SCID mice (Yang et al. 2011). Altering the cytokines used for T cell culture (e.g.: 
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IL-15 and IL-7 rather than IL-2) can enhance the formation of memory T cells (Gattinoni et al. 
2005; Alcantar-Orozco et al. 2013) and could be considered for future ACT experiments. 
 Secondly, the lack of cytokines in NSG mice, due to the lack of lymphocytes, can leave the T 
cells deprived of support for survival and engraftment. Injections of exogenous IL-2 have been 
shown to correlate with a better outcome in mice (Klebanoff et al. 2011b). IL-15 has also been 
shown to enhance T cell engraftment in immunodeficient mice (Sun et al. 2006). A superior 
strategy would have been to inject immunocomplexes of IL-2 and anti-IL-2 monoclonal Ab 
and/or IL-15 and IL-15α-Fc chimera as they have a longer half-life in vivo than the cytokines 
alone and they promote T cell survival in mice and enhance anti-tumour effects of leucocytes 
(Votavova et al. 2014). Additionally, the injection of irradiated PBMCs and cognate FLT peptide 
could possibly have enhanced the anti-tumour effect of the Mel+ T cells by providing APCs and 
further support.  
Thirdly, the expression of the Mel TCR transgenes in T cells will have led to the mispairing with 
endogenous TCR α and β chains. Although the Mel+ T cells showed potent target killing of 
Mel526 cells at E:T ratios as low as 0.3:1 in vitro in Chapter 5, the T cells expressing mispaired 
TCR might not be potent enough to induce measurable tumour killing in vivo. This hypothesis is 
supported by unpublished data from our group, where T cells from mice hemizygous for a 
tumour specific transgenic TCR were not able to protect against a B16 tumour when compared 
to T cells from homozygous transgenic TCR mice. 
Overall, future xenograft and ACT experiments in NSG mice should be done with ‘younger’ T 
cells and combined with injections of cytokine immunocomplexes and peptide pulsed 
irradiated PBMCs. However, regardless of how much exogenous support will be provided, NSG 
mice will always provide very limited lymphoid structures, with only the mesenteric LNs 
developing properly (Shultz et al. 2012). This, together with the incompatibility of some human 
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and mouse adhesion molecules and ligands, will be a major problem to study the effect of 
shedding-resistant L-selectin on the homing of T cells to LNs and to the tumour. 
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Chapter 8: General discussion and conclusions 
Alternative methods of generating SHP-1 deficient T cells 
It was demonstrated in this thesis that lentivirally delivered ZFNs can successfully generate 
mutations in the SHP-1 gene in human primary CD8+ T cells. However, it was not established 
whether these mutations were mono- or biallelic and whether they resulted in a complete loss 
of functional SHP-1 protein. For this assessment, T cells would have to be cloned and analysed 
on a clonal level, as the sorting of potential SHP-1 deficient primary T cells generated in this 
thesis was not possible. A possible improvement to the current ZFN delivery system would 
have been the inclusion of a surface marker within the ZFN1 delivery vector such as truncated 
versions of the nerve growth factor or CD19 receptors (Barese and Dunbar 2011). These two 
marker proteins have been found to be non-immunogenic and thus suitable for in vivo 
experiments. Double markers, rather than the currently used single rat CD2 marker, could be 
included into the vectors encoding ZFN1 and ZFN2 respectively, allowing doubly transduced 
cells to be isolated by FACS.  
Cells transduced with integrase proficient LV expressing the ZFNs will only ever be of use for 
experiments in vitro or in mice due to the high risk associated with the stable integration of the 
ZFNs and resulting possibility of increased off-target mutations and a conceivable risk of 
mutational integration. For clinical trials, an alternative delivery method where the ZFNs would 
only be expressed transiently would have to be used. One such method would be to use 
integrase deficient LVs. However, in this thesis no SHP-1 mutations were observed when 
employing integrase deficient LVs. As well as adeno-associated viral delivery of ZFNs, non-viral 
approaches might be used as ‘hit-and-run’ delivery methods. In the long term, direct protein 
delivery of ZFNs might be the most straightforward method if preliminary studies prove to be 
reproducible (Gaj et al. 2012; Liu et al. 2015). Currently, the most easily adoptable non-viral 
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delivery method would be electroporation of T cells with plasmid DNA or ideally mRNA. The 
latter eliminates all risk of ZFN genetic material integrating into the host genome and is less 
toxic than plasmid DNA. However, mRNA is significantly less stable in vitro and more elaborate 
to produce than plasmid DNA. Considerable optimisation would have to be done to establish 
optimal conditions for electroporation in order to achieve minimal toxicity to primary CD8+ T 
cells and this was not within the scope of this project.  
As well as altering the delivery method, the frequency of ZFN mediated SHP-1 mutations could 
potentially be increased by cold shocking the CD8+ T cells at 30°C for 2-3 days, as this was 
shown to increase mutations when cells were electroporated with  plasmid DNA or mRNA 
encoding for a pair of ZFNs (Doyon et al. 2010). It is thought that this is partly due to a 
decrease in protein and mRNA turnover in cells exposed to mild hypothermia. 
Although not of major concern for the in vitro functional assays or the in vivo experiments 
performed in this thesis, the specificity of the SHP-1 specific ZFN pair would have to be tested 
extensively before ZFN modified T cells could be used in a clinical setting. Firstly, the genome 
can be screened in silico for possible off-target DNA sequences, based on the sequence 
homology with the target sites. These sequences can then be screened for mutations in vitro 
and in cells. In addition, it would be preferable to screen the whole genome in a more 
unbiased way, as previous studies identified off-target mutations that were not predicted by 
the above mentioned method (Gabriel et al. 2011). However, the screening methods 
employed by Gabriel et al. are very labour intensive and outside of the scope of this thesis 
(Mussolino and Cathomen 2011). Since the pair of SHP-1 ZFNs used in this thesis were 
designed, newer, more specific versions of ZFNs that further enhance the need for 
dimerization by ZFNs have been described and could be used to reduce the potential of off-
target mutations (Doyon et al. 2011). 
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Newer methods of gene editing have emerged since the start of this project, namely 
transcription activator-like effector nucleases (TALENs) and RNA-guided nucleases derived 
from clustered regulatory interspaced short palindromic repeats (CRISPR). Both CRISPR and 
TALENs have been found to generate higher average mutation rates of approximately 20% 
compared to 10% for ZFNs (Kim and Kim 2014). A major advantage of the CRISPR system is that 
only the guide RNA sequence needs to be newly designed for each target whereas new arrays 
of DNA specific protein domains need to be assembled and tested for each target gene for 
ZFNs and TALENs. Due to the simplicity of designing short RNA sequences, genome editing 
using CRISPR has been used for the rapid generation and subsequent screening of large 
libraries of knockout mouse embryonic stem cells in vitro (Koike-Yusa et al. 2014). However, to 
date CRISPR modified cells have not been used for clinical trials. The DNA sequence encoding 
for the ZFN pairs (  ̴ 1 kb x 2) is at least two times smaller than that of the CRISPR system (   ̴4.3 
kb) and TALENs (   ̴ 3kb x 2) and thus the former is preferential for encoding into non-
integrating adenoviral based vectors used extensively in clinical settings. A problem with the 
TALEN DNA sequence, and to a lesser degree with that of ZFNs, is that it is very repetitive, 
which can lead to recombination between the ZFN pairs or TALENs and the deletion of 
sequence when packaging into adeno-associated viral vectors and LVs, as observed in this 
thesis. The CRISPR system does not have this issue.  
It is believed that the system with the possibly lowest off-target rate is TALENs, followed by 
CRISPR and ZFNs (Ain et al. 2014). However, it has been shown that the CRISPR system can 
tolerate up to 5 nucleotides of mismatch DNA (Fu et al. 2013). Additionally, the study on 
specificity was performed with non-commercial ZFNs. It is of importance to note that ZFNs 
which are designed and tested by commercial companies have the advantage of being selected 
for high efficiency and against off-target mediated toxicity.  
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An alternative to genome editing is genome silencing. Here, ZFs are not linked to the nuclease 
domain of FokI but to the catalytic domain of the DNA methyltransferase 3A or to the 
transcription repressor domain of the Krueppel associated box (KRAB) (Davis and Stokoe 
2010). The former has been shown resulting in inheritable epigenetic changes leading to a 
prolonged silencing of the target gene (Stolzenburg et al. 2015). The use of ZF-KRAB repressors 
has shown to result in over 50% repression of targeted genes in mammalian cells (Ren et al. 
2002). This could be advantageous to ZFNs as the latter potentially introduce mutations that 
do not lead to the complete loss of target gene expression. Additionally, as opposed to genetic 
changes, methylation of the gene is reversible provided the engineered genome silencing or 
repressor protein is only expressed transiently. 
Although ZFNs maybe not as efficient at inducing high frequencies of mutations, ZFNs still 
seem to be the safest option for clinical applications, due to the depth of experience with ZFNs 
and with the approval of clinical trials using ZFN modified human T cells (Tebas et al. 2014). 
This might change in the future, once more progress has been made with studying the 
biosafety of TALENs and CRISPR modified human cells in preclinical studies. For now, ZFNs are 
still the safest choice. 
 
SHP-1 deficiency and adoptive T cell therapy 
In this thesis, a phenotype associated with human SHP-1 deficient primary CD8+ T cells was not 
detected, possibly due to the low frequency of SHP-1 deficient cells in the studied population. 
However, the initial hypothesis that a genetic deletion of SHP-1 in human CD8+ T cell is 
beneficial for ACT, due to an enhanced entrance into proliferation leading to a greater number 
of tumour-specific T cells, is still valid. Based on mouse data using T cells from motheaten or 
SHP-1 floxed mice, it was shown that a lack of SHP-1 decreases the activation threshold of T 
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cells (Kilgore et al. 2003; Fowler et al. 2010) and that SHP-1 deficient T cells are activated by 
epitopes that induce anergy or tolerance in wt T cells (Schnell et al. 2009). The latter is 
important for ACT, especially for TIL therapy, as the TAA are often weakly immunogenic and 
SHP-1 sufficient T cells might not be fully activated. Thus loss of SHP-1 in these TILs could 
potentially ‘unmask’ a tumour reactivity of T cells in the tumour environment, where the 
tumour is employing a multitude of mechanisms to limit T cell activation. It was shown that 
pharmacological inhibition of SHP-1 in T cells from elderly patients, which generally express 
increased levels of catalytically active SHP-1 protein, could recover T cell responses in these 
cells (Le Page et al. 2014). This supports the hypothesis that loss of SHP-1 in T cells can unleash 
T cell responses and may be especially relevant when conducting ACT in elderly patients, 
where the T cells are potentially less responsive. 
One major concern about genetically deleting SHP-1 in T cells is the potential development of 
severe autoimmunity. Even though it was shown that the inflammation and autoimmunity 
observed in motheaten mice was not dependent on T cells (Yu et al. 1996), it is possible that 
SHP-1 deficient T cells, when injected in large numbers (up to 1011) for ACT, could lead to 
severe autoimmunity. Contrary to this hypothesis is a study that showed that the transfer of 
SHP-1 deficient mouse T cells to treat leukaemia in mice did not cause any autoimmunity in 
the liver which expressed the cognate self-Ag (Stromnes et al. 2012). Although this study 
showed no autoimmunity, it is possible that cells with different TCR specificities together with 
different Ags with different patterns of expression could lead to SHP-1 deficient T cells causing 
autoimmunity where wt T cells would not. 
To enhance the safety of SHP-1 deficient CD8+ T cells, suicide genes could be delivered to T 
cells, alongside other genes such as TCRs or CARs, to enable clinicians to abolish the T cell 
response if symptoms of autoimmunity or leukaemia were to occur. Leukaemia is a concern as 
a number of leukaemias have been shown to be SHP-1 deficient, however whether this is 
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causal or not is not known (Oka et al. 2001). Two such suicide genes that have been used in 
phase I and II clinical trials of leukaemia patients are the Herpes simplex virus thymidine kinase 
gene and the inducible caspase 9 gene (Ciceri et al. 2007; Di Stasi et al. 2011). Drug induced 
dimerization of the latter in patients that had received haploidentical hematopoietic stem cells 
and experienced graft-versus-host disease led to a rapid elimination of 90% of the alloreactive 
T cells, stopping the most severe symptoms within 24 hours (Di Stasi et al. 2011). A third 
option is the truncated human epidermal growth factor receptor polypeptide which not only 
provides rapid elimination of T cells via Ab-dependant cell-mediated cytotoxicity, but also 
allows for in vitro selection of transduced cells and ex vivo analysis of cells by flow cytometry 
(Wang et al. 2011). These suicide genes would be an additional layer of safety if a SHP-1 
deficiency (as well as other genetic modifications such as TCRs or CARs) caused unpredicted 
off-tumour effects, excessive autoimmunity and damage to vital organs. To reduce these risks 
further, mispairing of the endogenous and exogenous TCR α and β chains could be avoided by 
deleting the endogenous TCR chains (Provasi et al. 2012), thus eliminating the possible 
generation of new TCR specificities. 
Overall, abolishing SHP-1 expression in human CD8+ T cells is still a valid target for improving 
ACT as it might release the ‘brake’ from both low and high affinity tumour specific T cells 
(Hebeisen et al. 2013). Preclinical studies in mice have shown SHP-1 deficient T cells to be 
superior at protecting against disseminating leukaemia (Stromnes et al. 2012) and against B16 
melanoma in mice (unpublished data from our group, A. Watson). Biochemical SHP-1 
inhibition would be the simplest treatment method, however all chemical SHP-1 inhibitors 
have shown considerable cross-reactivity with SHP-2 and no clinical benefit (Kundu et al. 2010; 
Naing et al. 2011; Yi et al. 2011). Additionally, systemic inhibition of SHP-1 might lead to an 
enhanced risk of developing severe neutrophil and myeloid cell driven inflammation and 
autoimmunity, as observed in motheaten mice (Jiao et al. 1997). Thus the best strategy is to 
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silence SHP-1 gene expression or mutate the SHP-1 gene in vitro in T cells prior to transfer of 
the T cells into patients. 
 
L-selectin and adoptive T cell therapy 
In this thesis, the process of L-selectin shedding in response to cognate peptide was studied in 
leukaemic T cells and it was determined that the main sheddase responsible for this activity is 
ADAM17. If time had allowed, the human primary Mel+ CD8+ T cells transduced with wt or ΔM-
N L-selectin, generated in Chapter 6, would have been studied for their lytic activity in vitro 
and in vivo. Previous reports showed reduced killing of Mel526 cells by human tumour-specific 
T cells expressing shedding-resistant L-selectin (Yang et al. 2011). This contrasts with our 
hypothesis that shedding-resistant L-selectin is beneficial for ACT, however our main 
hypothesis is that prolonged expression of L-selectin on the cell surface of T cells will enhance 
the homing of T cells to LNs and possibly to the tumour. Unpublished data from our group 
have shown no differences in target cell killing by mouse CD8+ T cells expressing wt or 
shedding-resistant L-selectin. Ideally, in vivo ACT experiments would be done in xenograft 
bearing immunodeficient mice comparing T cells expressing wt and shedding-resistant L-
selectin. The major problem with using immunodeficient IL2rγ-/- mice is the lack of fully 
developed lymphoid structures (Shultz et al. 2012). In IL-2rγ-/-/Rag2-/- mice it was shown that 
IL-7 signalling is needed for the persistence of LN structures after birth and that the transfer of 
IL-7R+ NK or T cells into these mice at one week of age rescues LN development (Coles et al. 
2006). Another study showed that injection of human IL-7 can enhance the maturation of 
neonatal LNs (Chappaz and Finke 2010). In addition to altered LN development, mouse and 
human molecules involved in cell trafficking and adhesion are often not compatible. Two such 
species specific molecules are LFA-1 and ICAM1 (Johnston et al. 1990), both molecules 
involved in the leucocyte adhesion cascade. To address this problem, immunodeficient mouse 
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strains would have to be generated to express the relevant ligands or receptors. However, it is 
still not fully understood what cell adhesion molecules and chemokine receptors govern T cell 
recruitment to tumours and it is possible that different combinations are important in 
different tumours and at different stages of cancer development. Overall, these studies 
indicate that further optimisation of the existing mouse models is necessary to generate 
models to study T cell homing and trafficking for ACT and other settings. 
There are many more unanswered questions about the biology of L-selectin which our group is 
currently aiming to address. Firstly, the fate of the cytoplasmic tail, generated upon proteolysis 
of the MRF by the γ-secretase, is completely unknown and it would be interesting to 
determine whether it is simply degraded or whether it can act as a transcription factor. Further 
work should thus focus on imaging the cytoplasmic tail in cells and on generating a γ-
secretase-resistant form of L-selectin which can be shed normally via the activation of 
ADAM17 but the MRF cannot be processed further. This would allow a comparison of the 
impact of wt, shedding-resistant and γ-secretase-resistant L-selectin expression on CD8+ T cells 
in vitro and in vivo and might unveil a new role of L-selectin in cell signalling. Experiments are 
currently being done to compare the anti-tumour effect of mouse CD8+ T cells expressing wt or 
shedding-resistant L-selectin in B16 melanoma bearing mice. A crucial difference between the 
mouse T cells, used in these experiments, and patient T cells is that the mouse T cells are from 
a L-selectin knockout background and do not express endogenous L-selectin, whereas patient 
T cells do. It is thus of importance to study the effect of endogenous L-selectin expression in 
combination with shedding-resistant L-selectin expression in T cells and this can be done in 
mice. 
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Mouse xenograft models to study the effect of immunotherapy 
Mice have been used extensively to study cancer development, metastasis and cancer 
treatment. ‘Proof of principle’ for cancer treatments have often been obtained in mice, prior 
to clinical trials in humans. Early studies were done in immunodeficient mice lacking T and B 
cells and having decreased innate immune cell functions and one such mouse is the NOD-SCID 
mouse, used in this thesis. However it was found that NOD-SCID mice and other strains with 
similar levels of immunodeficiency, exhibited much lower human tumour take than NSG mice 
(Quintana et al. 2008). This is probably due to the different levels of xenograft rejecting NK 
cells in the NOD-SCID and NSG mouse strains. NSG mice lack NK cells, due to a mutation in the 
IL-2rγ gene whereas NOD-SCID mice have some residual NK activity. NSG mice support 
metastasis and thus these mice have become the strain of choice to study the development of 
the metastatic process itself as well as its treatment (Zhou et al. 2014). The latter is important 
as the life-threatening symptoms of cancer often do not stem from the primary tumour but 
rather from highly aggressive metastasis. NSG mice, although costly, are thus a popular mouse 
strain for tumour immunotherapy studies. 
Even though NSG mice are permissive to the development of human xenografts, they have 
considerable drawbacks for analysing the interplay between immune cells and cancer. One 
such drawback is the lack of fully developed LNs, discussed in the section above. Another 
disadvantage of NSG mice is the lack of cytokines that support T cell engraftment and 
development. Two ways to overcome this problem are to either administer exogenous 
cytokines or immunocomplexes of IL-2 or/and IL-15 (Votavova et al. 2014) or to knock-in 
human cytokine genes into mouse embryonic stem cells (Shultz et al. 2012). Additionally, NSG 
and all other mouse strains lack the expression of human HLA, which renders the generation of 
de novo anti-tumour T cell responses following vaccination or other treatments unlikely, unless 
the mice have been additionally reconstituted with human PBMCs or human haematopoietic 
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stem cells. Unfortunately, such humanized mice are both labour intensive and expensive and 
thus not available to most laboratories. To overcome the lack of HLA, HLA-A2 transgenic NSG 
mice have been generated (Strowig et al. 2009).  
In summary, results from studies in mice can only ever be used as an indication for the possible 
success of a therapy in man. An example of a therapy that was first shown to be beneficial in 
mice was the anti-CTLA Ab therapy, which provided a well-tolerated, robust antitumour 
response in mice, but when used in patients caused severe side-effects such as colitis (June 
2007). This shows that due to the species specific differences, a certain level of risk will always 
remain for when a therapy is taken into the first patients. Thus, the most reliable experimental 
model for all immunotherapies will be human patients. 
 
Future of adoptive T cell therapy and immunotherapy 
A major problem with ACT is the cost associated with the production of the personalised T cells 
and the question arises whether this therapy will ever be cost-efficient and adopted by health 
services (Kaiser et al. 2015). For it to become more extensively used some issues need to be 
addressed and these will be discussed below. 
ACT requires many hours of skilled labour in sterile conditions and due to the many open 
handling steps is liable to infections and thus failure. Currently, PBMCs are extracted from 
patients’ blood, T cells selected, activated and transduced to express transgenes, expanded 
and tested in vitro prior to reinfusion into patients. One big advance would be the 
development of partly or fully automated closed-systems that do the isolation, transduction 
and expansion steps following standardised protocols (Kaiser et al. 2015). This would allow for 
a more robust, reproducible and, in the long-term, a more cost-efficient final product. As well 
as the processing of T cells, the production of clinical-grade transduction agents needs to be 
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optimised to reduce costs. For this goal, major efforts have been put into developing stable 
viral packaging systems for large scale clinical-grade production of LVs (Sanber et al. 2015). 
Secondly, the selection of the TCR or CAR is crucial for a successful outcome and more 
research needs to be done to derive new receptors with maximal on-tumour and minimal off-
tumour effects. Another strategy is to make ACT less personalised by developing ‘universal T 
cells’. These T cells would ideally be endogenously TCR and HLA negative, express a non-
classical HLA to prevent recognition by NK cells and have the potential to be expanded and 
transduced in vitro for many cycles without losing their memory and effector potential (Kaiser 
et al. 2015). These T cells would be redirected with carefully selected TCRs or CARs that 
recognise tumour-associated Ags. However, there are still many hurdles to overcome for the 
development of universal T cells, not the least exhaustion of these T cells following long-term 
in vitro culture. 
Thirdly, alternative T cell delivery strategies should be trialled to improve safety and efficiency 
of ACT. For example, delivering the T cells in several doses of smaller T cell numbers instead of 
all in one injection could decrease the risk of life-threatening effects such as early cytokine 
release syndrome to occur (Qasim and Thrasher 2014). Additionally, T cells might be more 
potent when delivered locally, in the proximity of the tumour, instead of systemically by 
intravenous injections. This was shown to be the case in a mouse xenograft model where 
locally delivered T cells outperformed those administered intravenously, possibly due to rapid 
local Ag-dependant activation of the T cells administered locally (Adusumilli et al. 2014). 
ACT and other immunotherapies, such as anti-CTLA-4 and anti-PD-1/PD-L1, have been shown 
to be successful in a subset of patients (Rosenberg and Restifo 2015; Sharma and Allison 2015). 
It is thus essential to determine biomarkers associated with successful outcomes to help 
choose the best therapy for each patient. These biomarkers can be tumour-associated or 
immune- associated. For example, increased mutation loads in tumours might be an indication 
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that higher levels of neo-Ag specific T cells are present and that checkpoint inhibitor therapy 
might be successful. However, it was shown that checkpoint inhibitor therapy did also improve 
the outcome of low immunogenic kidney tumour patients (Sharma and Allison 2015). Other 
biomarkers could be molecules within the tumour that inhibit T cell activity, molecules on 
blood vessels that regulate T cell infiltration into tumours or molecules expressed by T cells 
within the tumour. Successful ACT might be associated with phenotypic markers on T cells 
after in vitro expansion, such as L-selectin, which has already been shown to be associated 
with a more favourable outcome in ACT experiments in mice (Gattinoni et al. 2005). 
Currently, the field of immunotherapy is showing very encouraging results, possibly the most 
exciting being checkpoint inhibitor therapies, such as anti-CTLA-4 and anti-PD-1/PD-L1 Abs. 
The latter are considerably easier to manufacture than T cells and it is thus going to be 
important to decide when either or both therapies are beneficial. Many more possible targets 
are being explored for improved immunotherapy and in particular ACT, including both SHP-1 
and L-selectin, as discussed in this thesis. As well as the blockade of inhibitory signalling 
pathways such as PD-1 and CTLA-4, current research also focuses on activating stimulatory 
pathways (Sharma and Allison 2015). One scenario where ACT might be necessary is in poorly 
immunogenic tumours with low T cell infiltration, where an injection of a high numbers of 
tumour-specific T cells could boost the anti-tumour immune response considerably.  
Overall, it is likely that the most successful cancer immunotherapies will be combinatorial 
treatments. For example a patient could undergo a lymphodepleting chemotherapy treatment 
prior to ACT, followed by a checkpoint inhibitor treatment such as anti-PD-1. To determine 
optimal combinations, many more trials will have to be done and the complexity and costs of 
production, especially of the ACT, will have to be reduced. 
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Appendix 
Appendix A1: Primers 
Primer 
number 
Primer sequence 
 
 
Reference to 
figure or assay 
9 
 
ATTCGGATCCTCTAGAGCCGCCACCATGGACTACAAAGACCA
TGACGG 
F 
 3.2.2 
10 CGCTGCCGCTCTCGAGAGATCTGAAGTTGATCTCGCCGTTG R   
17 ATCCACGGGGTTCCCGCCGCTAT F 3.2.3 
18  ATAGCGGCGGGAACCCCGTGGAT R   
19 
 
ACCCTGGCCCGCGCGGTACCATGAGATCTGACTACAAAGACC
ATGAC 
F 
 3.2.4 
20 CTTGGATCCGCGGCCGCGAAGTTGATCTCGCCGTTGTTGAAC R   
57 ATCAACTTCGCGGCCGCAAGCGGCTCCGGTGCCA F 3.2.5 
30 TTGGATCCGCGGCCGCTTACCGTTTTTTCCTCTTGCAG R   
52 CGCCCGGGGGGGATCCGCCGCCACCATGGACTACAA F 3.2.6 
32 CTCGAGCCCGGGATCCTTACCGTTTTTTCCTCTTGCAG R   
60 
 
CGCCCGGGGGGGATCCGCCGCCACCATGGACTACAAAGACC
ATGACG 
F 
 3.3.1 
61 CTCGAGCCCGGGATCCTCAAGATCTGAAGTTGATCTCGC R   
55 GAGTCCGAGGATACAGCCAA F Cel-I assay 
56 GAGGGTGGAGACCTGTGAGA R 398bp SHP-1 
58 GGCACACAGTAGGTGCTTGA F 3.2.10 
59 CCTAGCAGCTGGTTCTGGAC R 1733bp SHP-1 
62 
 
 
CGCCCGGGGGGGATCCGCCGCCACCATGGGTAAGCCTATCC
CTAACCCTCTCCTCGGTCTCGATTCTACGATGGCCCCCAAGA
AGAAGAGGA 
F 
 
 
3.3.2 
 
63 CTCGAGCCCGGGATCCTCAGAAGTTGATCTCGCCGTTG R 
 66 
 
CGCCCGGGGGGGATCCGCCGCCACCATGGCCCCCAAGAAGA
AGA 
F 
 3.3.3 
32 CTCGAGCCCGGGATCCTTACCGTTTTTTCCTCTTGCAG R   
68 GCCGCCACCATGGTGAGGTGGTTTCACCGAGACCTC F 3.8.1 A) 
69 TCACTTCCTCTTGAGGGAAC R   
70 CGCCCGGGGGGGATCCGCCGCCACCATGGTGA F 3.8.1 B) 
71 CTCGAGCCCGGGATCCTCACTTCCTCTTGAGGGAACCC R   
80 GTGTACGGCTACAGGGGAAA F FokI domain  
81 TGGGGTTGAGGTGCTTATTC R not used 
Table A1: Primers used for cloning in Chapter 3. Numbered forward (F) and reverse (R) 
primers for In-Fusion reactions (orange), site-directed mutagenesis (red) or other uses 
(magenta) are shown. For In-Fusion reactions, primer sequence homology with the vector 
backbone is indicated in italics followed by the underlined sequence of the restriction enzyme 
sites utilised (BamHI=GGATCC, KpnI=GGTACC, NotI=GCGGCCGC, XbaI=TCTAGA and 
XhoI=CTCGAG). Start (ATG) and stop (TAA, TGA, TAG) codons are indicated in bold and the 
Kozak consensus sequence is shown in green. The red nucleotide either indicates an altered 
nucleotide for site-directed mutagenesis or an introduction of additional nucleotide. The V5 
tag sequence highlighted in green. 
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Table A2: Primers used for sequencing. Numbered forward (F) and reverse (R) primers used 
for sequencing are shown and the binding site within a gene is indicated. 
 
 
 
 
 
 
 
 
Primer 
number 
Primer sequence 
 
 
Binding site of primer 
 
4 AGATCTCAAATGCTCCCGAT R CD2 219 
5 ATCGGGAGCATTTGAGATCT F CD2 219 
6 GCTGACCCTGTTTACCGCCT R CD2 539 
7 AGGCGGTAAACAGGGTCAGC F CD2 539 
8 GAAACAGCTATGACCATGTT R pUC19 downstream of stop codon 
11 CTGCAAGGCGATTAAGTTGGG F pUC19 75 upstream of start codon 
12 CGACACTGGAAGGGCCGTTG R ZFN1 298 
13 CAACGGCCCTTCCAGTGTCG F ZFN1 298 
14 CCAGGTGCTTTCCCCTGTAG R ZFN1 717 
15 CTACAGGGGAAAGCACCTGG F ZFN1 717 
16 ATCGCCCTCGCCCTCGCCGG R within GFP 
21 CACATCACCAACTGCAATGGC F ZFN1 1015 
22 AGGTGGCCGGACTGACTGAA R ZFN2 253 
23 TTCAGTCAGTCCGGCCACCT F ZFN2 253 
24 CTGCCCACTGTATAGATGGC R ZFN2 766 
25 GCCATCTATACAGTGGGCAG F ZFN2 766 
26 GCAGTGAGCGCAACGCAATT R pUC reverse 
33 AATCAGCCTGCTTCTCGCT F pSxW 
34 GCGTATCCACATAGCGTAAA R pSxW 
53 AGATCTCTCGAGAGCGGCAG F within T2A 
54 CTGCCGCTCTCGAGAGATCT R within T2A 
72 GGGCGAGCCCTGGACGT F SHP-1 381 
73 GGTCCGACTACATCAATGCC F SHP-1 893 
74 CCAAGGGCCTGGACTGTG F SHP-1 1424 
75 CAGCCTTGGGCTGGTCA R SHP-1 453 
76 TGACCGTGGCCTCCAGACA R SHP-1 979 
77 ACTTGTACTGCGCCTCCG R SHP-1 1502 
T7 TAATACGACTCACTATAGGG F TA cloning 
SP6 CTATAGTGTCACCTAAATA R TA cloning 
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Primer 
number Primer sequence   Reference to figure 
45 CGCCCGGGGGGGATCCGCCGCCACCATGGGCTGC
AGAAGAACTAGAG 
F 
 
6.2 
 
46 CTCGAGCCCGGGATCCTTAATATGGGTCATTCATAC
TTCTC 
R 
 
6.2 and 6.6 
 
47 AGAATCCAGGCCCCATGCATATGGGCTGCAGAAGA
ACTAGAG 
F 
 
6.4 
 
48 TATCTTATTAGTCGACTTAATATGGGTCATTCATAC
TTCTC 
R 
 
6.4 
 
49 ATTTAATTAATCTAGAGCCGCCACCATGAGATGTAA
ATTCCTAGGGAG 
F 
 
6.5 
 
50 CGGAGCCGCTCTCGAGCCGTTTTTTCCTCTTGCAGA
TAC 
R 
 
6.5 
 
51 CGCCCGGGGGGGATCCGCCGCCACCATGAGAT F 6.6 
64 GGGTTGGCATTTATCAAGTGGCTGGCAAGGAGA F 6.2 
65 TCTCCTTGCCAGCCACTTGATAAATGCCAACCC R 6.2 
Primer 
number Primer sequence   Binding site of primer 
37 ATGGGCTGCAGAAGAACTAG F L-selectin start codon 
38 CTGTGTAATTGTCTCGGCAG R L-selectin 206 
39 TACACAGCTTCTTGCCAGCC F L-selectin 504 
40 CCTCCAAAGGCTCACACTGA R L-selectin 623  
41 GCATGTACCTTCATCTGCTCAG F L-selectin 888  
42 ATATGGGTCATTCATACTTC R L-selectin stop codon 
33 AATCAGCCTGCTTCTCGCT F pSxW 
34 GCGTATCCACATAGCGTAAA R pSxW 
4 AGATCTCAAATGCTCCCGAT R CD2 219 
5 ATCGGGAGCATTTGAGATCT F CD2 219 
6 GCTGACCCTGTTTACCGCCT R CD2 539 
7 AGGCGGTAAACAGGGTCAGC F CD2 539 
8 
GAAACAGCTATGACCATGTT R 
pUC19 downstream of 
stop codon 
Table A3: Primers used for cloning and sequencing in Chapter 6. Numbered forward (F) and 
reverse (R) primers for In-Fusion reactions (orange), site-directed mutagenesis (red) and 
sequencing (blue) are shown. For In-Fusion reactions, primer sequence homology with the 
vector backbone is indicated in italics followed by the underlined sequence of the restriction 
enzyme sites utilised (BamHI=GGATCC, NsiI=ATGCAT, SalI=GTCGAC, KpnI=GGTACC, 
XbaI=TCTAGA and XhoI=CTCGAG). Start (ATG) and stop (TAA, TGA, TAG) codons are indicated 
in bold and the Kozak consensus sequence is shown in green. For the sequencing primers the 
binding site within a gene is indicated. 
 
 
 
 304 
 
Appendix A2: DNA sequences of plasmids generated in chapter 3 and 6 
All sequences below were inserted into the BamHI site in the lentiviral transfer pSxW plasmid. 
Kozak consensus sequences are shown in green letters, ZFN and L-selectin sequences are 
highlighted in grey, the CD2 sequence is highlighted in green and the T2A and P2A sequences 
are highlighted in turquoise. The 3xFlag or V5 tags are highlighted in pink. Unlabelled 
sequences correspond to restriction sites.  
pLenti-ZFN1-T2A-ZFN2-P2A-CD2 (from figure 3.2 and 3.7) 
GCCGCCACCATGGACTACAAAGACCATGACGGTGATTATAAAGATCATGACATCGATTACAAGGATGA
CGATGACAAGATGGCCCCCAAGAAGAAGAGGAAGGTGGGCATCCACGGGGTTCCCGCCGCTATGGCT
GAGAGGCCCTTCCAGTGTCGAATCTGCATGCGTAACTTCAGTCGCTCCGACCACCTGTCCCGCCACATC
CGCACCCACACCGGCGAGAAGCCTTTTGCCTGTGACATTTGTGGGAGGAAATTTGCCACCTCCGGCCAC
CTGTCCCGCCATACCAAGATACACACGGGCGGACAACGGCCCTTCCAGTGTCGAATCTGCATGCGTAAC
TTCAGTCGTAGTGACAGCCTGAGCGTACACATCCGCACCCACACAGGCGAGAAGCCTTTTGCCTGTGAC
ATTTGTGGGAGGAAATTTGCCACCAACCACAACCGCAAAACGCATACCAAGATACACACGGGCGAGAA
GCCCTTCCAGTGTCGAATCTGCATGCGTAAGTTTGCCCAGAACGCCCACCGCAAGACCCATACCAAGAT
ACACCTGCGGGGATCCCAGCTGGTGAAGAGCGAGCTGGAGGAGAAGAAGTCCGAGCTGCGGCACAA
GCTGAAGTACGTGCCCCACGAGTACATCGAGCTGATCGAGATCGCCAGGAACAGCACCCAGGACCGCA
TCCTGGAGATGAAGGTGATGGAGTTCTTCATGAAGGTGTACGGCTACAGGGGAAAGCACCTGGGCGG
AAGCAGAAAGCCTGACGGCGCCATCTATACAGTGGGCAGCCCCATCGATTACGGCGTGATCGTGGACA
CAAAGGCCTACAGCGGCGGCTACAATCTGCCTATCGGCCAGGCCGACGAGATGGAGAGATACGTGGA
GGAGAACCAGACCCGGAATAAGCACCTCAACCCCAACGAGTGGTGGAAGGTGTACCCTAGCAGCGTG
ACCGAGTTCAAGTTCCTGTTCGTGAGCGGCCACTTCAAGGGCAACTACAAGGCCCAGCTGACCAGGCT
GAACCACATCACCAACTGCAATGGCGCCGTGCTGAGCGTGGAGGAGCTGCTGATCGGCGGCGAGATG
ATCAAAGCCGGCACCCTGACACTGGAGGAGGTGCGGCGCAAGTTCAACAACGGCGAGATCAACTTCA
GATCTCTCGAGAGCGGCAGCGGGCGCAGCGGCAGCGGCGAAGGCCGCGGCAGCCTGCTGACCTGCG
GCGATGTGGAAGAAAACCCTGGCCCGCGCGGTACCATGAGATCTGACTACAAAGACCATGACGGTGAT
TATAAAGATCATGACATCGATTACAAGGATGACGATGACAAGATGGCCCCCAAGAAGAAGAGGAAGG
TGGGCATTCATGGGGTACCCGCCGCTATGGCTGAGAGGCCCTTCCAGTGTCGAATCTGCATGCGTAAG
TTTGCCACCTCCGGCCACCTGTCCCGCCATACCAAGATACACACGGGCGAGAAGCCCTTCCAGTGTCGA
ATCTGCATGCGTAACTTCAGTCAGTCCGGCCACCTGCAGCGCCACATCCGCACCCACACCGGCGAGAAG
CCTTTTGCCTGTGACATTTGTGGGAGGAAATTTGCCCAGTCCGGCGACCTGACCCGCCATACCAAGATA
CACACGGGATCTCAGAAGCCCTTCCAGTGTCGAATCTGCATGCGTAACTTCAGTCAGTCCGGCAACCTG
GCCCGCCACATCCGCACCCACACCGGCGAGAAGCCTTTTGCCTGTGACATTTGTGGGAGGAAATTTGCC
CAGTCCGGCGACCTGACCCGCCATACCAAGATACACCTGCGGGGATCCCAGCTGGTGAAGAGCGAGCT
GGAGGAGAAGAAGTCCGAGCTGCGGCACAAGCTGAAGTACGTGCCCCACGAGTACATCGAGCTGATC
GAGATCGCCAGGAACAGCACCCAGGACCGCATCCTGGAGATGAAGGTGATGGAGTTCTTCATGAAGG
TGTACGGCTACAGGGGAAAGCACCTGGGCGGAAGCAGAAAGCCTGACGGCGCCATCTATACAGTGGG
CAGCCCCATCGATTACGGCGTGATCGTGGACACAAAGGCCTACAGCGGCGGCTACAATCTGCCTATCG
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GCCAGGCCGACGAGATGCAGAGATACGTGAAGGAGAACCAGACCCGGAATAAGCACATCAACCCCAA
CGAGTGGTGGAAGGTGTACCCTAGCAGCGTGACCGAGTTCAAGTTCCTGTTCGTGAGCGGCCACTTCA
AGGGCAACTACAAGGCCCAGCTGACCAGGCTGAACCACAAAACCAACTGCAATGGCGCCGTGCTGAGC
GTGGAGGAGCTGCTGATCGGCGGCGAGATGATCAAAGCCGGCACCCTGACACTGGAGGAGGTGCGG
CGCAAGTTCAACAACGGCGAGATCAACTTCGCGGCCGCAAGCGGCTCCGGTGCCACCAACTTCTCTCTG
CTGAAGCAGGCCGGGGATGTCGAAGAGAATCCAGGCCCCATGCATATGAGATGTAAATTCCTAGGGA
GTTTCTTTCTGCTCTTCAGCCTGTCCAGCAAAGGAGCAGACTGCAGAGACAGTGGGACCGTCTGGGGT
GCCCTGGGTCATGGCATCAACCTGAACATCCCTAACTTTCAAATGACTGATGATATTGATGAGGTGCGA
TGGGAGAGGGGGAGCACCCTGGTTGCCGAGTTTAAAAGGAAGATGAAGCCTTTTTTGAAATCGGGAG
CATTTGAGATCTTAGCAAATGGAGACTTGAAGATAAAGAATCTGACAAGAGATGACAGTGGCACCTAT
AATGTAACGGTATACAGCACAAATGGGACACGTATCCTGAACAAGGCACTGGACTTGAGGATTCTGGA
GATGGTCTCAAAGCCGATGATCTACTGGGAGTGCAGCAACGCAACCCTGACCTGTGAGGTCTTGGAAG
GAACAGATGTTGAACTAAAGCTGTACCAAGGAAAGGAGCATCTCAGGAGCCTCCGTCAGAAGACCATG
AGTTACCAGTGGACCAACCTGAGAGCACCGTTTAAGTGCAAGGCGGTAAACAGGGTCAGCCAGGAGT
CTGAGATGGAAGTTGTCAACTGTCCAGAGAAAGGTCTGCCCCTCTATCTCATAGTGGGGGTCAGTGCA
GGAGGACTCCTCTTGGTGTTCTTTGGGGCGCTGTTTATTTTCTGTATCTGCAAGAGGAAAAAACGGTAA 
 
pLenti-3xFlag-ZFN1 (from figure 3.15) 
GCCGCCACCATGGACTACAAAGACCATGACGGTGATTATAAAGATCATGACATCGATTACAAGGATGA
CGATGACAAGATGGCCCCCAAGAAGAAGAGGAAGGTGGGCATCCACGGGGTACCCGCCGCTATGGCT
GAGAGGCCCTTCCAGTGTCGAATCTGCATGCGTAACTTCAGTCGCTCCGACCACCTGTCCCGCCACATC
CGCACCCACACCGGCGAGAAGCCTTTTGCCTGTGACATTTGTGGGAGGAAATTTGCCACCTCCGGCCAC
CTGTCCCGCCATACCAAGATACACACGGGCGGACAACGGCCCTTCCAGTGTCGAATCTGCATGCGTAAC
TTCAGTCGTAGTGACAGCCTGAGCGTACACATCCGCACCCACACAGGCGAGAAGCCTTTTGCCTGTGAC
ATTTGTGGGAGGAAATTTGCCACCAACCACAACCGCAAAACGCATACCAAGATACACACGGGCGAGAA
GCCCTTCCAGTGTCGAATCTGCATGCGTAAGTTTGCCCAGAACGCCCACCGCAAGACCCATACCAAGAT
ACACCTGCGGGGATCCCAGCTGGTGAAGAGCGAGCTGGAGGAGAAGAAGTCCGAGCTGCGGCACAA
GCTGAAGTACGTGCCCCACGAGTACATCGAGCTGATCGAGATCGCCAGGAACAGCACCCAGGACCGCA
TCCTGGAGATGAAGGTGATGGAGTTCTTCATGAAGGTGTACGGCTACAGGGGAAAGCACCTGGGCGG
AAGCAGAAAGCCTGACGGCGCCATCTATACAGTGGGCAGCCCCATCGATTACGGCGTGATCGTGGACA
CAAAGGCCTACAGCGGCGGCTACAATCTGCCTATCGGCCAGGCCGACGAGATGGAGAGATACGTGGA
GGAGAACCAGACCCGGAATAAGCACCTCAACCCCAACGAGTGGTGGAAGGTGTACCCTAGCAGCGTG
ACCGAGTTCAAGTTCCTGTTCGTGAGCGGCCACTTCAAGGGCAACTACAAGGCCCAGCTGACCAGGCT
GAACCACATCACCAACTGCAATGGCGCCGTGCTGAGCGTGGAGGAGCTGCTGATCGGCGGCGAGATG
ATCAAAGCCGGCACCCTGACACTGGAGGAGGTGCGGCGCAAGTTCAACAACGGCGAGATCAACTTCA
GATCTTGA 
 
 
 306 
 
pLenti-V5-ZFN2 (from figure 3.16) 
GCCGCCACCATGGGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCTACGATGGCCCCCAAGAAG
AAGAGGAAGGTGGGCATTCATGGGGTACCCGCCGCTATGGCTGAGAGGCCCTTCCAGTGTCGAATCTG
CATGCGTAAGTTTGCCACCTCCGGCCACCTGTCCCGCCATACCAAGATACACACGGGCGAGAAGCCCTT
CCAGTGTCGAATCTGCATGCGTAACTTCAGTCAGTCCGGCCACCTGCAGCGCCACATCCGCACCCACAC
CGGCGAGAAGCCTTTTGCCTGTGACATTTGTGGGAGGAAATTTGCCCAGTCCGGCGACCTGACCCGCC
ATACCAAGATACACACGGGATCTCAGAAGCCCTTCCAGTGTCGAATCTGCATGCGTAACTTCAGTCAGT
CCGGCAACCTGGCCCGCCACATCCGCACCCACACCGGCGAGAAGCCTTTTGCCTGTGACATTTGTGGGA
GGAAATTTGCCCAGTCCGGCGACCTGACCCGCCATACCAAGATACACCTGCGGGGATCCCAGCTGGTG
AAGAGCGAGCTGGAGGAGAAGAAGTCCGAGCTGCGGCACAAGCTGAAGTACGTGCCCCACGAGTACA
TCGAGCTGATCGAGATCGCCAGGAACAGCACCCAGGACCGCATCCTGGAGATGAAGGTGATGGAGTT
CTTCATGAAGGTGTACGGCTACAGGGGAAAGCACCTGGGCGGAAGCAGAAAGCCTGACGGCGCCATC
TATACAGTGGGCAGCCCCATCGATTACGGCGTGATCGTGGACACAAAGGCCTACAGCGGCGGCTACAA
TCTGCCTATCGGCCAGGCCGACGAGATGCAGAGATACGTGAAGGAGAACCAGACCCGGAATAAGCAC
ATCAACCCCAACGAGTGGTGGAAGGTGTACCCTAGCAGCGTGACCGAGTTCAAGTTCCTGTTCGTGAG
CGGCCACTTCAAGGGCAACTACAAGGCCCAGCTGACCAGGCTGAACCACAAAACCAACTGCAATGGCG
CCGTGCTGAGCGTGGAGGAGCTGCTGATCGGCGGCGAGATGATCAAAGCCGGCACCCTGACACTGGA
GGAGGTGCGGCGCAAGTTCAACAACGGCGAGATCAACTTCTGA 
 
pLenti-ZFN2-P2A-CD2 (from figure 3.17) 
GCCGCCACCATGGCCCCCAAGAAGAAGAGGAAGGTGGGCATTCATGGGGTACCCGCCGCTATGGCTG
AGAGGCCCTTCCAGTGTCGAATCTGCATGCGTAAGTTTGCCACCTCCGGCCACCTGTCCCGCCATACCA
AGATACACACGGGCGAGAAGCCCTTCCAGTGTCGAATCTGCATGCGTAACTTCAGTCAGTCCGGCCACC
TGCAGCGCCACATCCGCACCCACACCGGCGAGAAGCCTTTTGCCTGTGACATTTGTGGGAGGAAATTTG
CCCAGTCCGGCGACCTGACCCGCCATACCAAGATACACACGGGATCTCAGAAGCCCTTCCAGTGTCGAA
TCTGCATGCGTAACTTCAGTCAGTCCGGCAACCTGGCCCGCCACATCCGCACCCACACCGGCGAGAAGC
CTTTTGCCTGTGACATTTGTGGGAGGAAATTTGCCCAGTCCGGCGACCTGACCCGCCATACCAAGATAC
ACCTGCGGGGATCCCAGCTGGTGAAGAGCGAGCTGGAGGAGAAGAAGTCCGAGCTGCGGCACAAGC
TGAAGTACGTGCCCCACGAGTACATCGAGCTGATCGAGATCGCCAGGAACAGCACCCAGGACCGCATC
CTGGAGATGAAGGTGATGGAGTTCTTCATGAAGGTGTACGGCTACAGGGGAAAGCACCTGGGCGGAA
GCAGAAAGCCTGACGGCGCCATCTATACAGTGGGCAGCCCCATCGATTACGGCGTGATCGTGGACACA
AAGGCCTACAGCGGCGGCTACAATCTGCCTATCGGCCAGGCCGACGAGATGCAGAGATACGTGAAGG
AGAACCAGACCCGGAATAAGCACATCAACCCCAACGAGTGGTGGAAGGTGTACCCTAGCAGCGTGACC
GAGTTCAAGTTCCTGTTCGTGAGCGGCCACTTCAAGGGCAACTACAAGGCCCAGCTGACCAGGCTGAA
CCACAAAACCAACTGCAATGGCGCCGTGCTGAGCGTGGAGGAGCTGCTGATCGGCGGCGAGATGATC
AAAGCCGGCACCCTGACACTGGAGGAGGTGCGGCGCAAGTTCAACAACGGCGAGATCAACTTCGCGG
CCGCAAGCGGCTCCGGTGCCACCAACTTCTCTCTGCTGAAGCAGGCCGGGGATGTCGAAGAGAATCCA
GGCCCCATGCATATGAGATGTAAATTCCTAGGGAGTTTCTTTCTGCTCTTCAGCCTGTCCAGCAAAGGA
GCAGACTGCAGAGACAGTGGGACCGTCTGGGGTGCCCTGGGTCATGGCATCAACCTGAACATCCCTAA
CTTTCAAATGACTGATGATATTGATGAGGTGCGATGGGAGAGGGGGAGCACCCTGGTTGCCGAGTTTA
AAAGGAAGATGAAGCCTTTTTTGAAATCGGGAGCATTTGAGATCTTAGCAAATGGAGACTTGAAGATA
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AAGAATCTGACAAGAGATGACAGTGGCACCTATAATGTAACGGTATACAGCACAAATGGGACACGTAT
CCTGAACAAGGCACTGGACTTGAGGATTCTGGAGATGGTCTCAAAGCCGATGATCTACTGGGAGTGCA
GCAACGCAACCCTGACCTGTGAGGTCTTGGAAGGAACAGATGTTGAACTAAAGCTGTACCAAGGAAAG
GAGCATCTCAGGAGCCTCCGTCAGAAGACCATGAGTTACCAGTGGACCAACCTGAGAGCACCGTTTAA
GTGCAAGGCGGTAAACAGGGTCAGCCAGGAGTCTGAGATGGAAGTTGTCAACTGTCCAGAGAAAGGT
CTGCCCCTCTATCTCATAGTGGGGGTCAGTGCAGGAGGACTCCTCTTGGTGTTCTTTGGGGCGCTGTTT
ATTTTCTGTATCTGCAAGAGGAAAAAACGGTAA 
 
pLenti-L-selectin wt (from figure 6.2) 
GCCGCCACCATGGGCTGCAGAAGAACTAGAGAAGGACCAAGCAAAGCCATGATATTTCCATGGAAATG
TCAGAGCACCCAGAGGGACTTATGGAACATCTTCAAGTTGTGGGGGTGGACAATGCTCTGTTGTGATTT
CCTGGCACATCATGGAACCGACTGCTGGACTTACCATTATTCTGAAAAACCCATGAACTGGCAAAGGGC
TAGAAGATTCTGCCGAGACAATTACACAGATTTAGTTGCCATACAAAACAAGGCGGAAATTGAGTATCT
GGAGAAGACTCTGCCTTTCAGTCGTTCTTACTACTGGATAGGAATCCGGAAGATAGGAGGAATATGGA
CGTGGGTGGGAACCAACAAATCTCTCACTGAAGAAGCAGAGAACTGGGGAGATGGTGAGCCCAACAA
CAAGAAGAACAAGGAGGACTGCGTGGAGATCTATATCAAGAGAAACAAAGATGCAGGCAAATGGAAC
GATGACGCCTGCCACAAACTAAAGGCAGCCCTCTGTTACACAGCTTCTTGCCAGCCCTGGTCATGCAGT
GGCCATGGAGAATGTGTAGAAATCATCAATAATTACACCTGCAACTGTGATGTGGGGTACTATGGGCC
CCAGTGTCAGTTTGTGATTCAGTGTGAGCCTTTGGAGGCCCCAGAGCTGGGTACCATGGACTGTACTCA
CCCTTTGGGAAACTTCAGCTTCAGCTCACAGTGTGCCTTCAGCTGCTCTGAAGGAACAAACTTAACTGG
GATTGAAGAAACCACCTGTGGACCATTTGGAAACTGGTCATCTCCAGAACCAACCTGTCAAGTGATTCA
GTGTGAGCCTCTATCAGCACCAGATTTGGGGATCATGAACTGTAGCCATCCCCTGGCCAGCTTCAGCTT
TACCTCTGCATGTACCTTCATCTGCTCAGAAGGAACTGAGTTAATTGGGAAGAAGAAAACCATTTGTGA
ATCATCTGGAATCTGGTCAAATCCTAGTCCAATATGTCAAAAATTGGACAAAAGTTTCTCAATGATTAAG
GAGGGTGATTATAACCCCCTCTTCATTCCAGTGGCAGTCATGGTTACTGCATTCTCTGGGTTGGCATTTA
TCATTTGGCTGGCAAGGAGATTAAAAAAAGGCAAGAAATCCAAGAGAAGTATGAATGACCCATATTAA 
 
pLenti-L-selectin ΔM-N (from figure 6.2) 
GCCGCCACCATGGGCTGCAGAAGAACTAGAGAAGGACCAAGCAAAGCCATGATATTTCCATGGAAATG
TCAGAGCACCCAGAGGGACTTATGGAACATCTTCAAGTTGTGGGGGTGGACAATGCTCTGTTGTGATTT
CCTGGCACATCATGGAACCGACTGCTGGACTTACCATTATTCTGAAAAACCCATGAACTGGCAAAGGGC
TAGAAGATTCTGCCGAGACAATTACACAGATTTAGTTGCCATACAAAACAAGGCGGAAATTGAGTATCT
GGAGAAGACTCTGCCTTTCAGTCGTTCTTACTACTGGATAGGAATCCGGAAGATAGGAGGAATATGGA
CGTGGGTGGGAACCAACAAATCTCTCACTGAAGAAGCAGAGAACTGGGGAGATGGTGAGCCCAACAA
CAAGAAGAACAAGGAGGACTGCGTGGAGATCTATATCAAGAGAAACAAAGATGCAGGCAAATGGAAC
GATGACGCCTGCCACAAACTAAAGGCAGCCCTCTGTTACACAGCTTCTTGCCAGCCCTGGTCATGCAGT
GGCCATGGAGAATGTGTAGAAATCATCAATAATTACACCTGCAACTGTGATGTGGGGTACTATGGGCC
CCAGTGTCAGTTTGTGATTCAGTGTGAGCCTTTGGAGGCCCCAGAGCTGGGTACCATGGACTGTACTCA
CCCTTTGGGAAACTTCAGCTTCAGCTCACAGTGTGCCTTCAGCTGCTCTGAAGGAACAAACTTAACTGG
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GATTGAAGAAACCACCTGTGGACCATTTGGAAACTGGTCATCTCCAGAACCAACCTGTCAAGTGATTCA
GTGTGAGCCTCTATCAGCACCAGATTTGGGGATCATGAACTGTAGCCATCCCCTGGCCAGCTTCAGCTT
TACCTCTGCATGTACCTTCATCTGCTCAGAAGGAACTGAGTTAATTGGGAAGAAGAAAACCATTTGTGA
ATCATCTGGAATCTGGTCAAATCCTAGTCCAATATGTCAAAAATTGGACAAAAGCTTCTCACCCCTCTTC
ATTCCAGTGGCAGTCATGGTTACTGCATTCTCTGGGTTGGCATTTATCATTTGGCTGGCAAGGAGATTA
AAAAAAGGCAAGAAATCCAAGAGAAGTATGAATGACCCATATTAA 
 
pLenti-CD2-P2A-L-selectin wt (from figure 6.3) 
GCCGCCACCATGAGATGTAAATTCCTAGGGAGTTTCTTTCTGCTCTTCAGCCTGTCCAGCAAAGGAGCA
GACTGCAGAGACAGTGGGACCGTCTGGGGTGCCCTGGGTCATGGCATCAACCTGAACATCCCTAACTT
TCAAATGACTGATGATATTGATGAGGTGCGATGGGAGAGGGGGAGCACCCTGGTTGCCGAGTTTAAA
AGGAAGATGAAGCCTTTTTTGAAATCGGGAGCATTTGAGATCTTAGCAAATGGAGACTTGAAGATAAA
GAATCTGACAAGAGATGACAGTGGCACCTATAATGTAACGGTATACAGCACAAATGGGACACGTATCC
TGAACAAGGCACTGGACTTGAGGATTCTGGAGATGGTCTCAAAGCCGATGATCTACTGGGAGTGCAGC
AACGCAACCCTGACCTGTGAGGTCTTGGAAGGAACAGATGTTGAACTAAAGCTGTACCAAGGAAAGGA
GCATCTCAGGAGCCTCCGTCAGAAGACCATGAGTTACCAGTGGACCAACCTGAGAGCACCGTTTAAGT
GCAAGGCGGTAAACAGGGTCAGCCAGGAGTCTGAGATGGAAGTTGTCAACTGTCCAGAGAAAGGTCT
GCCCCTCTATCTCATAGTGGGGGTCAGTGCAGGAGGACTCCTCTTGGTGTTCTTTGGGGCGCTGTTTAT
TTTCTGTATCTGCAAGAGGAAAAAACGGCTCGAGAGCGGCTCCGGTGCCACCAACTTCTCTCTGCTGAA
GCAGGCCGGGGATGTCGAAGAGAATCCAGGCCCCATGCATATGGGCTGCAGAAGAACTAGAGAAGG
ACCAAGCAAAGCCATGATATTTCCATGGAAATGTCAGAGCACCCAGAGGGACTTATGGAACATCTTCAA
GTTGTGGGGGTGGACAATGCTCTGTTGTGATTTCCTGGCACATCATGGAACCGACTGCTGGACTTACCA
TTATTCTGAAAAACCCATGAACTGGCAAAGGGCTAGAAGATTCTGCCGAGACAATTACACAGATTTAGT
TGCCATACAAAACAAGGCGGAAATTGAGTATCTGGAGAAGACTCTGCCTTTCAGTCGTTCTTACTACTG
GATAGGAATCCGGAAGATAGGAGGAATATGGACGTGGGTGGGAACCAACAAATCTCTCACTGAAGAA
GCAGAGAACTGGGGAGATGGTGAGCCCAACAACAAGAAGAACAAGGAGGACTGCGTGGAGATCTAT
ATCAAGAGAAACAAAGATGCAGGCAAATGGAACGATGACGCCTGCCACAAACTAAAGGCAGCCCTCT
GTTACACAGCTTCTTGCCAGCCCTGGTCATGCAGTGGCCATGGAGAATGTGTAGAAATCATCAATAATT
ACACCTGCAACTGTGATGTGGGGTACTATGGGCCCCAGTGTCAGTTTGTGATTCAGTGTGAGCCTTTGG
AGGCCCCAGAGCTGGGTACCATGGACTGTACTCACCCTTTGGGAAACTTCAGCTTCAGCTCACAGTGTG
CCTTCAGCTGCTCTGAAGGAACAAACTTAACTGGGATTGAAGAAACCACCTGTGGACCATTTGGAAACT
GGTCATCTCCAGAACCAACCTGTCAAGTGATTCAGTGTGAGCCTCTATCAGCACCAGATTTGGGGATCA
TGAACTGTAGCCATCCCCTGGCCAGCTTCAGCTTTACCTCTGCATGTACCTTCATCTGCTCAGAAGGAAC
TGAGTTAATTGGGAAGAAGAAAACCATTTGTGAATCATCTGGAATCTGGTCAAATCCTAGTCCAATATG
TCAAAAATTGGACAAAAGTTTCTCAATGATTAAGGAGGGTGATTATAACCCCCTCTTCATTCCAGTGGC
AGTCATGGTTACTGCATTCTCTGGGTTGGCATTTATCATTTGGCTGGCAAGGAGATTAAAAAAAGGCAA
GAAATCCAAGAGAAGTATGAATGACCCATATTAA 
 
 
 309 
 
pLenti-CD2-P2A-L-selectin ΔM-N (from figure 6.3) 
GCCGCCACCATGAGATGTAAATTCCTAGGGAGTTTCTTTCTGCTCTTCAGCCTGTCCAGCAAAGGAGCA
GACTGCAGAGACAGTGGGACCGTCTGGGGTGCCCTGGGTCATGGCATCAACCTGAACATCCCTAACTT
TCAAATGACTGATGATATTGATGAGGTGCGATGGGAGAGGGGGAGCACCCTGGTTGCCGAGTTTAAA
AGGAAGATGAAGCCTTTTTTGAAATCGGGAGCATTTGAGATCTTAGCAAATGGAGACTTGAAGATAAA
GAATCTGACAAGAGATGACAGTGGCACCTATAATGTAACGGTATACAGCACAAATGGGACACGTATCC
TGAACAAGGCACTGGACTTGAGGATTCTGGAGATGGTCTCAAAGCCGATGATCTACTGGGAGTGCAGC
AACGCAACCCTGACCTGTGAGGTCTTGGAAGGAACAGATGTTGAACTAAAGCTGTACCAAGGAAAGGA
GCATCTCAGGAGCCTCCGTCAGAAGACCATGAGTTACCAGTGGACCAACCTGAGAGCACCGTTTAAGT
GCAAGGCGGTAAACAGGGTCAGCCAGGAGTCTGAGATGGAAGTTGTCAACTGTCCAGAGAAAGGTCT
GCCCCTCTATCTCATAGTGGGGGTCAGTGCAGGAGGACTCCTCTTGGTGTTCTTTGGGGCGCTGTTTAT
TTTCTGTATCTGCAAGAGGAAAAAACGGCTCGAGAGCGGCTCCGGTGCCACCAACTTCTCTCTGCTGAA
GCAGGCCGGGGATGTCGAAGAGAATCCAGGCCCCATGCATATGGGCTGCAGAAGAACTAGAGAAGG
ACCAAGCAAAGCCATGATATTTCCATGGAAATGTCAGAGCACCCAGAGGGACTTATGGAACATCTTCAA
GTTGTGGGGGTGGACAATGCTCTGTTGTGATTTCCTGGCACATCATGGAACCGACTGCTGGACTTACCA
TTATTCTGAAAAACCCATGAACTGGCAAAGGGCTAGAAGATTCTGCCGAGACAATTACACAGATTTAGT
TGCCATACAAAACAAGGCGGAAATTGAGTATCTGGAGAAGACTCTGCCTTTCAGTCGTTCTTACTACTG
GATAGGAATCCGGAAGATAGGAGGAATATGGACGTGGGTGGGAACCAACAAATCTCTCACTGAAGAA
GCAGAGAACTGGGGAGATGGTGAGCCCAACAACAAGAAGAACAAGGAGGACTGCGTGGAGATCTAT
ATCAAGAGAAACAAAGATGCAGGCAAATGGAACGATGACGCCTGCCACAAACTAAAGGCAGCCCTCT
GTTACACAGCTTCTTGCCAGCCCTGGTCATGCAGTGGCCATGGAGAATGTGTAGAAATCATCAATAATT
ACACCTGCAACTGTGATGTGGGGTACTATGGGCCCCAGTGTCAGTTTGTGATTCAGTGTGAGCCTTTGG
AGGCCCCAGAGCTGGGTACCATGGACTGTACTCACCCTTTGGGAAACTTCAGCTTCAGCTCACAGTGTG
CCTTCAGCTGCTCTGAAGGAACAAACTTAACTGGGATTGAAGAAACCACCTGTGGACCATTTGGAAACT
GGTCATCTCCAGAACCAACCTGTCAAGTGATTCAGTGTGAGCCTCTATCAGCACCAGATTTGGGGATCA
TGAACTGTAGCCATCCCCTGGCCAGCTTCAGCTTTACCTCTGCATGTACCTTCATCTGCTCAGAAGGAAC
TGAGTTAATTGGGAAGAAGAAAACCATTTGTGAATCATCTGGAATCTGGTCAAATCCTAGTCCAATATG
TCAAAAATTGGACAAAAGCTTCTCACCCCTCTTCATTCCAGTGGCAGTCATGGTTACTGCATTCTCTGGG
TTGGCATTTATCATTTGGCTGGCAAGGAGATTAAAAAAAGGCAAGAAATCCAAGAGAAGTATGAATGA
CCCATATTAA 
 
pLenti-L-selectin I-K (from figure 6.7) 
GCCGCCACCATGGGCTGCAGAAGAACTAGAGAAGGACCAAGCAAAGCCATGATATTTCCATGGAAATG
TCAGAGCACCCAGAGGGACTTATGGAACATCTTCAAGTTGTGGGGGTGGACAATGCTCTGTTGTGATTT
CCTGGCACATCATGGAACCGACTGCTGGACTTACCATTATTCTGAAAAACCCATGAACTGGCAAAGGGC
TAGAAGATTCTGCCGAGACAATTACACAGATTTAGTTGCCATACAAAACAAGGCGGAAATTGAGTATCT
GGAGAAGACTCTGCCTTTCAGTCGTTCTTACTACTGGATAGGAATCCGGAAGATAGGAGGAATATGGA
CGTGGGTGGGAACCAACAAATCTCTCACTGAAGAAGCAGAGAACTGGGGAGATGGTGAGCCCAACAA
CAAGAAGAACAAGGAGGACTGCGTGGAGATCTATATCAAGAGAAACAAAGATGCAGGCAAATGGAAC
GATGACGCCTGCCACAAACTAAAGGCAGCCCTCTGTTACACAGCTTCTTGCCAGCCCTGGTCATGCAGT
GGCCATGGAGAATGTGTAGAAATCATCAATAATTACACCTGCAACTGTGATGTGGGGTACTATGGGCC
 310 
 
CCAGTGTCAGTTTGTGATTCAGTGTGAGCCTTTGGAGGCCCCAGAGCTGGGTACCATGGACTGTACTCA
CCCTTTGGGAAACTTCAGCTTCAGCTCACAGTGTGCCTTCAGCTGCTCTGAAGGAACAAACTTAACTGG
GATTGAAGAAACCACCTGTGGACCATTTGGAAACTGGTCATCTCCAGAACCAACCTGTCAAGTGATTCA
GTGTGAGCCTCTATCAGCACCAGATTTGGGGATCATGAACTGTAGCCATCCCCTGGCCAGCTTCAGCTT
TACCTCTGCATGTACCTTCATCTGCTCAGAAGGAACTGAGTTAATTGGGAAGAAGAAAACCATTTGTGA
ATCATCTGGAATCTGGTCAAATCCTAGTCCAATATGTCAAAAATTGGACAAAAGTTTCTCAATGATTAAG
GAGGGTGATTATAACCCCCTCTTCATTCCAGTGGCAGTCATGGTTACTGCATTCTCTGGGTTGGCATTTA
TCAAGTGGCTGGCAAGGAGATTAAAAAAAGGCAAGAAATCCAAGAGAAGTATGAATGACCCATATTA
A 
 
 
Appendix A3: In vitro flow assay of gag+ MOLT-3 cells over TNF-α 
activated HUVEC cells 
Please find attached a DVD with a representative movie of each MOLT-3 cell type (no, wt or 
ΔM-N L-selectin). 
